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Abstract 
Depression is common in people with coronary heart disease (CHD) and is 
associated with worse physical outcomes. The nature of the causal association 
between CHD and depression, and the mechanism underpinning the association of 
depression with worse physical outcomes, remains unclear. Perseverative negative 
thinking may contribute to the development of depression in people with CHD.  
The aim of this thesis was to investigate the prospective association of 
perseverative negative thinking with depression, anxiety and worse physical outcomes 
in people with CHD, and to explore factors that may mediate this association. 
First, a systematic review identified 30 studies, of which the majority found an 
association between measures of perseverative negative thinking and subsequent 
depression, anxiety or emotional distress in people with long term conditions. Studies 
that controlled for covariates showed more mixed results, though the majority (15 / 
25) still supported a significant association, with effects being small in magnitude. 
Findings were limited mainly to the association of rumination and/or catastrophizing 
with subsequent depression, and study quality was limited. 
Next, in an observational prospective cohort study 169 inpatients and 
outpatients with recent acute coronary syndrome (ACS) completed self-report 
assessments of rumination (Ruminative Responses Scale brooding subscale), worry 
(Penn State Worry Questionnaire), depression (Patient Health Questionnaire-8), 
anxiety (Beck Anxiety Inventory), and health-related quality of life (EuroQol-5D health-
related quality of life, Seattle Angina Questionnaire) after hospitalisation, and at 2 
month and 6 month follow-up. Additionally, assessments of potential mechanistic 
factors (social support, problem solving, instrumental behaviours and negative 
cognitive biases) were made. 
Baseline brooding was a significant independent predictor of depression at 6 
months after controlling for the effects of important confounding variables, accounting 
for 2% of the variance.  Findings suggested that the association of brooding with 
depression may be explained by deficits in problem solving ability. 
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 Rumination and problem solving may provide useful targets for the 
development of evidence-based interventions to improve depression among people 
with CHD, although the findings presented here fall short of proving a causal 
relationship. Future trials could be used to investigate the causal nature of the 
association of rumination and problem solving with depression in people with ACS. 
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Chapter 1 Introduction  
1.1 Chapter outline 
This thesis concerns repetitive thought such as rumination and worry (i.e. 
perseverative negative thinking) as a cognitive process that may contribute to the 
development of, or maintain, depression in the context of chronic physical illness, in 
particular coronary heart disease (CHD). The research presented here seeks to (a) 
clarify the association of perseverative negative thinking with depression, anxiety and 
health-related quality of life in people with CHD, and (b) explore factors that may 
mediate the association of perseverative negative thinking with subsequent 
depression, anxiety and health-related quality of life. 
This introductory chapter summarises key literature related to: 
i. The prevalence and impact of chronic physical illness and depression; and 
the association of depression and CHD. 
ii. How cognitions about health and illness may impact on mental and physical 
wellbeing. 
iii. Definition and theoretical models of perseverative negative thinking; and 
empirical research and theories related to the association of perseverative 
negative thinking with psychopathology and physical health.  
Following this, gaps in the literature are identified, the aims of this thesis are 
outlined, and the structure of the thesis is described. 
1.2 Background 
1.2.1 Definitons, prevalence and impact of long term conditions and depression 
1.2.1.1 Long term conditions 
Chronic physical illnesses (i.e. long term conditions – LTCs) are conditions that 
cannot currently be cured but can be controlled with medication and/or other 
therapies, and includes a broad spectrum of conditions such as CHD, asthma, diabetes, 
chronic kidney disease, hypothyroidism, chronic obstructive pulmonary disease, 
arthritis and hypertension among others. It is estimated that 15 million people in 
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England (approximately 30% of the population) have at least one LTC and this is set to 
rise to 18 million by 2025. LTCs can restrict physical and mental wellbeing, and can 
limit everyday activities including employment. In addition, the treatment of LTCs 
imposes a significant economic burden, accounting for 70% of all health and social care 
spending in England[1, 2].  
1.2.1.2 Coronary heart disease 
  CHD is a term used to describe a group of diseases caused by the gradual build-
up of fatty deposits (atheroma) in the walls of the blood vessels supplying the heart 
muscle that can restrict or block blood flow. Common symptoms of CHD include chest 
pain (angina), shortness of breath and heart attack (myocardial infarction). Risk of CHD 
rises with age and is higher in males than females[3]. Other risk factors include 
hypertension, raised cholesterol, smoking and diabetes mellitus[4]. Prevalence of CHD 
is estimated at 2.3 million people in the UK[5], and although prognosis among people 
with CHD has improved dramatically in the last two decades (e.g. [6, 7]) it remains the 
leading cause of mortality in the UK, accounting for approximately 80,000 deaths in 
2010. There were 405,000 inpatient admissions for CHD in England in the same year, 
and direct healthcare costs in the UK are estimated at £1.8billion annually[3]. CHD is 
also associated with poor health-related quality of life[8] and impaired functional 
status[9, 10].  
1.2.1.3 Depression 
Major depressive disorder is a heterogeneous disorder characterized by core 
symptoms of severe sadness, despondency, and/or a loss of interest or pleasure in 
activities that would previously have been considered enjoyable. DSM-V[11] defines a 
major depressive episode as depressed mood or loss of pleasure over a 2 week period, 
combined with at least 4 more of the following symptoms: weight loss or gain, changes 
in sleep, psychomotor agitation or retardation, fatigue, feelings of worthlessness or 
guilt, inability to concentrate, and recurrent thoughts of death or suicidal ideation. The 
symptoms must be present nearly every day, must cause clinically significant distress 
or impairment in social, occupational or other areas of functioning, and must not be 
due to the physiological effects of a substance or other medical condition. 
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The World Health Organisation (WHO) estimates that 350 million people 
worldwide are affected by depression[12]. Prevalence estimates vary although 
epidemiological surveys suggest a 12 month prevalence rate for major depressive 
disorder of approximately 5% in Europe[13, 14]. The total cost of depression in 
England, including health and social care spending and loss of earnings, was estimated 
at £7.5 billion in 2007[15].  
Globally depression is ranked the fourth largest cause of disease burden[16]. 
This is unsurprising considering that depressive episodes can be prolonged (estimates 
of duration vary although untreated episodes can last an average of 6 to 8 months[17], 
and likelihood of recovery worsens with increasing duration of the episode[18]), many 
episodes progress to a chronic course  (approximately 20% of episodes last 2 years or 
more e.g.[19, 20]) and relapse and recurrence are common [21-23]. In addition 
depression is frequently comorbid with other mental health conditions[24-27] 
particularly anxiety disorders (58% of people with a lifetime diagnosis of major 
depressive disorder will also receive a diagnosis of anxiety) and is linked with suicide 
risk[28, 29]. 
 
1.2.2 Comorbidity of depression and LTCs 
The prevalence of depression is elevated (approximately 20%) in people with 
LTCs including CHD [30-34], and comorbidity is problematic because it is associated 
with social problems, delayed return to work[35], increased healthcare utilisation and 
healthcare costs[36-38], and also with worse physical health outcomes including 
reduced quality of life and increased morbidity and mortality[10, 39-50].  
Several correlates of depression in LTCs and CHD have been identified. Egede et 
al. (2007)[30], for example, found that similar sociodemographic characteristics were 
associated with depression in adults with and without LTCs (younger age, female sex, 
lower income, higher BMI, unemployment, worsening health status and smoking). 
Koivula et al. (2009)[51] found that gender, perceived health, cardiac symptoms at rest 
and poor social support were associated with elevated depressive symptoms in long 
term CHD patients. 
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1.2.2.1 Evidence and direction of causal link 
The association of depression and CHD appears to be bi-directional[52, 53] 
although proof of the causal link has not been established. There are several strands of 
research that suggest (a) depression may have a causal role in the onset and 
progression of cardiac disease, (b) depression may be a consequence of CHD, or that 
(c) depression and CHD may both be caused by a common underlying mechanism. The 
sections below outline some possibilities regarding each of these interpretations.  
1.2.2.1.1 Depression as a risk factor for CHD 
Evidence that depression may be causally associated with CHD comes from 
three main sources: etiological studies, prognostic studies, and studies demonstrating 
a dose-response relationship. 
1.2.2.1.1.1 Etiological studies 
First, many studies show that depression precedes CHD. A large multicentre 
case-controlled study (INTERHEART) based on retrospective reports showed that 
patients with first myocardial infarction (MI) experienced more psychosocial stress in 
the preceding 12 months compared to controls, and that cases were more likely than 
controls to have experienced depressive symptoms for at least 2 weeks in the 
preceding 12 months (odds ratio 1.55)[54].  
Several systematic reviews and meta-analyses, based upon partially 
overlapping etiological prospective cohort studies of samples without CHD at baseline, 
showed that  clinical depression and depressive symptoms increased the relative risk 
of coronary disease onset, MI or cardiac mortality by approximately 60% to 80%[43, 
55-57].  
1.2.2.1.1.2 Prognostic studies 
Second, once CHD is established depression appears to worsen prognosis[39, 
58]. For example, in a sample of 222 patients recruited immediately post-MI both 6 
month[59]and 18 month mortality[60] was predicted by depression, after controlling 
for severity of cardiac disease, and risk stratification based on standard risk factors 
(such as severity of cardiac disease and previous history of MI) was improved by 
additionally considering depression status. A large meta-analysis of 34 individual 
prognostic studies that involved a total of 17,842 participants, showed depression was 
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associated with an 80% increased risk of poor CHD prognosis over an average follow-
up period of 3.2 years, although the effect size was considerably smaller after 
controlling for confounding variables such as severity of cardiac disease[43].  
Studies have also shown that depression is associated with lack of functional 
benefits after coronary artery bypass surgery or revascularisation, even after 
controlling for severity of cardiac disease[48, 61]. 
1.2.2.1.1.3 Dose response relationship 
Finally, a dose response relationship has been observed between depression 
and cardiac morbidity, such that more severe depression is associated with worse 
cardiac outcomes. For example, meta-analyses have shown that the association of 
depressive symptoms with onset of CHD and worse CHD prognosis is weaker than the 
association of clinical depression with CHD onset and worse CHD prognosis[43, 57].  
A graded relationship was also reported in the Whitehall II cohort study of 
cardiovascular disease using a ‘cumulative caseness’ approach[62].  Depression was 
measured on six occasions over 20 years and fatal and non-fatal CHD events were 
recorded. The results showed a 50% increase in risk of incident CHD events for those 
who had satisfied criteria for depression on two or three occasions, compared to those 
who had been classified as depressed on one occasion only. 
 
The sections above are intended to illustrate that there is a large volume of 
work suggestive of a causal link between depression and CHD. Effect sizes are 
comparable to those of other conventional risk factors for CHD. However, it remains 
unclear whether depression is an independent predictor of CHD.  Alternative 
explanations for the observed association between depression and poor physical 
health outcomes, for example due to the confounding effects of other risk factors 
including severity of cardiac disease, remain possible (e.g.[35, 43, 63]). This is 
important since increasing levels of left ventricular dysfunction (an index of severity of 
cardiac disease) have been associated with increasing severity of depressive disorder 
at hospitalisation and with increased rates of depressive order over 12 months follow-
up[64].  
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Further, it is unclear whether the time at which depressive symptoms present, 
relative to onset of CHD, is important for prognosis (e.g.[65]) or whether the duration 
of depression is associated with CHD[58]. 
1.2.2.1.2 Depression as a consequence of CHD 
On the other hand, depression might arise as a reaction to the illness or as the 
result of adjustment to the burden of chronic disease[66]. Although this would suggest 
that greater disease burden rather than depression itself causes worse CHD outcomes, 
which is not consistent with the results of studies that find depression is associated 
with poorer outcomes even after controlling for disease burden e.g.[61]. 
The high prevalence of ‘incident’ depression following MI may also suggest that 
depression is triggered by CHD. It has been estimated that approximately half of post-
MI cases of depression are new[67], and several researchers have suggested that the 
nature of incident depression is different from pre-existing or recurrent depression[65, 
67-71]. Whereas the factors associated with depression that precedes CHD appear to 
be similar to those observed in typical psychiatric populations (e.g. being female, 
younger age, social isolation, low educational level, previous psychiatric history, 
neuroticism), incident depression is characterised by more severe cardiac disease 
(including worse left ventricular ejection fraction, higher probability of coronary 
revascularisation during hospitalisation, and more arrhythmic events), greater 
functional disability and reduced response to antidepressant therapy. This raises the 
possibility that post-MI depression could be a particularly ‘cardiotoxic’ subtype of 
depression[70]. 
1.2.2.1.3 Possibility of a common underlying mechanism 
An alternative explanation is that there is a common underlying cause of both 
CHD and depression[72-74]. Davidson (2012) argues, for example, that since 
depressive symptoms can be the result of cerebrovascular disease, it is possible that 
(vascular) depression could be the result of the same risk factors responsible for 
CHD[72], and Mosovich et al. (2008) propose a model in which chronic stress initiates a 
cascade of effects via changes in immune function that lead to disrupted production of 
serotonin and increased platelet aggregation contributing to both depression and 
heart disease[73]. 
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1.2.2.2 Mechanisms linking depression with CHD 
A variety of plausible behavioural and physiological mechanisms have been 
proposed to explain the link between depression and worse physical health outcomes 
in CHD, though none has been proven to explain the association[58, 72, 75-78].  
Suggested physiological mechanisms include: (1) increased platelet ‘stickiness’ 
and thrombus formation, (2) changes in heart rhythms and cardiac autonomic tone, 
particularly decreased heart rate variability, (3) elevated inflammatory response, (4) 
hypothalamic-pituitary-adrenal axis dysregulation, (5) alterations in vascular 
endothelial function, and (6) the ‘vascular depression’ hypothesis.  
The main behavioural mechanism that has received attention is lack of 
adherence to treatment. For example, CHD patients with elevated depressive 
symptoms during hospitalisation for MI were less likely than those without depressive 
symptoms to adhere to daily aspirin therapy[79] or to comply with advice to reduce 
cardiac risk in the months following discharge (e.g. implementing changes to diet and 
exercise, and smoking cessation)[80, 81]. Lack of motivation and memory problems 
associated with depression may explain reduced adherence to medication and 
rehabilitation advice[45]. 
Other suggested behavioural mechanisms include: (1) unhealthy lifestyle 
choices, or poor adherence to recommendations to alter lifestyle factors as described 
above, (2) lack of social support/failure to recognise or utilise available social support 
resources, and (3) failure to adapt to adverse symptoms of physical illness. 
1.2.2.3 Recognition and treatment of depression in CHD 
1.2.2.3.1 Recognition of depression 
Depression is underdiagnosed and undertreated in patients with CHD, despite 
its high prevalence and association with poor physical outcomes. For example, 
Zieglestein et al. (2005) reported that among CHD inpatients 75% of cases with 
elevated depressive symptomatology were not recognised by cardiac nurses or 
medical students[82]. Similarly, Huffman et al. (2006) found that <15% of cardiac 
inpatients with major depressive disorder or with elevated depressive 
symptomatology were identified by medical care providers and only 11% of patients 
with depression were receiving antidepressant therapy[83].  
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Detection of depression in people with CHD could be confounded by the 
presence of physical symptoms related to CHD (e.g. fatigue, weight loss, sleep 
disturbance). However, since depression in CHD could contribute to non-compliance 
with medical treatment and poorer CHD prognosis, its detection and treatment should 
be a priority. Early screening for depression and case-finding in CHD patients is 
recommended[84-86]. 
1.2.2.3.2 Treatment strategies 
The National Institute for Health and Care Excellence (NICE) recommends a 
variety of treatment options for depression in people with LTCs using a stepped-care 
model: low intensity psychological therapies (such as group-based physical activity or 
peer support programs, guided self-help and computerised cognitive behavioural 
therapy) for subthreshold or mild depression, high intensity group or individual 
cognitive behavioural therapy, couples therapy, antidepressant drugs or, where other 
high intensity therapies have not succeeded, collaborative care[87]. Functional 
limitations related to the physical illness should be considered when selecting a 
treatment approach, and adaptations to delivery mode made where necessary. It is 
recommended that side effect profiles and interactions with other drug treatments are 
considered when prescribing antidepressant drug treatments. 
1.2.2.3.3 Effects on depression and cardiac outcomes 
Due to the association of depression with poor CHD outcomes, some 
researchers have suggested that treating depression among people with CHD may not 
only improve psychological well-being, but could also improve physical health 
outcomes[59, 66, 88].  
1.2.2.3.3.1 Antidepressants  
Randomised, double blind, placebo controlled trials have shown limited or 
small effects of antidepressant drug treatments on depression. For example, Glassman 
et al. (2002) found 24 weeks of sertraline treatment in acute coronary syndrome (ACS) 
patients provided no improvement in depression compared to placebo [89], and in the 
SADHART study[90] 12 weeks of sertraline treatment was only effective in a subgroup 
of ACS patients with non-incident depression. In a Cochrane review Baumeister et al. 
(2011) identified 8 trials (including the SADHART[90], CREATE[91] and MIND-IT[92, 93] 
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studies) that compared pharmacological treatment with placebo and concluded that 
there was a small beneficial effect of SSRIs in improving depression[94].  
However, both observational studies and trials have failed to demonstrate 
convincingly that treatment with antidepressants improves cardiac health 
outcomes[90, 95-97]. It is unclear whether the effects of pharmacological treatment 
on depression were too small to impact upon cardiac outcomes, or whether this 
indicates that there is no causal association between depression and CHD[95].  
1.2.2.3.3.2 Psychological treatments 
Baumeister et al. (2011) identified 6 trials that compared the effectiveness of 
psychological treatments for depression in CHD patients with usual care[94]. 
Psychological interventions included cognitive behavioural therapy, interpersonal 
therapy, resource-orientated psychotherapy, telephone counselling and an 
intervention based on health education. Overall there was a small beneficial effect of 
psychological interventions on outcomes related to depression. This is consistent with 
reviews by Whalley et al. (2011)[98] that reported small to moderate improvements in 
depression and anxiety following psychological interventions, and Dickens et al. 
(2013)[99] that found small beneficial effects of cognitive behavioural therapy (CBT) 
and problem solving. 
However, evidence that psychological interventions improve cardiac outcomes 
is sparse.  In both a randomised controlled trial[100] and a non-randomised study[101] 
a cognitive behavioural therapy-based disease management approach to challenge 
misconceptions about angina appeared to reduce angina frequency, use of medication 
for the symptomatic treatment of angina and hospital admissions. On the other hand, 
in a randomised controlled trial (the ENRICHD study[88]) cognitive behavioural therapy 
aimed at reducing depression and improving perceptions of social support after 
myocardial infarction was compared to treatment as usual. Despite some 
improvements in depression and social support there was no improvement in 
cardiovascular outcomes including mortality and event-free survival in the treatment 
arm. Reviews of observational studies[97] and of randomised trials[94, 98] support this 
finding, concluding that there is no effect of psychological interventions on cardiac 
outcomes such as mortality, risk of revascularisation, or other non-fatal CHD events. 
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Interestingly, some studies have shown that depression in CHD patients is 
characterised by fewer cognitive/affective symptoms (e.g. depressed mood, feelings of 
guilt) than that seen in typical psychiatric populations[102], and that somatic/affective 
symptoms of depression (e.g. fatigue, psychomotor agitation) are particularly 
associated with greater severity of cardiac disease (left ventricular dysfunction, 
previous history of myocardial infarction and more comorbidities). In addition only the 
somatic symptoms predicted mortality and cardiac events[103, 104]. As a result it is 
suggested that treatments for depression which selectively focus on somatic/affective 
symptoms might be more beneficial in cardiac patients[103].  
 
1.2.3 Cognitions about health and illness 
Cognitive processes could be implicated in the association between depression 
and CHD.  Leventhal’s self-regulatory ‘common sense model’ of illness 
representations[105-107] proposes that when faced with a chronic physical illness 
patients generate cognitive and emotional representations of their illness related to 
several key dimensions of the illness: (1) consequences, (2) duration, (3) 
controllability/curability, (4) cause (5) identity/symptoms, and (6) emotional 
perceptions.  The representations of illness are thought to influence coping efforts, 
which in turn impacts on outcomes. Thus, the way people think about their illness acts 
as a mediator between the disease process and physical/psychological wellbeing[108]. 
Studies in CHD patients show that negative illness perceptions are associated 
with adverse outcomes. For example, negative perceptions of illness related to longer 
course, greater severity and limited controllability were correlated with greater 
depressive symptoms in ACS patients[109]. Similarly, a prospective study showed that 
negative beliefs about the anticipated duration and perceived likely outcome of 
coronary disease soon after MI predicted the development of depression in the 12 
months afterwards[110]. In addition, a systematic review of illness perceptions after 
CHD showed that negative beliefs about illness predicted quality of life as well as 
depression[111]. 
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Persistently dwelling on negative illness perceptions could, then, initiate and 
maintain depression and worse quality of life following CHD. Such repetitive thinking 
has been linked with depression in healthy and psychiatric populations, and could 
therefore be helpful in better understanding depression in people with CHD. 
 
1.2.4 Perseverative negative thinking 
Repetitive thought involves frequent, prolonged and recurrent thoughts about 
oneself and one’s concerns[112], and is central to a number of constructive and 
unconstructive cognitive processes such as, but not limited to, rumination, worry, 
perseverative cognition, mind wandering, counterfactual thinking, post-event 
processing and reflection[113]. This thesis will focus specifically on unconstructive, 
negative forms of repetitive thought i.e. perseverative negative thinking. 
The literature on perseverative negative thinking has been dominated by the 
concepts of rumination and worry. These constructs have emerged from distinct 
theoretical backgrounds, although they share in common, with other forms of 
perseverative negative thinking, three defining characteristics: they are (a) repetitive, 
(b) passive / relatively uncontrollable and (c) focused on negative content[114]. 
1.2.4.1 Rumination 
1.2.4.1.1 Definition 
Rumination has been defined as repetitive thought that revolves around a 
personal theme in the absence of any external cues to provoke such thoughts[115] or, 
in the case of ‘depressive rumination’, as a response to negative mood which involves 
“passively and repetitively focusing on one’s symptoms of distress and the 
circumstances surrounding those symptoms”[116]. In each of these views, rumination 
is considered to be past-orientated with a focus on understanding the meaning of 
events and gaining insight. Rumination is considered a maladaptive coping strategy 
involving elaboration of negative content, and has been closely associated with 
depression. 
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1.2.4.1.2 Theoretical models of rumination 
Several theoretical accounts of rumination have been proposed (for a review 
see[117]), the most prominent being (1) ‘control theory’ approaches[115] and (2) 
Nolen-Hoeksema’s ‘response styles theory’[118]. 
The control theory approach conceptualises rumination as recurrent 
instrumental thinking about an unresolved goal. This is based on a self-regulation 
model in which all behaviour (including cognitive activity) is controlled by feedback 
processes[119]. It is proposed that individuals compare perceptions of their current 
state with reference values such as desired goals, and that discrepancies between the 
current state and the reference value lead to changes in behaviour in an attempt to 
move closer to the reference value. Control theory approaches to rumination suggest 
that rumination is triggered by unresolved goals or inadequate progress towards goals, 
and that rumination will continue until the discrepancy between current state and 
reference value is resolved either by attainment or abandonment of the desired 
goal[115].  Therefore, in the context of chronic physical illness such as CHD, control 
theory would predict that rumination would be the result of actual or perceived 
limitations related to physical function and lifestyle that might make desired goals 
seem less attainable. 
Response styles theory[118, 120] focuses on the process of ‘depressive 
rumination’ which is conceptualised as a stable dispositional style of responding to 
negative mood that is linked with the onset, duration and severity of depression[121, 
122]. Rumination is thought to exacerbate and prolong distress by passively focusing 
attention on the possible causes and consequences of negative mood, without 
initiating active problem solving to change the circumstances surrounding the 
symptoms of distress, resulting in a vicious circle of negative self-focus and negative 
mood.  A conceptual extension of the response styles theory is the ‘stress-reactive 
rumination’ model of Robinson & Alloy (2003)[123]. This suggests that negative 
cognitive styles associated with hopelessness (negative inferential styles and 
dysfunctional attitudes) encourage negative thought content in response to stressful 
life events, and that this negative content is activated and rehearsed through the 
process of rumination. Together the stress-reactive model of rumination and response 
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styles theory would suggest that the experience of chronic physical illness triggers 
negative thoughts and appraisals of illness, and that rumination, in turn, would be 
triggered by that negative thought content leading to a ruminative-depressive cycle. 
1.2.4.2 Worry 
1.2.4.2.1 Definition 
Worry is defined as “a chain of thoughts and images, which are negatively 
affect laden and relatively uncontrollable” [124]. It is conceptualised as a future-
focused avoidant process closely related to fear that involves repetitive thought about 
anticipated future threats in an attempt to plan and problem solve. Worry is a central 
cognitive feature of generalised anxiety disorder[11]. 
1.2.4.2.2 Theoretical models of worry 
The dominant theoretical models of worry can be broadly grouped into models 
concerned with the avoidant function of worry (e.g.[124-127]) and those that deal with 
beliefs about worry itself[128, 129]. 
Borkovec and colleagues propose a cognitive avoidance model of worry that 
suggests worry is motivated by avoidance of threatening stimuli (both internal and 
external experiences) and that it is maintained by a process of negative 
reinforcement[124, 125]. Suppression of somatic anxiety, discovery of ways to avoid 
threatening events, and distraction from deeper fears are suggested mechanisms 
through which worry may function. In addition, since worry concerns feared 
catastrophic events that often do not come to pass, the process of worry is reinforced 
and maintained.  
The intolerance of uncertainty model also proposes that worry serves an 
avoidant function. Intolerance of uncertainty is a trait disposition characterised by 
negative beliefs about, and the tendency to respond negatively to, uncertain situations 
and events[126]. High intolerance of uncertainty, even of improbable events, is 
thought to trigger worry as a means of attempting to increase control and eliminate 
the threat of uncertainty[127].  
On the other hand, the metacognitive model of worry suggests that worry 
arises as a result of positive and negative appraisals about the nature and 
consequences of worry[128, 129]. This model distinguishes between worries that 
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occur in response to everyday events and experiences (as a form of coping strategy) 
and ‘meta-worry’. Worrying as a coping strategy (‘Type 1 worry’) is thought to be 
associated with positive beliefs about worry (e.g. that worrying is useful). Meta-worry 
on the other hand tends to be associated with negative beliefs (e.g. that worry is 
uncontrollable or dangerous). Type 1 worries once initiated trigger meta-worry and a 
cycle of intensifying worry and anxiety is initiated.  
Each of these models are relevant in the context of chronic physical illness. 
Disease and treatment may present threats to physical function, wellbeing and lifestyle 
that the individual would prefer to avoid for example, and aspects of both illness and 
treatment may be uncertain (e.g. likely duration of illness, treatment outcome). 
Furthermore, lay understandings of illness (e.g. ‘stress is bad for your heart’) may 
contribute to meta-worry. 
1.2.4.3 Overlap of rumination and worry 
There is some debate over the extent to which rumination and worry represent 
distinct or overlapping processes[114, 130].  
The two concepts have emerged from separate theoretical backgrounds, and as 
a result the suggested functions, content, processes and measurement of the 
constructs differ. For example, it is proposed rumination is a maladaptive coping style 
that involves elaboration of negative material[131] whereas worry is motivated by 
cognitive avoidance[125]. Rumination tends to be focused on symptoms of distress 
and failure to achieve personal goals[115, 118, 120], whereas the content of worry 
centres around future threats[125]. It has also been suggested that rumination and 
worry may vary along process and metacognitive dimensions such as past vs. future 
focus, use of verbal thought vs. imagery, effort and confidence in problem solving, and 
compulsion to act[132]. A raft of self-report instruments have been developed to 
measure the frequency, severity and content of worry (e.g.[133-139]), and the 
tendency to ruminate (e.g.[140-145]). The wide range of individual measures 
illustrates that the assessment of rumination and worry have previously been separate 
endeavours, and that the measures have tended to emerge from distinct research 
areas.  Furthermore, some empirical studies suggest that rumination and worry have 
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differing effects on psychological and physical wellbeing suggesting that they may 
represent distinct processes (e.g. [112, 146-148]. 
On the other hand, worry and rumination are at least moderately correlated 
e.g.[146, 148, 149] and are frequently comorbid[150]. Ehring & Watkins[114] note 
three key features common to both rumination and worry: they are repetitive, 
relatively uncontrollable, and focused on negative content. Others have suggested that 
while the content of ruminative and worrisome thoughts may vary the processes 
involved are alike[114, 146, 150].  Results of correlational and experimental studies 
show that both rumination and worry are involved in depression and anxiety in clinical 
and non-clinical samples (e.g.[146, 148, 151-158]), and that they both are linked with a 
wide range of psychiatric conditions suggesting they may be transdiagnostic 
phenomena[114, 159]. Research using confirmatory factor analyses and structural 
equation modelling to investigate if measures of rumination and worry load on to 
single or separate factors provides some evidence to suggest that the similarities 
between rumination and worry may be greater than the differences[130, 146]. 
1.2.4.4 Association of perseverative negative thinking with psychopathology 
Although there is some overlap with clinical symptoms perseverative negative 
thinking, such as in rumination and worry, is a common, everyday phenomenon. 
However, there is evidence that when it becomes excessive and chronic perseverative 
negative thinking is associated with the exacerbation and maintenance of adverse 
mental health outcomes such as depression and anxiety[113, 125]. 
A number of strands of evidence suggest that perseverative negative thinking is 
associated with negative effects on mood in otherwise healthy samples. First, 
perseverative negative thinking is elevated in people at greater risk for depression e.g. 
it is higher in females compared to males[160, 161] and in individuals with a history of 
depression compared to those without[162]. 
Second, a large number of empirical studies show that there are cross-sectional 
and prospective associations between perseverative negative thinking and negative 
affect including the onset, maintenance and relapse of depression e.g.[118, 121, 122, 
140, 146, 152, 163, 164] and increased anxiety e.g.[153, 165-167] (for reviews see[113, 
168-171]). While cross-sectional studies strongly support the association between 
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perseverative negative thinking and adverse mental health outcomes such as 
depression and anxiety the findings of prospective studies which would allow tentative 
causal inferences to be made have been more mixed (e.g. [169]), although the majority 
of such studies still support an association. Narrative and systematic reviews have 
suggested that some of the variability in findings may be explained by characteristics 
of the population (e.g. gender, psychopathology[168, 170]), ‘intrapersonal context’ 
(e.g. self-efficacy, dysfunctional attitudes[113]) and by aspects of perseverative 
negative thinking itself (e.g. valence and content of thoughts[113]). A meta-analysis of 
the association of emotion regulation strategies with different classes of 
psychopathology showed that associations of rumination with depression and anxiety 
were strongest in clinical samples compared to non-clinical participants[168].   
Third, experimental studies have shown that inducing rumination and/or worry 
or allowing participants to ruminate increases both depressed and anxious mood[145, 
157, 158, 172, 173].  
Thus, a large body of converging evidence is strongly suggestive of an 
association between perseverative negative thinking with changes in mood, 
depression and anxiety. However, the majority of previous research has focused on 
physically healthy populations. 
1.2.4.4.1 Perseverative negative thinking and psychopathology in people with 
LTCs 
Cross-sectional studies in people with LTCs show that perseverative negative 
thinking is correlated with adverse mental health outcomes. For example, Schroevers 
et al. (2008) investigated associations among goal adjustment, cognitive emotion 
regulation strategies and positive/negative affect in 108 mixed cancer patients an 
average of 7 years post-diagnosis. Rumination and catastrophizing were measured 
using the self-report Cognitive Emotion Regulation Questionnaire (CERQ; [174]) and 
positive and negative affect with the positive and negative affect schedule (PANAS; 
[175]). Rumination (r=0.37) and catastrophizing (r=0.40) were significantly correlated 
with negative affect, and the associations remained significant after controlling for age 
and time since diagnosis[176]. 
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 Dickens et al. (2012) examined the strength of associations of perseverative 
negative cognitive processes (worry, thought suppression, and avoidance of undesirable 
thoughts) with depression in 190 outpatients with heart disease, diabetes, rheumatoid 
arthritis and chronic obstructive pulmonary disease. A tertile split of self-report worry 
scores (Penn State Worry Questionnaire, PSWQ; [133]) was used to categorise 
participants according to trait tendency to worry. Those in the top tertile (compared to 
the lower tertile) were 20 times more likely to have Hospital Anxiety and Depression 
Scale (HADS; [177]) scores indicative of possible depression (after controlling for age, 
sex, education, marital and work status, and type and duration of LTC). This study also 
showed (a non-significant trend) that severity of depression was associated with 
worry[178]. 
 Other cross-sectional studies in people with LTCs have found that rumination 
and catastrophizing are associated with symptoms of depression and anxiety in people 
with visual impairments[179], hearing loss[180], and peripheral arterial disease[181]. 
These studies demonstrate that perseverative negative thinking is associated with 
depression and anxiety, although they are limited by their cross-sectional design since 
it does not allow the direction of the association to be established. 
 Prospective studies would allow tentative causal inferences to be made, 
although few such studies have been conducted to date in people with LTCs including 
CHD. Exceptions include a small study by Garnefski et al. (2010) in post-MI patients 
that investigated the association of rumination and catastrophizing with depressive 
symptoms at 1 year follow-up[182], and a larger study by Denton et al. (2012) in which 
the effects of rumination and psychosocial vulnerabilities immediately post-ACS on 
depression at 3 month follow-up were investigated[183]. 
 Garnefski et al. (2010) recruited 160 patients (88 available for follow-up) who 
had experienced an MI in the preceding 3 to 12 months. They took self-report 
measures of rumination and catastrophizing (CERQ) and depressive symptoms (HADS) 
at initial assessment and again 1 year later. Rumination (r=0.43) and catastrophizing 
(r=0.45) at baseline were significantly correlated with depressive symptoms at follow-
up, and these associations remained significant after controlling for sex, age, and 
physical limitations. 
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 Denton et al. (2012) selected patients with Beck Depression Inventory (BDI; 
[184]) scores of 0 to 4 or >10 within 1 week of hospital admission for ACS (387 
available for follow-up). Self-report assessments of psychosocial vulnerabilities for 
depression (including dyadic adjustment, engagement in pleasant events and 
dysfunctional attitudes), rumination (Ruminative Responses Scale;[118]) and 
depression were completed at baseline and repeated 3 months later. Rumination at 
baseline predicted depression severity both independently and in interaction with 
other psychosocial vulnerabilities at 3 months, after adjusting for confounding 
variables including age, sex and baseline depression. The association was strongest in 
patients who were depressed at baseline.  
 The findings of these studies are consistent with a prospective association of 
rumination and catastrophizing with subsequent depression in people with CHD. 
However, these studies are limited by a large amount of attrition and selection of 
participants based on a subset of depression scores which could affect the 
generalisability of findings. The findings are also limited to the associations between 
rumination and catastrophizing with depression. 
 Thus, there is emerging empirical evidence that suggests perseverative 
negative thinking is associated with depression in people with LTCs including CHD, 
although this remains to be confirmed in high quality prospective studies.  
1.2.4.5 Mechanisms of the association between perseverative negative thinking and 
psychopathology 
Within vulnerability-stress frameworks perseverative negative thinking has 
been conceptualised as a maladaptive response to stressful life events that amplifies 
and maintains the effect of a stressor leading to the development and maintenance of 
depressive and anxious symptoms (e.g.[123, 185]). 
Several specific mechanisms have been suggested by which perseverative 
negative thinking, specifically rumination, may contribute to depression. These include 
(1) erosion of social support, (2) impaired problem solving, (3) reduced motivation to 
perform instrumental behaviours, and (4) negative cognitive biases[120, 186]. These 
mechanisms are unlikely to be independent. 
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1.2.4.5.1 Reduced social support 
Low perceived social support correlates with depression in the general 
population (e.g.[187]) and in people with CHD the inability to form and maintain close 
relationships due to the burden of a medical condition, low perceived availability of 
social support, and the number of close network members have been associated with 
depression, anxiety and worse quality of life[71, 188-193]. Importantly, lack of a close 
confidant has also been shown to predict further cardiac events over 12 months after 
myocardial infarction[194]. Social support may be protective because a partner could 
encourage faster treatment seeking[195] and better adherence to treatment[196]. 
High levels of support seeking, low perceived availability of social support and 
social friction are correlated with elevated rumination and worry[120, 197] and 
ruminators appear to erode social support by engaging in behaviours that are 
detrimental to their relationships. For example by placing high emotional and practical 
demands on members of their social network[198], excessive reassurance-
seeking[199], and by creating conflict and disturbances in their interpersonal 
relationships due to social support discontent[200]. 
1.2.4.5.2 Impaired problem solving 
Social problem solving is defined as a “cognitive-behavioural process by which a 
person attempts to identify or discover effective or adaptive solutions for specific 
problems encountered in the course of everyday living”[201]. Studies in healthy 
participants have shown that poor problem solving is prospectively associated with 
depressive and anxious symptoms[202-204] and that it mediates the association of 
stressful life events with depression and anxiety[205]. 
 Rumination appears to interfere with multiple aspects of problem solving 
ability: problem solving confidence, generation of effective solutions, and ability or 
motivation to implement problem solutions. Ruminators, compared to non-
ruminators, lack confidence in the quality of their problem solutions[206, 207] and 
following rumination induction dysphoric and depressed indivduals appraise their 
problems as overwhelming and unsolvable[208, 209]. Rumination inductions in 
individuals with dysphoria, current depression or a history of depression lead to the 
generation of fewer effective problem solutions[208-211]. Ruminators are also less 
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likely to implement problem solutions, even when they generate effective 
solutions[206, 207].  
1.2.4.5.3 Inhibition of instrumental behaviours 
Lack of interest and reduced engagement in pleasant activities is a symptom of 
depression[11], and depressed mood has been correlated with lower frequency of 
engagement in pleasant events[212]. In a sample of ACS patients Denton et al. (2012) 
found that both depression and rumination were associated with self-reported 
infrequency of engagement in pleasant events[183]. 
Rumination may contribute to depression by sapping motivation to engage in 
constructive behaviours. Additionally, persistent focus on negative mood could act to 
convince the individual that they lack the self-efficacy to initiate potentially mood-
alleviating activities. Lyubomirsky & Nolen-Hoeksema (1993) found that following a 
rumination induction dysphoric individuals were less willing to engage in a number of 
pleasant activities, despite believing that the activities would be pleasant. Ruminators 
also indicated that they perceived value in their rumination (e.g. gaining insight) and so 
were encouraged to continue ruminating rather than engaging in pleasant 
activities[213]. 
1.2.4.5.4 Negative cognitive biases 
Negative biases in processing emotional information are central to cognitive 
theories of depression[214, 215] and include the tendency to interpret ambiguous 
stimuli as negative[216, 217], selectively allocate attention to negative material[218], 
difficulty disengaging attention from negative material[219] and preferential memory 
for self-relevant negative over positive material[220]. Impaired cognitive control 
accounts of depression[221] and rumination [222] suggest that deficits in cognitive 
control are responsible for these biases. 
Rumination is associated with the tendency to view past, present and future 
events more negatively. For example, dysphoric individuals induced to ruminate will 
recall more negative events from the past, will spontaneously talk about their 
concerns, and have low expectations for future positive events[208, 209, 223]. 
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1.2.4.6 Association of perseverative negative thinking with physical outcomes 
Perseverative negative thinking may be associated with adverse physical as well 
as mental health outcomes. For example, trait and experimentally induced 
perseverative negative thinking has been associated with: impaired wound healing 
following routine surgery[224], immune dysfunction following a stressful event[225], 
changes in cortisol levels in response to exam stress[226] and changes in physiological 
measurements such as raised blood pressure and increased heart rate[227]. In 
addition, worry has been shown to predict incident heart disease over 20 year follow-
up in a longitudinal cohort study of men who were free of known chronic disease at 
entry to the study[228]. 
 Thayer and colleagues have proposed the ‘perseverative cognition hypothesis’ 
that might explain the association between perseverative negative thinking and 
adverse physical outcomes[229, 230]. Perseverative cognition (“the repeated or 
chronic activation of the cognitive representation of one or more psychological 
stressors”) is conceptualised as the core feature of processes involving repetitive 
thought (such as rumination and worry). Perseverative cognition is said to occur in 
anticipation of, or as a reaction to, an acute stressor and maintains a cognitive 
representation of that stressor. In turn, the prolonged cognitive representation is 
associated with chronic low level physiological activation of stress-related systems 
including cardiovascular, hypothalamic–pituitary–adrenal and immune systems (a state 
of ‘action readiness’), which can lead to somatic and health consequences. The 
perseverative cognition hypothesis is consistent with allostatic load models of stress 
that suggest biological reactivity to stress is adaptive in the short term, but over longer 
durations causes wear and tear on physiological systems[231, 232]. In addition, an 
extended version of the model accounts for the association between CHD and 
depression. Larsen & Christenfeld (2009) suggest that perseverative cognition 
mediates the association of depression with subsequent cardiovascular health by 
delaying physiological recovery from acute stress[233]. Reviews of empirical studies 
showing that perseverative negative thinking is associated with adverse physiological 
changes such as elevated cortisol, altered immune response, increased heart rate and 
reduced heart rate variability[227, 229, 234] provide some support for the 
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perseverative cognition hypothesis. However, existing empirical evidence is limited 
largely to cross-sectional and experimental studies in healthy participants, and the 
longer term effects in patients with CHD remain to be confirmed.  
Finally, a behavioural pathway has recently been suggested through which 
perseverative negative thinking may also impact on worse health outcomes. Clancy et 
al. (2016) conducted a systematic review and meta-analysis of studies investigating the 
association of perseverative negative thinking with health behaviours that may directly 
or indirectly influence health outcomes. They found that perseverative negative 
thinking was associated with increased health risk behaviours e.g. substance use, 
alcohol consumption, unhealthy eating, and smoking[235].   
1.2.4.7 Existing treatments for depression involving perseverative negative thinking 
Behavioural activation (BA), rumination-focused cognitive behavioural therapy 
(RFCBT) and mindfulness-based cognitive behavioural therapy (MCBT) are current 
psychological treatment approaches for depression that contain components that 
target rumination.  
BA explicitly focuses on reducing rumination using functional analysis and self-
monitoring to help patients identify when they are ruminating, to identify triggers for 
rumination and to find alternative strategies with which to replace rumination[236]. 
RFCBT uses the same function-analytical approach but also incorporates a novel 
element that focuses on shifting thinking style to increase concrete, process-focused 
thinking styles and reduce abstract and judgemental thinking[237]. MCBT could 
interfere with ruminative thoughts by teaching patients to shift their attention to the 
present moment and to relate to their thoughts in a more detached and less 
judgemental way[238]. Beneficial effects of these treatment approaches have been 
demonstrated in patients with depression (e.g. [237, 239-242]) although evidence of 
their acceptability and efficacy in treating depression in CHD populations is currently 
lacking. 
1.3 Summary 
Depression is common in people with LTCs including CHD and is associated with 
worse physical outcomes. A large body of work is highly suggestive of a link between 
40 
 
 
depression and CHD and a variety of plausible mechanisms have been suggested. 
However the nature of the causal association between depression and CHD is not fully 
understood, and the mechanism underpinning the association between depression 
and poor medical outcomes remains unclear.  
Depression is under-recognised and undertreated in people with CHD, and the 
effectiveness of antidepressant drugs and psychological interventions appear limited. 
Furthermore trials have failed to demonstrate convincingly that improving depression 
also improves physical health outcomes, meaning proof that depression causes poor 
physical health outcomes among people with CHD is currently lacking.  
Cognitive processes could be linked with depression and reduced quality of life in 
people with CHD. The tendency to dwell persistently on negative thoughts (i.e. 
perseverative negative thinking) could act to maintain and prolong the effect of 
stressors in the context of chronic physical illness. Perseverative negative thinking 
might therefore explain the observed association between depression and poor 
medical outcomes. In otherwise healthy populations, perseverative negative thinking 
has been strongly associated with the onset and maintenance of depression in healthy 
and psychiatric populations, and also predicts adverse medical outcomes. Most 
previous prospective research investigating the association of perseverative negative 
thinking with depression has focused on physically healthy populations, however.  
Therefore, the nature of the association and the mechanisms by which 
perseverative negative thinking may impact on both mood and physical health 
outcomes in people with CHD are unclear. Better understanding the factors that 
contribute to the development of depression in people with CHD and the mechanisms 
that explain the association of depression with increased mortality and morbidity 
could (a) help predict which patients are at increased risk of developing depression 
and, as a consequence, are at increased risk of adverse medical outcomes, (b) facilitate 
personalisation of treatment based on risk of developing depression, and (c) inform 
the development of novel interventions that could target processes which might 
improve both physical and mental health outcomes.   
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1.4 Aims 
This thesis seeks to (a) clarify the association of perseverative negative thinking 
with depression, anxiety and health-related quality of life in people with CHD, and (b) 
explore factors that may mediate the association of perseverative negative thinking 
with subsequent depression, anxiety and health-related quality of life in people with 
CHD.  
The main aims of this thesis will be addressed by:  
i. Conducting a systematic review to identify, synthesise and evaluate existing 
empirical evidence of the prospective association of perseverative negative 
thinking with depression, anxiety and emotional distress in people with 
LTCs.  
ii. Conducting an observational prospective cohort study to investigate 
whether rumination and worry are prospectively associated with 
depression, anxiety and worse health-related quality of life over 6 months 
in people with recent CHD. In addition, the study will explore potential 
mechanisms by which perseverative negative thinking may impact on mood 
and worse physical health outcomes in people with CHD.  
1.5 Thesis structure 
This thesis is presented in chapters to address various aspects of the aims 
described above. This section outlines the content of each of the remaining chapters. 
Chapter 2: Systematic review 
Chapter 2 presents a systematic review and narrative synthesis of studies 
investigating the prospective association of perseverative negative thinking with 
depression, anxiety and emotional distress in people with LTCs. Since the majority of 
previous prospective research in this area has focused on physically healthy 
individuals, the aim of this review was to evaluate and synthesise the existing empirical 
evidence in people with LTCs. The characteristics, quality and findings of existing 
studies are appraised and summarised, and implications for future work are drawn 
out. 
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Chapter 3: Methods 
 Chapter 3 outlines the methods of a prospective observational cohort study 
that forms the basis of the results chapters that follow. Recruitment, inclusion and 
exclusion criteria, selection of questionnaires and measures, procedural methods, data 
collection and data management are described. Generic statistical methods are 
described in this chapter, although details of methods specific to addressing the aims 
of each chapter are presented in the relevant chapter. Specific hypotheses are set out 
at the start of each of the relevant results chapters. 
Chapter 4: Results Part I (Prospective association of rumination and worry with 
depression, anxiety and quality of life) 
 Chapter 4 presents the results of a series of multiple regression analyses to 
investigate whether baseline rumination and worry predict 6 month depression, 
anxiety and quality of life in people with ACS. Additionally, prospective associations 
were also explored using longitudinal multilevel (repeated measures) models to take 
account of within-participant correlations due to repeated measurements, and the 
findings of these models are also presented in this chapter.  
Chapter 5: Results Part II (Mechanisms of the association between rumination and 
worry with depression and quality of life) 
Chapter 5 presents the results of a series of mediation analyses to explore 
whether low social support, impaired problem solving, reduced instrumental 
behaviours and negative cognitive biases may represent mechanisms that explain the 
associations of perseverative negative thinking with depression and quality of life 
found in the preceding chapter.  A causal steps approach to mediation was used 
combined with a bootstrapping test of indirect effects. Predictors of depression and 
quality of life, and possible mediators the association between rumination and worry 
with depression and quality of life, are identified. 
Chapter 6: General discussion 
 Chapter 6 is divided into sections providing a brief re-statement of background 
and aims, summary of findings, discussion of strengths and limitations, and an 
integrated discussion of the findings from the thesis as a whole with reference to 
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existing literature. Implications of the findings are considered and suggestions for 
future work are made. 
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Chapter 2 The association of perseverative negative thinking with 
depression, anxiety and emotional distress in people with LTCs: A 
systematic review 
2.1 Chapter outline 
The primary aim of this systematic review was to identify, synthesise and 
evaluate existing empirical evidence of the prospective association of perseverative 
negative thinking with depression, anxiety and emotional distress in people with long 
term conditions (LTCs).  
This chapter presents: 
i. A description of the methods used to identify, select, evaluate and 
synthesise relevant studies. 
ii. Detailed findings and a summary of results. 
iii. Discussion of the methods and findings with reference to strengths, 
weaknesses and comparison with existing literature.  
2.2 Methods 
This review was conducted following the guidance of the University of York 
Centre for Reviews and Dissemination[243] and is reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement[244]. 
The review protocol was not registered with a database such as PROSPERO as the 
review did not fit within the scope of these registers, however the protocol was 
published[245] in the interests of transparency. 
2.2.1 Inclusion/exclusion criteria 
Studies were included if they investigated among people with LTCs the 
prospective association between perseverative negative thinking, on the one hand, 
and depression, anxiety and emotional distress, on the other. To clarify the temporal 
relationship, studies examining the prospective association between perseverative 
negative thinking and subsequent depression, anxiety or emotional distress, or the 
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reverse association, i.e. depression, anxiety or emotional distress predicting 
perseverative negative thinking, were included. 
Perseverative negative thinking was defined as repetitive, prolonged and 
recurrent negative thoughts about oneself and one’s concerns (including worry, 
rumination, perseverative cognition, counterfactual thinking, mind wandering, post-
event processing, habitual negative self-thinking and catastrophizing [113, 246, 247]). 
Studies with measures of constructive repetitive thought such as reflection, rehearsal, 
planning, and problem solving were not included. The terms depression, anxiety and 
emotional distress were used to refer to symptoms of mood disorders and negative 
emotional states including negative mood. We defined LTCs broadly, as conditions 
which cannot be cured but which can be managed with treatment[2].  
Studies meeting the following criteria were included: 
i. Population Studies in adults (>16 years) with any LTC.  
ii. Interventions & Comparators Use of an intervention and comparator was 
not a requirement.  
iii. Outcomes Studies including a standardised measure of perseverative 
negative thinking and a standardised measure of depression, anxiety or 
emotional distress (including negative mood and negative affect). Data 
were extracted on physical outcomes as well as depression, anxiety or 
emotional distress, where available. 
iv. Study design Observational, prospective studies, and experimental or 
quasi-experimental studies. It was anticipated that findings from such 
studies would clarify temporal relationships between perseverative 
negative thinking and depression, anxiety or emotional distress, enabling 
tentative causal inferences to be drawn. Cross-sectional and other study 
designs that would not allow such inferences were excluded. 
v. Other limiters No date or language restrictions were applied. Studies 
published as papers in peer reviewed journals, conference proceedings and 
dissertations were included.  
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2.2.2 Information sources and search strategy 
MEDLINE, EMBASE, PsycINFO, and CINAHL databases were searched on 4th 
June 2013, and searches repeated on 19th June 2015 and 7th Sept 2016. Search terms 
included subject headings and free text words relevant to: (1) depression, anxiety, 
emotional and psychological distress, (2) perseverative negative thinking, and (3) 
prospective study design (see Appendix 1 for search strategy). As there is no 
comprehensive and definitive list of LTCs available, studies of people with LTCs were 
not searched using electronic search terms; suitable studies of people with LTCs were 
identified by hand-searching papers meeting criteria 1-3 above, to maximise sensitivity 
of our search strategy. Backward and forward citation searches of eligible studies were 
undertaken, and authors of included studies were contacted to identify any additional 
unpublished studies.  
2.2.3 Study selection 
Eligibility screening of titles and abstracts, and then of full text records, was 
completed independently by two reviewers. Agreement between reviewers was 80% 
at title/abstract screening stage, and 94% at full text screening. Disagreements were 
resolved by discussion, with the involvement of a third reviewer where agreement 
could not be reached. Findings from single, independent studies presented in multiple 
reports/publications were presented only once, to avoid double counting studies. 
2.2.4 Data extraction 
Data from included studies was extracted independently by two reviewers and 
included characteristics of the study (design, participants, measures, timing of 
assessments, physical health/medical outcomes included, statistical methods) and the 
study findings (covariates controlled, strength of association). Agreement between 
reviewers for the primary outcome of bivariate associations was 93%, with 
disagreements resolved by discussion. Authors were contacted for further data in 
cases where suitable measures were taken but outcomes of interest were not 
presented in the published papers. 
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2.2.5 Risk of bias 
Risk of bias within each study was independently evaluated by two reviewers 
using the Effective Public Health Practice Project (EPHPP) Quality Assessment 
Tool[248]. Ratings were made for six components (selection bias, study design, 
confounders, blinding, data collection methods, and withdrawals). Each component 
was rated strong, moderate or weak, and additionally these ratings were combined 
into a global quality score, such that globally strong studies had at least 4 strong and 
no weak ratings, moderate studies had 1 weak rating, and weak studies had more than 
1 weak rating.  
 Minor adaptions to the confounders and blinding components of the EPHPP 
tool were necessary due to the design of the included studies. First, the confounders 
component is intended to evaluate whether there were important differences 
between study groups prior to an intervention. However, as there were no group 
comparisons in the included studies (or data related to group comparisons was not 
extracted because it was not relevant) we evaluated ‘Were any relevant confounders 
controlled for, in the design of the study or in the analysis?’. Relevant confounders 
were defined as age, sex and baseline depression as these are all known to be 
associated with depression. Studies were rated strong where all three of these 
confounders were controlled for, moderate where some of these confounders were 
controlled for, and weak where no confounders (or others not listed) were controlled 
for. Second, the blinding component is intended to evaluate whether outcome 
assessors were aware of the intervention or exposure status of participants. However, 
as participants were not allocated to groups or conditions in the included studies (or if 
they were, data relating to groups or conditions was not extracted because it was not 
relevant) the blinding component evaluated: (a) ‘was the researcher exposed to 
information about the participant that could lead to bias?’ For example, was the 
researcher aware of participants’ previous responses when administering 
questionnaires, or did researchers have access to participant data from previous or 
other assessments when scoring questionnaires, and (b) ‘was the participant aware of 
the research question?’. 
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 Agreement between reviewers for global quality ratings was 73%, with 
disagreements resolved by discussion. 
 
2.2.6 Data synthesis 
Characteristics and findings of included studies are summarised in tables. 
Findings are  narratively synthesized (informed by the guidelines of the ESRC methods 
programme[249] where possible) based on grouping studies according to: i) type of 
perseverative negative thinking measured, ii) type of psychological outcome measured 
(i.e. depression, anxiety or emotional distress), iii) timing of follow-up (6 months or less 
versus more than 6 months), iv) type of  LTC, and v) type of analysis conducted 
(bivariate versus multivariable). 
2.3 Results 
2.3.1 Study selection 
Details of study selection are shown in Figure 2.1. Thirty eligible studies were 
included in the review [182, 183, 250-279]. Authors of a further 46 potentially eligible 
studies were contacted for additional data; authors of 15 studies were unable to 
provide additional data, and authors of 31 did not respond. It was not possible to 
contact authors of a further 2 studies for additional information and these studies 
were therefore excluded. 
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Figure 2.1: PRISMA flowchart 
 
 
 
 
2.3.2 Study characteristics 
There were 26 observational cohort studies, 3 prospective evaluations of an 
intervention, and 1 randomised controlled trial. Characteristics of all included studies 
are given in Table 2.1. 
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2.3.2.1 Samples  
Sample sizes ranged between n=22 to n=560 in relevant prospective analyses 
(median n=99). Mean age ranged between 24.3 to 70.1 years, with subjects ranging 
from 0% to 100% female.  
There were 5 studies in people with vascular disease [182, 183, 251, 253, 270, 
273]), 4 in rheumatoid arthritis[260, 266-268], 10 in cancer[250, 252, 254, 255, 263, 
264, 271, 272, 275, 278], 2 in individuals experiencing infertility[261, 262], 2 in 
muscular dystrophy or cerebral palsy[258, 265], and 7 in chronic pain-related 
conditions[257, 259, 269, 274, 276, 277, 279].  
2.3.2.2 Measures  
Included studies measured five types of perseverative negative thinking 
(rumination, catastrophizing, worry, anxious pre-occupation and preoccupation with 
death) using a total of 15 different measures. Six types of psychological outcome were 
identified (depression, anxiety, psychological distress, psychological functioning, 
negative affect and negative mood) measured using 15 different scales.  
2.3.2.3 Timing of assessments  
Duration of LTC at baseline assessment was up to 1 month in 6 studies, up to 1 
year in 3 studies, more than one year in 12 studies (maximum 16.5 years), and unclear 
in 9 studies. Median duration of LTC was 12.6 months. In 16 studies there was one 
follow-up assessment, in 12 studies there were between 2 and 5 follow-ups, and in 2 
studies follow-ups took the form of daily diary measures completed over 14 – 30 days. 
The median number of follow-up assessments was 1. Follow-up assessments took 
place within 1 month (8 studies), between 1 and 6 months (17 studies), 6 months to 1 
year (11 studies), and 1 to 2 years (5 studies). The median time to follow-up was 6 
months. 
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Table 2.1: Characteristics of included studies 
ID Authors and date Condition  
 
Sample size 
Recruited 
(Analysed)a 
Mean 
age 
(years)b 
Males 
(%)b 
Sample Assessments PNT measure Anxiety, depression or 
distress measure 
1 Denton et al. (2012, 
2011) 
Acute coronary 
syndrome 
457 (387) 61.1 58.6 Eligible patients on coronary care 
and cardiac step-down units of 
three hospitals; USA 
T1=within 1 week of index 
event, T2=3 months post-
ACS 
Ruminative responses 
scale of the Response 
Styles Questionnaire @ T1 
and T2 
Beck Depression Inventory 
@ T1 and T2 
2 Garnefski & Kraaij 
(2010) 
Myocardial 
infarction 
160 (88) 56.0 80.7 Patients aged <70 years from 
cardiology outpatient clinic 
database who had received PCI in 
the previous 3-12 months; 
Netherlands 
T1=within 3-12 months 
following PCI, T2=12 
months later 
Rumination and 
catastrophizing subscales 
of the Cognitive Emotion 
Regulation Questionnaire 
@ T1 
Hospital Anxiety & 
Depression Scale @ T1 and 
T2 (depression subscale) 
3 Vogele et al. (2012) Myocardial 
infarction 
36 (24c) 57.6 89 Patients with acute first MI 
contacted in hospital; Germany 
T1=5-15 days post-MI, 
T2=6-8 weeks post-MI, 
T3=6 months post-MI 
Rumination subscale of the 
Trierer Skalen zur 
Krankheitbewaltigung 
(Coping questionnaire) @ 
T1 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1, T2, and T3 
4 Baker (2014) Coronary heart 
disease 
101 (85) 66 – 75 
modal 
range 
76.2 Inpatients or outpatients 
presenting for cardiac care at 
hospital; UK 
T1=after attendance at 
inpatient or outpatient 
cardiology service, T2=3 
months later 
Ruminative Responses 
Scale  of the Response 
Styles Questionnaire @ T1 
and T2 
Patient Health 
Questionnaire-9 
(depression) @ T1 and T2 
5 Xiao et al. (2011) Hypertension 650 (560) 55.4 51.8 Randomly selected  from 1200 
hypertension patients at one 
hospital; China 
T1=following at least 1 
year of hypertension, T2=6 
months later 
Rumination and 
catastrophizing subscales 
of the Cognitive Emotion 
Regulation Questionnaire 
@ T1 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1 and T2 
6 Keefe et al. (1989) Rheumatoid 
arthritis 
Unclear 
(223) 
52.7 25 Patients identified by 
rheumatology practices; USA 
T1=within 7 years of 
diagnosis, T2=6 months 
later 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1 and 
T2 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1 and T2 
Table continues on following page… 
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ID Authors and date Condition  
 
Sample size 
Recruited 
(Analysed)a 
Mean 
age 
(years)b 
Males 
(%)b 
Sample Assessments PNT measure Anxiety, depression or 
distress measure 
7 Sturgeon & Zautra 
(2013) 
Rheumatoid 
arthritis 
231 (93% 
completion 
of diaries) 
55.0 30.4 Patients invited to participate at 
health fairs, Arthritis Foundation 
members, local physicians 
offices, Veterans Administration 
Hospital; USA 
Daily diary for 30 days 
(once per day), starting an 
average of 13.6 years post-
diagnosis 
2 items from the 
catastrophizing subscale of 
the Coping Strategies 
Questionnaire @ daily 
Positive and Negative 
Affect Schedule; 
depressive symptoms @ 
daily  
8 Schiaffano & 
Revenson (1995) 
Rheumatoid 
arthritis 
101 (64) NR 20 Eligible patients from hospital  
outpatient clinic, or from 
rheumatology practices; USA 
T1=within 2 years of 
diagnosis, T2=18 months 
later 
5-point Likert scale of 
rumination @ T2 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1 and T2 
9 Sharpe et al. (2001) Rheumatoid 
arthritis 
53 (22) 55.1 
 
30 Consecutive patients at 
rheumatology clinics of three 
general hospitals, enrolled into 
RCT; UK 
T1=within 2 years of 
diagnosis,T2=3 months , 
T3=6 months, T4=9 
months, T5=15 months, 
T6=21 months later 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1, T2, 
T3, T4, T5 and T6 
Hospital Anxiety & 
Depression Scale @ T1, T2, 
T3, T4, T5 and T6 
10 Wang et al. (2014) Breast cancer 509 (504) 48.3 0 Eligible women who had 
undergone surgery for breast 
cancer at two hospitals; China 
T1=approx. 1 week post-
diagnosis (5-7 days post-
surgery), T2=1 month later 
Rumination and 
catastrophizing subscales 
of the Cognitive Emotion 
Regulation Questionnaire 
@ T1 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1 and T2 
11 Andreu et al. (2012) Breast cancer 174d (102) 50.5 0 Consecutive patients attending 
pre-operative visit at department 
of surgery at oncology clinic; 
Spain 
T1=pre-surgery (at 
preliminary diagnosis), 
T2=2-7 days post-surgery, 
T3=at definitive diagnosis, 
T4=at chemotherapy 
Anxious preoccupation 
subscale of the Mental 
Adjustment to Cancer 
Scale @ T4 
Brief Symptom Inventory 
18 (distress)  @ T1, T2, T3 
and T4 
12 Ferrero et al. (1994) Breast cancer 68 (66) 53.0 0 Consecutive newly diagnosed 
patients attending hospital 
oncology clinic; Spain 
T1=after diagnosis 
(approx. 1 month post-
surgery), T2=4 months 
post-surgery, T3=7 months 
post-surgery   
Anxious preoccupation 
subscale of the Mental 
Adjustment to Cancer 
Scale @ T1, T2 and T3 
Breast Cancer Quality of 
Life Questionnaire 
(psychological distress 
subscale) @ T1, T2 and T3 
Table continues on following page… 
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ID Authors and date Condition  
 
Sample size 
Recruited 
(Analysed)a 
Mean 
age 
(years)b 
Males 
(%)b 
Sample Assessments PNT measure Anxiety, depression or 
distress measure 
13 Groarke et al. (2013) Breast cancer 355 (221) 24.3 0 Consecutive eligible patients 
attending a breast symptomatic 
unit at a University-affiliated 
hospital; Ireland 
T1=within 1 week of 
diagnosis, T2=4 months 
later 
Anxious preoccupation 
subscale of the Mental 
Adjustment to Cancer 
Scale @ T1 and T2 
Hospital Anxiety & 
Depression Scale; Positive 
and Negative Affect 
Schedule @ T1 and T2 
14 Lam et al. (2013) Advanced breast 
cancer 
228 (192) 53.5 0 Hospital outpatients identified 
from clinic lists of 6 
breast/oncology clinics; China 
T1=post- diagnosis 
(awaiting or receiving 
initial chemotherapy), 
T2=6 weeks, T3=3 months, 
T4=6 months, T5=12 
months later 
Cancer-related Rumination 
Scale @T1  
Hospital Anxiety & 
Depression Scale @ T1, T2 
and T5 
15 Thomsen et al. 
(2013) 
Colon cancer 67 (54) 63.5 54 Patients referred for 
chemotherapy at hospital 
oncology department; Denmark 
T1=1-7 months post-
diagnosis (mean 72 days), 
T2=8 months later 
Rumination-Reflection 
Questionnaire @ T1 and 
T2 
Beck Depression Inventory 
@ T1 and T2 
16 Couper et al. (2010) Early and advanced  
prostate cancer 
367 (265) 66.2 
early; 
70.1 
advanced 
100 Consecutive patients recruited by 
their oncologist/urologist from 
public hospitals and practices; 
Australia 
T1=after diagnosis, at 
beginning treatment 
(early) or after patients 
informed disease 
metastatic (advanced), 
T2=12 months later 
Anxious preoccupation 
subscale of the Mental 
Adjustment to Cancer 
Scale @ T1 and T2 
Brief Symptom Inventory 
53 (anxiety and 
depression) @ T1 and T2 
17 Lehto & Cimprich 
(2009) 
Suspected lung 
cancer 
52 (42) 64.0 64.3 Patients undergoing surgical 
evaluation for lung cancer at a 
comprehensive cancer center; 
USA 
T1=at diagnosis (14 days 
prior to surgery), T2=5-6 
weeks later 
Penn State Worry 
Questionnaire @ T1 and 
T2 
State-Trait Anxiety 
Inventory @ T1 and T2 
18 Lampic et al. (1994) Mixed cancer 197 (121) 61.0 37 Consecutive patients scheduled 
for hospital appointment at 
oncology clinic; Sweden  
T1=at clinic appointment 
(median 6 yrs from 
diagnosis), T2=few days 
after appointment, T3=3 
weeks after appointment 
Anxious preoccupation 
subscale of the Mental 
Adjustment to Cancer 
Scale @ T2; Cancer-related 
worry @ T1, T2, and T3 
Visual analogue ratings of 
anxiety @ T1, T2 and T3 
Table continues on following page… 
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ID Authors and date Condition  
 
Sample size 
Recruited 
(Analysed)a 
Mean 
age 
(years)b 
Males 
(%)b 
Sample Assessments PNT measure Anxiety, depression or 
distress measure 
19 Vollmer et al. (2011) Haematologic 
malignancy 
102e (45) 46.7 51.6 Consecutively enrolled patients 
with haematologic malignancies 
identified from weekly lists of 
inpatients; Germany 
T1=within 7 days post-
admission, T2=at least 4 
weeks later 
Preoccupation with death 
subscale of the Subjective 
Assessment of the Course 
of Disease & Death @ T1 
and T2 
Hospital Anxiety & 
Depression Scale @ T1 and 
T2 
20 Kraaij et al. (2008) Definitive infertility 169 (99) 41.0 38 
 
Individuals with definitive 
infertility responding to 
announcements in local media 
and online self-help groups; 
Netherlands 
T1=average 5 years post-
diagnosis, T2=2 years later 
Rumination and 
catastrophizing subscales 
of the Cognitive Emotion 
Regulation Questionnaire 
@ T1 and T2 
Depression subscale of the 
Symptom Check List @ T1 
and T2 
21 Kraaij et al. (2010) Infertility 313 (139) 35.0 22 Patients who had attended an 
infertility clinic for treatment 
within the previous 4 months; 
Netherlands 
T1=within 4 months of 
most recent treatment, 
T2=9 months later 
Rumination and 
catastrophizing subscales 
of the Cognitive Emotion 
Regulation Questionnaire 
@ T1 
Hospital Anxiety & 
Depression Scale @ T1 and 
T2 
22 Nieto et al. (2012) Muscular dystrophy 395f (107) 50.2 43 Participants identified from 
National Registry of Myotonic 
Dystrophy & 
Facioscapulohumeral Muscular 
Dystrophy Patients & Family 
Members, and from 
neuromuscular disease clinic; 
USA 
T1=average 16.5 years 
post-diagnosis, T2=24 
months later 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1; Pain 
Catastrophizing Scale @ T2  
5 item SF-36 mental health 
scale (psychological 
functioning) @ T1 and T2 
23 Jensen et al. (2006) Cerebral palsy 48 (48) 40.1 50 Patients who participated in a 
previous cross-sectional study; 
USA 
T1=after previous study 
(pain duration ≥3 months) 
, T2=6 months later 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1 and 
T2 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1 and T2 
Table continues on following page… 
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ID Authors and date Condition  
 
Sample size 
Recruited 
(Analysed)a 
Mean 
age 
(years)b 
Males 
(%)b 
Sample Assessments PNT measure Anxiety, depression or 
distress measure 
24 Turner et al. (2004) Tempromandibular 
disorder 
110 (100) 38.8 13 Patients evaluated at a TMD 
clinic and enrolled in a RCT; USA 
T1= prior to enrolment in 
RCT, where facial pain ≥3 
months, T2= daily diary for 
next 14 days (3 times per 
day)  
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1; brief 
daily diary measure of 
catastrophizing/ruminatio
n (3 Likert-style items) @ 
T2 
Beck Depression Inventory 
@ T1; brief daily diary 
measure of negative mood 
(‘unhappy’, ‘annoyed’, 
‘anxious’) @ T2 
25 Hanley et al. (2004), 
Jensen et al. (2002) 
Phantom limb pain 89 (70g) 44.7 73 Consecutive admissions at 
Department of Orthopaedic 
Surgery for lower limb 
amputation invited to participate 
in RCT; USA 
T1=1 month post-
amputation, T2=6 months 
post-amputation, T3=12 
months post-amputation, 
T4=24 months post-
amputation 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1, T2, 
T3 and T4 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1, T2, T3 and T4 
26 Jensen et al. (2001) Chronic pain (mixed 
primary sites) 
197 (141) 44.7 49 Patients enrolled in 
multidisciplinary pain 
management program; USA 
T1=pre-treatment (mean 
pain duration 3.2 years), 
T2=post-treatment 
(approx. 3 weeks later), 
T3=6 months later, T4=12 
months later  
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1, T2, 
T3 and T4 
Centre for Epidemiologic 
Studies Depression Scale 
@ T1, T2, T3 and T4 
27 Sparkes et al. (2015) Mixed pain 
conditions 
75 (56) 47.4 44.6 Consecutive patients assessed by 
a multidisciplinary team at a 
secondary care centre and 
referred for a spinal cord 
stimulation (SCS) trial; UK 
T1= 1 week before SCS 
trial (mean pain duration 
8.2 years), T2=6 months 
post-SCS, T3=12 months 
post-SCS 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1, T2, 
T3 
Hospital Anxiety & 
Depression Scale @ T1, T2, 
T3 
28 Mehlsen et al. 
(2015) 
Chronic pain  87 (73) 52 15 Patients Invited to attend a pain 
self-management course by local 
health care and social work 
professionals (pain duration >3 
months); Denmark 
T1= 2-14 days before 
course; T2=1-3 weeks after 
course, T3=5-6 months 
after course  
Pain Catastrophizing Scale 
@ T1, T2, T3 
Depression and anxiety 
subscales of the Common 
Mental Disorders 
Questionnaire @ T1, T2, 
T3 
Table continues on following page… 
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ID Authors and date Condition  
 
Sample size 
Recruited 
(Analysed)a 
Mean 
age 
(years)b 
Males 
(%)b 
Sample Assessments PNT measure Anxiety, depression or 
distress measure 
29 Bourgault et al. 
(2015) 
Fibromyalgia 
syndrome 
58 (37) 50 7.1 Patients  recruited via newspaper 
adverts for a fibromyalgia self-
management intervention (mean 
duration of pain >10 years); 
Canada 
T1=prior to intervention, 
T2=post-intervention (~11 
weeks), T3=3 months, 
T4=6 months, T5=12 
months later 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1, T2, 
T3, T4, T5 
Beck Depression Inventory 
@ T1, T2, T3, T4, T5 
30 Rzewuska et al. 
(2015) 
Musculo- 
skeletal pain 
502 (502h) 64.8 38.6 Consecutive older adults 
presenting with musculoskeletal 
pain in five general practices; UK 
T1=following GP 
consultation, T2=3 
months, T3=6 months, 
T4=12 months 
Catastrophizing subscale 
of the Coping Strategies 
Questionnaire @ T1, T2, 
T3, T4 
Hospital Anxiety & 
Depression Scale @ T1, T2, 
T3, T4 
aWhere more than one follow-up, ‘(Analysed)’ refers to N included in appropriate analyses at final time point. 
bDemographics (age and sex) of whole sample at baseline. 
cRefers to Pearsons correlations, for partial correlations n=17. 
d126 met inclusion criteria. 
eDoes not include 33 controls who participated at T1 but were not required to participate at T2. 
f279 met inclusion criteria. 
g61 at T2. 
h392 completers at T4, but all cases who completed at least one assessment were included in analyses. 
Abbreviations: PNT = perseverative negative thinking, PCI = percutaneous coronary intervention, MI=myocardial infarction, T1 = time 1 (baseline), T2 = time 2 
(follow-up), T3 = time 3 (follow-up), T4 = time 4 (follow-up), T5 = time 5 (follow-up), T6 = time 6 (follow-up). 
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2.3.3 Perseverative negative thinking and negative psychological outcomes 
Findings from all included studies are summarised in Table 2.2.  
2.3.3.1 Bivariate analyses  
Prospective, bivariate correlations between perseverative negative thinking 
and subsequent depression, anxiety or emotional distress were reported in 20 of the 
30 studies identified.  The most commonly studied associations were of rumination (7 
studies) and catastrophizing (9 studies) with depression. Eighteen studies found a 
significant association between perseverative negative thinking at one assessment 
time with depression, anxiety or emotional distress at a subsequent time. One of these 
studies[254] found mixed evidence of an association (3 out of 4 correlations 
significant). The 2 studies that did not find a significant association had particularly low 
sample sizes at follow-up (n=24[270] and n=22[267]). Bivariate effect sizes ranged 
between r=.23 and r=.73, representing small to moderate effects. 
The significant associations did not appear to be influenced by type/measure of 
perseverative negative thinking, type/measure of depression, anxiety or emotional 
distress, or whether follow-ups took place at less than or greater than 6 months 
(median time to follow-up) after baseline. 
2.3.3.1.1 Reverse-associations  
7 of the 30 identified studies reported bivariate correlations between baseline 
depression, anxiety or emotional distress with subsequent perseverative negative 
thinking, and 6 of these found a significant positive association.  
2.3.3.2 Multivariable analyses  
Multivariable analyses of the association between perseverative negative 
thinking with subsequent depression, anxiety or emotional distress were available for 
25 of the 30 included studies and included partial correlations (4 studies), multiple 
regression (19 studies), and latent growth models combined with logistic regression to 
predict trajectories of depression and anxiety (2 studies). Consistent with bivariate 
analyses the most commonly studied associations were of rumination with depression 
(8 studies) and catastrophizing with depression (10 studies). 
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Age, sex and baseline depression (or anxiety, as appropriate) were the variables 
most commonly controlled for (15, 14 and 17 studies, respectively). Only 8 studies 
controlled for all three of these confounders (and 2 studies in entirely female samples 
controlled for both age and baseline depression). A variety of other demographic, 
disease, physical and psychosocial factors were also controlled for.  
Ten studies found significant positive associations between measures of 
perseverative negative thinking and subsequent depression, anxiety or emotional 
distress, and a further 5 showed mixed results, i.e. some associations significant but 
some not. Five of these studies controlled for age, sex and baseline depression, and 3 
studies controlled for baseline depression alone. One study found a negative 
association, i.e. where high catastrophization at baseline predicted greater 
improvement in depression over the subsequent period. 
Significant multivariable associations were found more often in studies that 
measured the effect of catastrophizing on subsequent depression, anxiety or 
emotional distress compared to studies that measured the effect of rumination. 
However, associations did not appear to be influenced by the measure of depression, 
anxiety or emotional distress used. In addition, associations did not vary according to 
whether follow-ups took place before or after the median time to follow-up (6 
months), although significant effects were found less often in studies with particularly 
short (up to 1 month) and long (>1 year) follow-ups and most frequently among 
studies with follow-up periods between 1 month and 1 year (although there were 
fewer studies with particularly short or long follow-ups). 
A variety of effect sizes and coefficients were reported. Partial correlations 
ranged from r=.23 to r=.35. For multiple regression analyses, the contribution of 
perseverative negative thinking to subsequent depression, anxiety or emotional 
distress was indicated using ΔR2 (range=.01 to .083), β (range=.21 to .53), or B 
(range=.0865 to .62). Odds ratios (range=1.15 to 8.75) were given for logistic 
regression analyses. In studies that controlled for baseline depression, anxiety or 
emotional distress, the range of partial correlations, ΔR2 and odds ratios were 
unchanged, however the range of B was higher (range=.61 to .62; but based on only 2 
observations) and β was available for only one study with a value of .21.  
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2.3.3.2.1 Reverse-associations 
 Only 2 studies reported multivariable analyses (multiple regression in both 
cases) of the association of depression, anxiety or emotional distress with subsequent 
perseverative negative thinking, and neither found a significant association.  
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Table 2.2: Findings of included studies 
ID Authors and date 
 
Bivariate findings Multivariable findings Variables controlled for 
1 Denton et al. (2012; 
2011) 
T1 rumination correlates with T2 depression (r=.49, p<.001); 
T1 depression correlates with T2 rumination (r=.52, p<.001) 
T1 rumination predicts T2 depression independently (ΔR2=.01, ΔF=9.21, p=.003) 
and in interaction with poor dyadic adjustment (ΔR2=.01, ΔF=2.67, p=.03) 
In patients depressed at baseline T1 rumination independently predicts T2 
depression (ΔR2 =.03, ΔF=6.65, p=0.01) 
In patients non-depressed at baseline T1 rumination does not independently 
predict T2 depression (ΔR2=.002, ΔF=.80, p=.37), but T1 rumination predicts T2 
depression in interaction with poor dyadic adjustment (ΔR2=.06, ΔF=5.31, p<0.001) 
Age, sex, partner, years of 
schooling, work status, ethnicity, 
baseline depression, Charlson 
comorbidity index, cardiac disease 
severity 
2 Garnefski & Kraaij 
(2010) 
T1 rumination correlates with T2 depression (r=.43, p<.001); 
T1 catastrophizing correlates with T2 depression (r=.45, 
p<.001) 
T1 rumination/catastrophizing predicts T2 depression (β=.35, p<.001) Sex, age, physical limitations 
3 Vogele et al. (2012) T1 rumination does not correlate with depression at T2 
(r=.01, ns) or T3 (r=.14, ns) 
T1 rumination does not correlate with depression at T2 (r=.10, ns)  or T3 (r=.24, ns) Baseline depression 
4 Baker (2014) T1 rumination correlates with T2 depression (r=.73, p=.01); T1 
depression correlates with T2 rumination (r=.70, p=.01) 
T1 rumination predicts T2 depression (β=.46, B=.202, SE=.043, t=4.705, p<.001, 
R2=.083) 
Baseline depression, cardiac quality 
of life, age, sex, body mass index, 
social support 
5 Xiao et al. (2011) Greater rumination at T1 correlates with greater depression 
at T2 (r=.38, p<.001); greater catastrophizing at T1 correlates 
with greater depression at T2 (r=.37, p<.001) 
Higher T1 rumination (B=.62, t=0.18, p<.001) and T1 catastrophizing (B=.61, t=.18, 
p<.001) predicts increases in T2 depressive symptoms  
Sex, baseline depression, smoking, 
alcohol use, coffee consumption 
6 Keefe et al. (1989) T1 catastrophizing correlates with T2 depression (r=.62, 
p<.01) 
T1 catastrophizing predicts T2 depression (sr2=.043, F=20.87, p=<.001) Baseline depression, age, SES, sex, 
disability support status, duration 
of disease 
7 Sturgeon & Zautra 
(2013) 
Bivariate analyses not reported Previous day catastrophizing predicts subsequent day depressive symptoms 
(B=.0865, p<.05) but not negative affect (B=.0016, ns) 
Age, sex, neuroticism, positive 
affect (negative affect analysis only) 
8 Schiaffano & 
Revenson (1995) 
T1 depression correlates with T2 rumination (r=.30, p<.05) T1 depression does not predict T2 rumination (β=.22, ΔR2=.05, F=2.84, p<.10) Education 
9 Sharpe et al. (2001)b T1 catastrophizing does not correlate with T2 
depression(r=.18, p=.461), T6 depression (r=.03, p=.891), T2 
anxiety (r=.32, p=.177) or T6 anxiety (r=.12, p=.607) 
T1 catastrophizing does not correlate with T2 depression (r=.11, p=.671) or anxiety 
(r=.34, p=.17) 
Age, baseline depression, baseline 
anxiety 
10 Wang et al. (2014) Bivariate analyses not reported T1 rumination (β=.09, SE=0.12, ns) and catastrophizing (β=.26, SE=.15, ns) do not 
predict T2 depression 
Age, place of residence, marital 
status, years of schooling, 
employment status, disease 
severity, baseline depression 
11 Andreu et al. (2012) T4 anxious preoccupation does not correlate with T1 (-.08, 
ns), T2 (-.04, ns) or T3 (.02, ns) distress 
Multivariable analyses not reported None 
Table continues on following page… 
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ID Authors and date 
 
Bivariate findings Multivariable findings Variables controlled for 
12 Ferrero et al. (1994) T1 anxious preoccupation does not correlate with T2 distress 
(r=.21, ns) but does correlate with T3 distress (r=.40, p<.001); 
T2 anxious preoccupation correlates with T3 distress (r=.32, 
p<.01) 
T1 anxious preoccupation does not predict T2 or T3 distress (relevant regression 
statistics not reported) 
T2 anxious preoccupation predicts T3 distress (full model R2=.428, p<.001, including 
predictors MAC ‘fighting spirit’, ‘fatalism’, and ‘denial’ , and T1 psychological 
distress and physical symptoms) 
Baseline distress, physical 
symptoms 
13 Groarke et al. 
(2013)b 
T1 anxious preoccupation correlates with T2 depression 
(r=.23, p <.001) and T2 anxiety (r=.35, <.001) 
T1 anxious preoccupation does not predict T2 depression (β=.014, B=.010, 
SE(B)=.048, t=.216, ΔR2 =.000, ΔF=.046, p=.830), T2 anxiety (β=.038, B=.036, 
SE(B)=.058, t=.617,  ΔR2 =.001, ΔF=.381, p=.538) or T2 negative affect (β=.022, 
B=.041, SE(B)=.121, t=.340,  ΔR2 =.000, ΔF=.115, p=.734) 
Baseline depression/anxiety, age, 
disease severity, type of surgery 
14 Lam et al. (2013) Bivariate analyses not reported Four coping-related factors including negative cancer-related rumination 
differentiated depression (χ2(8)=132.83, p<.001, R2=.52) and anxiety 
(χ2(12)=107.00, p<.001, R2=.45) trajectories. T1 rumination greater in ‘High-
stable/high-recovering’ (OR=1.38 (95% CI=1.18-1.61), p<.001) and ‘Recovering’ (OR 
=1.15 (95% CI=1.03-1.30), p=.017) trajectories compared to low-depression 
referent group. T1 rumination greater in ‘High-stable’ (OR =1.22 (95% CI=1.06-
1.39), p=.005) and ‘Recovering’ (OR = 1.18 (95% CI=1.04-1.34), p=.012), but not 
‘Intermediate’, trajectories compared to low-anxiety referent group. 
Radiation therapy and occupational 
status (depression model only) 
15 Thomsen et al. 
(2013) 
T1 rumination correlates with T2 depression (r=.32, p<.05.); 
T1 depression correlates with T2 rumination (r=.37, p<.05.) 
T1 rumination does not predict T2 depression (β=.07, ns) Age, baseline depression 
16 Couper et al. (2010) Bivariate analyses not reported T1 anxious preoccupation does not predict T2 depression (early β=NR, ns; advanced 
β=.15, ns) 
T1 anxious preoccupation does not predict T2 anxiety in early (β=NR, ns), but does 
predict anxiety in late prostate cancer (β=.21, p<.001) 
Baseline depression, health-related 
quality of life 
17 Lehto & Cimprich 
(2009)b 
Worry at T1 correlates with state anxiety at T2 (r=.34, p=.027)  Multivariable analyses not reported None 
18 Lampic et al. (1994) T2 anxious preoccupation correlates with T3 anxiety (r=.31, 
p<.01) 
Multivariable analyses not reported None 
19 Vollmer et al. 
(2011)a 
T1 preoccupation with death correlates with T2 depression 
(r=.37, p=.013) and anxiety (r=.38, p=.012); T1 depression 
(r=.42, p=.009) and anxiety (r=.44, p=.006) correlates with T2 
preoccupation with death 
T1 preoccupation with death does not predict T2 depression (ΔR2=.004, ΔF=.301, 
p=.586) or T2 anxiety (ΔR2=.010, ΔF=.670, p=.418) 
T1 depression (ΔR2=.002, ΔF=.114, p=.738) and T1 anxiety (ΔR2<.000, ΔF=.021, 
p=.887) does not predict T2 preoccupation with death (after controlling for age, 
sex, and T1 preoccupation with death)   
Age, sex, baseline depression (or 
anxiety as appropriate) 
20 Kraaij et al. (2008) T1 rumination correlates with T2 depression (r=.29, p<.001); 
T1 catastrophizing correlates with T2 depression (r=.31, 
p<.001) 
T1 rumination does not predict T2 depressive symptoms (test statistics not 
reported) 
T1 catastrophizing predicts increased depressive symptoms at T2 (β=.26, p<.05) 
Sex, wish to have children 
21 Kraaij et al. (2010) T1 rumination / catastrophizing correlates with depression 
(r=.37, p<.001) and anxiety (r=.40, p<.001) at T2 
T1 rumination/catastrophizing predicts T2 depression (β=.26, p<.05) and T2 anxiety 
(β=.24, p<.05) 
Sex, number of children, time since 
treatment, success of treatment 
Table continues on following page… 
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ID Authors and date 
 
Bivariate findings Multivariable findings Variables controlled for 
22 Nieto et al. (2012) Change (T2-T1) in catastrophizing correlates with change in 
psychological functioning (r=.25, p<.01) 
Change (T2-T1) in catastrophizing does not predict change in psychological 
functioning (β=.18, ns) 
Pain intensity 
23 Jensen et al. (2006) Change (T2-T1) in catastrophizing correlates with change in 
depression (r=.49, p<.001) 
No relevant multivariable analyses reported None 
24 Turner et al. (2004) T1 depression correlates with T2 catastrophizing/rumination 
(r=.39, p<.0001) 
Daily catastrophizing/rumination at previous time point does not predict daily 
negative mood at subsequent time point (B=.05, ns) 
Baseline negative mood 
25 Hanley et al. (2004), 
Jensen et al. (2002) 
Bivariate analyses not reported Greater T1 catastrophizing predicts improvements in depression from T1 to T2 (β 
=.53, p<.001), from T1 to T3; β=.46, p<.01) and from T1 to T4; β=.43, p<.05) 
Pain intensity, age, sex 
26 Jensen et al. (2001) Change in catastrophizing correlates with change in 
depression (T1-T2 r=.64, p<.001; T1-T3 r=.61, p<.001; T1-T4 
r=.53, p<.001) 
Change in catastrophizing predicts change in depression (T1-T2 β =.44, p<.001; T1-
T3 β =.48, p<.001; T1-T4 β =.38, p<.001) 
Baseline pain intensity 
27 Sparkes et al. 
(2015)b 
T1 catastrophizing correlates with T2 (r=.55, p<.01) and T3 
(r=.57, p<.01) depression, and with T2 (r=.51, p<.01) and T3 
(r=.42, p<.01) anxiety  
T1 catastrophizing correlates with T2 depression (r=.30, p=.026), T3 depression 
(r=.35, p=.009), T2 anxiety (r=.31, p=.02) but not T3 anxiety (r=.21, p=.119) 
Age, gender, baseline depression 
28 Mehlsen et al. 
(2015)b 
Bivariate analyses not reported T1 catastrophizing correlated with T2 (r=.23, p=.018) and T3 (r=.24, p=.014) 
depression, and with T2 (r=.24, p=.015) and T3 (r=.31, p=.001) anxiety 
Age, gender, baseline depression 
29 Bourgault et al. 
(2015)b 
T1 catastrophizing correlates with T2 (r=.27, p=.0002) and T3 
(r=.29, p=.0002) depression 
T1 catastrophizing does not predict T2 (β=.35, p=.3562) or T3 (β=-.04, p=. 9231) 
depression 
Age, gender, baseline depression, 
treatment arm 
30 Rzewuska et al. 
(2015) 
Bivariate analyses not reported T1 catastrophizing differentiated depression- and anxiety-related trajectories over 
12 months. T1 catastrophizing greater in ‘persistent depression’ group compared to 
‘no depression’ referent group (adj. OR=3.20 (95% CI=1.53-6.66)). No significant 
difference between ‘depression symptom recovery’ group and ‘no depression’ 
referent group. 
T1 catastrophizing greater in ‘persistent anxiety’ (adj. OR=8.75 (95% CI=3.66-20.89)) 
and ‘transient anxiety’ (adj. OR=4.09 (95% CI=1.38-12.13)) groups compared to ‘no 
anxiety’ referent group. 
Age (depression model only), 
gender, baseline 
depression/anxiety, coping 
strategies, emotional support, pain-
related variables 
aBased on additional data provided by the authors. 
bBased on additional analyses provided by the authors. 
Abbreviations: SES=socioeconomic status, T1 = time 1 (baseline), T2 = time 2 (follow-up), T3 = time 3 (follow-up), T4 = time 4 (follow-up), T5 = time 5 (follow-up), 
T6 = time 6 (follow-up), NR=not reported.
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2.3.4 Long term conditions 
Studies reporting multivariable associations were grouped according to LTC 
(see Appendix 2). 
In heart disease and chronic pain the majority of studies reported significant 
associations between perseverative negative thinking and depression, anxiety or 
emotional distress. In rheumatoid arthritis and infertility there was mixed evidence of 
an association between perseverative negative thinking and depression, anxiety or 
emotional distress. The majority of studies in cancer patients did not find an 
association between perseverative negative thinking and depression, anxiety or 
emotional distress. In one small study there was no evidence of an association 
between perseverative negative thinking and depression, anxiety or emotional distress 
in patients with muscular dystrophy. 
2.3.5 Physical outcomes 
Associations between perseverative negative thinking and physical outcomes 
(such as health-related quality of life, functional limitations, pain intensity and pain 
interference) were reported in 9 studies[251, 256-260, 265, 266, 268, 269]. Four 
studies found evidence of an association, 1 study found mixed evidence, and 4 studies 
found no evidence of an association. Rumination was not related to subsequent quality 
of life or functional disability. Catastrophizing was associated with impairments in 
physical outcomes, improvements in physical outcomes, and in some studies was not 
associated with physical outcomes.  
2.3.6 Reporting bias 
23 studies reported the results of bivariate analyses, and of those multivariable 
analyses were also available for 19 studies. Significant bivariate associations were 
found in 89% of the 19 studies for which both types of analyses were available, and 
ranged between r=.23 to r=.73. In the 4 studies for which multivariable findings were 
not available, significant bivariate associations were found less frequently (75% of the 
studies) and the range of effect sizes was smaller (r=.31 to r=.49). This hints at a 
possible bias toward reporting multivariable analyses where significant or large 
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associations were most likely to be found, although this suggestion is based on only 4 
observations. 
2.3.7 Risk of bias 
Component and global risk of bias ratings for each study are presented in Table 
2.3. Based on global ratings, 23 of the included studies were moderate quality and 7 
were weak quality. Studies with overall moderate ratings were not all equivalent; 5 
studies were assigned 3 strong component ratings and these were comparatively good 
quality[183, 251, 272, 273, 276] with particular strengths in retention of participants at 
follow-up (>80%), control for appropriate confounders, and reliability/validity of data 
collection methods. Four of these 5 studies found significant associations between 
perseverative negative thinking and subsequent depression, anxiety or emotional 
distress after controlling for relevant confounders including baseline depression. 
Among the overall weak quality studies, selection bias and retention of 
participants were identified as areas of concern. In multivariable analyses associations 
between perseverative negative thinking and subsequent depression, anxiety or 
emotional distress were found less often in studies of weak methodological quality.  
In heart disease and chronic pain, studies which did not find an effect had small 
sample sizes at follow-up [270, 274], or used unusual methods to collect or analyse 
data (time series data and use of change scores[269]).  
In rheumatoid arthritis, where evidence of an association was weak, studies 
tended to be of weak quality due to low sample sizes, high numbers of withdrawals at 
follow-up, and limited reliability of measures. Similarly, there was weak evidence of an 
association in people experiencing infertility and these studies tended to be weak 
quality due to use of self-selected samples and high numbers of withdrawals.  
Studies in cancer patients, in whom evidence of an association between 
perseverative negative thinking and depression, anxiety or emotional distress was 
weak, recruited quite heterogeneous participants and, unlike other studies, focused on 
‘anxious preoccupation’ and ‘preoccupation with death’, which may have influenced 
findings. 
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Table 2.3: Risk of bias/quality assessment 
ID Authors and date 
 
Selection 
bias 
Designa Confounding Blindingb Data 
collection 
Withdrawals Global 
rating 
1 Denton et al. (2012, 2011) 2 2 1 2 1 1 2 
2 Garnefski & Kraaij (2010) 2 2 2 2 1 3 2 
3 Vogele et al. (2012) 3 2 2 2 1 3 3 
4 Baker (2014) 2 2 1 2 1 1 2 
5 Xiao et al. (2011) 1 2 2 2 1 1 2 
6 Keefe et al. (1989) 3 2 1 2 1 3 3 
7 Sturgeon & Zautra (2013) 3 2 2 2 3 3 3 
8 Schiaffano & Revenson (1995) 2 2 3 2 3 2 3 
9 Sharpe et al. (2001) 2 2 2 2 1 3 2 
10 Wang et al. (2014) 2 2 1 2 1 1 2 
11 Andreu et al. (2012) 2 2 3 2 1 1 2 
12 Ferrero et al. (1994) 2 2 2 2 1 1 2 
13 Groarke et al.(2013) 3 2 1 2 1 2 2 
14 Lam et al. (2013) 2 2 3 2 1 1 2 
15 Thomsen et al. (2013) 2 2 2 2 1 1 2 
16 Couper et al. (2010) 2 2 2 2 1 2 2 
17 Lehto & Cimprich (2009) 2 2 3 2 1 1 2 
18 Lampic et al. (1994) 2 2 3 2 1 2 2 
19 Vollmer et al. (2011) 2 2 1 2 1 3 2 
20 Kraaij et al. (2008) 3 2 2 2 1 3 3 
21 Kraaij et al. (2010) 3 2 2 2 1 3 3 
22 Nieto et al. (2012) 3 2 3 2 1 3 3 
23 Jensen et al. (2006) 2 2 3 2 1 1 2 
24 Turner et al. (2004) 3 2 2 2 1 1 2 
Table continues on following page… 
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ID Authors and date 
 
Selection 
bias 
Designa Confounding Blindingb Data 
collection 
Withdrawals Global 
rating 
25 Hanley et al. (2004), Jensen et al. (2002) 2 2 2c 2 1 2 2 
26 Jensen et al. (2001) 2 2 3 2 1 2 2 
27 Sparkes et al. (2015) 2 2 1 2 1 2 2 
28 Mehlsen et al. (2015) 2 2 1 2 1 1 2 
29 Bourgault et al. (2015) 3 2 1 2 1 2 2 
30 Rzewuska et al. (2015) 2 2 3 2 1 2 2 
1=strong, 2=moderate and 3=weak. 
aAll studies were rated as moderate quality on the study design component. There was 1 RCT[274] which would have qualified for a strong quality rating, however 
because the data extracted for this review related to changes in the whole cohort over several assessment times this study was treated as a cohort study for the 
purpose of quality assessment for this component. 
bThe blinding component was modified to be more suitable for the included study designs, although it remained difficult to assign ratings for this component and 
all studies were rated as moderate quality as it was not possible to tell if the researcher was exposed to information about the participant that could lead to bias, 
or if the participants were aware of the research question. 
cJensen et al. = 3 (no control for confounders at 6 month follow-up), and Hanley et al. = 2 (control for some confounders at 12 and 24 months follow-up). 
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2.4 Discussion 
The aim of this systematic review was to clarify among people with LTCs the 
temporal relationship between perseverative negative thinking, on the one hand, and 
depression, anxiety or emotional distress, on the other, and to determine the strength 
of the prospective associations. Findings were limited mainly to the association of 
rumination and/or catastrophizing with subsequent depression. The majority of 
uncontrolled studies showed an association between measures of perseverative 
negative thinking and subsequent depression, anxiety or emotional distress. Studies 
controlling for the effects of covariates, including depression at baseline, using 
multivariable analysis showed more mixed results, though the majority of studies (15 / 
25 studies) still supported a significant association, with effects being small in 
magnitude.  
Strongest associations were observed in studies measuring catastrophizing. The 
strength of association between perseverative negative thinking and subsequent 
depression, anxiety or emotional distress appeared to vary across studies of different 
LTCs, with greatest effects seen in people with heart disease and chronic pain. Whilst 
degrees of perseverative negative thinking and of depression, anxiety or emotional 
distress might reasonably be expected to vary across long term conditions, it isn’t 
immediately obvious why the relationship between such thinking and depression, 
anxiety or emotional distress should vary between LTCs. It is possible that some of the 
variability between LTCs could be due to the use of different perseverative negative 
thinking constructs in the different samples (e.g. studies in pain conditions tended to 
measure pain catastrophizing, studies in cancer patients tended to measure anxious 
preoccupation and preoccupation with death). The different measures are likely to 
reflect different dimensions of repetitive thinking, suggesting that some dimensions 
are important predictors of depression, anxiety or emotional distress while others are 
not. 
Contrary to expectation, one study found that greater catastrophizing at 
baseline predicted improvements in depression from baseline to 6, 12 and 24 month 
follow-ups. Baseline catastrophizing was concurrently associated with higher levels of 
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depression in this study, as might be expected. Since the authors did not control for 
the effects of depression at baseline, this counter-intuitive finding may have arisen 
because individuals with high levels of catastrophizing (and therefore also depression) 
at baseline had more potential for improvement in depression during follow-up.  
Too few studies investigated the association of baseline depression, anxiety or 
emotional distress with subsequent perseverative negative thinking to be able to draw 
firm conclusions about the reverse association. Among the studies identified, few 
included measures of physical health outcomes, and findings from those studies were 
very mixed.  
The quality of studies identified was highly variable, with no “strong” studies 
being identified. Quality was most frequently low due to studies failing to control 
adequately for potential confounding variables or due to high numbers of participants 
dropping-out, which reduced the generalisability of findings. Interestingly, we found 
significant associations least frequently in the studies rated as weak compared to 
studies rated moderate, suggesting that poor control for confounders did not increase 
the likelihood of an association being found in studies identified for this review. A 
number of studies had small sample sizes and the majority of such studies failed to find 
an association between perseverative negative thinking and subsequent depression, 
anxiety or emotional distress. There was significant variation in study quality across 
LTCs.  
This systematic review is the first to investigate the prospective association of 
perseverative negative thinking with subsequent depression, anxiety or emotional 
distress specifically in people with LTCs. The main strengths of this review are that it 
adhered to established guidelines[243, 244] to ensure rigorous methods were used. A 
comprehensive search strategy was used, combined with supplementary backward 
and forward citation searches of included papers. In addition, we are confident that 
our strategy of hand-searching records for LTCs ensured that all studies containing 
relevant samples were identified. A priori restrictions were not applied to the 
definition of LTCs. The group of conditions identified was heterogeneous and this may 
have contributed to the heterogeneity of findings although it is unclear whether 
variations in study quality across different LTC groups may explain this observation. 
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Eligibility screening, data extraction and quality assessment were undertaken by two 
reviewers to minimise bias and maximise reliability. To clarify the temporal 
relationships between perseverative negative thinking and depression, anxiety or 
emotional distress, studies investigating prospective associations in either direction 
were included. 
There are some limitations of this systematic review. First, the majority of this 
review is based on published journal articles so the conclusions are vulnerable to the 
effects of publication bias. There was some suggestion of publication bias, in that 
studies presenting multivariable findings were more likely to have larger bivariate 
associations, compared to those that did not present multivariable findings. Second, 
meta-analysis was not performed due to the multitude of measures of both 
perseverative negative thinking and depression, anxiety or emotional distress, and also 
due to heterogeneity in research methods used (including variables controlled for, and 
study quality). Rather, findings were synthesized using vote counts, which is a crude 
method of synthesis and does not take account of the effect sizes or precision of 
individual studies. Conducting a meta-analysis using only studies presenting bivariate 
analyses would have allowed synthesis of a subset of more comparable studies. 
However this would have led to an overestimate of the associations since important 
confounding variables would not have been controlled for. Third, findings were 
presented for associations of perseverative negative thinking with physical health 
outcomes, such as quality of life, where these were presented within the eligible 
papers. However, we acknowledge that our searches were not designed to identify all 
such studies, since investigating the impact on physical health outcomes was not a 
primary objective of our review. There are likely to be other studies relevant to this 
objective that were not identified by our search processes. As a consequence, no firm 
conclusion on the association of perseverative negative affect and physical health 
outcomes can be drawn from our review. 
The findings of this review are interpreted as indicating that perseverative 
negative thinking (particularly catastrophizing) is prospectively associated with a range 
of subsequent negative affective states among people with LTCs, even after controlling 
for important covariates such as depression at baseline. Evidence of perseverative 
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negative thinking predicting subsequent adverse medical outcomes in the studies 
identified was too mixed to enable firm conclusions. There was no convincing evidence 
that depression, anxiety or emotional distress predicted subsequent perseverative 
negative thinking, particularly after controlling for covariates.  
The findings are consistent with perseverative negative thinking causing 
depression, anxiety or emotional distress among people with LTCs, but current 
evidence falls short of proving causation. Perseverative negative thinking has been 
described within the context of a number of theoretical models, and these models 
offer either overt or implicit suggestions as to how perseverative negative thinking 
could lead to depression. The response styles theory[120] posits that perseverative 
negative thinking (in particular depressive rumination) could lead to depression via 
several mechanisms including focusing attention on and elaboration of negative 
thoughts, interfering with problem solving, reducing motivation to engage in 
constructive behaviours, and eroding social support. On the other hand control theory 
approaches[115, 119] emphasize managing discrepancies between actual and desired 
states. This suggests that perseverative negative thinking could lead to depression 
when it is not possible to reduce such discrepancies (either by making progress 
toward, or changing, the desired state) because the discrepancy focuses attention on 
the unresolved issue and makes it more salient. These models of perseverative 
negative thinking were not developed specifically with people with chronic physical 
illnesses in mind, and previous research has tended to focus on otherwise healthy 
individuals, and so it is unclear to what extent these models apply to people with LTCs. 
There did not appear to be any variation in findings based on whether follow-
up took place before or after the median follow-up time of 6 months. However, closer 
inspection suggested that effects were identified more often in studies with 
intermediate length follow-up. This variation with length of follow-up could be due to 
significant changes in the status of the LTC or due to fluctuations in levels of 
perseverative negative thinking over time. Future studies should carefully consider the 
length of follow-up or risk missing a true association. It seems most likely that a follow-
up between 1 and 12 months would be most appropriate. 
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The results of this review are consistent with the findings of previous narrative 
([113, 169, 171]) and systematic ([168, 170]) reviews focused on physically healthy 
individuals. Similar to ours, these previous reviews noted that, compared to the results 
of cross-sectional studies, the findings from prospective research are more mixed 
although the majority of such studies did support an association. In these previous 
reviews, moderators of the association between perseverative negative thinking and 
subsequent symptoms of depression and anxiety or negative affect that relate to 
characteristics of the population (e.g. gender, psychopathology) and to aspects of 
repetitive thinking itself (e.g. valence, content) have been suggested to explain some 
of the variability in findings.  
Further high quality research is required to clarify the association of 
perseverative negative thinking, on the one hand, with psychological and other 
medical outcomes such as quality of life, morbidity and mortality, on the other. 
Experimental studies in which perseverative negative thinking is induced or 
interrupted, with effects on depression, anxiety or emotional distress monitored, 
would provide good evidence of a causal association and indicate that perseverative 
negative thinking is a relevant target for treatment of depression and other 
psychological outcomes in people with LTCs. Future prospective and experimental 
research should investigate differences of associations of perseverative negative 
thinking with  depression, anxiety or emotional distress in groups of individuals with 
different LTCs. In addition, attempts should be made to clarify mechanisms that might 
explain how and why perseverative negative thinking contributes to depression, 
anxiety and emotional distress. A number of possible mechanisms have been 
suggested in the research literature, including via a reduction in social support, 
impairment of problem solving, reduced motivation to perform positive instrumental 
behaviours and increased negative thinking[113, 120]. These mechanisms could also 
provide potential targets for intervention aimed at improving depression and also 
physical health outcomes. 
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Chapter 3 Methods 
3.1 Chapter outline 
This chapter outlines the methods of a prospective observational cohort study to 
investigate the role of rumination and worry in predicting depression, anxiety and 
quality of life in people with acute coronary syndrome (ACS). The findings of this study 
form the basis of the results chapters that follow.  
This chapter provides an overview of: 
i. The methodological approach chosen and explains how previous 
literature has informed the design of the current research. 
ii. The procedural methods including recruitment, inclusion and exclusion 
criteria, description of measures and questionnaires. 
iii. Generic statistical methods (details of statistical analyses specific to 
addressing the aims of each of the results chapters are presented in the 
relevant chapter). 
3.2 General methodology 
3.2.1 Design 
An observational prospective cohort design was used. This study design 
requires the outcome to be measured after the exposure (i.e. variables of interest are 
measured in chronological order) meaning that tentative inferences about causality 
can be made on the basis of demonstrating temporal precedence (although temporal 
precedence alone is not a sufficient condition to demonstrate causality). Other 
advantages of this type of longitudinal study design are that observation of within-
subject changes in responses over time controls for confounds related to individual 
differences[280] and mechanisms of changes in responses can be studied[281]. 
Cross-sectional studies in people with chronic physical illnesses including 
coronary heart disease (CHD) have shown a strong association between depression 
and perseverative negative thinking (e.g. [176, 178]). However the design of these 
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studies leaves open 3 possibilities: (1) that depression causes perseverative negative 
thinking, (2) perseverative negative thinking causes depression, or (3) both depression 
and perseverative negative thinking are related to a third, measured or unmeasured, 
factor. A prospective study can establish whether one variable precedes another, 
increasing confidence in the direction of the association, but cannot rule out the 
involvement of a third factor. Five previous prospective studies in people with CHD 
were identified in the systematic review presented in Chapter 2. These studies all 
measured the association of rumination with subsequent depression within the first 
year after CHD, and follow-ups took place once or twice within 6 weeks to 1 year later. 
Some studies were limited by small sample size[270], a large number of dropouts[182, 
270] and inadequate or incomplete control for confounders. Samples were selected in 
some studies according to pre-defined criteria related to depression scores[183] or 
age[182]. 
The current study was designed to extend the previous research in the 
following ways: 
i. A representative sample of ACS patients, based in the UK, at various stages 
of treatment, were invited to participate. 
ii. Confounding variables known to be associated with depression (age, sex, 
socioeconomic status, history of depression, social support, severity of 
cardiac disease) were controlled. 
iii. Worry was assessed in addition to rumination, to investigate the 
association of a broader range of perseverative negative thinking with 
depression. 
iv. Since depression and anxiety are highly comorbid, (and both predict cardiac 
morbidity e.g.[282]) anxiety was included as an additional outcome 
measure. 
v. To investigate whether perseverative negative thinking is prospectively 
associated with worse physical health outcomes as well as depression in 
people with CHD, health-related quality of life was included as an additional 
outcome measure. 
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vi. Mechanisms that could explain why rumination is associated with 
depression in people with CHD were explored (low social support, poor 
problem solving, reduced instrumental behaviours and negative cognitive 
biases).  
3.2.2 Self-report measures 
Consistent with previous research in this area, this study relied on the use of 
self-report measures of the main predictors and main outcome variables. Despite the 
disadvantages associated with self-report methods (including incomplete or missing 
data and response biases, for example) self-report measures were the preferred 
option because (a) it was not feasible to use other appropriate alternatives e.g. 
clinician ratings of depression and anxiety, experience sampling measures of 
rumination and worry[283, 284], and (b) participant burden was minimised by using 
self-report measures. In addition, the use of self-report measures of quality of life was 
an advantage because they allowed a more nuanced assessment of physical health 
status than ‘hard’ outcomes such as mortality might[285-287].  
Self-report measures with demonstrated reliability and validity and that had 
previously been used in a CHD population were selected where possible (details are 
given in Section 3.3.2.2). 
3.2.3 Timing of follow-up assessments 
Assessments were completed by each participant on three occasions: (1) 
baseline assessments within 6 months of hospitalisation for ACS, (2) follow-up at 2 
months after baseline, and (3) follow-up at 6 months after baseline. 
How the temporal relationship between depression and CHD evolves is 
unclear[33, 288] although elevated prevalence of depression has been reported both 
immediately after and in the year post-MI[289-292]. Therefore, participants for this 
study were recruited within 6 months of their hospital admission in order that follow-
up assessments could be completed within the first year post-ACS. 
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3.2.4 Reporting 
The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement makes specific recommendations on the content that should be 
included in an accurate and complete published report of an observational study[293]. 
Where possible reporting of the observational prospective cohort study described in 
this thesis follows STROBE recommendations, with adaptations made to accommodate 
the thesis-format. 
 
3.3 Procedural methods 
3.3.1 Participants 
Patients attending specialist inpatient and outpatient cardiology services at the 
Royal Devon & Exeter hospital between September 2014 and May 2015 were recruited 
following admission for ACS.  
ACS is subcategory of coronary heart disease (CHD) that refers to disorders 
caused by sudden loss of blood flow to the heart and includes unstable angina, non-ST-
segment elevation myocardial infarction (NSTEMI) and ST-segment elevation 
myocardial infarction (STEMI). 
The Royal Devon & Exeter hospital is a teaching hospital with over 800 beds 
that provides specialist and emergency services to a population of approximately 
500,000 people in Exeter, East, Mid and North Devon. The hospital employs 7000 staff 
and manages 100,000 emergency department attendances, 300,000 outpatient 
attendances, and over 115,000 day case or inpatient admissions per year. There are 
three cardiology wards including a coronary care unit (CCU), and 7 consultant 
cardiologists who provide diagnostic and interventional cardiology services including a 
24 hour primary angioplasty service. 
Patients with suspected ACS access cardiology services at the Royal Devon & 
Exeter hospital from home or from primary care through two main routes: (i) by 
emergency admission to the CCU, acute medical unit or cardiology ward, or (ii) by 
outpatient appointment at a chest pain clinic (Rapid Access Chest Pain Clinic; RACPC). 
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Patients admitted with a STEMI are transferred directly to the cardiac catheterisation 
laboratory for percutaneous coronary intervention (PCI) immediately. Those admitted 
with a NSTEMI or unstable angina undergo angiography, usually within 7 days of 
admission, and approximately 50% undergo coronary revascularization with PCI. 
Approximately 30% do not undergo PCI but are managed medically (i.e. receive drug 
treatments only), and the remainder are transferred to another hospital, locally or 
nationally, to consider surgical revascularisation with coronary artery bypass graft 
(CABG) surgery. Patients with STEMI are discharged within 3 days of admission, on 
average, and other ACS patients are generally discharged the day following PCI. On 
discharge, patients are typically prescribed drug treatments for secondary prevention 
that include antiplatelet therapy (e.g. aspirin), beta-blockers, ACE-inhibitors and 
statins, as per current clinical guidelines[294]. Approximately one third of the patients 
who enter cardiology services via the RACPC outpatient clinic have angina requiring 
PCI, and are admitted to a day case cardiology ward for an elective procedure (PCI) 
approximately 3 months after their outpatient clinic appointment.  
ACS patients receive information about their condition, treatment and recovery 
from a cardiac rehabilitation nurse before discharge from hospital. In addition, all 
patients who live locally are invited to participate in a community-based cardiac 
rehabilitation programme which takes place on average 4 to 8 weeks after discharge 
from hospital. Approximately 50% of patients attend a cardiac rehabilitation 
programme, consistent with UK participation rates[295]. 
3.3.1.1 Inclusion criteria 
In order to be included in the study participants had to: 
i. Be aged 18 years or over. 
ii. Have been diagnosed with ACS (including unstable angina or myocardial 
infarction - MI) within the previous 6 months. 
3.3.1.2 Exclusion criteria 
Participants were excluded from the study if:  
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i. For reasons of physical frailty or cognitive impairment it was considered 
inappropriate to involve them in this research (either by the patients 
themselves, a carer or a member of the clinical team). 
ii. They suffered from severe mental illness (including severe depression with 
significant suicide risk, or psychosis). 
3.3.1.3 Sample size 
A sample size calculation indicated that a sample of 113 participants assessed 
at baseline, 2 months and 6 months would provide 90% power to detect an association 
of r=0.30 the p=0.05 significance level. An effect size of r=0.30 was chosen since this 
represents a small degree of association and because levels of association r< 0.30 can 
often occur by chance alone. A similar previous study in ACS patients found a 
correlation of r=0.49 between baseline brooding and depression at 3 month follow-
up[183] and so r=0.30 represents a conservative estimate. Participants who dropped 
out were not replaced, therefore a target sample size of 142 participants was chosen 
to allow for up to 20% attrition during follow-up whilst retaining adequate power.  
 
3.3.2 Measures 
3.3.2.1 Sample characteristics 
The following background details were collected in order to describe the study 
population and to allow for statistical control of confounders.  
3.3.2.1.1 Socio-demographics 
Demographic and lifestyle details were collected using a custom-designed 
questionnaire. Participants were asked to self-report: age, sex, employment status, 
occupation, years of education, relationship status, whether they lived alone, smoking 
status, alcohol use, recreational drug use and frequency of exercise.  
3.3.2.1.1.1 Age and sex 
Age and sex were recorded from medical notes at the time of recruitment and 
confirmed with self-reports. Age was collected as a continuous variable and sex as a 
binary categorical variable. Both were used unchanged in all summary statistics and 
analyses.  
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3.3.2.1.1.2 Employment status 
Response options for employment status consisted of employed full-time, 
employed part-time, self-employed, unemployed, retired, homemaker and other. This 
was collapsed into a binary variable for use in summary statistics by creating two 
categories: ‘in employment’ (consisting of employed full-time, employed part-time, 
self-employed and homemaker) and ‘not in employment’ (consisting of unemployed, 
retired and other). 
3.3.2.1.1.3 Socioeconomic status 
Index of Multiple Deprivation (IMD)[296] decile was derived from the 
participants current postcode and used as a proxy of socioeconomic status.  IMD ranks 
each of 32,844 small areas or neighbourhoods in England according to their relative 
level of deprivation. The rank is based on 7 weighted dimensions of deprivation: 
income, employment, education/skills/training, health and disability, crime, barriers to 
housing and services, and living environment. The ranks do not quantify the absolute 
level of deprivation in a small area, but rather provide a means for comparison among 
areas. The ranks are split into deciles of most to least deprived areas to facilitate this, 
with lower scores indicating greater deprivation.  
For summary statistics the IMD decile was collapsed into a binary variable 
based on creating two even groups using a median split (median decile = 6). Two 
categories were created: most deprived (consisting of deciles 1 to 6) and least 
deprived (consisting of deciles 7 to 10). For regression analyses and multilevel 
(repeated measures) models the IMD decile was entered to represent socioeconomic 
status, which was an ordinal variable with a possible range of scores between 1 to 10 
(where lower scores indicated greater deprivation). 
3.3.2.1.1.4 Years of education 
Participants were asked to report an integer to represent the number of years 
spent in education. For summary statistics years of education was collapsed into two 
categories consisting of participants who reported 11 or less years of education 
(equivalent to completion of secondary education or less) or more than 11 years of 
education (equivalent to further or higher education).  
79 
 
 
3.3.2.1.1.5 Relationship status 
Response options for relationship status consisted of single, married, co-
habiting, civil partnership, widowed, divorced/separated and other. This was collapsed 
into a binary variable for summary statistics by creating two categories: ‘in a 
relationship’ (consisting of married, co-habiting and civil partnership) and ‘not in a 
relationship’ (consisting of single, divorced/separated, widowed and other). 
 In addition, a binary response (‘yes’/‘no’) was required to indicate whether a 
participant lived alone. 
3.3.2.1.1.6 Smoking status 
Response options for smoking status were yes, no and quitting. For summary 
statistics these responses were coded into a binary variable (‘smoker’/‘non-smoker’). 
Since there were few smokers and few participants attempting to quit smoking if 
quitting was endorsed this was coded as ‘smoker’. 
3.3.2.1.1.7 Alcohol use, recreational drug use and frequency of exercise 
Response options for alcohol use, drug use and exercise frequency were never, 
monthly or less, 2-4 times a month, 2-3 times a week, and 4 or more times a week. For 
summary statistics these were collapsed into binary variables by creating two 
categories: ‘never/infrequent’ (consisting of never, monthly or less, and 2-4 times a 
month) and ‘regular’ (consisting of 2-3 times a week, and 4 or more times a week). 
 
3.3.2.1.2 Medical and psychiatric history 
Where available, objective measures of severity of cardiac disease assessed 
during hospitalisation were obtained from medical records in order to describe the 
sample at baseline. Paper and electronic medical records were interrogated to collect 
the following information: diagnosis (unstable angina/NSTEMI/STEMI), days since 
index event, severity of cardiac disease (number of diseased coronary vessels, left 
ventricular function, cardiac enzymes during hospitalisation, blood markers of 
inflammation during hospitalisation), pre-existing physical health conditions, current 
medication and history of depression. 
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3.3.2.1.2.1 Days since index event 
The number of days between the admission date of the most recent 
hospitalisation for ACS prior to baseline assessments and the date baseline 
assessments were undertaken. For the majority of participants the date of index event 
was also the admission date of the most recent hospitalisation for ACS prior to 
recruitment into this study. 
3.3.2.1.2.2 Number of diseased coronary vessels 
The number of coronary vessels >50% occluded, ranging from 0 to 3, was 
recorded. There were 4 participants who met criteria for ACS but with all vessels ≤50% 
occluded. These participants were included in the study and the number of diseased 
coronary vessels was coded as 0. The medical records contained inconsistent 
information for 6 participants due to multiple admissions for ACS. For these 
participants the largest (most severe) number of occluded vessels was recorded. 
3.3.2.1.2.3 Left ventricular function 
Left ventricular function was represented using a categorical variable created 
from information contained within the cardiac catheterisation reports: (1) left 
ventricular ejection fraction (%), or (2) a clinical description of left ventricular function 
(good function, mild dysfunction, moderate dysfunction or severe dysfunction). Using 
a single data source for left ventricular function led to a large amount of missing data, 
so the sources described above were combined. The clinical description was used 
preferentially where available. Ejection fraction between 55-70% was considered 
good/normal function, 45-54% mild dysfunction, 36-44% moderate dysfunction and 
<35% severe dysfunction. This measure of left ventricular function was used for 
descriptive purposes only. 
 It was not possible to obtain a measure of left ventricular function from the 
medical records for 37 participants. In order to maximise the number of cases available 
for analyses the New York Heart Association (NYHA) functional status classification 
system[297] was used as an indicator of severity of heart disease in statistical analyses 
instead, since this was available for almost all participants. The NYHA classification 
system is a commonly used tool for assessing limitations of physical activity due to 
chest discomfort, palpitations, shortness of breath and fatigue. As a prognostic tool 
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the NYHA classification has been shown to predict mortality among patients with heart 
failure[298-300]. In addition, it has been used as a selection tool and as an outcome 
measure in clinical research[301], and a self-rated version has been shown to predict 
hospitalisations, quality of life and mortality[302].  
 The NYHA classification system consists of four possible response options that 
represent no limitations, slight limitations, moderate limitations or severe limitations. 
It was collapsed into a binary variable for summary statistics and analyses by creating 
two categories:  ‘no impairment’ (consisting of no limitations) and ‘some impairment’ 
(consisting of mild, moderate or severe limitations).  
3.3.2.1.2.4 Cardiac enzymes and blood markers of inflammation 
Where available, blood levels of cardiac enzymes (troponin) during 
hospitalisation were recorded as measures of disease severity. Presence of troponin 
indicates injury to the heart muscle, and increasing concentrations of troponin have 
been associated with greater complexity and severity of coronary artery disease[303]. 
Where troponin was measured on more than one occasion during hospitalisation the 
highest value was recorded. 
Blood markers of inflammation during hospitalisation (white cell count – WCC, 
and C-reactive protein - CRP) were also recorded. These markers have also been 
associated with worse outcomes in patients with coronary heart disease[304, 305]. In 
addition, inflammation is increasingly being implicated in the development of 
depression[306-309] including in patients with coronary heart disease[310]. For 
summary statistics WCC was collapsed into a binary variable consisting of the 
categories ‘normal’ (<12 x109/L) or ‘raised’ (≥12 x109/L). CRP was collapsed into a 
binary variable consisting of the categories ‘inflammation present’ (>10 mg/L) or 
‘inflammation absent’ (<10 mg/L). Since there were some ambiguous values for CRP 
(e.g. <1 mg/L) which could not be used as a continuous value but could be categorised, 
collapsing this variable allowed more cases to be retained for analysis.  
3.3.2.1.2.5 Comorbidities 
Number and severity of comorbidities was assessed using the Charlson Co-
morbidity Index[311, 312]. The index was developed as a prognostic indicator of short 
term mortality and is an indicator of disease burden[313]. The Charlson Co-morbidity 
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Index has been shown to predict mortality in patients with coronary artery 
disease[314].  Weighted scores are summed for 16 conditions, with higher scores 
indicating greater relative risk of death. One point is given for each of the following: 
myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective 
tissue disease, peptic ulcer disease, diabetes mellitus without end organ damage and 
mild liver disease. Two points are given for: diabetes mellitus with end organ damage, 
moderate to severe kidney disease, hemiplegia, leukemia, malignant lymphoma and 
non-metastatic solid tumour. Three points are given for moderate to severe liver 
disease, and six points are given for metastatic solid tumour or AIDS.  
The comorbidity score was obtained by harvesting information from the 
medical records regarding comorbid conditions. Comorbidity score was used for 
descriptive purposes only, and was collapsed into a binary variable consisting of the 
categories ‘1 or less’ or ‘2 or more’. 
3.3.2.1.2.6 History of depression 
Medical records were inspected to ascertain whether participants had a history 
of depression (including current depression). Based on this information a binary 
variable (‘yes’/‘no’) was created. 
 
3.3.2.2 Questionnaire assessments of main predictor and outcome variables 
All self-report assessments were combined into one questionnaire pack for 
ease of use. A copy of the baseline questionnaire pack is provided in Appendix 3. 
Each scale was chosen based on its ability to reliably measure the construct of 
interest, ideally having previously been used in a cardiac population. Since there were 
multiple constructs of interest, brief versions of some scales were chosen in order to 
minimise participant burden.  
The primary constructs of interest were the predictor variables rumination and 
worry, and the main outcome measure depression. Secondary outcome measures 
were anxiety and quality of life. Finally, possible explanatory variables were social 
support, problem solving, and engagement in instrumental behaviours. 
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Scale and subscale scores for the main predictors and outcome variables were 
prepared in accordance with standardised instructions from the authors if available, 
and are described below. In this section missing items refers to missing, incomplete or 
ambiguous responses (e.g. 2 response options endorsed). 
3.3.2.2.1 The Ruminative Responses Scale – Brooding subscale 
The Ruminative Responses Scale (RRS) of the Response Styles 
Questionnaire[140] is a 22-item self-report measure that assesses the degree to which 
individuals characteristically respond to depressed mood with ruminative thoughts, 
feelings and behaviours. The frequency of self-focused, symptom-focused and 
consequence-focused ruminative thoughts are rated using a 4-point Likert scale 
ranging from 1 (‘almost never’) to 4 (‘almost always’). The RRS can be decomposed 
into ‘brooding’ and ‘reflection’ subscales. Brooding is a 5-item subscale characterised 
by ‘moody pondering’ and omits items that contain overlap with depression and 
‘neutral contemplation’ (i.e. reflection). RRS brooding is the subscale is most often 
associated with depression. Scores range from 5 to 20, with higher scores indicating 
greater trait brooding. The RRS brooding subscale has been shown to have good 
internal consistency (Cronbach α=.77) and test-retest reliability (r=0.62)[315], and 
correlates with measures of negative mood and onset, maintenance and severity of 
depression (e.g. [121, 146, 152]) in samples including ACS patients[183]. 
RRS brooding score was obtained by summing items 5, 10, 13, 15 and 16 of the 
RRS. Missing items were not replaced, and if any items were missing RRS brooding was 
coded as missing for that assessment. Internal consistency of the RRS brooding 
subscale in this sample at baseline was Cronbach α=0.85. 
3.3.2.2.2 Penn State Worry Questionnaire 
The Penn State Worry Questionnaire (PSWQ)[133] is a 16-item trait measure of 
frequency, severity and perceived control over worry. Items are rated using a 5-point 
Likert scale ranging from 1 (‘not at all typical of me’) to 5 (‘very typical of me’). Scores 
range from 16 to 80, with high scores reflecting high levels of worry. The PSWQ is 
positively correlated with other self-report and experimental measures of worry[133], 
and is able to discriminate patients with generalised anxiety disorder from non-anxious 
samples[316, 317] and from patients with social anxiety disorder[318]. The PSWQ has 
84 
 
 
good test-retest reliability and high internal consistency in undergraduates, community 
volunteers and older adults with anxiety disorders (r>0.90, α>0.88)[133, 316, 319]. The 
PSWQ has been shown to correlate with depression in patients with long term 
conditions including CHD[178]. 
Total PSWQ score was obtained by summing all items (with the negatively 
worded items 1, 3, 8 10 and 11 reverse scored). Missing items were replaced with the 
mean value of all completed items. If more than 2 items were missing PSWQ was 
coded as missing for that assessment. Internal consistency of the PSWQ in this sample 
at baseline was Cronbach α=0.91. 
3.3.2.2.3 The Patient Health Questionnaire-8 item version 
The 8 item Patient Health Questionnaire (PHQ-8)[320] is a brief self-rated 
diagnostic and severity measure of depression. The items of the PHQ-8 index the DSM-
IV criteria for diagnosis of depressive disorders, but omits a ninth item addressing 
thoughts of death or self-harm. Respondents rate how often in the past two weeks 
they have experienced each of eight depressive symptoms, using a 4-point Likert scale 
ranging from 0 (‘not at all’) to 3 (‘nearly every day’). Items are summed with the total 
score ranging between 0 to 24. Higher scores indicate greater severity of depression. A 
cut-point of ≥10 indicates current depression. The PHQ-8 has been used previously in a 
range of populations including those with CHD e.g.[48, 321]. 
The psychometric properties of the PHQ-8 are equivalent to the more 
commonly used 9 item version (PHQ-9), providing scores that are highly correlated 
(r=0.997) and identical cut-points on the receiver operating characteristics curve for 
indicating possible cases of depression to the PHQ-9. Sensitivity and specificity of 88% 
for detecting depressive disorders using the PHQ-8 have been reported[320, 322]. 
Sensitivity to change of the PHQ-9 has also been established, being comparable to the 
clinician-rated Hamilton Depression Rating Scale[322]. Internal consistency of the PHQ-
8 is high (Cronbach α=0.86)[323]. The PHQ-8 is also recommended in medically ill 
patients, including CHD patients, since passive thoughts of death (unrelated to suicidal 
intent) may be more common among this group than in the general population 
meaning the ninth item may not represent an accurate suicide screen[321].  
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Total PHQ-8 score was obtained by summing all items. Missing items were 
replaced with the mean value of all completed items, unless more than 2 items were 
missing in which case PHQ-8 was coded as missing for that assessment. Internal 
consistency of the PHQ in this sample at baseline was Cronbach α=0.89. 
3.3.2.2.4 Beck Anxiety Inventory 
The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety 
severity[324]. The items focus on somatic or autonomic symptoms of anxiety (such as 
trembling hands, nervousness, dizziness, sweating) and on subjective and panic-related 
aspects of anxiety (such as inability to relax, fear of the worst happening). Respondents 
rate how much they have been bothered by symptoms in the past four weeks on a 4-
point Likert scale ranging from 0 (‘not at all’) to 3 (‘severely’). Items are summed to 
give a single score ranging from 0 to 63. Scores of 10 - 18 represent mild to moderate 
anxiety, 19 – 29 moderate to severe anxiety, and 30 – 63 severe anxiety. BAI correlates 
with other measures of anxiety such as the Hamilton Anxiety Rating Scale (r=0.51), the 
State-Trait Anxiety Inventory (r=0.47 to 0.58) and the anxiety subscale of the Symptom 
Checklist-90 (r=0.81)[325, 326]. BAI is correlated with depression and negative 
attributions about the cause of illness in people with CHD[327]. Internal consistency is 
high (Cronbach α=0.90 to 0.94) and test-retest reliability of the BAI is good (r=0.62 to 
0.93). 
Among medical populations the somatic symptoms of anxiety may overlap with 
symptoms related to physical illness. However the BAI was selected for use in this 
study despite its focus on somatic symptoms due to its relative lack of items 
addressing cognitive aspects of anxiety (including worry). This is important because 
inclusion of items related to worry in the BAI could result in a spurious association 
between worry and anxiety. 
Total BAI was obtained by summing all 21 item scores. Missing items were 
replaced with the mean value of all completed items, unless more than 2 items were 
missing in which case BAI was coded as missing for that assessment. Internal 
consistency of the BAI in this sample at baseline was Cronbach α=0.92. 
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3.3.2.2.5 EuroQol-5D 
The EuroQol-5D (EQ5D) is a standardised self-report, assessment of generic 
health-related quality of life[328, 329]. Respondents are asked to indicate their 
perceived current health status in relation to difficulties in five dimensions: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is 
rated on a scale with five levels of severity (1=no problems, 2=slight problems, 
3=moderate problems, 4=severe problems, and 5=extreme problems). Scores for each 
dimension can be reported individually, and an algorithm (based upon weights 
assigned to each response according to population norms) is provided to facilitate 
calculation of a single index value based on the profile of responses to the five 
dimensions[330]. In addition, respondents are asked to rate their current overall 
health using a 200mm vertical visual analogue scale (VAS), anchored at each end with 
0 (‘the worst health you can imagine’) and 100 (‘the best health you can imagine’). The 
EQ5D has been used extensively in cardiovascular research and its validity and 
reliability in this population is supported (e.g.[331-335]).  
Individual EQ5D dimensions were scored from 1 (‘no problems’) to 5 (‘extreme 
problems’), and if any items were missing the relevant dimension was coded as missing 
for that assessment. The dimensions were combined into a single index value using the 
interim UK EQ5D-5L crosswalk value set[330]. If any subscale scores were missing the 
index value could not be calculated and was coded as missing for that assessment. 
Index values range from -0.594 to +1 with higher positive values indicating better 
health state.  
The EQ5D VAS required participants to mark a visual analogue scale labelled 
from 0 – 100 and to write the corresponding value into a box adjacent. If there was a 
discrepancy between the number marked on the VAS and the number entered in the 
box, the number entered in the box was used preferentially. If one of the values was 
missing, the value of the completed item was used. If both values were missing EQ5D 
VAS was coded as missing for that assessment. 
3.3.2.2.6 Seattle Angina Questionnaire 
The Seattle Angina Questionnaire (SAQ)[336] is a 19 item coronary disease 
specific self-report measure of health-related quality of life, including domains related 
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to both physical and emotional function. The scale is divided into five factors that 
assess physical limitations, frequency of angina, stability of angina, treatment 
satisfaction, and disease perception. Responses to all items are made using 5- or 6-
point Likert scales, and scores for each of the five factors range from 0 to 100 with 
lower scores indicating worse health status. The psychometric properties of the SAQ 
have been established in patients with CHD: internal consistency (Cronbach α≥0.67) 
and test-retest reliability is good (r≥0.76), the scale is responsive to small and large 
clinical changes (a change of 10 points equates to a change perceptible to patients) 
and SAQ scores are correlated with clinical measures such as hospitalisation for angina 
and nitroglycerin refills [336-339].  
The SAQ subscales were scored in the following way: 
i. Physical limitations.  Items 1a to 1i were scored 1 to 5 (working from most 
to least limitations) and standardised using the formula 100*(Mean score – 
1)/4. The items in this subscale are grouped into three levels of difficulty 
(lowest level = items 1a, 1b and 1c; middle level = items 1d, 1e, 1f; highest 
level = items 1g, 1h, 1i). Missing items were replaced with the mean of the 
other items of the same difficulty level. If all items of the lowest or highest 
difficulty level were missing they were replaced with the mean of the 
middle difficulty level. If all items of the middle difficulty level were missing 
they were replaced with the mean of the lower and higher difficulty levels. 
If response option 6 (‘Limited or did not do for other reasons’) was 
endorsed the item was treated as missing. If more than 4 items were 
missing the subscale was coded as missing for that assessment. 
ii. Angina frequency.  Items 3 and 4 were scored 1 to 6 (working from most to 
least frequent) and standardised using the formula 100*(Mean score – 1)/5. 
If one item was missing the subscale was calculated without that item. 
iii. Angina stability.  Item 2 was scored 1 to 5 (working from ‘much more often’ 
to ‘much less often’) and standardised using the formula 100*(Response - 
1)/4. If response option 6 (‘I’ve had no chest pain over the last 4 weeks’) 
was endorsed the item was assigned a score of 3 (equivalent to response 
option 3 ‘About the same’).  
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iv. Treatment satisfaction.  Items 5, 6, 7 and 8 were scored from 1 to 5 
(working from least satisfied to most satisfied) and standardised using the 
formula 100*(Mean score – 1)/4. For item 5 if response option 6 (‘My 
doctor has not prescribed pills’) was endorsed a score of 5 (equivalent to 
response option 5 ‘Not bothersome at all’) was assigned. Missing items 
were replaced with the mean of completed items. If more than 2 items 
were missing the subscale was coded as missing for that assessment. 
v. Disease perception.  Items 9, 10 and 11 were scored 1 to 5 (working from 
worst to best perceptions) and standardised using the formula 100*(Mean 
score – 1)/4. Missing values were replaced with the mean of the completed 
items. If more than 1 item was missing the subscale was coded as missing 
for that assessment. 
3.3.2.2.7 ENRICHD Social Support Inventory  
The Enhancing Recovery in Coronary Heart Disease (ENRICHD) study Social 
Support Inventory (ESSI) is a seven-item self-report measure of the perceived 
availability of social support. The ESSI was designed for use in a trial of a psychosocial 
intervention for cardiac patients with depression and low social support[340]. The 
items do not differentiate between sources of support but instead focus on perceived 
availability of support from any social network member. Respondents rate the 
availability of support in three domains (emotional support, practical support and 
informational support) using a 5-point Likert scale ranging from 0 (‘none of the time’) 
to 4 (‘all of the time’). Items are summed to give a single score, with higher scores 
indicating greater perceived support. The ESSI has been shown to correlate with the 
social functioning subscale of the Short Form-36, and ESSI scores were lower in cardiac 
patients with depression compared to those without depression[192]. Internal 
reliability (Cronbach α=0.88) and test-retest reliability (r=0.94) of the ESSI are 
good[192]. 
The ESSI was unique in this study in that it was the only questionnaire measure 
included as both a potential confounding variable (in the analyses presented in 
Chapter 4) and also as a potential mediator variable (in the analyses presented in 
Chapter 5). Total ESSI score was obtained by summing items 1 to 6. Missing items were 
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replaced with the mean of all completed items. If more than 1 item was missing ESSI 
was coded as missing. 
3.3.2.2.8 Social Problem Solving Inventory 
The Social Problem Solving Inventory-revised short version (SPSI-R:S) is a 25 
item self-report scale which assesses ‘real-world’ problem solving[201].  Respondents 
rate 25 items describing typical ways in which they might respond when faced with an 
important problem, using a 5-point Likert scale ranging from 0 (‘not at all true of me’) 
to 4 (‘extremely true of me’). The items relate to 2 problem solving processes: problem 
orientation and specific problem solving style. Problem orientation (positive problem 
orientation or negative problem orientation) refers to cognitive-emotional sets 
including appraisals, beliefs expectancies and emotional responses that involve the 
tendency to approach problems in a characteristic way. Problem solving styles (rational 
problem solving, impulsivity/carelessness style and avoidance style) describe the 
implementation of activities to solve a specific problem. Positive problem orientation 
and rational problem solving are constructive dimensions of problem solving, whereas 
negative problem orientation, impulsivity and avoidance are dysfunctional dimensions 
of problem solving. Internal consistency (Cronbach α≥0.80) and test-retest reliability 
(r=0.68 to r=0.91) of the SPSI-R:S are good, and normative data is available for healthy 
adults and clinically depressed populations[201, 341]. SPSI-R:S has been associated 
with depression and anxiety in a community sample[205], and with severity of 
depression in a chronically depressed sample[342]. In addition, SPSI-R:S has been 
shown to correlate with pain intensity and pain frequency in patients with cardiac and 
non-cardiac chest pain[343]. 
SPSI-R:S subscale scores were calculated by summing the appropriate items: 
positive problem orientation=items 4, 5, 9, 13 and 15; rational problem solving=items 
12, 16, 19, 21 and 23; negative problem orientation=items 1, 3, 7, 8, and 11; 
impulsivity-carelessness=items 2, 14, 20, 24 and 25; and avoidance=items 6, 10, 17, 18 
and 22. Subscale scores range from 5 to 20 with higher scores indicating greater 
endorsement of the relative dimension. SPSI-R:S total score was calculated by 
summing the mean of each of the subscales (where negative problem orientation, 
impulsivity and avoidance were reversed) and higher scores indicate more 
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adaptive/positive problem solving. Missing items were replaced with the mean of all 
other items. If >2 items were missing, SPSI-R:S was coded as missing for that 
assessment. All SPSI subscales were used in analyses to identify particular areas of 
problem solving that might be related to both depression and rumination, although it 
was anticipated that associations with subscales indexing unconstructive aspects of 
problem solving (negative problem orientation, impulsivity and avoidance) would be 
strongest. For example, negative problem orientation (defined as a set of dysfunctional 
schemas that involve the tendency to view problems as threatening, to lack problem-
solving confidence and to become easily frustrated when confronted with problems)  
has been prospectively associated with depressive symptoms[202, 203].  
3.3.2.2.9  Pleasant Events Schedule for the elderly 
The Pleasant Events Schedule for the elderly (PES-E) is a self-report 20-item 
short version of the original Pleasant Events Schedule[344] containing only items 
endorsed by respondents from the original validation sample aged over 50 years[345]. 
The scale assesses behavioural engagement by asking respondents to indicate on a 3-
point scale how frequently they engaged in a variety of pleasant events over the past 
month (from 0=‘not at all’ to 2=‘7+ times’) and how pleasant they found the activities 
(from 0=‘not pleasant’ to 2=‘very pleasant’). PES-E correlates well with the original 
long version of the Pleasant Events Schedule which has been shown to correlate with 
daily diary reports of activity (r=0.68 to 0.81) and depression scores[344]. PES-E 
measured post-MI has been associated with concurrent rumination and depression in 
a sample of acute coronary syndrome patients[183]. 
PES-E frequency items were scored 0 to 2 (working from least frequent to most 
frequent) and total frequency score was calculated as the mean of all completed 
frequency items (excluding missing items). Similarly, PES pleasantness items were 
scored 0 to 2 (working from least pleasant to most pleasant) and total pleasantness 
score was calculated as the mean of all completed pleasantness items (excluding 
missing items). The ‘obtained pleasure’ score for each item was obtained by 
multiplying the frequency x pleasantness ratings. Where relevant frequency or 
pleasantness items were missing, obtained pleasure was coded as missing for that 
item. Total obtained pleasure was calculated as the mean of all obtained pleasure 
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scores. Higher PES-E subscale scores indicated greater frequency and pleasantness of 
pleasant events, and greater obtained pleasure. 
3.3.2.3 Assessment of negative cognitive biases 
3.3.2.3.1 Memory bias 
Preferential memory for self-referent negative information was assessed using 
an incidental recall task (based on that of Teasdale & Dent, 1987[346]). A list of 26 
adjectives were read aloud and immediately after each adjective the participant was 
asked to rate whether the word was self-descriptive (answering ‘yes’ or ‘no’ for each 
adjective). Immediately afterwards, participants were given up to 3 minutes to verbally 
recall as many of the words as possible. Of the 26 adjectives, 12 referred to negative 
traits (deficient, failure, inadequate, incompetent, inferior, pathetic, stupid, unloved, 
unwanted, useless, weak, worthless), 12 referred to positive traits (capable, confident, 
dynamic, entertaining, important, optimistic, outgoing, respected, skilful, sociable, 
successful, valuable) and the first and last words were neutral filler words (ordinary, 
modern). Depressed individuals have been shown to endorse a higher number of 
negative adjectives and to recall more self-referent negative words using this 
task[346], in line with other research showing biased recall of negative over positive 
material in people with depression[220, 347, 348]. Recall of negative self-referential 
words has also been shown to predict depressive episodes in people with a history of 
recurrent major depression[349]. 
For descriptive purposes outcome measures were: (a) number of positive and 
negative adjectives endorsed, (b) number of positive and negative adjectives recalled, 
(c) number of negative adjectives recalled as a percentage of the total number recalled 
(excluding filler words), (d) number of endorsed (self-referential) positive words 
recalled, (e) number of endorsed (self-referential) negative words recalled, and (f) 
number of endorsed negative words recalled as a percentage of the total number of 
endorsed words recalled (excluding filler words). For statistical analyses the number of 
negative words endorsed, the percentage of negative words recalled and the 
percentage of endorsed negative words recalled were used. 
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3.3.2.3.2 Interpretation bias 
A lexical ambiguity task based on that of Halberstadt et al. (1995)[350] was 
used to assess interpretation bias. A list of 19 adjectives was read aloud. Immediately 
following each adjective the participant was instructed first to give a brief sentence 
that included the word and then to verbally give the spelling of the word. Participants 
were encouraged to respond as quickly as possible after hearing each word, and to 
give the first answer that came to mind. The adjectives were homophones with one 
spelling related to a neutral meaning and another spelling related to an affective 
meaning. Affective meanings related to happiness (10 items: bridal-bridle, dear-deer, 
heal-heel, hymn-him, peace-piece, presents-presence, pride-pried, rose-rows, sweet-
suite, won-one) or sadness (8 items: banned-band, bored-board, die-dye, fined-find, 
missed-mist, mourning-morning, pain-pane, poor-pore).  
Each adjective was coded by the researcher according to whether the affective 
meaning or the neutral meaning had been accessed. If the definition and spelling given 
did not match the definition was preferentially used to code that adjective. If any 
answer was ambiguous that item was excluded. For descriptive purposes and 
statistical analyses the percentage of words for which the affective meaning was 
accessed (with reference to the percentage for which the neutral meaning was 
accessed) was calculated for both happy and sad homophones.  
In a sample of healthy young adults a sad mood induction resulted in more 
affective meanings being accessed for sad homophones using this task[350]. 
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3.3.3 Procedure 
The flowchart in Figure 3.1 illustrates the main stages of the study.  
 
Figure 3.1: Flowchart of study procedures 
 
 
 
 
3.3.3.1 Identification of eligible patients 
Eligible patients were identified by a member of the clinical team during 
inpatient admission for ACS or at outpatient follow-up with a member of the cardiac 
rehabilitation team. Eligible patients were initially approached by a member of the 
Recruitment
• Eligible patients identified and approached by clinical team
• Study information given to potential participants by researcher
• Follow-up phone call and/or baseline assessments provided
Baseline 
assessments
• Sociodemographics collected
• Medical records inspected
• Questionnaire pack completed: RRS, PSWQ, PHQ, BAI, EQ5D, SAQ, 
NYHA, ESSI, SPSI, PES
• Assessments completed by telephone
2 month 
assessments
• Questionnaire pack completed: RRS, PSWQ, PHQ, BAI, EQ5D, SAQ, 
NYHA, ESSI, SPSI, PES
• Assessments completed by telephone
6 month 
assessments
• Questionnaire pack completed: RRS, PSWQ, PHQ, BAI, EQ5D, SAQ, 
NYHA, ESSI, SPSI, PES
• Assessments completed by phone
94 
 
 
clinical team, and asked to consent verbally to be contacted about the study by the 
researcher. If they agreed they were signposted to the researcher.1 
Each signposted patient was contacted by the researcher in the cardiology 
department. A short verbal description of the study was provided along with a brief 
written information sheet introducing the researcher and the study (see Appendix 4). 
Patients were asked to provide their name and telephone number if they were willing 
to receive further information about the study.  
Patients who agreed to receive further information about the study were 
contacted in the cardiology department if time and opportunity permitted or at home 
by telephone, and were given a verbal description of the study and opportunity to ask 
questions. Patients who expressed an interest in participating after the study had been 
fully explained to them were given an information sheet (Appendix 5), a consent form 
(Appendix 6), a questionnaire pack containing baseline assessments and a freepost 
envelope (for patients contacted by telephone arrangements were made to send these 
by post). 
Where it was not possible to ask eligible patients to consent verbally to be 
contacted about the study (e.g. because they were admitted and discharged before a 
member of the clinical team was able to speak to them, or they were not well enough 
on the ward), a letter of invitation from the consultant cardiologist was posted and 
patients were asked to contact the researcher directly or to complete a reply slip 
indicating that they agreed to be contacted by telephone in order to receive details 
about the study.  
3.3.3.2 Consent and participation 
Patients who subsequently decided to participate in the study were asked to 
sign the consent form and return it with the pack of self-rated assessments in the 
freepost envelope provided. The date of completion was recorded on the front of the 
pack by the participant.  
                                                     
1The clinical team recorded age and sex of all participants approached to allow a crude comparison of 
the participants who participated and those who declined to participate. 
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Participants were encouraged to contact the researcher for assistance 
completing the consent form or assessments if needed. In the event that a participant 
who expressed an interest in participating did not return the consent form and self-
rated assessments a reminder phone call was made after approximately two weeks, as 
agreed with the participant.  
Once the consent form and questionnaire pack was received by the researcher, 
the participant was telephoned in order to complete the memory and interpretation 
bias tasks.  
3.3.3.3 Follow-ups 
At two months and six months after completion of the baseline assessments, 
another pack of self-rated assessments was sent to each participant by post. If a 
participant failed to return the self-rated assessments at either of these follow-ups a 
reminder phone call was made after approximately two weeks, as previously agreed 
with the participant. Once the 2 month and 6 month questionnaire packs were 
received by the researcher the participant was again contacted by telephone to 
complete the memory and interpretation bias tasks. 
 
3.3.4 Ethical review and research site approval 
This study was reviewed by the NRES Committee South West – Frenchay 
Research Ethics Committee, and received a favourable ethical opinion on 5th August 
2014 (reference: 14/SW/0133).  
Permission to recruit participants at the Royal Devon & Exeter hospital 
Cardiology department was granted by the Research & Development directorate of the 
Royal Devon & Exeter NHS Foundation Trust on 13th August 2014 (reference: 1502058). 
 
3.4 Statistical methods 
3.4.1 Data management 
Raw data was checked for accuracy, completeness and legibility and prepared as 
described in Section 3.3.2.  All analyses were conducted using Stata SE statistical 
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software release 14 (StataCorp. 2015; College Station, TX).  Before any analyses were 
conducted, the following preliminary steps were taken. 
3.4.1.1 Missing data analysis 
Missing data at case and scale/subscale level was identified for all predictor, 
outcome and explanatory variables and summaries are presented in the relevant 
results chapters.  
Methods for dealing with missing data in specific cases are described in the 
relevant results chapters. In general for correlations and other tests within a single 
assessment time pairwise deletion was used (i.e. available case analysis) in order to 
maximise the number of cases. For analyses that used data from multiple assessment 
times listwise deletion was used (i.e. data was included only for participants who 
completed all assessments). 
3.4.1.2 Collapsing response options for categorical variables 
In order to simplify the analysis of some categorical sociodemographic and 
disease variables with multiple response options, the levels of response were collapsed 
to create binary variables. Where relevant this is described in Section 3.3.2. 
3.4.1.3 Detection of outliers 
Minimum and maximum values of each variable at each assessment time were 
inspected, and a boxplot of each variable was produced to visually screen for potential 
outliers. For illustration purposes an example is included in Appendix 7 (boxplots for 
the main predictors and outcome variables at baseline). For the majority of plots there 
were a small number of values lying outside of the whiskers indicating potential 
outliers. Inspection of the individual data points indicated that these were plausible 
values for the relevant measure and in order to maximise the amount of data available 
for analyses these cases were retained. 
3.4.1.4 Normality 
The distribution of each variable was inspected using histograms and normal-
probability plots. In addition, a Shapiro-Wilk test was conducted for each continuous 
variable to indicate whether the distribution was normal. Results of the Shapiro-Wilk 
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tests are summarised in Appendix 8. The majority of variables had a distribution that 
was significantly different from normal. 
 Several transformations were applied (square, square root, log, inverse, cubic) 
to correct the distributions, although none were successful. Therefore, non-parametric 
statistical tests were used for bivariate analyses. Since the multivariate statistical 
analyses used in this thesis rely upon normally distributed residuals rather than 
normally distributed raw scores, evaluation of the distribution of residuals is dealt with 
in the relevant results chapters.  
3.4.2 Descriptive statistics 
Overall descriptive statistics (mean and standard deviation, median and 
interquartile range, or number and percentages, as appropriate) were prepared for all 
sociodemographic and disease variables, predictors (rumination and worry), outcome 
variables (depression, anxiety and quality of life) and explanatory variables (social 
support, problem solving, instrumental behaviours, memory bias and interpretation 
bias). These are presented in the relevant results chapters. 
3.4.3 Inferential statistics 
Statistical analyses are described in detail in the relevant results chapters. 
Briefly, the key analyses are summarised below: 
i. Chapter 4 presents a series of staged multivariable and ordered logistic 
regression analyses investigating prospective associations of rumination and 
worry with subsequent depression, anxiety and quality of life.  These analyses 
are extended with the use of multilevel mixed-effects linear regression analyses 
(multilevel (repeated measures) models) in order to account for the nested 
structure of the longitudinal data involved.  
ii. Chapter 5 presents a series of mediation analyses exploring social support, 
problem solving, instrumental behaviours and cognitive biases as potential 
mechanisms of the prospective association between rumination and worry with 
subsequent depression, anxiety and health-related quality of life. Mediation 
was tested by evaluating causal steps with multiple regression analyses, and 
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was combined with a bootstrapping approach to test the significance of 
indirect effects. 
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Chapter 4 Cohort study results - Part I: Prospective association of 
rumination and worry with depression, anxiety and worse quality of 
life 
4.1 Chapter outline 
The primary aim of this observational prospective cohort study was to 
investigate whether perseverative negative thinking predicts the development of 
depression, anxiety and poor physical health outcomes in people with coronary heart 
disease (CHD).  
Detailed methods were presented in Chapter 3.  This data chapter presents: 
i. The hypotheses under test that pertain to the main aims of the study. 
ii. A description of the statistical methods used. 
iii. Detailed results. 
iv. A brief summary of findings. 
 
Discussion of the methods and findings with reference to strengths, weaknesses, 
comparison with existing literature and implications for future research is combined 
with that relating to the next results chapter (Chapter 5), and is presented in the 
general discussion chapter (Chapter 6). 
4.2 Hypotheses 
The primary hypotheses are that: 
i. In patients with recent acute coronary syndrome (ACS), rumination and 
worry measured following hospitalisation will predict depression at six 
month follow-up, after controlling for other confounding variables 
including baseline levels of depression. 
ii. In patients with recent ACS, rumination and worry at a previous 
assessment time (t) will predict depression at the next assessment time 
(t+1), after controlling for other confounding variables. 
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The secondary hypotheses are that: 
iii. In patients with recent ACS, rumination and worry measured following 
hospitalisation will predict anxiety and worse quality of life at six month 
follow-up, after controlling for other confounding variables including 
baseline levels of anxiety and worse quality of life. 
iv. In patients with recent ACS, rumination and worry at a previous 
assessment time (t) will predict anxiety and worse quality of life at the 
next assessment time (t+1), after controlling for other confounding 
variables. 
 
A note on abbreviations 
The measures used to assess predictors, outcomes and covariates of interest were 
described fully in Chapter 3. Throughout this chapter the following abbreviations will be 
used: brooding (‘RRS brooding’), worry (‘PSWQ’), depression (‘PHQ’), anxiety (‘BAI’), 
general health-related quality of life (‘EQ5D’), cardiac disease-specific quality of life 
(‘SAQ’), social support (‘ESSI’), socioeconomic status (‘IMD’). 
4.3 Statistical analysis 
4.3.1 Sample characteristics 
The number of participants, demographic variables (age, sex, years of 
education, employment status, relationship status, whether the participant lives alone, 
socioeconomic status, history of depression, smoking status, alcohol use, recreational 
drug use, exercise frequency, and perceived availability of social support) and disease-
related sample characteristics (diagnosis, days since index event, left ventricular 
function, New York Heart Association (NYHA) functional classification, number of 
diseased vessels, comorbidity score, troponin, C-reactive protein and white cell count) 
were summarised using descriptive statistics.  
Age and sex of individuals who participated in the study were compared to 
those who declined to participate using the Mann-Whitney U test for age, and the Chi-
Square test for sex. Differences in sample characteristics according to depression 
status at baseline were explored in a similar way to allow inferences about the 
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representativeness of the sample according to features related to depression to be 
made (where depressed PHQ≥10 and non-depressed PHQ<10). 
4.3.2 Description of baseline data 
The main predictor variables (RRS brooding and PSWQ) and main outcome 
variables (PHQ, BAI, EQ5D visual analogue scale - VAS, EQ5D index value, EQ5D 
subscales mobility, self-care, usual activities, pain, anxiety/depression and SAQ 
subscales physical limitations, angina frequency, angina stability, treatment 
satisfaction, disease perception) at baseline were summarised using descriptive 
statistics. Missing data were summarised, and key characteristics (age, sex, baseline 
PHQ) of cases with and without missing data were compared using Mann Whitney U or 
Chi-Square tests.  
Differences between predictor variables and main outcomes according to 
depression status at baseline were explored using Mann Whitney U or Chi-Square tests 
(depressed PHQ≥10, non-depressed PHQ<10). 
 Spearman’s rho or Kendall’s Tau-b correlations, as appropriate, were used to 
explore bivariate associations among baseline sample characteristics with main 
predictors (RRS brooding and PSWQ) and main outcome variables (PHQ, BAI, EQ5D and 
SAQ). For dichotomous variables related to sample characteristics, Mann-Whitney U 
tests were used instead to look at differences in predictor and outcome variables at 
different levels of the sample characteristics. 
 Spearman’s rho or Kendall’s Tau-b correlations were also used to explore 
bivariate associations among main predictors (RRS brooding and PSWQ) and main 
outcome variables (PHQ, BAI, EQ5D and SAQ) at baseline.  
4.3.3 Description of 2 month and 6 month data 
Timing of 2 month assessments were described using number of days from 
baseline assessments. The number of participants who completed (or did not 
complete) 2 month assessments were noted, and reasons for non-completion were 
listed. 
Sample characteristics at baseline along with main predictor and outcome 
variables at baseline, of completers compared to non-completers at 2 months, were 
compared using Mann-Whitney U or Chi-Square tests as appropriate. 
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Similar to baseline assessments, the main predictor variables and main 
outcome variables at 2 months were summarised using descriptive statistics, and 
missing data was described. Key characteristics (age, sex, baseline PHQ) of cases with 
and without missing data at 2 months were compared using Mann Whitney U or Chi-
Square tests.  
Data pertaining to 6 month assessments were treated in the same way as data 
pertaining to 2 month assessments, as described above. 
 
4.3.4 Changes in main predictors and outcomes over time 
To investigate changes over time in each of the main predictors and outcome 
variables a series of Friedman’s tests with assessment time as the independent 
variable were used, combined with Wilcoxon’s tests for post-hoc exploration of 
significant main effects. 
 
4.3.5 Prospective associations of baseline predictors with 6 month outcomes 
To investigate if baseline brooding or worry predicted depression, anxiety or 
worse quality of life at 6 months a series of simple correlations, simple regression 
analyses and staged multivariable regression analyses were conducted. Bivariate 
correlations and simple regression analyses were conducted first to directly investigate 
the associations of interest, and staged multivariable models were conducted next in 
order to explore the impact of adding important covariates to the models. 
4.3.5.1 Correlation of baseline predictors with 6 month outcomes 
Spearman’s rho or Kendall’s tau correlations, as appropriate, were used to 
explore bivariate associations between the predictor variables (RRS brooding and 
PSWQ) at baseline, with the main outcome variables (PHQ, BAI, EQ5D and SAQ) at 6 
months.  
Since some attrition was anticipated during the study a sensitivity analysis was 
conducted by comparing bivariate correlations between the predictors and main 
outcomes at baseline for the participants who remained in the study at 6 months with 
baseline correlations for the participants who did not complete the study, in order to 
provide some indication whether there were any systematic differences in the strength 
or direction of observed associations between completers and non-completers. 
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4.3.5.2 Prospective associations using multiple regression 
First, in simple regression models, baseline RRS brooding or baseline PSWQ (as 
appropriate depending on the model) was entered as the predictor variable, and in 
separate models the outcome variables were 6 month depression (PHQ), anxiety (BAI), 
general health-related quality of life (EQ5D VAS and EQ5D index value) and cardiac 
disease-specific quality of life (SAQ subscales physical limitations, angina frequency, 
angina stability, treatment satisfaction, disease perception). Equivalent simple ordered 
logistic regression analyses were conducted for the EQ5D subscales mobility, self-care, 
usual activities, pain and anxiety/depression. 
Next, in separate staged multivariable regression models the outcome variables 
were 6 month depression (PHQ), anxiety (BAI), general health-related quality of life 
(EQ5D VAS and EQ5D index value) and cardiac disease-specific quality of life (SAQ 
subscales physical limitations, angina frequency, angina stability, treatment 
satisfaction, disease perception). Predictors were entered in blocks in successive steps. 
In order to control for the effects of demographic and other variables known to be 
associated with depression (age, sex, socioeconomic status, perceived availability of 
social support, history of depression2, severity of cardiac disease3) these were entered 
in the first step. These variables were chosen as covariates because they have been 
shown to predict depression in people with coronary heart disease (e.g. [30, 71, 192]). 
Baseline scores for the outcome variable (e.g. baseline depression) were entered 
separately into the second step of the model in order to control for them and to 
isolate the extent to which baseline scores on the outcome variable would predict 
subsequent scores on the same variable at 6 months. Finally, baseline brooding (RRS 
brooding) or baseline worry (PSWQ), in separate models, was entered as a predictor 
variable in the third step. Equivalent ordered logistic multiple regression models were 
used as an alternative to staged multivariable regression for the EQ5D subscales 
mobility, self-care, usual activities, pain and anxiety/depression. 
Raw or prepared scores (as described in Chapter 3) for continuous predictor 
and outcome variables (RRS brooding, PSWQ, PHQ, BAI, EQ5D VAS, EQ5D index value, 
                                                     
2History of depression was omitted from models where quality of life was the outcome measure. 
3Using baseline NYHA classification in preference over left ventricular function, as more data was 
available for NYHA therefore allowing number of complete data sets for analysis to be maximised. 
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SAQ subscales, age, social support4) were used in the models. Binary categorical 
variables (sex, history of depression, NYHA functional classification) were entered as 
0/1. Index of multiple deprivation (IMD) decile was entered to represent 
socioeconomic status. 
The user-written Stata command hireg[351] was used to perform staged 
multivariable regression. The ‘nomiss’ option was specified in order to ensure listwise 
deletion of cases with missing data (i.e. to ensure that all steps of a given model were 
estimated based on the same cases as all other steps).  
4.3.5.3 Regression assumptions and diagnostics 
Standard regression diagnostics were used to investigate compliance with test 
assumptions: 
i. The distribution of standardised residuals for each model were 
inspected using histograms, and the Shapiro-Wilk test was used to 
detect deviations from normality.   
ii. The Breusch-Pagan test was used to confirm that the variance of 
residuals at each level of the predictors were equal (homoscedasticity).   
iii. The Durbin-Watson test was used to detect non-independence of 
residuals (autocorrelation). For samples in the region of N=100, Durbin-
Watson <1.34 for a model with 9 predictor variables, or <1.36 for a 
model with 8 predictors, was taken to indicate no autocorrelation[352]. 
iv. Variance inflation factor (VIF) was calculated for all predictor variables 
in each model, and VIF >10 was taken to indicate multicollinearity[353].  
 
Finally, the fit of each model to the sample data was evaluated. Studentized 
residuals were inspected using stem and leaf plots to detect potential outliers, plus 
>5% studentized residuals outside the range <-2 or >2 were taken to indicate that a 
model may contain outliers[354]. Cook’s distance >1 was used to indicate influential 
cases[355]. 
 
                                                     
4Assessed using the ENRICHD study Social Support Inventory (ESSI). 
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4.3.6 Prospective associations of predictors and outcomes at other assessment 
times 
Prospective associations of baseline predictors with 6 month outcomes were 
deemed to be the most conservative hypothesis test owing to the greatest time 
elapsed between assessments. However, associations of baseline predictors with 2 
month outcomes, and of 2 month predictors with 6 month outcomes were also 
investigated using the same methods as described in the previous section (Section 
4.3.5), in order to explore the stability of prospective associations at other 
combinations of assessment times.  
 
4.3.7 Prospective associations of predictors and outcomes using multilevel 
(repeated measures) models 
Multilevel modelling is an extension of conventional regression that allows for 
the analysis of associations among data with nested structures, including from 
longitudinal studies where an individual contributes data at multiple times (i.e. data 
from different assessment times is nested within the individual). Acknowledging the 
nested structure of such data is an advantage because it could be argued that multiple 
observations from the same participant are correlated, which violates the assumption 
of independence of conventional regression approaches. 
A further benefit of using multilevel models for the analysis of longitudinal data 
is that it maximises the amount of data available for analysis since, in contrast to other 
regression approaches that are based on the use of complete cases only, all available 
observations are included in the analysis even where there are missing data (e.g. 
because a participant missed an assessment, or withdrew from the study). Use of all 
cases increases power to detect effects, and improves the representativeness of the 
sample included in analyses.  
To extend the staged multivariable regression models previously described, and 
to investigate if worry or brooding at one assessment time predicted depression, 
anxiety or worse quality of life at a subsequent assessment time, while properly 
allowing for the effects of within-participant correlations between outcome variables 
at each of the assessment times, a series of multilevel mixed-effects linear regression 
analyses (multilevel (repeated measures) models) were conducted. 
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Multilevel modelling was conducting using the Stata mixed command, and 
proceeded in the following steps:  
i. Definition of data structure. 
ii. Hypothesis tests for random intercept variance. 
iii. Specification of random coefficients (‘growth curve’) models. 
iv. Selection and evaluation of models. 
 
4.3.7.1 Definition of data structure 
The data structure was declared such that assessment time (baseline, 2 
months, 6 months) was the level 1 variable (coded sequentially as assessment 1, 2 or 
3) and participants were the level 2 clusters (since in theory each participant could 
contribute a value of the outcome variable at each assessment time).  
4.3.7.2 Hypothesis test for random-intercept variance 
If a model does not contain random intercepts (in this case, between-participant 
variance in means) then multilevel modelling is not necessary since all clusters can be 
treated as equivalent and a single level (‘ordinary’) regression model is adequate. 
Therefore, a series of variance components models were used to investigate whether 
multilevel (repeated measures) models were justified.  
Participants were declared as random clusters with repeated measures of the 
relevant outcomes (PHQ, BAI, EQ5D and SAQ) as the outcome variable. The likelihood-
ratio test was used to indicate whether there was significant between-subjects 
variance in means (i.e. random intercepts), and intra-class correlation coefficients (ICC) 
were used to estimate the amount of variance attributable to within-participant 
correlations. Further multilevel (repeated measures) models were specified only where 
the likelihood-ratio test of the variance components model was significant and ICC 
>10%. 
4.3.7.3 Specification of random coefficients (‘growth curve’) models 
Random coefficients models are multilevel (repeated measures) models that 
allow random slopes to be specified in addition to random intercepts. In longitudinal 
models where participants are declared as clusters nested within occasions these are 
known as ‘growth curve’ models, and allow for between-participant variation in 
trajectories of the outcome variable over time (random slopes). 
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A series of growth curve models of increasing complexity were used to 
investigate the prospective association of rumination or worry with subsequent 
depression, anxiety and worse health-related quality of life. Random intercepts and 
random slopes were specified in each of these models for the level 1 unit (assessment 
time) and level 2 clusters (participants). The models are described below, and 
represent the following questions: 
i. Does the outcome variable at t predict the outcome variable at t+1?5 
ii. Does the predictor variable at t predict the outcome variable at t+1, after 
controlling for previous responses on the outcome variable? 
iii. Does the predictor variable at t predict the outcome variable at t+1, after 
controlling for previous responses on the outcome variable and other 
confounders? 
 
In all of these models, since the focus of the research question was to investigate 
prospective associations between predictors at one assessment time with outcomes at 
a subsequent assessment time, autoregressive lag-1 variables (n-1, where the current 
response was regressed on the previous response) were incorporated.  
The simplest models (‘i’, above) consisted of two fixed effects: time and a lag 
variable (n-1) to represent the previous response of the outcome variable. Similar to 
the staged multivariable regression models described previously, the outcome 
variables (in separate models) were PHQ, BAI, EQ5D and SAQ.  
Next, these models were extended (‘ii’, above) to include a fixed lag variable (n-1) 
to represent the main predictor (RRS brooding or PSWQ) at the previous assessment 
time.  
Finally, consistent with the staged multivariable regression models described 
earlier, other covariates (age, sex, socioeconomic status, social support, history of 
depression6 and severity of cardiac disease) were added to the models as fixed 
variables ( ‘iii’, above). Patients were recruited from both inpatient and outpatient 
settings and there was a degree of variability in time between index event (defined 
here as the admission date of the most recent hospitalisation for ACS) and baseline 
                                                     
5Where t refers to assessment time. 
6History of depression was omitted from models where quality of life was the outcome measure. 
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assessments. To investigate whether time from index event would predict any of the 
outcomes, the number of days from index event to baseline assessment was included 
as an additional covariate.  In addition, in order to explore whether differences in the 
time from baseline to completion of 2 and 6 month assessments would predict any of 
the outcomes, a sensitivity analysis was performed whereby the fully adjusted 
multilevel (repeated measures) models were conducted both with and without the 
number of days from baseline as an additional covariate. 
All multilevel (repeated measures) models assumed linear associations and 
were estimated using maximum likelihood estimation with the covariance structure 
set to unstructured. 
 In place of standard multilevel (repeated measures) models, random-
coefficient proportional-odds models and random-intercept proportional-odds models 
were used for the EQ5D subscales mobility, self-care, usual activities, pain and 
anxiety/depression, proceeding in the same steps as described above for the 
continuous outcome variables and using the user-written Stata command 
gllamm[356]). 
4.3.7.4 Selection and evaluation of multilevel (repeated measures) models 
Estimates produced by the growth curve models described in the previous 
section were stored and in each case compared to estimates produced by an 
alternative, nested, model that omitted the random effect of assessment time 
(random intercept model). A likelihood ratio test was used to compare the two 
models, and in doing so to indicate whether the random slope for time was required. If 
the likelihood ratio test was significant the model with random slope for time (growth 
curve, or random coefficient model) was retained, and if the likelihood ratio test was 
not significant the random slope was deemed unnecessary and the alternative model 
with random intercept only (random intercept model) was used. 
 The overall significance of the selected model was assessed using the Wald 
test, and the significance of individual predictors was derived from z tests associated 
with each coefficient.  
4.3.7.5 Assumptions of multilevel (repeated measures) models 
Following estimation and selection of the preferred models, relevant 
assumption checks were performed. First, the distribution of level 1 and level 2 
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residuals were visually inspected using histograms, and normality was statistically 
assessed using the Shapiro-Wilk test. Second, homoscedasticity (homogeneity of 
residual variance) at all levels of the explanatory variables and within clusters (i.e. 
within participant) was assessed by visual inspection of residuals vs. fitted values plots. 
 
4.3.8 Post-hoc analyses 
In order to explore the findings in greater depth, the following post-hoc analyses 
were conducted:  
i. Some previous studies suggest that the association of brooding with 
depression may be weaker in samples without elevated depressive 
symptoms e.g.[118, 183]. Since there were low levels of depression in this 
study this could explain the weak association in some analyses presented 
here between brooding and depression. An exploratory subgroup analysis 
was performed to compare the strength of bivariate correlations between 
brooding with PHQ in (a) participants with PHQ scores ≥10 at baseline 
(depressed subgroup), and (b) participants with PHQ scores of <10 at 
baseline (non-depressed subgroup).  
ii. The association of rumination and depression could be bidirectional. In 
order to investigate the prospective reverse association (i.e. the association 
of baseline depression with 6 month brooding), first a simple regression 
analysis was conducted with baseline depression as the predictor and 6 
month brooding as the outcome variable.  Next, in order to control for 
covariates (age, sex, socioeconomic status, social support, history of 
depression, and severity of cardiac disease) a staged multivariable 
regression analysis was performed with the covariates entered in the first 
step, baseline brooding entered in the second step and baseline depression 
entered in the final step. 
iii. Low perceived availability of social support was a strong predictor of the 
majority of outcomes including depression. The findings of multilevel 
(repeated measures) models showed that brooding was a significant 
predictor of subsequent depression. However after covariates including 
social support were entered into the model, the association of brooding 
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with subsequent depression became marginally non-significant. It is 
possible that social support could confound the association of brooding and 
depression. In order to better understand the association between 
brooding and social support, the multilevel (repeated measures) model 
with a lag variable for RRS brooding as the main predictor and PHQ as the 
outcome was repeated without including social support as a covariate (all 
other aspects of the model remained unchanged). 
4.4 Results 
4.4.1 Sample 
The flow of participants through each stage of recruitment and participation in 
the study is summarised in Figure 4.1.  
4.4.1.1 Characteristics of individuals invited to participate 
A total of 397 individuals (163 inpatients, 169 outpatients, and 65 contacted by 
letter) were invited to participate in the study. The average age of those approached 
was 67.3 years (SD 12.6 years, range 25 – 96 years), and 74.5% were male (290 male, 
100 female, 5 unknown). Females invited to participate were significantly older than 
males invited to participate (70.5 years vs. 66.2 years; z=-2.99, p=0.0028). 
4.4.1.2 Characteristics of participants at baseline  
169 individuals who met the inclusion criteria consented to participate and 
returned the baseline questionnaire measures. Demographic and disease variables for 
all participants who completed baseline questionnaire measures are summarised in 
Table 4.1.  
The mean age of participants was 66.8 years and 77.5% were male. Females 
were significantly older than males (70.0 years vs. 65.9 years; z=-2.11, p=0.0353). Just 
over one quarter of participants had a diagnosis of angina, and the remaining three 
quarters had a diagnosis of myocardial infarction, split approximately evenly between 
ST-Elevation Myocardial Infarction (STEMI) and non-ST-Elevation Myocardial Infarction 
(NSTEMI). Clinical records indicated that approximately half of the sample had good 
left ventricular function, and approximately half of the sample reported no functional 
impairments related to ACS. Approximately three quarters of participants were in a 
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relationship and lived with another person, and almost two thirds were not in 
employment.  
4.4.1.3 Comparison of participants with individuals who declined to participate  
There was no difference in age between participants who returned the baseline 
questionnaire measures compared with individuals who were invited but did not 
participate in the study (z=-0.68, p>0.05). Similarly, there was no difference in the 
proportion of males and females who returned the baseline questionnaire measures 
compared with those who were invited but did not subsequently participate in the 
study (χ²(1)=1.28, p>0.05). Other comparisons were not possible because other sample 
characteristics at approach were unknown (this information could only be accessed if 
an individual consented to participate). 
4.4.1.4 Comparison of depressed and non-depressed participants at baseline 
There were 143 participants who were not depressed at baseline (PHQ<10) and 
24 who were depressed at baseline (PHQ≥10) i.e. 14.4% of the sample were depressed 
at baseline.  
Comparison of demographic variables showed that the subgroup of 
participants with depression at baseline were younger and more of them were not in a 
relationship, lived alone, had a history of depression, were smokers, exercised less 
frequently and had worse socioeconomic status than the group without depression at 
baseline (results of these analyses are summarised in Appendix 9).  Comparison of 
disease related variables showed that there were no group differences in diagnosis, 
left ventricular function, days since index event, number of comorbidities, troponin, or 
white blood cell count. However, more of the subgroup of participants with depression 
had raised C-reactive protein (CRP) during hospital admission compared to those 
without depression (results of these analyses are summarised in Appendix 9).  
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Figure 4.1: Flow of participants through recruitment and study completion 
 
Q1=baseline assessments, Q2=2 month assessments, Q3=6 month assessments.
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Table 4.1: Sample characteristics at baseline 
 Baseline sample n=169 
 N % Mean SD 
Demographic variables     
Age (years)  169  66.78 11.60 
Sex Male 131  77.51   
 Female 38  22.49   
Years of education Secondary (11 years or less) 58 38.16   
 Higher (more than 11 years) 94 61.84   
Employment status 
 
In employment  
(full-time, part-time, self- employed, homemaker) 
65  38.46   
 Not in employment  
(unemployed, retired, other) 
104  61.54   
Relationship status In a relationship 
(married, co-habiting, civil partnership) 
122  72.62   
    
 
Not in a relationship 
(single, divorced/separated, widowed, other) 
46  27.38   
Lives alone Yes 125 25.60   
 No 43 74.40   
Index of multiple 
deprivation 
Most deprived (deciles 1 to 6) 82 50.31   
Least deprived (deciles 7 to 10) 81 49.69   
History of depression Yes 16  9.47   
 No 153  90.53   
Smoking status Smoker 18 10.71   
 Non-smoker 150  89.29   
Alcohol use Never / infrequent (once a week or less) 95 57.23   
 Regular (twice a week or more) 71 42.77   
Drug use Never / infrequent (once a week or less) 167 98.82   
 Regular (twice a week or more) 2 1.18   
Table continues on following page… 
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 Baseline sample n=169 
 N % Mean SD 
Exercise Never / infrequent (once a week or less) 57 34.13   
 Regular (twice a week or more) 110 65.87   
ESSI social support  169  25.50 5.75 
Disease variables     
Diagnosis Angina 47  27.81   
 STEMI 63  37.28   
 NSTEMI 58  34.32   
 Unknown 1 0.59   
Days since index event*  161  110.63 75.38 
Left ventricular function Good / normal function 63 47.73   
 Mild dysfunction 42 31.82   
 Moderate dysfunction 21 15.91   
 Severe dysfunction 6 4.55   
NYHA functional 
classification 
No impairment 78 46.99   
Some impairment (mild, moderate, severe) 88 53.01   
Number of diseased 
vessels (>50% occluded) 
0 4 2.37   
1 70 41.42   
2 53 31.36   
3 42 24.85   
Comorbidity score 1 or less 121 71.60   
 2 or more 48 28.40   
Troponin  116  936.08 1858.85 
C-reactive protein Inflammation absent (<10 mg/L) 54 59.34   
 Inflammation present (≥10 mg/L) 37 40.66   
White cell count Normal (<12 x109/L) 114 69.94   
 Raised (≥12 x109/L) 49 30.06   
*Index event = admission date of most recent hospitalisation for ACS prior to the baseline questionnaires being completed (for the majority of patients this was 
also the admission date of the most recent hospitalisation for ACS prior to recruitment).  
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4.4.2 Baseline assessments 
4.4.2.1 Description of main predictors and outcomes at baseline 
Summary statistics for RRS brooding, PSWQ, PHQ, BAI, EQ5D, and SAQ at 
baseline are presented in Table 4.2. 
Comparison of baseline predictors and main outcomes between participants 
who were depressed at baseline and participants who were not depressed at baseline 
showed that depressed participants had higher brooding and worry scores, higher 
anxiety and worse general health and cardiac specific quality of life. Descriptive 
statistics and results of statistical tests are summarised in Appendix 10. 
4.4.2.2 Missing data at baseline 
The number of missing cases for any of the main predictors or outcome 
variables at baseline ranged from 0 to 13 (0% to 7.7% of cases, based on total n=169), 
and the total number of missing items for any multi-item variable at baseline ranged 
from 1 to 50 (0.1% to 5.1% of items). Missing data at case and scale/subscale level is 
summarised in Appendix 11. 
For each main predictor and main outcome variable, characteristics (age, 
gender ratio, baseline PHQ) of respondents with missing data were compared to those 
for whom data was available.  Cases with missing RRS brooding (z=-2.37, p=0.0179), 
PSWQ (z=-3.49, p=0.0005), and PHQ (z=-1.949, p=0.0513) data were older than cases 
for whom data was available. A greater number of cases with missing EQ5D VAS data 
were female (χ2(1)=6.98, p=0.050), and cases with missing SAQ frequency data had 
higher PHQ scores (z=-2.01, p=0.0444) compared to cases for whom data was 
available. These comparisons were based on between 2 and 7 missing cases. 
4.4.2.3 Associations of sample characteristics with main predictors at baseline 
There were significant but weak correlations between RRS brooding with lower 
age and less perceived availability of social support, and between PSWQ with lower 
age and less perceived availability of social support. All other correlations were non-
significant, or correlation coefficients were of negligible magnitude (r<0.20). All 
correlations are summarised in Appendix 12. 
In addition, results of difference tests showed that RRS brooding was 
significantly greater in smokers compared to non-smokers (RRS 9 vs. 7; z=-2.43, 
p=0.0153). PSWQ was significantly higher in participants with a history of depression 
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compared to those without a history of depression (PSWQ=49 vs. 35; z=-2.19, 
p=0.0286) and in participants who were employed compared to those who were 
unemployed (PSWQ=39 vs. 34; z=-2.12, p=0.0336). 
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Table 4.2: Main predictor variables and main outcomes at baseline 
 N Min Max Mean SD Median IQR 
Main predictors        
Total PSWQ 163 16.00 73.00 37.63 13.69 35.00 21.00 
RRS Brooding 162 5.00 19.00 8.10 3.05 7.00 4.00 
Main outcomes        
Total PHQ 167 0.00 20.00 4.25 4.90 2.00 5.00 
Total BAI 167 0.00 41.00 8.70 9.21 5.53 10.00 
EQ5D VAS 167 20.00 100.00 72.89 17.56 75.00 25.00 
EQ5D Index value 165 -0.20 1.00 0.78 0.20 0.81 0.29 
EQ5D Mobility 167 1.00 4.00 1.64 0.89 1.00 1.00 
EQ5D Self-care 167 1.00 3.00 1.17 0.49 1.00 0.00 
EQ5D Usual activities 166 1.00 5.00 1.81 1.08 1.00 1.00 
EQ5D Pain 167 1.00 5.00 1.72 0.79 2.00 1.00 
EQ5D Anxiety / depression 166 1.00 5.00 1.55 0.86 1.00 1.00 
SAQ Physical limitations 162 8.33 100.00 73.90 24.30 80.56 41.72 
SAQ Angina frequency 167 20.00 100.00 88.98 17.13 100.00 20.00 
SAQ Angina stability 156 0.00 100.00 83.49 24.35 100.00 50.00 
SAQ Treatment satisfaction 164 31.25 100.00 89.98 14.70 100.00 15.63 
SAQ Disease perception 160 8.33 100.00 70.34 25.14 75.00 41.67 
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4.4.2.4 Associations of sample characteristics with main outcomes at baseline  
There were small to medium sized correlations between NYHA functional 
classification with PHQ, BAI and the majority of EQ5D and SAQ subscales (r=0.18 to 
r=0.53), such that greater severity of cardiac disease was associated with greater 
depression and anxiety, and with poorer quality of life. Social support was weakly 
correlated with all outcome variables (r=0.16 to r=0.38) such that greater social 
support was associated with lower depression and anxiety and with better quality of 
life. Increasing age was weakly correlated with less depression, less anxiety, better 
EQ5D anxiety/depression and greater SAQ physical limitations (r=0.15 to r=0.31). 
Finally, number of comorbidities was significantly correlated with greater limitations in 
EQ5D mobility (r=0.42). Other correlations were non-significant or coefficients were of 
negligible magnitude. All correlations are summarised in Appendix 13. 
In addition, results of difference tests showed that depression was greater in 
participants with a history of depression, smokers and participants who exercised 
infrequently. Anxiety was greater in participants who were smokers and who exercised 
infrequently. Quality of life was worse in participants who were female, in 
employment, not in a relationship, had a history of depression, were smokers, drank 
alcohol frequently and exercised infrequently. Significant results are summarised fully 
in Appendix 14. 
4.4.2.5 Bivariate associations among main predictors and outcomes at baseline 
The main predictor variables, RRS brooding and PSWQ, were moderately 
correlated at baseline (r=0.51, p<0.001). The majority of main outcome variables (PHQ, 
BAI, EQ5D and SAQ) were also significantly correlated with each other at baseline (see 
correlation matrix in Appendix 15).  
Correlations between the main predictor variables (RRS brooding and PSWQ) 
and the main outcome variables (PHQ, BAI, EQ5D and SAQ) at baseline are presented 
in Table 4.3. There were small to medium correlations between both PSWQ and RRS 
brooding with the majority of outcome measures, with the exception that PSWQ was 
not correlated with the EQ5D mobility subscale, and neither RRS brooding nor PSWQ 
was correlated with the SAQ stability of angina subscale. The strongest associations 
were between RRS brooding with greater PHQ, BAI and EQ5D anxiety/depression 
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(r=0.53 to r=0.55), and between PSWQ with greater PHQ, BAI and EQ5D 
anxiety/depression (r=0.39 to r=0.50). 
 
 
 
Table 4.3: Correlations between RRS brooding and PSWQ with main outcome 
variables at baseline 
 RRS brooding PSWQ  
 N r N r 
Total PHQ 162 0.55a 163 0.46a 
Total BAI 162 0.53a 162 0.45a 
EQ5D VAS 161 -0.31a 162 -0.29a 
EQ5D Index value 160 -0.43a 160 -0.35a 
EQ5D Mobility 160 0.17c 161 0.11 
EQ5D Self-care 160 0.19b 161 0.14c 
EQ5D Usual activities 160 0.27a 161 0.18b 
EQ5D Pain 160 0.23a 161 0.24a 
EQ5D Anxiety / depression 160 0.55a 160 0.39a 
SAQ Physical limitations 156 -0.18c 156 -0.19c 
SAQ Angina frequency 160 -0.27a 161 -0.26a 
SAQ Angina stability 151 -0.06 151 -0.12 
SAQ Treatment satisfaction 158 -0.27a 158 -0.21b 
SAQ Disease perception 155 -0.41a 155 -0.37a 
ap<0.001 bp≤0.01 cp≤0.05. 
 
 
 
4.4.3 2 month assessments 
4.4.3.1 Timing of 2 month assessments 
Assessments at 2 months were conducted as close to 2 months after baseline 
assessments as possible. The actual number of days from baseline to 2 month 
assessments ranged from 55 to 210. The mean number of days between baseline and 
2 month assessments was 95.6 (SD 29.9), and the median was 84.0 (IQR 32.0).  
4.4.3.2 Attrition at 2 months 
Of 169 participants who completed baseline assessments, 44 participants did 
not complete the 2 month questionnaire packs (i.e. 26.0%). Of these 1 was too unwell 
to continue, 4 did not wish to continue with the study, and 39 did not return the 
questionnaire pack and the reason for non-completion was unknown. 
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Compared to completers, non-completers at 2 months were significantly 
younger (62.4 years vs. 68.3 years; z=-2.41, p=0.0158) and had lower perceived social 
support (mean ESSI 24.8 vs. mean ESSI 25.7; z=-1.989, p=0.0467). More non-
completers than completers had no partner (43.2% vs. 21.8%; χ2(1)= 7.49, p=0.006), 
lived alone (40.9% vs. 20.2%; χ2(1)= 7.34, p=0.007), lived in a higher deprivation 
postcode (68.4% vs. 44.8%; χ2(1)= 6.50, p=0.011), and received a diagnosis of STEMI 
(52.3% vs. 32.0%; χ2(1)= 6.06, p=0.048).  
Characteristics of the sample that completed assessments at 2 months are 
summarised in Table 4.4, and compared with characteristics of the group that did not 
complete 2 month assessments.  
4.4.3.3 Description of main predictors and outcomes at 2 months 
Summary statistics for RRS brooding, PSWQ, PHQ, BAI, EQ5D and SAQ at 2 
months are presented in Table 4.5. 
4.4.3.4 Missing data at 2 months 
The number of missing cases for any of the main predictors or outcome 
variables at 2 months ranged from 1 to 9 (0.8% to 7.2% of cases, based on total 
n=125), and the total number of missing items for any multi-item variable at 2 months 
ranged from 4 to 78 (0.6% to 7.2% of items). Missing data at case and scale/subscale 
level is summarised in Appendix 16. 
For each main predictor and main outcome variable, characteristics (age, 
gender ratio, 2 month PHQ) of respondents with missing data were compared to those 
for whom data was available.  There were no significant differences in characteristics 
of participants with and without missing data. 
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Table 4.4: Sample characteristics (measured at baseline) of participants remaining in the study at 2 months 
  Completers n=125 Non-completers n=44 
 N % Mean SD N % Mean SD 
Demographic variables         
Age (years)*  125  68.33 9.63 44  62.41 15.23 
Sex Male 98 78.40   33 75.00   
 Female 27 21.60   11 25.00   
Years of education Secondary 45 39.13   13 31.14   
 Higher 70 60.87   24 64.86   
Employment status 
 
In employment  45 36.00   20 45.45   
 Not in employment  80 64.00   24 54.55   
Relationship status* In a relationship 97 78.23   25 56.82   
    Not in a relationship 27 21.77   19 43.18   
Lives alone* Yes 25 20.16   18 40.91   
 No 99 79.84   26 59.09   
Index of multiple 
deprivation* 
Most deprived 56 44.80   26 68.42   
Least deprived  69 55.20   12 31.58   
History of depression Yes 12 9.60   4 9.09   
 No 113 90.40   40 90.91   
Smoking status Smoker 10 8.00   8 18.60   
 Non-smoker 115 92.00   35 81.40   
Alcohol use Never / infrequent 69 56.10   26 60.47   
 Regular  54 43.90   17 39.53   
Drug use Never / infrequent  124 99.20   43 97.73   
 Regular  1 0.80   1 2.27   
Exercise Never / infrequent  40 32.26   17 39.53   
 Regular  84 67.74   26 60.47   
ESSI social support*  125  25.74 5.92 44  24.81 5.23 
Table continues on following page… 
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 Completers n=125 Non-completers n=44 
 N % Mean SD N % Mean SD 
Disease variables         
Diagnosis* Angina 36 28.80   11 25.00   
 STEMI 40 32.00   23 52.27   
 NSTEMI 48 38.40   10 22.73   
 Unknown 1 0.80   0 0   
Days since index event   118  110.09 79.73   112.09 62.72 
Left ventricular function Good / normal function 47 48.96   16 44.44   
 Mild dysfunction 31 32.29   11 30.56   
 Moderate dysfunction 14 14.58   7 19.44   
 Severe dysfunction 4 4.17   2 5.56   
NYHA functional 
classification 
No impairment 60 48.78   18 41.86   
Some impairment 63 51.22   25 58.14   
Number of diseased 
vessels (>50% occluded) 
0 2 1.60   2 4.55   
1 50 40.00   20 45.45   
2 38 30.40   15 34.09   
3 35 28.00   7 15.91   
Comorbidity score 1 or less 90 72.00   31 70.45   
 2 or more 35 28.00   13 29.55   
Troponin  87  974.88 1878.35 29  819.69 1826.51 
C-reactive protein Inflammation absent  40 60.61   14 56.00   
 Inflammation present  26 39.39   11 44.00   
White cell count Normal  90 74.38   24 57.14   
 Raised  31 26.45   18 42.86   
*Completers and dropouts significantly different. 
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Table 4.5: Main predictor variables and main outcomes at 2 months 
 N Min Max Mean SD Median IQR 
Main predictors        
Total PSWQ 124 16.00 76.00 36.03 13.44 34.50 18.50 
RRS Brooding 124 5.00 17.00 7.68 2.88 7.00 3.00 
Main outcomes        
Total PHQ 124 0.00 20.00 3.70 4.69 2.00 5.00 
Total BAI 122 0.00 40.00 7.87 8.74 5.00 10.00 
EQ5D VAS 124 7.00 100.00 74.74 19.18 80.00 20.00 
EQ5D Index value 123 0.11 1.00 0.81 0.19 0.84 0.28 
EQ5D Mobility 124 1.00 4.00 1.61 0.88 1.00 1.00 
EQ5D Self-care 124 1.00 3.00 1.13 0.38 1.00 0.00 
EQ5D Usual activities 124 1.00 5.00 1.57 0.85 1.00 1.00 
EQ5D Pain 123 1.00 4.00 1.63 0.75 1.00 1.00 
EQ5D Anxiety / depression 124 1.00 4.00 1.44 0.77 1.00 1.00 
SAQ Physical limitations 120 5.56 100.00 77.94 22.21 83.33 35.42 
SAQ Angina frequency 122 20.00 100.00 90.12 16.94 100.00 10.00 
SAQ Angina stability 116 0.00 100.00 76.51 24.74 75.00 50.00 
SAQ Treatment satisfaction 119 43.75 100.00 90.28 13.39 100.00 18.75 
SAQ Disease perception 118 16.67 100.00 75.85 21.58 83.33 33.33 
 
 
124 
 
4.4.4 6 month assessments 
4.4.4.1 Timing of 6 month assessments 
Assessments at 6 months were conducted as close to 6 months after baseline 
assessments as possible. The actual number of days from baseline to 6 month 
assessments ranged from 158 to 384. The mean number of days between baseline and 
6 month assessments was 200.6 (SD 31.8), and the median was 195.5, (IQR 31.5).  
4.4.4.2 Attrition at 6 months 
Of 169 participants who completed baseline assessments, 58 participants did 
not complete the 6 month questionnaire pack (i.e. 34.3%). Of these 3 were too unwell 
to continue, 4 did not wish to continue with the study, 2 died, and 49 did not return 
the questionnaire pack and the reason for non-completion was unknown. 
Characteristics of the sample that completed assessments at 6 months are 
summarised in Table 4.6, and compared with characteristics of the group that did not 
complete 6 month assessments.  
Compared to completers, more non-completers at 6 months had raised white 
cell count (41.1% vs. 24.3%; χ2(1)= 4.92, p= 0.027) and raised C-reactive protein (55.6% 
vs. 30.9%; χ2(1)= 5.48, p= 0.019) at hospital admission. There was no significant 
difference in PHQ scores at baseline between completers (mean=3.77, SD=4.38) and 
non-completers (mean=5.20, SD=5.70) (z=1.26, p=0.2091) at 6 months. However, 
fewer participants who were depressed at baseline completed the study (11 out of 24 
i.e. 45.8%) compared to participants who were not depressed at baseline (99 out of 
143 i.e. 69.2%; χ2=5.00, p=0.025).  
4.4.4.3 Description of main predictors and outcomes at 6 months 
Summary statistics for the RRS brooding, PSWQ, PHQ, BAI, EQ5D and SAQ at 6 
months are presented in Table 4.7.  
4.4.4.4 Missing data at 6 months 
The number of missing cases for any of the main predictors or outcome 
variables at 6 months ranged from 0 to 6 (0.0% to 9.0% of cases, based on total 
n=111), and the total number of missing items for any multi-item variable at 6 months 
ranged from 0 to 85 (0.0% to 3.8% of items). Missing data at case and scale/subscale 
level is summarised in Appendix 17. 
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For each main predictor and main outcome variable, characteristics (age, 
gender ratio, 6 month PHQ) of respondents with missing data were compared to those 
for whom data was available.  There were no significant differences in characteristics 
of participants with and without missing data. 
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Table 4.6: Sample characteristics (measured at baseline) of participants remaining in the study at 6 months 
 Completers n=111 Non-completers n=58 
 N % Mean SD N % Mean SD 
Demographic variables         
Age (years)  111  68.26 9.07 58  63.97 15.02 
Sex Male 86 77.48   45 77.59   
 Female 25 22.52   13 22.41   
Years of education Secondary 37 36.27   21 42.00   
 Higher 65 63.73   29 58.00   
Employment status In employment  39 35.14   26 44.83   
 Not in employment  72 64.86   32 55.17   
Relationship status In a relationship 84 76.36   38 44.82   
    Not in a relationship 26 23.64   20 34.48   
Lives alone Yes 25 22.73   18 31.03   
 No 85 77.27   40 68.97   
Index of multiple 
deprivation 
Most deprived 51 45.95   31 59.62   
Least deprived  60 54.05   21 40.38   
History of depression Yes 9 8.11   7 12.07   
 No 102 91.89   51 87.93   
Smoking status Smoker 8 7.21   10 17.54   
 Non-smoker 103 92.79   47 82.46   
Alcohol use Never / infrequent 64 58.72   31 54.39   
 Regular  45 41.28   26 45.61   
Drug use Never / infrequent  111 100.00   56 96.55   
 Regular  0 0.00   2 3.45   
Exercise Never / infrequent  35 31.82   22 38.60   
 Regular  75 68.18   35 61.40   
ESSI social support  111  25.59 6.07 58  25.32 5.13 
Table continues on following page… 
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 Completers n=111 Non-completers n=58 
 N % Mean SD N % Mean SD 
Disease variables         
Diagnosis Angina 30 27.03   17 29.31   
 STEMI 39 35.14   24 41.38   
 NSTEMI 42 37.84   16 27.59   
 Unknown 0 0.00   1 1.72   
Days since index event   107  110.45 81.20     
Left ventricular function Good / normal function 44 51.76   19 40.43   
 Mild dysfunction 27 31.76   15 31.91   
 Moderate dysfunction 11 12.94   10 21.28   
 Severe dysfunction 3 3.53   3 6.38   
NYHA functional 
classification 
No impairment 53 49.07   25 43.10   
Some impairment 55 50.93   33 56.90   
Number of diseased 
vessels (>50% occluded) 
0 2 1.80   2 3.45   
1 46 41.11   24 41.38   
2 35 31.53   18 31.03   
3 28 25.23   14 24.14   
Comorbidity score 1 or less 84 75.68   37 63.79   
 2 or more 27 24.32   21 36.21   
Troponin  76  958.69 1898.69 40  893.13 1803.65 
C-reactive protein* Inflammation absent 38 69.09   16 44.44   
 Inflammation present 17 30.91   20 55.56   
White cell count* Normal 81 75.70   33 58.93   
 Raised 26 24.30   23 41.07   
*Completers and dropouts significantly different. 
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Table 4.7: Main predictor variables and main outcomes at 6 months 
 N Min Max Mean SD Median IQR 
Main predictors        
Total PSWQ 110 16.00 76.00 35.17 13.86 34.00 18.00 
RRS Brooding 108 5.00 18.00 7.70 2.82 7.00 3.00 
Main outcomes        
Total PHQ 111 0.00 22.00 3.15 4.55 1.00 4.00 
Total BAI 110 0.00 33.00 7.36 8.08 5.00 7.00 
EQ5D VAS 110 20.00 100.00 76.67 18.25 80.00 20.00 
EQ5D Index value 110 0.07 1.00 0.82 0.19 0.84 0.27 
EQ5D Mobility 110 1.00 4.00 1.54 0.85 1.00 1.00 
EQ5D Self-care 110 1.00 3.00 1.11 0.37 1.00 0.00 
EQ5D Usual activities 110 1.00 4.00 1.49 0.75 1.00 1.00 
EQ5D Pain 110 1.00 5.00 1.72 0.87 1.50 1.00 
EQ5D Anxiety / depression 110 1.00 4.00 1.43 0.77 1.00 1.00 
SAQ Physical limitations 107 13.89 100.00 79.13 23.47 88.89 33.33 
SAQ Angina frequency 110 30.00 100.00 88.82 17.60 100.00 20.00 
SAQ Angina stability 101 0.00 100.00 69.06 28.54 50.00 50.00 
SAQ Treatment satisfaction 105 16.67 100.00 89.72 15.60 100.00 18.75 
SAQ Disease perception 105 25.00 100.00 78.25 20.56 83.33 33.33 
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4.4.5 Changes in main predictors and outcomes over time 
Friedman’s test indicated that there was no significant change in the mean 
scores of predictor variables, RRS brooding and PSWQ, at any of the assessment times. 
There were large and highly significant correlations between RRS brooding at the three 
assessment times, and between PSWQ at the three assessment times (correlation 
coefficients are presented in Table 4.8). 
There was also no significant change over time in the mean scores of main 
outcome variables related to depression (PHQ), anxiety (BAI) or quality of life (EQ5D or 
SAQ), with the exception that SAQ angina stability scores were significantly lower at 
each assessment compared to the previous one (F=8.24, p=0.0163; baseline vs. 2 
months z=2.10, p=0.0356; baseline vs. 6 months z=3.76, p=0.0002; 2 months vs. 6 
months z=2.33, p=0.0197). 
 
 
 
Table 4.8: Correlations among RRS brooding at different assessment times and PSWQ 
at different assessment times 
  Baseline RRS brooding 2 month RRS brooding 
 N r N r 
2 month RRS brooding 121 0.76a - - 
6 month RRS brooding 106 0.78a 103 0.81a 
  Baseline PSWQ 2 month PSWQ 
 N r N r 
2 month PSWQ 121 0.72a - - 
6 month PSWQ 108 0.77a 104 0.77a 
ap≤0.001 bp≤0.01 cp≤0.05. 
 
 
 
4.4.6 Prospective associations of baseline predictors with 6 month outcomes 
4.4.6.1 Correlation of baseline predictors with 6 month outcomes 
Bivariate correlations between the main predictor variables at baseline (RRS 
brooding, PSWQ) and the main outcome variables at 6 months (PHQ, BAI, EQ5D and 
SAQ) are presented in Table 4.9. 
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 There were small to medium sized correlations between baseline RRS brooding 
and PSWQ with all outcome measures related to depression and anxiety, and with the 
majority of outcomes related to quality of life. The strongest associations were 
between RRS brooding with PHQ, BAI, EQ5D anxiety/depression and SAQ disease 
perception (r=0.33 to r=0.47) (such that higher brooding was correlated with greater 
depression, greater anxiety and worse quality of life) and between PSWQ with PHQ, 
BAI, EQ5D index value, EQ5D anxiety/depression and SAQ disease perception (r=0.32 
to r=0.38) (such that higher worry was correlated with greater depression, greater 
anxiety and worse quality of life). 
4.4.6.1.1 Sensitivity analysis exploring differences in associations between completers 
and non-completers 
Correlations between the main predictors and outcome variables at baseline 
for participants who completed assessments at 6 months were broadly similar to those 
for participants who did not complete assessments at 6 months (see Appendix 18), 
although correlations between brooding and overall quality of life appeared marginally 
stronger in non-completers compared to completers. This suggests that the 
associations of perseverative negative thinking with depression and anxiety, at least 
cross-sectionally, were not different for participants who completed the study 
compared to participants who withdrew from the study.   
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Table 4.9: Correlations between baseline PSWQ and RRS Brooding with main 
outcomes at 6 months 
 Baseline RRS brooding Baseline PSWQ  
 N r N r 
PHQ 108 0.47a 109 0.38a 
BAI 108 0.37a 109 0.37a 
EQ5D VAS 107 -0.18 108 -0.28b 
EQ5D Index value 107 -0.19c 108 -0.32a 
EQ5D Mobility 107 0.05 108 0.17b 
EQ5D Self-care 107 0.15 108 0.14 
EQ5D Usual activities 107 0.11 108 0.15p=0.057 
EQ5D Pain 107 0.16c 108 0.22b 
EQ5D Anxiety / depression 107 0.33a 108 0.33a 
SAQ Physical limitations 104 -0.05 105 -0.16 
SAQ Angina frequency 107 -0.23b 108 -0.19c 
SAQ Angina stability 98 -0.07 99 -0.08 
SAQ Treatment satisfaction 102 -0.15 103 -0.24b 
SAQ Disease perception 102 -0.36a 103 -0.32a 
ap≤0.001 bp≤0.01 c≤0.05. 
 
 
 
4.4.6.2 Predictors of depression at 6 months 
Simple regression models showed that baseline RRS brooding (F(1,106)=71.78, 
p<0.001) and baseline PSWQ (F(1,107)=32.16, p<0.001) significantly predicted 6 month 
PHQ scores. Brooding and worry accounted for 40% and 22%, respectively, of variance 
in depression.  
In a staged multivariable regression model with demographic variables entered 
in the first step, baseline depression entered in the second step and RRS brooding 
entered in the third step, the overall model was significant at each step with the full 
model accounting for 64% of the variance in 6 month depression (full results are 
reported in Table 4.10). Low perceived social support, baseline depression and 
baseline brooding were significant predictors of 6 month depression. At step 1 low 
social support explained 31% of the variance in 6 month depression, and in step 2 
baseline PHQ explained an additional 30%. The addition of baseline brooding to the 
model in the final step accounted for a further 2% of variance in 6 month depression 
scores.  
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In a separate staged multivariable regression model with demographic details 
entered in the first step, baseline depression entered in the second step and PSWQ 
entered in the third step, the overall model was significant at each step with the full 
model accounting for 60% of the variance in 6 month depression (results of the 
regression model are reported in Table 4.11). Low social support and baseline 
depression were significant predictors of 6 month depression. In step 1 low social 
support explained 28% of the variance in 6 month depression scores, and in step 2 
baseline PHQ explained an additional 30%. PSWQ was not a significant predictor of 6 
month depression.  
4.4.6.2.1 Subgroup analysis of depressed vs. non-depressed participants 
Previous research suggests that the association of brooding with depression 
may be stronger in people with initially elevated depressive symptoms compared to 
those without. It was not possible to formally test this with depressed and non-
depressed subgroups because only 24 participants (14.2%) were depressed at baseline 
(PHQ≥10) and 6 month assessments were only available for 11 of the 24.  Exploratory 
bivariate correlations between baseline brooding and 6 month PHQ were conducted 
instead. The correlation for participants who were depressed at baseline (PHQ≥10) 
was r=0.67, p=0.0228 and the correlation for those who were not depressed at 
baseline (PHQ<10) was r=0.32, p=0.0014. 
4.4.6.2.2 Reverse association 
A sensitivity analysis was performed to investigate the reverse association i.e. 
the association of baseline depression with brooding at 6 months. A simple regression 
model showed that there was a significant association between baseline depression 
and 6 month brooding (F(1, 106)=62.53, p<0.001, β=0.96, t=7.91, p<0.001), although 
after controlling for baseline brooding (other covariates were not significant) the effect 
was no longer significant (F(2, 103)=105.88, p<0.001, β=0.06, t=1.15, p=0.254). 
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Table 4.10: Staged multivariable regression of baseline brooding with 6 month depression (N=106) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(6,99)=8.93a 0.31  
Age -0.14 -0.07 0.04 -1.62    
Sex 0.01 0.06 0.96 0.06    
IMD -0.02 -0.05 0.17 -0.27    
Q1 ESSI -0.44 -0.34 0.07 -4.78a    
Q1 NYHA 0.16 1.48 0.80 1.83    
History of depression 0.12 2.01 1.43 1.41    
Step 2     F(7,98)= 26.20a 0.63 0.30 (F(1,98)=84.55a) 
Age 0.01 0.01 0.03 0.22    
Sex 0.10 1.16 0.72 1.62    
IMD 0.01 0.01 0.12 0.10    
Q1 ESSI -0.23 -0.17 0.06 -3.14b    
Q1 NYHA 0.07 0.66 0.60 1.09    
History of depression -0.03 -0.47 1.09 -0.43    
Q1 PHQ  0.68 0.71 0.08 9.20a    
Step 3     F(8,97)=24.68a 0.64 0.02 (F(1,97)=5.55c) 
Age 0.03 0.02 0.03 0.53    
Sex 0.09 1.04 0.70 1.48    
IMD 0.01 0.02 0.12 0.15    
Q1 ESSI -0.23 -0.17 0.05 -3.22b    
Q1 NYHA 0.08 0.71 0.59 1.22    
History of depression -0.03 -0.54 1.06 -0.51    
Q1 PHQ 0.55 0.57 0.10 5.90a    
Q1 RRS Brooding 0.20 0.29 0.12 2.36c    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Table 4.11: Staged multivariable regression of baseline worry with 6 month depression (N=107) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(6,100)=8.03a 0.28  
Age -0.13 -0.07 0.04 -1.56    
Sex -0.01 -0.16 0.97 -0.17    
IMD -0.02 -0.03 0.17 -0.19    
Q1 ESSI -0.41 -0.31 0.07 -4.37a    
Q1 NYHA 0.15 1.39 0.82 1.70    
History of depression 0.14 2.31 1.45 1.60    
Step 2     F(7,99)=23.90a 0.60 0.30 (F(1,99)=80.74a) 
Age 0.02 0.01 0.03 0.26    
Sex 0.09 0.96 0.73 1.32    
IMD 0.01 0.02 0.13 0.15    
Q1 ESSI -0.19 -0.14 0.06 -2.55b    
Q1 NYHA 0.06 0.57 0.62 0.93    
History of depression -0.01 -0.20 1.11 -0.18    
Q1 PHQ  0.69 0.72 0.08 8.99a    
Step 3     F(8,98)=20.83a 0.60 0.00 (F(1,98)=0.39) 
Age 0.03 0.01 0.03 0.38    
Sex 0.08 0.94 0.74 1.28    
IMD 0.01 0.01 0.13 0.09    
Q1 ESSI -0.19 -0.14 0.06 -2.55b    
Q1 NYHA 0.06 0.58 0.62 0.94    
History of depression -0.01 -0.17 1.12 -0.15    
Q1 PHQ 0.66 0.69 0.09 7.41a    
Q1 PSWQ 0.05 0.02 0.03 0.63    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
135 
 
4.4.6.3 Predictors of anxiety at 6 months 
Simple regression models showed that baseline RRS brooding (F(1,106)=42.01, 
p<0.001) and baseline PSWQ (F(1,107)=26.52, p<0.001) significantly predicted 6 month 
BAI scores. Brooding and worry accounted for 28% and 19%, respectively, of variance 
in anxiety.  
In a staged multivariable regression model with demographic variables entered 
in the first step, baseline anxiety entered in the second step and RRS brooding entered 
in the third step, the overall model was significant at each step with the full model 
accounting for 60% of the variance in 6 month anxiety (full results are reported in 
Table 4.12). Low perceived availability of social support, greater severity of heart 
disease, and baseline anxiety were significant predictors 6 month anxiety. In step 1 
social support and severity of heart disease together explained 38% of the variance in 
6 month anxiety, and in step 2 baseline anxiety explained an additional 20%. Baseline 
brooding was not a significant predictor of 6 month anxiety. 
In a separate staged multivariable model where PSWQ was entered in the third 
step instead of RRS brooding, the overall model was significant at each step with the 
full model accounting for 60% of the variance in 6 month anxiety (full results are 
reported in Table 4.13). In step 1 low social support and greater severity of heart 
disease were significant predictors and together explained 39% of the variance in 6 
month anxiety. In step 2, where baseline anxiety was added to the model, low social 
support and baseline anxiety were significant predictors of 6 month anxiety (where 
baseline anxiety accounted for an additional 20% of the variance) although severity of 
heart disease was no longer a significant predictor at this step. In the final step, 
baseline PSWQ was not a significant predictor of 6 month anxiety. 
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Table 4.12: Staged multivariable regression of baseline brooding with 6 month anxiety (N=106) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(6,99)=11.88a 0.38  
Age -0.12 -0.10 0.07 -1.44    
Sex 0.01 0.23 1.61 0.14    
IMD 0.03 0.09 0.28 0.33    
Q1 ESSI -0.45 -0.61 0.12 -5.10a    
Q1 NYHA 0.27 4.34 1.35 3.21b    
History of depression 0.13 3.83 2.39 1.60    
Step 2     F(7,98)= 23.06a 0.60 0.20 (F(1,98)=52.84a) 
Age -0.04 -0.03 0.06 -0.53    
Sex 0.11 2.11 1.33 1.59    
IMD 0.07 0.24 0.23 1.04    
Q1 ESSI -0.30 -0.41 0.10 -4.14a    
Q1 NYHA 0.13 2.19 1.13 1.94    
History of depression -0.04 -1.31 2.06 -0.63    
Q1 BAI  0.58 0.54 0.07 7.27a    
Step 3     F(8,97)=20.74a 0.60 0.01 (F(1,97)=3.32) 
Age -0.01 -0.01 0.06 -0.22    
Sex 0.10 1.97 1.32 1.49    
IMD 0.07 0.24 0.23 1.04    
Q1 ESSI -0.30 -0.40 0.10 -4.05a    
Q1 NYHA 0.15 2.37 1.13 2.09c    
History of depression -0.04 -1.25 2.05 -0.61    
Q1 BAI 0.50 0.47 0.09 5.31a    
Q1 RRS Brooding 0.13 0.33 0.22 1.52    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Table 4.13: Staged multivariable regression of baseline worry with 6 month anxiety (N=106) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(6,99)=12.33a 0.39  
Age -0.14 -0.13 0.07 -1.77    
Sex -0.00 -0.02 1.59 -0.01    
IMD 0.04 0.15 0.29 0.54    
Q1 ESSI -0.46 -0.63 0.12 -5.34a    
Q1 NYHA 0.24 3.90 1.34 2.91b    
History of depression 0.13 3.70 2.38 1.55    
Step 2     F(7,98)=23.23a 0.60 0.20 (F(1,98)=51.14a) 
Age -0.05 -0.04 0.06 -0.74    
Sex 0.10 1.96 1.33 1.47    
IMD 0.073 0.26 0.23 1.12    
Q1 ESSI -0.31 -0.43 0.10 -4.26a    
Q1 NYHA 0.12 1.98 1.12 1.77    
History of depression -0.05 -1.32 2.06 -0.64    
Q1 BAI  0.57 0.54 0.08 7.15a    
Step 3     F(8,97)=20.65a 0.60 0.01 (F(1,97)=1.59) 
Age -0.03 -0.02 0.06 -0.40    
Sex 0.09 1.87 1.32 1.41    
IMD 0.07 0.24 0.23 1.01    
Q1 ESSI -0.31 -0.42 0.10 -4.22a    
Q1 NYHA 0.13 2.04 1.12 1.82    
History of depression -0.04 -1.17 2.06 -0.57    
Q1 BAI 0.52 0.49 0.08 6.00a    
Q1 PSWQ 0.09 0.05 0.04 1.26    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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4.4.6.4 Predictors of general health-related quality of life (EQ5D) at 6 months 
4.4.6.4.1 Predictors of EQ5D VAS at 6 months 
Simple regression models showed that baseline RRS brooding (F(1,105)=10.47, 
p=0.0016, adj R2=0.08) and baseline PSWQ (F(1,106)=13.17, p=0.0004, adj R2=0.10) 
significantly predicted worse 6 month EQ5D VAS scores.  
A staged multivariable model that included baseline RRS brooding as a 
predictor in step 3 was significant at each step with the full model accounting for 35% 
of the variance in 6 month EQ5D VAS (full results are reported in Table 4.14). In the 
final step of the model low social support and baseline EQ5D VAS were significant 
predictors of worse 6 month EQ5D VAS. Baseline brooding was not a significant 
predictor of 6 month EQ5D VAS.  
Where the staged multivariable model included baseline PSWQ instead of RRS 
brooding in step 3, the model was significant at each step and the full model 
accounted for 35% of the variance in 6 month EQ5D VAS (full results are reported in 
Table 4.15). Consistent with the previous model, low perceived social support and 
baseline EQ5D VAS, in the final step, were significant predictors of worse 6 month 
EQ5D VAS. Baseline worry was not a significant predictor of 6 month EQ5D VAS.  
 
4.4.6.4.2 Predictors of EQ5D index values at 6 months 
Simple regression models showed that baseline RRS brooding (F(1,105)=9.28, 
p=0.0029, adj R2=0.07) and baseline PSWQ (F(1,107)=12.03, p=0.008, adj R2=0.09) 
significantly predicted worse 6 month EQ5D index values.  
A staged multivariable model with baseline RRS brooding as a predictor in step 
3 was significant at each step with the full model accounting for 44% of the variance in 
6 month EQ5D index values (full results are reported in Table 4.16). In the final step of 
the model male sex, low perceived availability of social support and baseline EQ5D 
index values were significant predictors of worse 6 month EQ5D index values. Baseline 
brooding was not a significant predictor of 6 month EQ5D index values. 
Where the staged multivariable model included baseline PSWQ as a predictor 
in step 3, the overall model was significant at each step with the full model accounting 
for 42% of the variance in 6 month EQ5D index values (full results are reported in Table 
4.17). In the final step of the model male sex, low social support and baseline EQ5D 
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index values were significant predictors of worse 6 month EQ5D index values. Baseline 
worry was not a significant predictor of 6 month EQ5D index values. 
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Table 4.14: Staged multivariable regression of baseline brooding with 6 month quality of life (EQ5D VAS) (N=104) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,98)=6.91a 0.22  
Age -0.03 -0.06 0.19 -0.32    
Sex -0.05 -2.09 4.19 -0.50    
IMD -0.15 -1.19 0.73 -1.62    
Q1 ESSI 0.42 1.30 0.29 4.48a    
Q1 NYHA -0.18 -6.79 3.46 -1.96c    
Step 2     F(6,97)= 9.92a 0.34 0.12 (F(1,97)=18.73a) 
Age -0.03 -0.06 0.17 -0.33    
Sex -0.06 -2.73 3.86 -0.71    
IMD -0.11 -0.88 0.68 -1.30    
Q1 ESSI 0.29 0.89 0.28 3.15b    
Q1 NYHA -0.08 -2.78 3.32 -0.84    
Q1 EQ5D VAS 0.40 0.45 0.10 4.33a    
Step 3     F(7,96)=8.88a 0.35 0.01 (F(1,96)=2.01) 
Age -0.06 -0.13 0.18 -0.71    
Sex -0.07 -2.95 3.84 -0.77    
IMD -0.11 -0.92 0.68 -1.37    
Q1 ESSI 0.26 0.81 0.29 2.85b    
Q1 NYHA -0.08 -2.87 3.30 -0.87    
Q1 EQ5D VAS 0.37 0.42 0.11 3.93a    
Q1 RRS Brooding -0.13 -0.76 0.54 -1.42    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Table 4.15: Staged multivariable regression of baseline worry with 6 month quality of life (EQ5D VAS) (N=105) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,99)=6.17a 0.20  
Age -0.02 -0.04 0.20 -0.19    
Sex -0.03 -1.17 4.22 -0.28    
IMD -0.17 -1.37 0.75 -1.82    
Q1 ESSI 0.39 1.18 0.29 4.14a    
Q1 NYHA -0.17 -6.31 3.50 -1.80    
Step 2     F(6,98)=9.57a 0.33 0.13 (F(1,98)=20.52a) 
Age -0.02 -0.04 0.18 -0.22    
Sex -0.05 -2.10 3.86 -0.54    
IMD -0.12 -1.00 0.69 -1.45    
Q1 ESSI 0.26 0.79 0.28 2.88b    
Q1 NYHA -0.06 -2.26 3.32 -0.68    
Q1 EQ5D VAS 0.42 0.47 0.10 4.53a    
Step 3     F(7,97)=8.83a 0.35 0.02 (F(1,97)=3.14) 
Age -0.07 -0.15 0.19 -0.78    
Sex -0.05 -2.39 3.82 -0.62    
IMD -0.11 -0.93 0.69 -1.36    
Q1 ESSI 0.25 0.75 0.27 2.72b    
Q1 NYHA -0.06 -2.26 3.28 -0.69    
Q1 EQ5D VAS 0.37 0.42 0.11 3.93a    
Q1 PSWQ -0.16 -0.21 0.12 -1.77    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Table 4.16: Staged multivariable regression of baseline brooding with 6 month quality of life (EQ5D Index) (N=103) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,97)=10.15a 0.31  
Age -0.09 -0.00 0.00 -1.10    
Sex -0.20 -0.09 0.04 -2.33c    
IMD -0.13 -0.01 0.01 -1.49    
Q1 ESSI 0.43 0.01 0.00 4.85a    
Q1 NYHA -0.32 -0.12 0.03 -3.63a    
Step 2     F(6,96)= 14.61a 0.44 0.13 (F(1,96)=24.59a) 
Age -0.14 -0.00 0.00 -1.83    
Sex -0.19 -0.09 0.04 -2.39c    
IMD -0.12 -0.01 0.01 -1.55    
Q1 ESSI 0.35 0.01 0.00 4.33a    
Q1 NYHA -0.15 -0.06 0.03 -1.73    
Q1 EQ5D Index value 0.42 0.43 0.09 4.96a    
Step 3     F(7,95)=12.45a 0.44 0.01 (F(1,95)=0.22) 
Age -0.15 -0.00 0.00 -1.88    
Sex -0.19 -0.09 0.04 -2.40b    
IMD -0.12 -0.01 0.01 -1.57    
Q1 ESSI 0.34 0.01 0.00 4.12a    
Q1 NYHA -0.16 -0.06 0.04 -1.77    
Q1 EQ5D Index value 0.41 0.42 0.09 4.41a    
Q1 RRS Brooding -0.04 -0.00 0.01 -0.47    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Table 4.17: Staged multivariable regression of baseline worry with 6 month quality of life (EQ5D Index) (N=104) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,98)=8.27a 0.26  
Age -0.08 0.00 0.00 -0.84    
Sex -0.17 -0.08 0.04 -1.87    
IMD -0.14 -0.01 0.01 -1.56    
Q1 ESSI 0.40 0.01 0.00 4.41a    
Q1 NYHA -0.29 -0.11 0.04 -3.12b    
Step 2     F(6,97)=13.04a 0.41 0.15 (F(1,97)=26.26a) 
Age -0.12 0.00 0.00 -1.55    
Sex -0.16 -0.07 0.04 -1.95c    
IMD -0.14 -0.01 0.01 -1.73    
Q1 ESSI 0.32 0.01 0.00 3.84a    
Q1 NYHA -0.11 -0.04 0.03 -1.27    
Q1 EQ5D Index value 0.45 0.46 0.09 5.12a    
Step 3     F(7,96)=11.65a 0.42 0.01 (F(1,96)=2.30) 
Age -0.16 0.00 0.00 -1.92    
Sex -0.16 -0.07 0.04 -2.02c    
IMD -0.13 -0.01 0.01 -1.65    
Q1 ESSI 0.30 0.01 0.00 3.61a    
Q1 NYHA -0.12 -0.05 0.03 -1.39    
Q1 EQ5D Index value 0.40 0.41 0.09 4.42a    
Q1 PSWQ -0.13 0.00 0.00 -1.52    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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4.4.6.4.3 Predictors of EQ5D subscales at 6 months 
Simple logistic regression models showed that baseline RRS brooding was a 
significant predictor of worse EQ5D self-care (LR χ2(1)=4.70, p=0.0302, pseudo R2=0.06), 
pain (LR χ2(1)=5.51, p=0.0189, pseudo R2=0.02) and anxiety/depression (LR χ2(1)=18.76, 
p<0.001, pseudo R2=0.10) but not mobility or usual activities. In addition, baseline 
PSWQ significantly predicted worse 6 month EQ5D mobility (LR χ2(1)=6.17, p=0.0130, 
pseudo R2=0.03), pain (LR χ2(1)=6.77, p=0.0093, pseudo R2=0.03) and 
anxiety/depression (LR χ2(1)=18.17, p<0.001, pseudo R2=0.10), but not self-care or 
usual activities. 
In separate multiple ordered logistic regression models for each of the EQ5D 
subscales, baseline RRS brooding was not a significant predictor of any EQ5D subscales 
at 6 months. The full models were significant in all cases and the amount of variance 
explained ranged from 15% to 48%. In models that included baseline PSWQ instead of 
RRS brooding, PSWQ significantly predicted EQ5D mobility but none of the other 
subscales. The full models were significant in all cases and the amount of variance 
explained ranged from 14% to 47%.  
Findings are summarised in Table 4.18 and results of the individual ordered 
logistic regression models are presented in Appendix 19 (RRS brooding models) and 
Appendix 20 (PSWQ models).  
 
4.4.6.5 Predictors of cardiac disease-specific quality of life (SAQ) at 6 months 
Simple regression models showed that baseline RRS brooding was a significant 
predictor of worse SAQ angina frequency (F(1,105)=8.37, p=0.0046, adj R2=0.07) and 
disease perception (F(1,100)=13.93, p=.0046, adj R2=0.11) but not physical limitations, 
angina stability or treatment satisfaction. In addition, baseline PSWQ significantly 
predicted worse 6 month SAQ treatment satisfaction (F(1,101)=3.95, p=0.0496, adj 
R2=0.03) and disease perception (F(1,101)=8.82, p=0.0037, adj R2=0.07), but not 
physical limitations, angina frequency or angina stability.  
In separate staged multivariable regression models for each of the SAQ 
subscales that controlled for the effect of important covariates, neither baseline RRS 
brooding or baseline PSWQ were significant predictors of any SAQ subscale at 6 
months. The full models were significant in all cases (with the exception of one model 
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where PSWQ at baseline was the main predictor variable and angina stability at 6 
months was the outcome) and the amount of variance explained ranged from 10% to 
47%. Combinations of low social support, worse severity of cardiac disease and 
baseline scores on the relevant SAQ subscale were significant predictors of 6 month 
quality of life in the final steps of the significant models. The findings are summarised 
in Table 4.19, and the results of individual regression models are provided in Appendix 
21 (where RRS brooding was the main predictor) and in Appendix 22 (where PSWQ 
worry was the main predictor). 
 
 
 
Table 4.18: Summary of ordered logistic regression models of baseline brooding and 
worry with 6 month quality of life (EQ5D subscales) 
Brooding models EQ5D 
Mobility 
EQ5D  
Self-care 
EQ5D  
Usual 
activities   
EQ5D  
Pain 
EQ5D 
Anxiety/ 
depression 
Age      
Sex      
IMD      
Q1 ESSI      
Q1 NYHA      
Q1 EQ5D      
Q1 RRS Brooding       
 
Worry models EQ5D 
Mobility 
EQ5D  
Self-care 
EQ5D  
Usual 
activities   
EQ5D  
Pain 
EQ5D 
Anxiety/ 
depression 
Age      
Sex      
IMD      
Q1 ESSI      
Q1 NYHA      
Q1 EQ5D       
Q1 PSWQ      
 
p≤0.05 p≤0.01 p≤0.001 
Q1=baseline. 
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Table 4.19: Summary of staged multivariable regression models of baseline brooding 
and worry with 6 month quality of life (SAQ subscales) 
Brooding models SAQ  
Physical 
limitations 
SAQ  
Angina 
frequency 
SAQ  
Angina 
stability 
SAQ 
Treatment 
satisfaction 
SAQ  
Disease 
perception 
Age      
Sex      
IMD      
Q1 ESSI      
Q1 NYHA      
Q1 SAQ      
Q1 RRS Brooding      
 
Worry models SAQ  
Physical 
limitations 
SAQ  
Angina 
frequency 
SAQ  
Angina 
stability 
SAQ 
Treatment 
satisfaction 
SAQ  
Disease 
perception 
Age       
Sex      
IMD      
Q1 ESSI      
Q1 NYHA      
Q1 SAQ       
Q1 Total PSWQ      
 
p≤0.05 p≤0.01 p≤0.001 
Q1=baseline. 
 
 
 
4.4.6.6 Time since index event 
Patients were recruited from inpatient and outpatient settings and there was a 
degree of variability in the interval between index event (i.e. cardiac event) and 
baseline assessments (baseline assessments were conducted on average 111 days 
post-ACS). A sensitivity analysis was performed to investigate if time since index event 
would predict any outcomes at 6 month follow-up. All staged multivariable regression 
models were repeated with the inclusion of time since index event as an additional 
covariate. 
Time since index event was not a significant predictor of any outcome at 6 
months. In addition, the inclusion of time since index event as a covariate did not alter 
the results of any of the staged multivariable regression models, with the exception 
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that in the fully adjusted model brooding at baseline was associated with depression at 
6 months at trend level only (p=0.06). 
Since the inclusion of time since index event as an additional covariate did not 
significantly predict any 6 month outcomes or substantially alter any of the results, all 
models are presented without time since index event included as a covariate. 
 
4.4.6.7 Evaluation of regression assumptions 
Results of tests to assess standard regression assumptions for all staged 
multivariable regression models are summarised in Appendix 23. 
Shapiro-Wilk tests revealed that all but two of the staged multivariable 
regression models (with SAQ disease perception as the outcome variable) violated the 
assumption of normally distributed residuals. In addition, Breusch-Pagan tests 
indicated that the assumption of homoscedasticity was violated for 12 of the 18 staged 
multivariable regression models (including all models where PHQ, BAI, EQ5D VAS and 
SAQ physical limitations, angina frequency and disease perception were the outcome 
variables). Multivariable regression is relatively robust to violations of normality and 
homoscedasticity (e.g. [357]) and such findings are common with clinical indicators 
such as depression and anxiety scales. 
Fit of the regression models to the sample data is summarised in Appendix 24. 
Cases containing possible outliers were identified in 8 out of 18 staged multivariable 
regression models, although Cook’s distance for all cases in all models was <1 
suggesting that influential cases were unlikely to pose a risk of bias in these models. 
 
4.4.6.8 Summary of regression analyses of baseline predictors with 6 month 
outcomes 
Significant baseline predictors of 6 month outcomes, based on simple 
regression analyses and on regression analyses that adjusted for confounders, are 
summarised in Table 4.20.  
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Table 4.20: Summary of significant baseline predictors of all 6 month outcomes based on simple and adjusted staged multivariable regression 
models 
Outcome Brooding 
(unadjusted ) 
Brooding 
(adjusted) 
Worry 
(unadjusted) 
Worry 
(adjusted) 
Other predictors 
PHQ Depression     Baseline outcome, social support 
BAI Anxiety     Baseline outcome, social support, severity of cardiac disease 
EQ5D VAS      Baseline outcome, social support 
EQ5D index     Baseline outcome, social support, sex 
EQ5D Mobility     Baseline outcome, social support, severity of cardiac disease,  index of 
multiple deprivation, age 
EQ5D Self-care     Baseline outcome 
EQ5D Usual activities     Baseline outcome, social support, severity of cardiac disease, age 
EQ5D Pain     Baseline outcome, social support 
EQ5D Anxiety / depression     Baseline outcome, social support, severity of cardiac disease 
SAQ Physical limitations     Baseline outcome, social support, severity of cardiac disease, age 
SAQ Angina frequency     Baseline outcome, severity of cardiac disease 
SAQ Angina stability     Social support 
SAQ Treatment satisfaction     Baseline outcome, social support 
SAQ Disease perception     Baseline outcome, social support 
=significant predictor. 
Green=significant predictor in brooding models only. 
Red=significant predictor in worry models only. 
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4.4.7 Prospective associations of predictors and outcomes at other assessment 
times 
4.4.7.1 Association of baseline predictors and 2 month outcomes 
 Bivariate correlations between baseline RRS brooding and PSWQ with the main 
outcome variables at 2 months are summarised in Appendix 25.  The strongest 
associations were of RRS Brooding with PHQ, BAI, EQ5D index value, EQ5D 
anxiety/depression and SAQ disease perception (r=0.34 to r=0.51) and between PSWQ 
with PHQ, BAI, EQ5D index value, EQ5D anxiety/depression and SAQ disease 
perception (r=0.33 to r=0.50). These findings are consistent with correlations between 
baseline predictors and 6 month outcomes although, as expected due to the closer 
temporal spacing, equivalent correlations tended to be of slightly larger magnitude. 
Simple regression analyses indicated that baseline RRS brooding and baseline 
PSWQ significantly predicted all 2 month outcomes, with the exceptions that RRS 
brooding did not predict stability of angina, and PSWQ did not predict physical 
limitations related to cardiac disease or problems with mobility.  
Results of staged multivariable regression analyses that extended the simple 
models by controlling for the effects of potential confounding variables were broadly 
similar to those investigating the association of baseline predictors with 6 month 
outcomes, with the exception that baseline RRS brooding did not predict 2 month 
PHQ. The results are summarised in Appendix 26 (baseline RRS brooding with 2 month 
outcomes) and Appendix 27 (baseline PSWQ with 2 month outcomes). 
4.4.7.2 Association of 2 month predictors and 6 month outcomes 
Bivariate correlations between 2 month RRS brooding and PSWQ with the main 
outcome variables at 6 months are summarised in Appendix 28. The strongest 
associations were of RRS brooding with PHQ, BAI and SAQ disease perception (r=0.42 
to r=0.52) and between PSWQ with PHQ, BAI, EQ5D index value, and EQ5D 
anxiety/depression (r=0.41 to r=0.49). Again, this is largely consistent with correlations 
between baseline predictors and 6 month outcomes.  
Simple regression analyses showed that 2 month RRS brooding and 2 month 
PSWQ significantly predicted all 6 month outcomes, with the exceptions that RRS 
brooding did not predict stability of angina, and PSWQ did not predict physical 
limitations or stability of angina.  
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Staged multivariable regression analyses exploring associations of 2 month 
predictors with 6 month outcomes after controlling for possible confounding variables 
were largely consistent with those investigating the association of baseline predictors 
with 6 month outcomes. However, an additional finding was that 2 month PSWQ was a 
significant predictor of 6 month EQ5D VAS. The results are summarised in Appendix 29 
(2 month RRS brooding with 6 month outcomes) and Appendix 30 (2 month PSWQ 
with 6 month outcomes). 
 
4.4.8 Results of longitudinal multilevel (repeated measures) models 
4.4.8.1 Between-participant variability in outcomes 
Variance components models confirmed that there was significant between-
cluster (i.e. between-participant) variability in the outcome variables representing 
depression, anxiety and quality of life (PHQ, BAI, EQ5D VAS, EQ5D index value and SAQ 
subscales).  
Intra-class correlation coefficients indicated that between 27% and 81% of the 
total variance in these models was represented by cluster level (i.e. participant level) 
variation.  Results are summarised in Appendix 31. 
The variance component models indicated that it was appropriate to specify 
multilevel (repeated measures) models that included a term to represent participant 
level clusters for all continuous outcome variables. 
4.4.8.2 Predictors of depression 
A simple growth curve model with assessment time and depression at the 
previous assessment time as predictors (model i) showed that depression at a previous 
assessment time significantly predicted depression at the subsequent assessment 
time. The likelihood ratio test indicated that it was appropriate to include random 
slopes for assessment time, suggesting that trajectories of depression over time varied 
between participants. Results of these models, and the likelihood ratio test, are 
summarised in Appendix 32. 
In an extension of the simple model that included RRS brooding at a previous 
assessment time as an additional predictor (model ii), both depression at the previous 
assessment time and RRS brooding at the previous assessment time significantly 
predicted depression at the subsequent assessment time. After inclusion of the 
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covariates age, sex, socioeconomic status, social support, history of depression, 
severity of cardiac disease and days since index event (model iii) depression at a 
previous assessment time and low social support were the only significant predictors 
of depression. There was a trend towards brooding at a previous assessment time 
predicting depression at the subsequent assessment time (p=0.065). Consistent with 
the simple models, likelihood ratio tests indicated it was appropriate to include 
random slopes for assessment time, suggesting that trajectories of depression over 
time varied between participants. Results of these models and likelihood ratio tests 
are reported in Table 4.21.  
In a separate extension of the simple model that included PSWQ at a previous 
assessment time as an additional predictor (model ii), depression at the previous 
assessment time but not PSWQ at a previous assessment time predicted depression at 
the subsequent assessment time.  In a model that included the covariates age, sex, 
index of multiple deprivation, social support, history of depression, severity of cardiac 
disease, and days since index event (model iii) previous depression and low social 
support were the only significant predictors of depression. Likelihood ratio tests 
indicated that trajectories of depression varied between participants. Results of these 
models and likelihood ratio tests are summarised in Table 4.22.    
 
4.4.8.2.1 Sensitivity analysis without social support as a covariate 
The stage iii model that included a lag variable for RRS brooding as the main 
predictor and PHQ as the outcome was repeated, but omitting social support as a 
covariate in order to assess the impact of brooding on depression independent of 
social support.  
A random coefficient model failed to converge, and therefore a random 
intercept model was used instead. The results showed that after controlling for other 
confounders brooding at a previous assessment time was a significant predictor of 
depression at a subsequent assessment time (β=0.17, SE=0.09, z=1.98, p=0.048) i.e. 
brooding was a significant predictor of depression when social support was removed 
from the model. Other significant predictors were depression at a previous assessment 
time and greater severity of cardiac disease, consistent with the random intercept 
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model that included social support as a covariate. Results of this model are provided in 
Appendix 33. 
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Table 4.21: Multilevel (repeated measures) models of brooding with depression 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=225)        
Fixed       
Χ2(2)= 20.65a 
Time -0.09 0.44 -0.21 -0.08 0.37 -0.21 
Total PHQ (n-1 lag) 0.85 0.04 19.39a 0.74 0.05 13.53a 
RRS Brooding (n-1 lag) 0.16 0.07 2.25c 0.20 0.08 2.34c 
Random       
Participant √ψ  10.97 94.36  0.00 0.00  
Participant √θ  1.48 53.90  2.78 0.13  
Time √ψ 4.29 37.17     
Overall model Wald χ2(3)=817.13a, Log likelihood=-538.97 Wald χ2(3)=417.02a, Log likelihood=-549.30 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=212)        
Fixed       
Χ2(2)= 23.63a 
Time -0.05 0.45 -0.11 -0.03 0.37 -0.07 
Total PHQ (n-1 lag) 0.78 0.05 16.38a 0.64 0.06 10.35a 
RRS Brooding (n-1 lag) 0.12 0.07 1.85p=0.065 0.15 0.09 1.77p=0.076 
Age -0.01 0.02 -0.57 -0.02 0.02 -0.76 
Sex 0.48 0.38 1.26 0.35 0.52 0.67 
IMD 0.01 0.06 0.17 0.01 0.09 0.13 
Q1 ESSI -0.10 0.03 -3.62a -0.11 0.04 -2.89b 
Q1 NYHA 0.50 0.30 1.63 0.84 0.42 2.01c 
History of depression -0.29 0.51 -0.57 0.36 0.69 0.52 
Days since index event 0.00 0.00 0.30 0.00 0.00 0.44 
Random       
Participant √ψ  12.06 11.50  0.00 0.00  
Participant √θ  0.30 35.84  2.69 0.13  
Time √ψ 4.66 4.57     
Overall model Wald χ2(10)=830.74a, Log likelihood=-498.45 Wald χ2(10)=387.79a, Log likelihood=-510.27 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Table 4.22: Multilevel (repeated measures) models of worry with depression 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=226)        
Fixed       
Χ2(1)=18.84a 
Time -0.13 0.44 -0.29 -0.12 0.38 -0.31 
Total PHQ (n-1 lag) 0.89 0.04 21.20a 0.80 0.05 15.67a 
Total PSWQ (n-1 lag) 0.01 0.01 0.66 0.01 0.02 0.81 
Random       
Participant √ψ  11.32 0.90  0.00 0.00  
Participant √θ  -0.99 0.00  2.81 0.13  
Time √ψ 4.44 0.36     
Overall model Wald χ2(3)=773.35a, Log likelihood=-544.94 Wald χ2(3)=403.59a, Log likelihood=-554.36 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=212)        
Fixed       
Χ2(1)=18.35a 
Time 0.00 0.45 0.00 0.00 0.38 0.01 
Total PHQ (n-1 lag) 0.83 0.05 16.61a 0.70 0.06 11.60a 
Total PSWQ (n-1 lag) 0.00 0.01 -0.08 0.00 0.02 0.08 
Age -0.01 0.02 -0.79 -0.02 0.02 -1.03 
Sex 0.41 0.40 1.03 0.31 0.53 0.59 
IMD 0.02 0.07 0.31 0.02 0.09 0.24 
Q1 ESSI -0.09 0.03 -3.21a -0.10 0.04 -2.80b 
Q1 NYHA 0.44 0.32 1.35 0.76 0.43 1.78 
History of depression -0.15 0.54 -0.28 0.41 0.70 0.59 
Days since index event 0.00 0.00 0.42 0.00 0.00 0.52 
Random       
Participant √ψ  10.91 0.95  0.00 0.00  
Participant √θ  1.41 .  2.72 0.13  
Time √ψ 4.22 0.38     
Overall model Wald χ2(10)=729.42a, Log likelihood=-503.96 Wald χ2(10)=372.50a, Log likelihood=-513.13 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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4.4.8.3 Predictors of anxiety 
A simple random intercept model with assessment time and anxiety at the 
previous assessment time as predictors (model i) showed that anxiety at a previous 
assessment time significantly predicted anxiety at the subsequent assessment time. 
The equivalent random coefficient model including a random slope for assessment 
time failed to converge. Results of the random intercept model are summarised in 
Appendix 34. 
In an extension of the simple random intercept model that included RRS 
brooding at a previous assessment time as an additional predictor (model ii), anxiety at 
the previous assessment time significantly predicted anxiety at the subsequent 
assessment time, but there was no significant effect of RRS brooding. After inclusion of 
the covariates age, sex, index of multiple deprivation, social support, history of 
depression, severity of cardiac disease, and days since index event (model iii) anxiety 
at a previous assessment time and low social support were the only significant 
predictors of anxiety. Likelihood ratio tests indicated it was appropriate to include 
random slopes for assessment time, suggesting that trajectories of anxiety over time 
varied between participants. Results of these models and likelihood ratio tests are 
reported in Table 4.23.  
In a second extension of the simple model that included total PSWQ at the 
previous assessment time as an additional predictor (model ii), anxiety, but not PSWQ, 
at the previous assessment time predicted anxiety at the next assessment time.  In a 
model that included the covariates age, sex, index of multiple deprivation, social 
support, history of depression, severity of cardiac disease and days since index event 
(model iii), anxiety at the previous assessment time and low social support were the 
only significant predictors of anxiety. Likelihood ratio tests indicated that trajectories 
of anxiety varied between participants. Results of these models and the likelihood 
ratio tests are summarised in Table 4.24. 
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Table 4.23: Multilevel (repeated measures) models of brooding with anxiety 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=221)        
Fixed       
Χ2(2)=9.18b 
Time 0.27 0.76 0.36 0.20 0.69 0.29 
Total BAI (n-1 lag) 0.77 0.05 17.08a 0.70 0.05 13.79a 
RRS Brooding (n-1 lag) 0.21 0.14 1.46 0.27 0.16 1.73p=0.083 
Random       
Participant √ψ  17.71 886.98  0.00 0.00  
Participant √θ  3.11 387.91  5.10 0.24  
Time √ψ 6.75 357.94     
Overall model Wald χ2(3)=585.91a, Log likelihood=-669.01 Wald χ2(3)=398.73a, Log likelihood=-673.60 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=208)        
Fixed       
Χ2(1)=7.73b 
Time 0.17 0.74 0.23 0.11 0.67 0.16 
Total BAI (n-1 lag) 0.66 0.05 12.92a 0.57 0.06 10.05a 
RRS Brooding (n-1 lag) 0.11 0.14 0.75 0.18 0.16 1.11 
Age -0.03 0.04 -0.82 -0.03 0.04 -0.64 
Sex 1.24 0.81 1.52 1.10 0.95 1.16 
IMD 0.15 0.14 1.09 0.13 0.16 0.80 
Q1 ESSI -0.30 0.06 -4.66a -0.33 0.07 -4.61a 
Q1 NYHA 1.14 0.68 1.69 1.43 0.78 1.83p=0.067 
History of depression -0.40 1.12 -0.36 0.46 1.27 0.37 
Days since index event 0.00 0.00 -0.35 0.00 0.00 -0.25 
Random       
Participant √ψ  14.88 2.91  0.00 0.00  
Participant √θ  3.65 0.45  4.82 0.24  
Time √ψ 5.59 1.16     
Overall model Wald χ2(10)=586.37a, Log likelihood=-618.75 Wald χ2(10)=410.51a, Log likelihood=-622.62 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Table 4.24: Multilevel (repeated measures) models of worry with anxiety 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=220)        
Fixed       
Χ2(1)=9.61b 
Time 0.17 0.76 0.23 0.07 0.69 0.11 
Total BAI (n-1 lag) 0.79 0.04 19.32a 0.73 0.05 16.14a 
Total PSWQ (n-1 lag) 0.03 0.03 1.12 0.03 0.03 1.17 
Random       
Participant √ψ  17.35 3.04  0.00 0.00  
Participant √θ  3.28 0.69  5.12 0.24  
Time √ψ 6.59 1.21     
Overall model Wald χ2(3)=585.12a, Log likelihood=-666.49 Wald χ2(3)=397.58a, Log likelihood=-671.30 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=207)        
Fixed       
Χ2(2)=8.13c 
Time 0.14 0.74 0.19 0.04 0.68 0.06 
Total BAI (n-1 lag) 0.68 0.05 14.13a 0.60 0.05 11.41a 
Total PSWQ (n-1 lag) 0.01 0.03 0.34 0.01 0.03 0.40 
Age -0.03 0.04 -0.89 -0.03 0.04 -0.75 
Sex 1.18 0.82 1.45 1.07 0.95 1.13 
IMD 0.14 0.14 1.00 0.11 0.16 0.70 
Q1 ESSI -0.31 0.06 -4.82a -0.35 0.07 -4.77a 
Q1 NYHA 0.96 0.67 1.42 1.22 0.78 1.57 
History of depression -0.50 1.12 -0.44 0.35 1.27 0.27 
Days since index event 0.00 0.00 -0.34 0.00 0.00 -0.22 
Random       
Participant √ψ  18.25 43.49  0.00 0.00  
Participant √θ  2.23 27.34  4.85 0.24  
Time √ψ 6.95 17.58     
Overall model Wald χ2(10)=588.19a, Log likelihood=-616.38 Wald χ2(10)=408.75a, Log likelihood=-620.45 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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4.4.8.4 Predictors of general health-related quality of life (EQ5D) 
4.4.8.4.1 Predictors of EQ5D VAS 
A simple random intercept model (model i) showed that EQ5D VAS at a 
previous assessment time significantly predicted EQ5D VAS at the next assessment 
time. The likelihood ratio test comparing this model with an equivalent random 
coefficient model indicated that trajectories of EQ5D VAS did not vary significantly 
between participants. These results are summarised in Appendix 35. 
In an extension of the simple models that included RRS brooding as an 
additional predictor (model ii), both EQ5D VAS at the previous assessment time and 
RRS brooding at the previous assessment time significantly predicted EQ5D VAS at the 
subsequent assessment time.  After inclusion of covariates (model iii) EQ5D VAS at the 
previous assessment time and low social support were the only significant predictors 
of EQ5D VAS. Trajectories of EQ5D VAS over time did not vary between participants. 
Results of these models are reported in Table 4.25.  
In a second extension of the simple model that included total PSWQ as an 
additional predictor (model ii), EQ5D VAS at the previous assessment time and lower 
PSWQ at the previous assessment time predicted higher EQ5D VAS at the next 
assessment time.  In a model that controlled for covariates (model iii), higher EQ5D 
VAS at the previous assessment time, lower PSWQ at the previous assessment time 
and low social support were significant predictors of higher EQ5D VAS. Trajectories of 
EQ5D VAS did not vary between participants. Results of these models are summarised 
in Table 4.26. 
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Table 4.25: Multilevel (repeated measures) models of brooding with EQ5D VAS 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=223)        
Fixed       
Χ2(2)=2.68 
Time 0.32 2.05 0.16 0.37 1.89 0.20 
EQ5D VAS (n-1 lag) 0.70 0.05 13.64a 0.63 0.05 11.55a 
RRS Brooding (n-1 lag) -0.75 0.32 -2.33c -0.83 0.35 -2.40c 
Random       
Participant √ψ  35.61 238.40  0.00 0.00  
Participant √θ  11.82 55.21  14.02 0.66  
Time √ψ 14.00 93.26     
Overall model Wald χ2(3)=250.27a, Log likelihood=-903.84 Wald χ2(3)=182.98a, Log likelihood=-905.17 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=211)        
Fixed       
Χ2(2)=5.55 
Time 0.07 2.07 0.03 0.17 1.87 0.09 
EQ5D VAS (n-1 lag) 0.69 0.05 13.05a 0.61 0.06 10.43a 
RRS Brooding (n-1 lag) -0.44 0.34 -1.28 -0.57 0.38 -1.50 
Age -0.05 0.10 -0.53 -0.06 0.11 -0.49 
Sex -3.00 2.27 -1.32 -3.04 2.61 -1.16 
IMD -0.33 0.38 -0.89 -0.30 0.43 -0.69 
Q1 ESSI 0.48 0.16 3.03b 0.52 0.18 2.88b 
Q1 NYHA -1.83 1.82 -1.00 -2.40 2.09 -1.15 
Days since index event -0.01 0.01 -1.43 -0.01 0.01 -1.04 
Random       
Participant √ψ  49.64 131.37  0.00 0.00  
Participant √θ  6.48 77.37  13.47 0.66  
Time √ψ 19.30 51.99     
Overall model Wald χ2(9)=315.36a, Log likelihood=-845.37 Wald χ2(9)=216.56a, Log likelihood=-848.15 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Table 4.26: Multilevel (repeated measures) models of worry with EQ5D VAS 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=224)        
Fixed       
Χ2(1)=3.17 
Time 0.69 2.03 0.34 0.75 1.86 0.40 
EQ5D VAS (n-1 lag) 0.69 0.05 13.60a 0.62 0.05 11.42a 
Total PSWQ (n-1 lag) -0.22 0.07 -3.32a -0.24 0.07 -3.30a 
Random       
Participant √ψ  35.86 10.06  0.00 0.00  
Participant √θ  11.66 1.31  13.88 0.66  
Time √ψ 14.13 4.031     
Overall model Wald χ2(3)=263.84a, Log likelihood=-905.49 Wald χ2(3)=190.02a, Log likelihood=-907.08 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=211)        
Fixed       
Χ2(2)=5.68 
Time 0.05 2.06 0.02 0.23 1.86 0.12 
EQ5D VAS (n-1 lag) 0.68 0.05 12.97a 0.60 0.06 10.36a 
Total PSWQ (n-1 lag) -0.14 0.07 -2.01c -0.16 0.08 -2.06c 
Age -0.05 0.10 -0.51 -0.05 0.11 -0.44 
Sex -2.69 2.26 -1.19 -2.73 2.60 -1.05 
IMD -0.32 0.38 -0.85 -0.28 0.43 -0.64 
Q1 ESSI 0.43 0.15 2.78b 0.48 0.18 2.72b 
Q1 NYHA -1.95 1.82 -1.07 -2.57 2.09 -1.23 
Days since index event -0.02 0.01 -1.56 -0.01 0.01 -1.17 
Random       
Participant √ψ  48.94 1071.86  0.00 0.00  
Participant √θ  6.72 600.10  13.42 0.65  
Time √ψ 19.06 423.50     
Overall model Wald χ2(9)=320.13a, Log likelihood=-844.43 Wald χ2(9)=219.12a, Log likelihood=-847.27 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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4.4.8.4.2 Predictors of EQ5D index value 
A simple random intercept model (model i) showed that EQ5D index value at a 
previous assessment time significantly predicted EQ5D index value at the next 
assessment time. The likelihood ratio test comparing this model with an equivalent 
random coefficient model that trajectories of EQ5D index value did not vary 
significantly between participants. Results are summarised in Appendix 36. 
In an extension of the simple models that included RRS brooding as an 
additional predictor (model ii), EQ5D index value at the previous assessment time 
significantly predicted EQ5D index value at the subsequent assessment time, and there 
was a trend (p=0.057) toward higher RRS brooding at the previous assessment time 
also predicting worse EQ5D index value at the next assessment time. After inclusion of 
covariates (model iii) EQ5D index value at the previous assessment time, high RRS 
brooding at the previous assessment time, low social support and greater severity of 
cardiac disease were significant predictors of worse EQ5D index values. Trajectories of 
EQ5D index value did not vary between participants. Results are reported in Table 
4.27.  
In a second extension of the simple model that included total PSWQ as an 
additional predictor (model ii) EQ5D index value at the previous assessment time and 
higher PSWQ at the previous assessment time predicted worse EQ5D index values at 
the next assessment time.  In a model that included covariates (model iii) EQ5D index 
value at the previous assessment time, low PSWQ at the previous assessment time, 
low social support and greater severity of cardiac disease were significant predictors of 
worse EQ5D index values. Trajectories of EQ5D index values did not vary between 
participants. These results are summarised in Table 4.28. 
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Table 4.27: Multilevel (repeated measures) models of brooding with EQ5D Index value 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=222)        
Fixed       
Χ2(2)=1.44 
Time -0.02 0.02 -1.39 -0.03 0.02 -1.44 
EQ5D Index value (n-1 lag) 0.73 0.05 14.13a 0.71 0.05 13.44a 
RRS Brooding (n-1 lag) -0.01 0.00 -1.82p=0.069 -0.01 0.00 -1.91p=0.057 
Random       
Participant √ψ  0.31 -  0.00 0.00  
Participant √θ  0.10 0.01  0.13 0.01  
Time √ψ 0.13 0.01     
Overall model Wald χ2(3)=291.50a, Log likelihood=140.84 Wald χ2(3)=266.64a, Log likelihood=140.12 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=209)        
Fixed       
Χ2(2)=5.19 
Time -0.02 0.02 -0.98 -0.02 0.02 -1.06 
EQ5D Index value (n-1 lag) 0.61 0.06 10.73a 0.58 0.06 9.59a 
RRS Brooding (n-1 lag) -0.01 0.00 -2.18c -0.01 0.00 -2.23c 
Age 0.00 0.00 -1.69 0.00 0.00 -1.47 
Sex -0.04 0.02 -1.82 -0.04 0.02 -1.83 
IMD 0.00 0.00 -0.97 0.00 0.00 -1.13 
Q1 ESSI 0.01 0.00 3.82a 0.01 0.00 3.51a 
Q1 NYHA -0.05 0.02 -2.81b -0.06 0.02 -2.75b 
Days since index event 0.00 0.00 -0.08 0.00 0.00 -0.08 
Random       
Participant √ψ  0.23 9.96  0.00 0.00  
Participant √θ  0.11 1.66  0.12 0.01  
Time √ψ 0.10 3.40     
Overall model Wald χ2(9)=372.85a, Log likelihood=146.89 Wald χ2(9)=312.46a, Log likelihood= 144.29 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Table 4.28: Multilevel (repeated measures) models of worry with EQ5D Index value 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=222)        
Fixed       
Χ2(1)=1.99 
Time -0.02 0.02 -1.33 -0.02 0.02 -1.38 
EQ5D Index value (n-1 lag) 0.73 0.05 14.95a 0.72 0.05 13.94a 
Total PSWQ (n-1 lag) 0.00 0.00 -2.07c 0.00 0.00 -2.07c 
Random       
Participant √ψ  0.30 -  0.00 0.00  
Participant √θ  0.10 0.01  0.13 0.01  
Time √ψ 0.12 0.01     
Overall model Wald χ2(3)=307.19a, Log likelihood=141.43 Wald χ2(3)=269.97a, Log likelihood=140.43 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=209)        
Fixed       
Χ2(2)=5.45 
Time -0.02 0.02 -1.02 -0.02 0.02 -1.08 
EQ5D Index value (n-1 lag) 0.62 0.06 11.32a 0.59 0.06 10.00a 
Total PSWQ (n-1 lag) 0.00 0.00 -2.25c 0.00 0.00 -2.11b 
Age 0.00 0.00 -1.49 0.00 0.00 -1.24 
Sex -0.03 0.02 -1.55 -0.04 0.02 -1.60 
IMD 0.00 0.00 -0.81 0.00 0.00 -0.94 
Q1 ESSI 0.01 0.00 3.62a 0.01 0.00 3.38a 
Q1 NYHA -0.05 0.02 -2.64b -0.05 0.02 -2.63b 
Days since index event 0.00 0.00 -0.36 0.00 0.00 -0.30 
Random       
Participant √ψ  0.44 1.43  0.00 0.00  
Participant √θ  0.03 1.82  0.12 0.01  
Time √ψ 0.18 0.54     
Overall model Wald χ2(9)=375.31a, Log likelihood=146.17 Wald χ2(9)= 310.43a, Log likelihood=143.45 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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4.4.8.4.3 Predictors of EQ5D subscales 
Both random coefficient and random intercept proportional-odds models for all 
EQ5D subscales failed to converge. Since failure to converge was common to the 
simple (i) and extended (ii and iii) models, a possible explanation is that random 
intercepts and slopes were not necessary for these models.  
Since it was not possible to run multilevel (repeated measures) models with the 
EQ5D subscales as outcomes, an alternative approach in line with the multilevel 
(repeated measures) modelling method used for the other continuous outcome 
variables was sought. Therefore, ordered logistic regression analysis was performed 
for each EQ5D subscale using the cluster option (defining participants as clusters) to 
obtain robust standard errors due to the nested data structure. The predictor variables 
in each model consisted of: (1) a fixed lag variable (n-1) for RRS brooding or total 
PSWQ (in separate models) to investigate associations between predictors at one 
assessment time with outcomes at a subsequent assessment time, (2) a fixed lag 
variable (n-1) for the relevant EQ5D subscale (i.e. the current response was regressed 
on the previous response), and (3) the covariates age, sex, index of multiple 
deprivation, social support, severity of cardiac disease and days since index event.  
 Findings are summarised in Table 4.29. All overall models were significant, 
explaining from 23% to 48% of variance, and previous subscale responses predicted 
subsequent subscale responses in all models. Results of regression models with RRS 
brooding as the main predictor are presented in Appendix 37, and results of regression 
models with PSWQ as the main predictor are presented in Appendix 38. 
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Table 4.29: Summary of ordered logistic regression analyses with brooding and worry 
lag variables as predictors and EQ5D subscales as outcomes 
Brooding models EQ5D 
Mobility 
EQ5D  
Self-care 
EQ5D  
Usual 
activities   
EQ5D  
Pain 
EQ5D 
Anxiety/ 
depression 
Age      
Sex      
IMD      
Q1 ESSI      
Q1 NYHA      
Days since index event      
EQ5D outcome (n-1 lag)      
RRS Brooding (n-1 lag)     p=0.089 
 
Worry models EQ5D 
Mobility 
EQ5D  
Self-care 
EQ5D  
Usual 
activities   
EQ5D  
Pain 
EQ5D 
Anxiety/ 
depression 
Age      
Sex      
IMD      
Q1 ESSI p=0.074     
Q1 NYHA  p=0.070    
Days since index event      
EQ5D outcome (n-1 lag)      
Total PSWQ (n-1 lag)   p=0.056   
 
p≤0.05 p≤0.01 p≤0.001 
Q1=baseline. 
 
 
 
4.4.8.5 Predictors of cardiac disease-specific quality of life (SAQ) 
The results of fully adjusted multilevel (repeated measures) models with SAQ 
subscales as outcomes are summarised in Table 4.30.  
Simple random intercept models (model i) indicated that only trajectories of 
SAQ angina frequency varied significantly between participants. In extended models 
(models ii and iii) all SAQ subscales at the previous assessment time were significant 
predictors of responses on that SAQ subscale at the subsequent assessment time. Low 
social support, greater severity of cardiac disease and being male were identified as 
additional significant predictors of worse cardiac disease-related quality of life. After 
controlling for confounders there was a trend towards RRS brooding at the previous 
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assessment time significantly predicting SAQ disease perception (p=0.052) and SAQ 
angina frequency (p=0.077) at the subsequent assessment time.  
The results of all multilevel (repeated measures) models related to SAQ 
physical limitations are provided in Appendix 39, SAQ angina frequency in Appendix 
40, SAQ angina stability in Appendix 41, SAQ treatment satisfaction in Appendix 42 and 
SAQ disease perception in Appendix 43. 
 
 
 
Table 4.30: Summary of multilevel (repeated measures) models with brooding and 
worry lag variables as predictors and SAQ subscales as outcomes 
Brooding models SAQ  
Physical 
limitations 
SAQ  
Angina 
frequency 
SAQ  
Angina 
stability 
SAQ 
Treatment 
satisfaction 
SAQ  
Disease 
perception 
Age      
Sex*      
IMD      
Q1 ESSI  p=0.078    
Q1 NYHA      
Days since index event      
SAQ outcome (n-1 lag)      
RRS Brooding (n-1 lag)  p=0.077   p=0.052 
 
Worry models SAQ  
Physical 
limitations 
SAQ  
Angina 
frequency 
SAQ  
Angina 
stability 
SAQ 
Treatment 
satisfaction 
SAQ  
Disease 
perception 
Age       
Sex*      
IMD      
Q1 ESSI      
Q1 NYHA      
Days since index event      
SAQ outcome (n-1 lag)        
Total PSWQ (n-1 lag)      
 
p≤0.05 p≤0.01 p≤0.001 
*Being male was a significant predictor of poorer treatment satisfaction. 
Q1=baseline. 
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4.4.8.6 Impact of time from index event and time from baseline assessment 
The number of days from index event was added as a covariate to all multilevel 
(repeated measures) models and results showed that it did not significantly predict any 
outcomes, meaning that differences in time from index event did not confound the 
prospective association of brooding and worry with outcomes related to depression 
and quality of life.  
In addition, a sensitivity analysis was performed which involved adding the 
number of days from baseline to completion of 2 month and 6 month assessments as 
an additional covariate to all fully adjusted multilevel (repeated measures) models. 
Random intercept models were used for all outcomes since random coefficients 
models failed to converge where depression and anxiety were the outcome variables. 
The results showed that the number of days from baseline to both 2 and 6 month 
assessments did not predict any outcome variable, meaning that differences in time 
from baseline did not confound the prospective association of brooding and worry 
with outcomes related to depression and quality of life. Since the number of days from 
baseline was not a significant predictor of any outcome and it did not significantly alter 
the findings of any of the models, it was not included as a covariate in the final models. 
To allow comparison of the findings from models with and without number of days 
from baseline an example is provided in Appendix 44 (where brooding at the previous 
was the main predictor variable and depression at the subsequent assessment time 
was the outcome variable). 
4.4.8.7 Evaluation of multilevel (repeated measures) model assumptions 
Shapiro-Wilk tests of normality (of residuals) for all multilevel (repeated 
measures) models showed that level 1 and level 2 residuals were not normally 
distributed in any of the multilevel (repeated measures) models (results are 
summarised in Appendix 45). In addition, inspection of residuals versus fitted values 
plots indicated violation of the assumption of homoscedasticity for the majority of 
models (an example is provided in Appendix 46). Therefore, an attempt was made to 
re-estimate the models using a robust option (sandwich estimator) to adjust the 
standard errors. However, these models failed to converge and with this in mind the 
standard errors produced using standard maximum likelihood estimation for these 
models could be biased. However the multilevel (repeated measures) models were 
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exploratory in order to validate and extend the findings of the staged multivariable 
regression models presented previously. The results are consistent between the two 
approaches suggesting the multilevel (repeated measures) models are reliable. 
 
4.4.8.8 Summary of findings of multilevel (repeated measures) models 
Findings of unadjusted and adjusted multilevel (repeated measures) models 
that included lag-1 variables (n-1) to assess the impact of predictors at a previous 
assessment time (t) on outcomes at a subsequent assessment time (t+1) are 
summarised in Table 4.31.  
 
 
177 
 
Table 4.31: Summary of significant predictors of all outcomes based on unadjusted and adjusted multilevel (repeated measures) models 
Outcome Brooding 
(unadjusted ) 
Brooding 
(adjusted) 
Worry 
(unadjusted) 
Worry 
(adjusted) 
Other predictors 
PHQ Depression*  p=0.065   Previous outcome, social support 
BAI Anxiety*     Previous outcome, social support 
EQ5D VAS      Previous outcome, social support, severity of cardiac disease 
EQ5D index p=0.057    Previous outcome, social support, severity of cardiac disease 
EQ5D Mobility     Previous outcome, social support, severity of cardiac disease, age, 
index of multiple deprivation 
EQ5D Self-care p=0.060  p=0.059  Previous outcome, social support, age 
EQ5D Usual activities    p=0.056 Previous outcome, social support, severity of cardiac disease, age 
EQ5D Pain     Previous outcome, social support, severity of cardiac disease 
EQ5D Anxiety / depression  p=0.089   Previous outcome, social support, severity of cardiac disease 
SAQ Physical limitations     Previous outcome, social support, severity of cardiac disease 
SAQ Angina frequency  p=0.077   Previous outcome, social support, severity of cardiac disease 
SAQ Angina stability   p=0.061  Previous outcome, social support 
SAQ Treatment satisfaction   p=0.062  Previous outcome, social support, sex 
SAQ Disease perception  p=0.052   Previous outcome, social support, severity of cardiac disease 
=significant predictor. 
Green=significant predictor in brooding models only. 
Red=significant predictor in worry models only. 
*Significant between participant variation in trajectories of depression and anxiety.   
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4.5 Summary of findings 
The main aim of this study was to explore in patients with recent ACS whether 
rumination and worry would prospectively predict depression, anxiety and worse 
health-related quality of life over 6 months following hospital admission.  
A sample of 169 patients (mean age 67 years, 75% male) with ACS were 
recruited from secondary care cardiology services of a single hospital within 6 months 
of hospital admission for myocardial infarction or coronary revascularisation. Just over 
a quarter of the sample had a diagnosis of angina with the rest split approximately 
evenly between diagnoses of STEMI and NSTEMI.  
Of the 169 participants who completed baseline assessments only 66% 
completed repeat assessments at 6 months, although non-completers did not differ 
from completers in any sample characteristics. Otherwise, the quantity of missing data 
at case and item level was within acceptable ranges (e.g.[358]).  
At baseline 14% of the sample was depressed (PHQ≥10) and these participants 
were younger, more socially isolated, had a history of depression and worse 
socioeconomic status than the group without depression. Those who were depressed 
at baseline also reported greater functional limitations related to severity of cardiac 
disease compared to those without depression, although there was no difference 
between the groups in measures of severity extracted from medical records (left 
ventricular function, number of diseased coronary vessels, troponin level). A higher 
proportion of depressed participants failed to complete 6 month assessments 
compared to non-depressed participants. 
There were no significant changes in mean brooding, worry, depression, 
anxiety or quality of life scores across the three assessment times (baseline, 2 months 
and 6 months).  
There were small to medium sized correlations between baseline brooding and 
worry with worse 6 month depression, anxiety and some measures of quality of life. 
An exploratory analysis revealed that the prospective association of baseline brooding 
and 6 month depression was stronger in those who were depressed at baseline 
compared to those not depressed at baseline.  
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 Staged multivariable regression models that controlled for the effects of 
important confounding variables (age, sex, socioeconomic status, history of 
depression, social support, severity of cardiac disease, baseline 
depression/anxiety/quality of life) showed that baseline brooding was a significant 
predictor of depression at 6 months, accounting for 2% of the variance. Baseline worry 
was a significant predictor of worse quality of life related to mobility problems at 6 
months. 
Baseline values of outcome variables were strong predictors of 6 month 
outcomes and low perceived availability of social support was a strong predictor of 6 
month depression, anxiety and quality of life. Greater severity of cardiac disease was a 
consistent predictor of worse outcomes particularly in relation to measures of quality 
of life. 
Associations of baseline brooding and worry with 2 month outcomes (and of 2 
month brooding and worry with 6 month outcomes) were mostly consistent with 
associations observed between baseline brooding and worry with 6 month outcomes.  
Longitudinal multilevel (repeated measures) models were used to validate and 
extend the findings of staged multivariable regression analyses by allowing for within-
participant correlations due to repeated assessments (i.e. within-participant 
clustering). These models indicated that trajectories of depression and anxiety varied 
between participants over time suggesting that there may be subgroups of post-ACS 
patients particularly ‘at risk’ of worse outcomes. 
Longitudinal models also showed that time since index event (i.e. number of 
days between hospitalisation and baseline assessment) and time between consecutive 
assessments were not significant predictors of outcomes, meaning that they did not 
confound the associations of brooding and worry with depression and other outcomes.  
The association of brooding at the previous assessment time with depression at 
the next assessment time in multilevel (repeated measures) models was on the 
threshold of significance after controlling for confounding variables including social 
support. A sensitivity analysis in which social support was removed from the model 
showed that brooding was a significant predictor of depression.
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Chapter 5 Cohort study results – Part II: Mediators of the association 
between brooding and worry with depression and quality of life 
5.1 Chapter outline 
The secondary aim of this observational prospective cohort study was to explore 
potential mechanisms by which perseverative negative thinking may impact on mood 
and worse physical health outcomes in people with coronary heart disease (CHD).  
Several mechanisms have been suggested by which perseverative negative 
thinking may contribute to depression. These include reduced social support, impaired 
problem solving, reduced instrumental behaviours, and increased negative cognitive 
biases[120] (as detailed in section 1.2.4.5 of Chapter 1). Results from the previous 
chapter suggest that there is a prospective association between brooding and later 
depression, and between both brooding and worry with later quality of life, and so this 
chapter will focus on investigating whether reduced social support, impaired problem 
solving, reduced engagement in pleasant activities and increased negative cognitive 
biases may act as mediators for these associations. 
Detailed methods related to the cohort study were presented in Chapter 3.  This 
results chapter presents: 
i. Hypotheses relating to the secondary aim of the study. 
ii. A description of the statistical methods used. 
iii. Results of mediation analyses. 
iv. A brief summary of findings  
 
Discussion of the methods and findings with reference to strengths, weaknesses, 
comparison with existing literature and implications for future research is combined 
with that relating to the previous results chapter (Chapter 4) and is presented in the 
general discussion chapter (Chapter 6). 
5.2 Hypotheses 
Four potentially complementary hypotheses of how rumination may impact 
upon subsequent depression were tested. The main hypotheses are that: 
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i. In patients with recent acute coronary syndrome (ACS), the impact of 
rumination following the initial cardiac event upon depression at six month 
follow-up will be mediated by low social support. 
ii. In patients with recent ACS, the impact of rumination following the initial 
cardiac event upon depression at six month follow-up will be mediated by 
impaired problem solving. 
iii. In patients with recent ACS, the impact of rumination following the initial 
cardiac event upon depression at six month follow-up will be mediated by 
reduced instrumental behaviours, as indexed by engagement in pleasant 
activities. 
iv. In patients with recent ACS, the impact of rumination following the initial 
cardiac event upon depression at six month follow-up will be mediated by 
elevated negative cognitive biases, as indexed by negative self-relevant 
memory bias and negative interpretation bias. 
 
The secondary hypotheses are that: 
v. In patients with recent ACS, the impact of rumination and worry following 
the initial cardiac event upon worse quality of life at six month follow-up 
will be mediated by low social support. 
vi. In patients with recent ACS, the impact of rumination and worry following 
the initial cardiac event upon worse quality of life at six month follow-up 
will be mediated by impaired problem solving. 
vii. In patients with recent ACS, the impact of rumination and worry following 
the initial cardiac event upon worse quality of life at six month follow-up 
will be mediated by reduced instrumental behaviours, as indexed by 
engagement in pleasant activities. 
viii. In patients with recent ACS, the impact of rumination and worry following 
the initial cardiac event upon worse quality of life at six month follow-up 
will be mediated by elevated negative cognitive biases, as indexed by 
negative self-relevant memory bias and negative interpretation bias. 
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A note on abbreviations 
The measures used to assess the predictors, outcomes and mediator variables of 
interest were described fully in Chapter 3. Throughout this chapter the following 
abbreviations will be used: brooding (‘RRS brooding’), worry (‘PSWQ’), depression 
(‘PHQ’), anxiety (‘BAI’), general health-related quality of life (‘EQ5D’), cardiac disease-
specific quality of life (‘SAQ’), social support (‘ESSI’), problem solving (‘SPSI’), pleasant 
activities (‘PES’), socioeconomic status (‘IMD’). 
5.3 Statistical analysis 
5.3.1 Description of potential mediators at baseline 
Potential mediator variables at baseline (ESSI social support, SPSI problem 
solving, PES pleasant events, negative cognitive biases) were summarised using 
descriptive statistics. Missing data were summarised and key characteristics (age, sex, 
depression) of cases with and without missing data were compared using Mann 
Whitney U or Chi-Square tests.  
Spearman’s rho or Kendall’s Tau-b correlations, as appropriate, were used to 
explore bivariate associations among baseline sample characteristics (age, sex, years of 
education, employment status, relationship status, socioeconomic status, history of 
depression, smoking status, alcohol use, recreational drug use and exercise frequency) 
with potential mediator variables (ESSI, SPSI, PES, negative cognitive biases). For 
dichotomous variables related to sample characteristics, Mann-Whitney U tests were 
used instead to look at differences in mediator variables at different levels of the 
sample characteristics. 
Spearman’s rho or Kendall’s Tau-b correlations were also used to explore 
bivariate associations among main predictors (RRS brooding and PSWQ) with potential 
mediator variables, among potential mediators with outcomes (PHQ, BAI, EQ5D, SAQ) 
at baseline, and among the potential mediator variables themselves. 
5.3.2 Description of potential mediators at 2 months and 6 months 
Similar to baseline assessments, the potential mediator variables at 2 months 
were summarised using descriptive statistics, and missing data was described. Key 
characteristics (age, sex, baseline PHQ) of cases with and without missing data at 2 
months were compared using Mann Whitney U or Chi-Square tests.  
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Data pertaining to 6 month assessments were treated in the same way as data 
pertaining to 2 month assessments, as described above. 
5.3.3 Changes in potential mediator variables over time 
To investigate changes over time in each of the potential mediator variables a 
series of Friedman’s tests with assessment time as the independent variable were 
used, combined with Wilcoxon’s tests for post-hoc exploration of significant main 
effects. 
 
5.3.4 Testing for mediation using multiple regression analyses 
The role of social support, problem solving, engagement in pleasant activities 
and negative cognitive biases as potential mediators of the associations between (a) 
brooding with depression and (b) brooding and worry with quality of life were 
explored.  
Mediation was tested using a series of regression analyses in an approach based 
on the evaluation of a set of causal steps as described by Baron & Kenny (1986)[359], 
combined with a bootstrap test of the mediated effect[360]. The premise of mediation 
analysis is that the total effect of the predictor variable on the outcome can be 
partitioned into a direct component which represents the effect the predictor 
independently exerts on the outcome, and an indirect component which represents 
the effect the predictor exerts on the outcome via a third, causal, variable (the 
mediated effect). 
A series of three ordinary least squares regression analyses were conducted for 
each set of predictor, mediator and outcome variables (outcome regressed on 
predictor, proposed mediator regressed on predictor, and outcome regressed on both 
predictor and mediator in the same model) and the following conditions for mediation 
were evaluated (see Figure 5.1 for illustration):  
i. The predictor must significantly predict the outcome (the total, unadjusted, 
effect of predictor on outcome, path c’). 
ii. The predictor must significantly predict the proposed mediator (the direct 
effect of predictor on mediator, path a). 
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iii. The proposed mediator must significantly predict the outcome in a model 
that also includes the predictor (path b, the direct effect of mediator on 
outcome). 
iv. The regression coefficient of the predictor in a model that also includes the 
mediator (path c, the direct effect of predictor on outcome) must be 
smaller than the coefficient of the total effect (path c’).  
 
 
 
Figure 5.1: Path diagram of mediation 
 
 
 
 
According to the traditional Baron & Kenny (1986)[359] framework mediation is 
present if steps i to iv, above, are true. Full mediation is indicated if the predictor has 
no effect on the outcome after controlling for the mediator (i.e. there is no significant 
direct effect of the predictor on the outcome; path c), otherwise partial mediation is 
indicated. Ordinary regression coefficients and p values were considered acceptable 
tests of the total effect (path c’) and direct effects (paths a,b and c).  
In line with more contemporary approaches the significance and magnitude of 
the indirect effect of the predictor on outcome via the proposed mediator (path a x b; 
c’ = total effect of predictor on outcome.
a = direct effect of predictor on mediator.
b = direct effect of mediator on outcome.
c = direct effect of predictor on outcome.
a x b = indirect effect of predictor on outcome, via mediator.
Predictor Outcome
Mediator
a b
c'   (c)
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the mediated portion of the total effect) was also evaluated if the causal steps 
approach indicated findings consistent with mediation. The Sobel test recommended 
by Baron & Kenny (1986) for evaluating the significance of indirect effects has been 
criticized due to low power to detect effects[361, 362] and so the significance of the 
indirect effect was assessed using a bootstrap test with 5000 samples[360]. If 
bootstrapped bias corrected confidence intervals for the indirect effect did not cross 
zero the indirect effect was considered significant. 
Since the current study was designed to investigate prospective associations of 
perseverative negative thinking (brooding and worry) with subsequent depression, 
anxiety and health-related quality of life, the regression models used for mediation 
analyses were constructed to test the temporal precedence of associations (that is, to 
investigate whether brooding and worry would prospectively predict the proposed 
mediators, while at the same time investigating whether the proposed mediators 
would prospectively predict outcomes). Consistent with the staged multivariable 
regression models presented in the preceding chapter, for mediation analyses the 
main predictor variables (RRS brooding or PSWQ) were taken from the baseline 
assessment, and the main outcomes (PHQ, EQ5D or SAQ) were taken from the 6 
month assessment. The majority of proposed mediators (ESSI, SPSI, and PES) were 
taken from the 2 month assessment. It was intended that negative cognitive biases 
would also be taken from the 2 month assessment, however due to missing data at 2 
months negative cognitive biases were taken from the baseline assessment instead. 
Mediation analyses were conducted only where a significant association was 
previously demonstrated (using staged multivariable regression analyses or multilevel 
(repeated measures) models) between the predictor and outcome after controlling for 
important confounding variables (see Chapter 4). Specifically, mediation of the 
following associations was investigated: 
i. Baseline brooding with 6 month depression. 
ii. Baseline brooding with 6 month health-related quality of life (EQ5D index 
value)7. 
                                                     
7In order to limit the number of analyses significant associations between baseline brooding with EQ5D 
usual activities and EQ5D pain at 6 months were not explored with mediation analyses since these 
subscales contribute to EQ5D index value. 
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iii. Baseline brooding with 6 month cardiac disease-specific quality of life (SAQ 
disease perception). 
iv. Baseline worry with 6 month health-related quality of life (EQ5D VAS, EQ5D 
index value)8. 
 
Due to limited data available at 2 month assessments for measures of negative 
cognitive biases, cross-sectional mediation analyses (predictors, proposed mediators 
and outcomes at baseline only) were conducted for negative cognitive biases as 
mediators. These analyses were exploratory since they were based on cross-sectional 
associations, although the findings could highlight factors of potential importance for 
future research. 
 Two sets of analyses were run for each set of predictor, mediator and outcome 
variables. First, unadjusted models were used to directly explore the associations of 
interest. Next, models including important covariates (consistent with the previous 
chapter: age, sex, socioeconomic status, history of depression9, severity of cardiac 
disease and baseline values of the outcome variable) were conducted in order to 
control for confounding variables. Adjusted models were not conducted if results of 
the unadjusted model indicated no mediation. 
 Listwise deletion of cases was used for each set of regression analyses, to 
ensure that all steps of the mediation test were performed on the same subset of 
participants. Block entry method was used for all multiple regression analyses. 
 
5.3.4.1 Multiple mediation models 
The models outlined above considered the effect of each proposed mediator 
independently. Where multiple mediators of an association were identified, the 
models were extended to assess the combined effect of the mediators and to 
investigate the relative importance of each of the mediators. 
 The analyses proceeded in a similar manner to the single mediator approach. 
The regression models described above were extended so that in the third step direct 
                                                     
8Significant associations between baseline worry with EQ5D pain and EQ5D anxiety/depression at 6 
months were not explored since these subscales contribute to EQ5D index value. 
9Only where depression was the outcome variable. 
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effects from the mediator to the outcome (path b) were evaluated in a model that 
included the predictor and all proposed mediators, and in the fourth step the total 
effect (path c’) was compared to the direct effect (path c) of the predictor in a model 
that included all mediators. A bootstrapping method with 5000 samples and bias 
corrected confidence intervals was used to determine significance of the indirect 
effect. 
 
5.3.5 Post-hoc analyses 
In order to explore the findings in greater depth, a series of post-hoc analyses 
were conducted to investigate the associations of inflammation and negative cognitive 
biases with depression. A rationale and description of the analyses is presented with 
the results in Section 5.4.6. 
 
5.4 Results 
5.4.1 Baseline assessments 
5.4.1.1 Description of potential mediators at baseline 
Summary statistics for potential mediator variables (ESSI, SPSI, PES, negative 
cognitive biases) at baseline are summarised in Table 5.1.  
5.4.1.2 Missing data at baseline 
The number of missing cases for any of the questionnaire measures of potential 
mediator variables (ESSI, SPSI, PES) at baseline ranged from 0 to 5 (0% to 3.0% of cases, 
based on total n=169), and the total number of missing items for any multi-item 
variable at baseline ranged from 1 to 188 (0.1% to 5.6% of items).  
The number of missing cases for task-based measures of potential mediator 
variables (negative cognitive biases) at baseline was 81 (47.9% of cases). Task-based 
measures were administered over the telephone just before or just after completion of 
the other self-report assessments. It was not possible to complete the tasks with a 
large number of participants because the participant was either unwilling or could not 
complete assessments over the phone for some practical reason (e.g. hard of hearing), 
or the participant did not answer the telephone after several attempts. Since negative 
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cognitive biases were not the primary outcome of the study participants were not 
excluded from the study if they were unwilling or unable to complete the tasks. 
Missing data at case and subscale level for all potential mediator variables at 
baseline is summarised in Appendix 47.  
For each potential mediator variable, there was no significant difference in 
characteristics (age, gender ratio, baseline PHQ) of respondents with missing data 
compared to those for whom data was available.  
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Table 5.1: Potential mediators at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*For positive and negative homophones the percentage of adjectives for which the affective meaning was accessed was calculated with reference to the 
percentage for which the neutral meaning was accessed. Therefore the variables for positive and negative homophones are independent. 
 N Min Max Mean SD Median IQR 
Social support        
ESSI social support 169 7.00 30.00 25.50 5.75 28.00 6.00 
Problem solving              
SPSI Positive problem orientation 168 0.00 20.00 11.44 4.04 12.00 5.00 
SPSI Rational problem solving 168 0.00 20.00 9.52 4.15 9.00 5.00 
SPSI Negative problem orientation 168 0.00 18.00 4.59 4.30 4.00 6.00 
SPSI Impulsivity 168 0.00 16.00 4.59 3.37 4.00 5.00 
SPSI Avoidance 168 0.00 16.00 4.67 3.55 4.00 5.00 
SPSI Total score 168 4.80 18.80 13.42 2.66 13.80 3.40 
Pleasant events              
PES Frequency 169 0.00 2.00 1.56 0.36 1.65 0.40 
PES Pleasantness 164 0.20 2.00 1.65 0.30 1.70 0.35 
PES Obtained pleasure 164 0.00 4.00 2.82 0.80 2.95 1.09 
Memory bias        
Positive words endorsed 88 1.00 12.00 9.00 2.63 10.00 3.50 
Negative words endorsed 88 0.00 10.00 1.01 1.99 0.00 1.00 
Positive words recalled 88 0.00 8.00 2.95 1.96 2.50 3.00 
Negative words recalled 88 0.00 8.00 2.31 1.85 2.00 2.00 
Negative words recalled (%) 84 0.00 100.00 41.81 24.19 48.33 27.86 
Endorsed positive words recalled 88 0.00 7.00 2.27 1.81 2.00 3.00 
Endorsed negative words recalled 88 0.00 3.00 0.19 0.54 0.00 0.00 
Endorsed negative words recalled (%) 75 0.00 100.00 7.00 18.79 0.00 0.00 
Interpretation bias*        
Positive affective homophones (%) 88 40.00 100.00 66.72 13.09 68.33 17.78 
Negative affective homophones (%) 88 12.50 100.00 49.80 18.39 50.00 25.00 
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5.4.1.3 Association of sample characteristics with potential mediators at baseline 
There were no significant bivariate correlations of note between sample 
characteristics and any of the potential mediator variables at baseline. Correlations are 
presented in Appendix 48. 
Results of difference tests showed that more negative words were endorsed as 
self-descriptive in the memory task in patients with elevated C-reactive protein at 
hospital admission. Other potential mediators varied according to sample 
characteristics in plausible ways. For example, those with a history of depression had 
lower obtained pleasure from pleasant activities and endorsed more negative words as 
self-descriptive. Perceived social support was higher in those with a spouse or partner 
compared to those without a partner. Significant findings are summarised fully in 
Appendix 49. 
5.4.1.4 Association of potential mediators with predictors and outcomes at baseline 
Correlations between each potential mediator variable with the main 
predictors and main outcome variables at baseline are presented in Table 5.2. The 
strongest associations were of brooding with SPSI subscales related to negative 
problem orientation and other negative aspects of problem solving (r=0.40 to r=0.62). 
There were similar associations of worry (r=0.29 to r=0.50), depression (r=0.30 to 
r=0.51), anxiety (r=0.32 to r=0.45) and more weakly overall health-related quality of 
life (r=0.20 to r=0.40) with negative aspects of problem solving. 
There were small correlations between ESSI social support with depression and 
anxiety (r=0.37 to r=0.38), and more weakly between ESSI with the predictors brooding 
and worry, and with outcomes related to overall health-related quality of life (EQ5D 
index value, in particular) and cardiac disease-specific quality of life. 
Brooding, depression, anxiety, overall health-related quality of life (EQ5D index 
value) and disease-specific quality of life related to poor treatment satisfaction and 
disease perception were weakly but significantly correlated with reduced frequency 
and pleasantness of pleasant activities (r=0.22 to r=0.36). In addition, quality of life 
measures related to reduced mobility and physical limitations were weakly associated 
with reduced frequency of pleasant events.  
Finally, there was a small but significant correlation between more negative 
words endorsed in the memory task with greater brooding (r=0.32), and between a 
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higher proportion of negative endorsed words recalled with greater brooding, worry 
and depression (r=0.31 to r=0.41). 
5.4.1.5 Associations among proposed mediators at baseline 
A matrix of bivariate correlations among the proposed mediator variables at 
baseline is presented in Appendix 50. The strongest correlations were between 
subscales within each measure (e.g. correlations among SPSI subscales related to 
negative aspects of problem solving r=0.33 to r=0.56, correlations among PES 
subscales r=0.62 to r=0.89). There were also small correlations between low social 
support and lack of engagement in pleasant activities (r=0.36 to r=0.39), and a 
constellation of weak correlations between a number of variables indicating a general 
tendency towards negativity (high number of negative words endorsed as self-
descriptive, high negative problem orientation, and low pleasantness ratings of 
enjoyable activities).  
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Table 5.2: Correlations between potential mediators with predictors and outcome variables at baseline 
 ESSI social 
support 
SPSI 
Positive 
problem 
orientation 
SPSI 
Rational 
problem 
solving 
SPSI 
Negative 
problem 
orientation 
SPSI 
Impulsivity 
SPSI 
Avoidance 
SPSI Total PES 
Frequency 
PES 
Pleasantness 
Predictors          
Total PSWQ -0.26a -0.18c -0.03 0.50a 0.29a 0.26a -0.34a -0.13 -0.13 
RRS brooding -0.27a -0.27a -0.11  0.62a 0.40a 0.45a -0.53a -0.24b -0.24b 
Outcomes          
Total PHQ -0.38a -0.31a -0.22b 0.49a 0.30a 0.38a -0.51a -0.30a -0.34a 
Total BAI -0.37a -0.20b -0.18c 0.44a 0.35a 0.32a -0.45a -0.34a -0.32a 
EQ5D VAS 0.26a 0.18c 0.12 -0.22b -0.25b -0.20b 0.30a 0.24b 0.15c 
EQ5D Index value 0.30a 0.22b 0.17c -0.31a -0.31a -0.24b 0.40a 0.36a 0.28a 
EQ5D Mobility -0.13c -0.18b -0.15c 0.20b 0.27a 0.18b -0.28a -0.28a -0.20b 
EQ5D Self-care -0.15c -0.09 -0.07 0.19b 0.28a 0.10 -0.24a -0.12a 0.00b 
EQ5D Usual activities -0.21a -0.13c -0.08 0.19b 0.23a 0.09 -0.23a -0.23a -0.16b 
EQ5D Pain -0.16c -0.03 -0.09 0.15c 0.24a 0.14c -0.22a -0.20a -0.18b 
EQ5D Anxiety / depression -0.28a -0.21b -0.10 0.41a 0.20b 0.29a -0.34a -0.22a -0.25a 
SAQ Physical limitations 0.27a 0.15c 0.03 -0.18c -0.24b -0.10 0.25b 0.39a 0.18c 
SAQ Angina frequency 0.31a 0.12 -0.04 -0.21b -0.12 -0.12 0.17c 0.25a 0.26b 
SAQ Angina stability 0.19c 0.05 -0.05 -0.01 -0.08 -0.09 0.08 0.16c 0.15 
SAQ Treatment satisfaction 0.30a 0.15 0.13 -0.13 -0.15c -0.05 0.21b 0.26a 0.28a 
SAQ Disease perception 0.40a 0.14 -0.01 -0.30a -0.25b -0.13 0.27a 0.28a 0.27a 
Table continued on following page… 
 
  
193 
 
 PES 
Obtained 
pleasure 
Negative 
words 
endorsed 
Negative 
words 
recalled (%) 
Endorsed 
negative words 
recalled (%) 
Positive 
affective 
(%) 
Negative 
affective 
(%) 
Predictors       
Total PSWQ -0.14 0.20 -0.15 0.31b 0.01 0.01 
RRS brooding -0.22b 0.32b 0.00 0.41a -0.02 0.16 
Outcomes       
Total PHQ -0.32a 0.22c 0.20 0.38a -0.19 0.22c 
Total BAI -0.33a 0.10 0.14 0.11 -0.08 0.11 
EQ5D VAS 0.21b -0.13 -0.17 -0.23c 0.17 -0.10 
EQ5D Index value 0.35a -0.16 -0.11 0.03 0.03 -0.17 
EQ5D Mobility -0.25a 0.18c 0.11 -0.03 -0.03 0.09 
EQ5D Self-care -0.07a -0.04 0.07 -0.02 -0.02 -0.01 
EQ5D Usual activities -0.21a 0.02 0.05 -0.06 -0.04 0.15 
EQ5D Pain -0.21a 0.06 0.03 -0.06 -0.02 0.09 
EQ5D Anxiety / depression -0.25a 0.21c 0.04 0.33b -0.11 0.09 
SAQ Physical limitations 0.30a -0.07 -0.12 0.09 0.06 -0.22 
SAQ Angina frequency 0.25b 0.02 -0.14 0.05 0.05 -0.05 
SAQ Angina stability 0.16c 0.06 0.03 -0.07 0.01 0.13 
SAQ Treatment satisfaction 0.34a 0.05 0.05 -0.02 0.04 -0.10 
SAQ Disease perception 0.29a 0.04c -0.18 0.05 -0.08 -0.14 
ap<0.001 bp≤0.01 cp≤0.05. 
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5.4.2 2 month assessments 
5.4.2.1 Description of mediators at 2 months 
Summary statistics for potential mediator variables (ESSI, SPSI, PES, negative 
cognitive biases) at 2 months are summarised in Table 5.3.  
5.4.2.2 Missing data at 2 months 
The number of missing cases for any of the questionnaire measures (ESSI, SPSI, 
PES) of potential mediator variables at baseline ranged from 2 to 4 (1.6% to 3.2% of 
cases, based on total n=125), and the total number of missing items for any multi-item 
variable at baseline ranged from 12 to 78 (1.9% to 3.1% of items).  
The number of missing cases for task-based measures of potential mediator 
variables (negative cognitive biases) at baseline ranged from 90 to 91 (72.0% to 72.8% 
of cases). There was a large amount of missing data since many participants were 
unwilling/unable to complete the assessments over the telephone, or could not be 
reached by telephone after several attempts. 
Missing data at case and subscale level for all potential mediator variables at 2 
months is summarised in Appendix 51. 
For each potential mediator variable, there was no significant difference in 
characteristics (age, gender ratio, 2 month PHQ) of respondents with missing data 
compared to those for whom data was available.  
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Table 5.3: Potential mediators at 2 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N Min Max Mean SD Median IQR 
Social support        
ESSI social support 123 6.00 30.00 25.11 6.26 28.00 8.00 
Problem solving              
SPSI Positive problem orientation 121 0.00 20.00 11.51 3.76 12.00 5.00 
SPSI Rational problem solving 121 0.00 20.00 10.04 4.23 10.00 6.00 
SPSI Negative problem orientation 121 0.00 19.00 3.98 4.10 3.00 5.00 
SPSI Impulsivity 121 0.00 18.00 4.42 3.53 4.00 4.00 
SPSI Avoidance 121 0.00 18.00 4.43 3.58 4.00 4.00 
SPSI Total score 121 2.00 18.40 13.74 2.71 13.60 3.40 
Pleasant events              
PES Frequency 123 0.00 2.00 1.58 0.31 1.65 0.44 
PES Pleasantness 123 0.80 2.00 1.63 0.29 1.70 0.41 
PES Obtained pleasure 123 0.00 4.00 2.80 0.79 2.90 1.05 
Memory bias        
Positive words endorsed 35 5.00 12.00 9.29 2.31 10.00 5.00 
Negative words endorsed 35 0.00 9.00 0.49 1.65 0.00 0.00 
Positive words recalled 35 0.00 8.00 2.77 2.03 3.00 3.00 
Negative words recalled 35 0.00 6.00 2.03 1.65 2.00 2.00 
Negative words recalled (%) 35 0.00 100.00 36.54 23.67 40.00 16.67 
Endorsed positive words recalled 35 0.00 7.00 2.11 1.83 2.00 2.00 
Endorsed negative words recalled 35 0.00 0.00 0.00 0.00 0.00 0.00 
Endorsed negative words recalled (%) 28 0.00 0.00 0.00 0.00 0.00 0.00 
Interpretation bias        
Positive affective homophones (%) 34 50.00 90.00 67.06 10.57 70.00 17.78 
Negative affective homophones (%) 34 12.50 75.00 49.26 15.16 50.00 25.00 
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5.4.3 6 month assessments 
5.4.3.1 Description of mediators at 6 months 
Summary statistics for potential mediator variables (ESSI, SPSI, PES, negative 
cognitive biases) at 2 months are summarised in Table 5.4.  
5.4.3.2 Missing data at 6 months 
The number of missing cases for any of the questionnaire measures (ESSI, SPSI, 
PES) of potential mediator variables at baseline ranged from 0 to 3 (0% to 2.7% of 
cases, based on total n=111), and the total number of missing items for any multi-item 
variable at baseline ranged from 0 to 85 (0% to 3.8% of items).  
The number of missing cases for task-based measures of potential mediator 
variables (negative cognitive biases) at baseline was 97 (87.4% of cases). There was a 
large amount of missing data since many participants were unwilling/unable to 
complete the assessments over the telephone, or could not be reached by telephone 
after several attempts. 
Missing data at case and subscale level for all potential mediator variables at 6 
months is summarised in Appendix 52. 
For each potential mediator variable characteristics (age, gender ratio, 6 month 
PHQ) of respondents with missing data were compared to those for whom data was 
available. Cases with missing SPSI subscales were older than cases for whom data was 
available (82 years vs. 68 years; z=-1.99, p=0.0463), and cases with missing negative 
cognitive bias tasks were older than cases for whom data was available (68 years vs. 66 
years; z=2.02, p=0.0430).
197 
 
Table 5.4: Potential mediators at 6 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N Min Max Mean SD Median IQR 
Social support        
ESSI social support 111 3.00 30.00 25.05 6.81 28.00 7.00 
Problem solving              
SPSI Positive problem orientation 109 0.00 20.00 11.84 4.05 11.04 5.00 
SPSI Rational problem solving 109 1.00 20.00 9.85 4.56 10.00 7.00 
SPSI Negative problem orientation 109 0.00 18.00 3.42 3.61 3.00 5.00 
SPSI Impulsivity 109 0.00 15.00 4.34 3.41 4.00 6.00 
SPSI Avoidance 109 0.00 18.00 4.16 3.31 4.00 4.00 
SPSI Total score 109 2.40 19.20 13.95 2.63 13.80 3.00 
Pleasant events              
PES Frequency 109 0.00 2.00 1.58 0.36 1.65 0.40 
PES Pleasantness 108 0.30 2.00 1.63 0.34 1.74 0.41 
PES Obtained pleasure 108 0.00 4.00 2.84 0.83 3.05 1.15 
Memory bias        
Positive words endorsed 14 6.00 12.00 9.71 1.94 10.00 3.00 
Negative words endorsed 14 0.00 2.00 0.21 0.58 0.00 0.00 
Positive words recalled 14 1.00 6.00 3.36 1.78 4.00 3.00 
Negative words recalled 14 0.00 5.00 2.71 1.64 3.00 2.00 
Negative words recalled (%) 14 0.00 80.00 41.88 23.16 44.16 22.22 
Endorsed positive words recalled 14 0.00 6.00 2.86 1.88 3.00 3.00 
Endorsed negative words recalled 14 0.00 0.00 0.00 0.00 0.00 0.00 
Endorsed negative words recalled (%) 13 0.00 0.00 0.00 0.00 0.00 0.00 
Interpretation bias        
Positive affective homophones (%) 14 30.00 80.00 66.19 13.89 70.00 20.00 
Negative affective homophones (%) 14 12.50 75.00 51.28 19.05 50.00 25.00 
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5.4.4 Changes over time in potential mediators  
There were no significant changes in mean values of any potential mediators 
related to social support, pleasant events or negative cognitive biases, indicating that 
these measures were stable over time. The negative problem orientation subscale of 
the SPSI problem solving measure was significantly lower at 6 months compared to 
baseline (F=6.95, p=0.0310, z=2.68, p=0.0073) and 2 months (F=6.95, p=0.0310, z=2.15, 
p=0.0319), indicating an improvement in problem orientation at the 6 month 
assessment. 
 
5.4.5 Testing mediation using regression analyses 
5.4.5.1 Mediators of the association of brooding with depression 
A summary of the findings of each series of regression analyses and bootstrap 
tests conducted to investigate potential mediators of the association between baseline 
brooding and 6 month depression10 is presented in Table 5.5.  
In the first step, Table 5.5 shows that in simple regression models unadjusted 
for confounding variables, baseline brooding was a significant direct predictor of 6 
month depression11 (path c’ was significant).   
In the second step, where Table 5.5 shows that path a was significant, baseline 
brooding predicted the relevant proposed mediator. Baseline brooding was a 
significant predictor of low perceived availability of social support at 2 months, all SPSI 
problem solving subscales at 2 months (indicating poorer problem solving), low 
frequency of engaging in pleasant activities, low pleasantness ratings of pleasant 
activities at 2 months, low obtained pleasure from engaging in pleasant activities at 2 
months, more negative adjectives endorsed in the memory task at baseline and a 
greater proportion of negative over positive endorsed adjectives recalled in the 
memory task at baseline.   
In the third step, where Table 5.5 shows that path b was significant the 
proposed mediator predicted depression. Low perceived availability of social support 
at 2 months, greater negative problem orientation at 2 months, low pleasantness 
                                                     
10Association of baseline brooding and baseline depression for negative cognitive biases. 
11Baseline brooding was a significant predictor of baseline depression for analyses involving negative 
cognitive biases. 
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ratings of pleasant activities at 2 months, and low obtained pleasure from engaging in 
pleasant activities at 2 months significantly predicted depression at 6 months. More 
negative adjectives endorsed in the memory task at baseline and a greater proportion 
of negative over positive endorsed adjectives recalled in the memory task at baseline 
both significantly predicted depression at baseline. 
In the fourth step, the regression coefficient of the total effect was larger than 
the regression coefficient of the direct effect (where significant effects of paths c’, b 
and a had already been demonstrated in the previous steps) consistent with the 
presence of mediation (according to the causal steps approach), as follows:  
i. Baseline brooding was associated with 6 month depression via low 
perceived availability of social support. The direct effect of baseline 
brooding was still a significant predictor of 6 month depression after 
controlling for 2 month social support, consistent with partial mediation. In 
line with these findings a bootstrap test of the indirect effect was also 
significant, and the proportion of the total effect mediated by social 
support was 10.5%. These findings are illustrated in Figure 5.2. 
ii. Baseline brooding was associated with 6 month depression via greater 
negative problem orientation. The direct effect of baseline brooding was 
still a significant predictor of 6 month depression after controlling for 2 
month negative problem orientation, consistent with partial mediation. In 
line with these findings, a bootstrap test of the indirect effect was 
significant, and the proportion of the total effect mediated by negative 
problem orientation was 40.2%. These findings are illustrated in Figure 5.3. 
iii. Baseline brooding was associated with 6 month depression via low 
pleasantness ratings of pleasant activities at 2 months and via low obtained 
pleasure from engaging in pleasant activities at 2 months. In both cases the 
direct effect of baseline brooding was still a significant predictor of 6 month 
depression after controlling for these aspects of pleasant activities, 
consistent with partial mediation. In line with these findings bootstrap tests 
of the indirect effects were significant, and the proportion of the total 
effect mediated by pleasantness ratings and obtained pleasure was 9.5% 
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and 9.3%, respectively. These findings are illustrated in Figure 5.4 
(pleasantness ratings) and Figure 5.5 (obtained pleasure). 
iv. In exploratory analyses, baseline brooding was associated with baseline 
depression via a greater proportion of negative over positive endorsed 
words recalled at baseline. The direct effect of baseline brooding was still a 
significant predictor of baseline depression after controlling for the 
proportion of negative over positive endorsed words recalled at baseline, 
consistent with partial mediation. In contrast to the findings of the causal 
steps approach, a bootstrap test of the indirect effect was not significant 
suggesting there was no mediation by proportion of negative over positive 
endorsed words. These findings are illustrated in Figure 5.6. 
 
Table 5.5 also summarises the results of multiple regression analyses that 
controlled for confounders (age, sex, socioeconomic status, history of depression, 
severity of cardiac disease and baseline depression) in instances where the simple 
models found evidence of mediation. After adjusting for confounders there was no 
evidence that 2 month social support, negative problem orientation, pleasantness 
ratings of pleasant activities or obtained pleasure from engaging in pleasant activities 
mediated the association of baseline brooding with 6 month depression. In addition 
there was no evidence that the effect of baseline brooding on depression at the same 
time was mediated by the proportion of negative over positive endorsed words 
recalled. 
Results of all unadjusted and adjusted regression analyses and bootstrap tests 
are presented in Appendix 53. 
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Table 5.5: Summary of mediation analyses for the association of brooding with depression 
Proposed mediator Adjusted Step 1 
Path c’ 
Step 2 
Path a 
Step 3 
Path b 
Step 4 
c’ > c 
Direct 
effect 
Indirect 
effect 
Mediation 
ESSI social support No       Partial 
SPSI Positive problem orientation No     - -  
SPSI Rational problem solving No  p=0.064   - -  
SPSI Negative problem orientation No       Partial 
SPSI Impulsivity No     - -  
SPSI Avoidance No     - -  
SPSI Total score No     - -  
PES Frequency No     - -  
PES Pleasantness No       Partial 
PES Obtained pleasure No       Partial 
Negative words endorsed No     - -  
Negative words recalled No     - -  
Proportion negative endorsed words recalled No       ~Partial 
Positive affective homophones (%) No     - -  
Negative affective homophones (%) No     - -  
         
ESSI social support Yes     - -  
SPSI Negative problem orientation Yes     - -  
PES Pleasantness Yes     - -  
PES Obtained pleasure Yes     - -  
Proportion negative endorsed words recalled Yes     - -  
= significant =not significant. 
~Findings of causal steps and indirect effect approaches inconsistent. 
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Figure 5.2: Social support mediates the effect of brooding on depression (unadjusted 
model) 
 
 
 
 
Figure 5.3: Negative problem orientation mediates the effect of brooding on 
depression (unadjusted model) 
 
 
 
 
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
Brooding Depression
Social support
-0.41c -0.25a
1.00a    (0.89a)
Indirect effect = 0.10 (0.00, 0.29)
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
Brooding Depression
Negative problem 
orientation
0.88a -0.46a
1.00a (0.60a)
Indirect effect = 0.40 (0.16, 0.73)
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Figure 5.4: Pleasantness ratings mediate the effect of brooding on depression 
(unadjusted model) 
 
 
 
 
Figure 5.5: Obtained pleasure ratings mediate the effect of brooding on depression 
(unadjusted model) 
 
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
Brooding Depression
PES 
pleasantness
-0.03a -3.21c
1.00a    (0.90a)
Indirect effect = 0.09 (0.02, 0.24)
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
Brooding Depression
PES Obtained
pleasure
-0.08a -1.13c
1.00a (0.91a)
Indirect effect = 0.09 (0.02, 0.26)
204 
 
Figure 5.6: Proportion of negative endorsed words recalled mediates the effect of 
brooding on depression (unadjusted model) 
 
 
 
 
5.4.5.1.1 Multiple mediation 
An unadjusted multiple mediation model was used to investigate the combined 
effects of social support, problem solving, and engagement in pleasant activities as 
mediators of the association between baseline brooding with 6 month depression.  
The SPSI negative problem orientation subscale was chosen to represent 
problem solving since the single mediator models suggested this was the only SPSI 
subscale that might mediate the association of brooding with depression. Two PES 
subscales related to engagement in pleasant activities were identified as potential 
mediators of the association between brooding with depression. The PES obtained 
pleasure subscale was chosen to represent engagement in pleasant activities because 
it indexed both frequency and pleasantness aspects of engagement in pleasant 
activities and was therefore considered the broadest measure. 
The results are shown in Figure 5.7. Steps 1 and 2 were unchanged from the 
individual models: baseline brooding significantly predicted each of the mediators at 2 
months and depression at 6 months. In step 3, significant predictors of 6 month 
depression (path b) were low perceived availability of social support at 2 months and 
greater negative problem orientation at 2 months. Obtained pleasure from 
engagement in pleasant events at 2 months was not a significant predictor of 
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
Brooding Depression
Recall
3.17a 0.07b
0.96a    (0.75a)
Indirect effect = 0.21 (-0.08, 0.37)
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depression at 6 months. In the fourth step, the regression coefficient of the total effect 
was larger than the regression coefficient of the direct effect (where significant effects 
of paths c’, b and a had already been demonstrated in the previous steps). The direct 
effect of baseline brooding remained a significant predictor of 6 month depression 
after controlling for all three proposed mediators at 2 months, consistent with partial 
mediation.  In line with these findings, a bootstrap test of the indirect effect was also 
significant, and the proportion of the total effect mediated by the combination of 
social support and problem solving was 40.3%. 
In the combined model, the regression coefficient representing the direct 
association (path b) of problem solving with depression was larger than the coefficient 
representing the direct association of social support with depression. In addition, the 
proportion of the total effect accounted for by problem solving in the single mediator 
model was not improved by the addition of social support and engagement in pleasant 
activities as further mediators.  
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Figure 5.7: Multiple mediation model of the association of baseline brooding with 6 
month depression (unadjusted model) 
 
 
 
 
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
-0.20a
Brooding Depression
Problem solving
-0.41c
1.00a (0.60a)
Combined indirect effect = 0.40 (0.13, 0.66)
Pleasant events
Social support
0.88a 0.34
b
-0.35-0.08a
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5.4.5.2 Mediators of the association between brooding and health-related quality 
of life 
A summary of the findings of each series of regression analyses and bootstrap 
tests conducted to investigate potential mediators of the association between baseline 
brooding and 6 month health-related quality of life (EQ5D index value)12 is presented 
in Table 5.6.  
In the first step, in simple regression models, baseline brooding was a 
significant direct predictor of 6 month EQ5D index value13 (indicating poorer overall 
quality of life), i.e. path c’ was significant.  
In the second step, significant path a models showed that baseline brooding 
was a significant predictor of low perceived availability of social support at 2 months, 
all SPSI problem solving subscales at 2 months (indicating poorer problem solving), low 
frequency of engaging in pleasant activities at 2 months, low pleasantness ratings of 
pleasant activities at 2 months and low obtained pleasure from engaging in pleasant 
activities at 2 months. Baseline brooding was also a significant predictor of more 
negative adjectives endorsed in the memory task at baseline and a greater proportion 
of negative over positive endorsed adjectives recalled in the memory task at baseline.   
In the third step, significant path b models showed that low perceived 
availability of social support at 2 months, low frequency of engaging in pleasant 
activities at 2 months, low pleasantness ratings of pleasant activities at 2 months and 
low obtained pleasure from engaging in pleasant activities at 2 months significantly 
predicted EQ5D index value at 6 months.  
In the fourth step, there was no evidence of mediation using the causal steps 
approach i.e. where significant effects of paths c’, b and a had already been 
demonstrated in the previous steps, the regression coefficient of the total effect was 
not larger than the regression coefficient of the direct effect. Results of all regression 
analyses and bootstrap tests are presented in Appendix 54. 
                                                     
12Association of baseline brooding and baseline EQ5D index for negative cognitive biases. 
13Baseline brooding was a significant predictor of baseline EQ5D index value for analyses involving 
negative cognitive biases. 
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Table 5.6: Summary of mediation analyses for the association of brooding with EQ5D index value 
Proposed mediator Adjusted Step 1 
Path c’ 
Step 2 
Path a 
Step 3 
Path b 
Step 4 
c’ > c 
Direct 
effect 
Indirect 
effect 
Mediation 
ESSI social support No     - -  
SPSI Positive problem orientation No     - -  
SPSI Rational problem solving No  p=0.064   - -  
SPSI Negative problem orientation No     - -  
SPSI Impulsivity No   p=0.081  - -  
SPSI Avoidance No     - -  
SPSI Total score No     - -  
PES Frequency No     - -  
PES Pleasantness No     - -  
PES Obtained pleasure No     - -  
Negative words endorsed No     - -  
Negative words recalled No     - -  
Proportion negative endorsed words recalled No     - -  
Positive affective homophones (%) No     - -  
Negative affective homophones (%) No     - -  
= significant =not significant. 
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5.4.5.3 Mediators of the association between brooding with cardiac disease-specific 
quality of life 
A summary of the findings of each series of regression analyses and bootstrap 
tests conducted to investigate potential mediators of the association between baseline 
brooding and 6 month cardiac disease-related quality of life14 (SAQ disease perception) 
are presented in Table 5.7. 
In the first step, simple regression models showed that baseline brooding was a 
significant direct predictor of worse SAQ disease perception at 6 months (i.e. path c’ 
was significant). 
In the second step, significant path a models showed that baseline brooding 
was a significant predictor of the proposed mediators: low perceived availability of 
social support at 2 months, poor problem solving (all SPSI subscales with the exception 
of rational problem solving) at 2 months, low engagement in pleasant activities at 2 
months (all PES subscales), more negative adjectives endorsed in the memory task at 
baseline and a greater proportion of negative over positive endorsed adjectives 
recalled in the memory task at baseline.   
In the third step, significant path b models showed that low perceived 
availability of social support at 2 months, greater negative problem orientation at 2 
months and all PES subscales related to engagement in pleasant activities at 2 months 
predicted worse SAQ disease perception at 6 months. In addition, a greater proportion 
of negative over positive endorsed adjectives recalled in the memory task at baseline 
predicted worse SAQ disease perception at baseline (p=0.054). 
In the fourth step, there were no significant effects consistent with mediation 
of the association between baseline brooding and 6 month SAQ disease perception 
according to the causal steps approach (i.e. where significant effects of paths c’, b and 
a had already been demonstrated in the previous steps, the regression coefficient of 
the total effect was not larger than the regression coefficient of the direct effect.)  
Results of all regression analyses and bootstrap tests are presented in Appendix 55. 
 
                                                     
14Association of baseline brooding and baseline cardiac disease-related quality of life for negative 
cognitive biases. 
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Table 5.7: Summary of mediation analyses for the association of brooding with SAQ disease perception 
Proposed mediator Adjusted Step 1 
Path c’ 
Step 2 
Path a 
Step 3 
Path b 
Step 4 
c’ > c 
Direct 
effect 
Indirect 
effect 
Mediation 
ESSI social support No     - -  
SPSI Positive problem orientation No     - -  
SPSI Rational problem solving No     - -  
SPSI Negative problem orientation No     - -  
SPSI Impulsivity No     - -  
SPSI Avoidance No     - -  
SPSI Total score No     - -  
PES Frequency No     - -  
PES Pleasantness No     - -  
PES Obtained pleasure No     - -  
Negative words endorsed No     - -  
Negative words recalled No     - -  
Proportion negative endorsed words recalled No   p=0.054  - -  
Positive affective homophones (%) No     - -  
Negative affective homophones (%) No     - -   
= significant =not significant. 
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5.4.5.4 Mediators of the association between worry and overall health-related 
quality of life 
A summary of the findings of each series of regression analyses and bootstrap 
tests conducted to investigate potential mediators of the association between baseline 
worry and 6 month health-related quality of life15 are presented in Table 5.8 (EQ5D 
VAS) and Table 5.9 (EQ5D index value). 
In the first steps, simple regression models showed that baseline worry was a 
significant direct predictor of worse EQ5D VAS and worse EQ5D index value at 6 
months (i.e. path c’ was significant). 
In the second steps, significant path a models showed that baseline worry was 
a significant predictor of poor problem solving (all SPSI subscales with the exception of 
impulsivity) at 2 months, more negative adjectives endorsed in the memory task at 
baseline and a greater proportion of negative over positive endorsed adjectives 
recalled in the memory task at baseline.   
In the third steps, significant path b models showed that the proposed 
mediators predicted outcomes as follows: low perceived availability of social support 
at 2 months predicted worse EQ5D VAS and EQ5D index value at 6 months; and all PES 
subscales related to low engagement in pleasant activities at 2 months predicted 
worse EQ5D VAS and EQ5D index value at 6 months. 
In the fourth step, there were no significant effects consistent with mediation 
of the association between baseline worry and 6 month EQ5D VAS or EQ5D index 
value (i.e. where significant effects of paths c’, b and a had already been demonstrated 
in the previous steps, the regression coefficient of the total effect was not larger than 
the regression coefficient of the direct effect.)  Results of all regression analyses and 
bootstrap tests are presented in Appendix 56 (EQ5D VAS) and Appendix 57 (EQ5D 
index value).
                                                     
15Association of baseline worry and baseline health-related quality of life for negative cognitive biases. 
212 
 
Table 5.8: Summary of mediation analyses for the association of worry with EQ5D VAS 
Proposed mediator Adjusted Step 1 
Path c’ 
Step 2 
Path a 
Step 3 
Path b 
Step 4 
c’ > c 
Direct 
effect 
Indirect 
effect 
Mediation 
ESSI social support No     - -  
SPSI Positive problem orientation No     - -  
SPSI Rational problem solving No     - -  
SPSI Negative problem orientation No   p=0.059  - -  
SPSI Impulsivity No     - -  
SPSI Avoidance No     - -  
SPSI Total score No     - -  
PES Frequency No     - -  
PES Pleasantness No  p=0.054   - -  
PES Obtained pleasure No     - -  
Negative words endorsed No     - -  
Negative words recalled No   p=0.064  - -  
Proportion negative endorsed words recalled No     - -  
Positive affective homophones (%) No     - -  
Negative affective homophones (%) No     - -  
= significant =not significant. 
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Table 5.9: Summary of mediation analyses for the association of worry with EQ5D index value 
Proposed mediator Adjusted Step 1 
Path c’ 
Step 2 
Path a 
Step 3 
Path b 
Step 4 
c’ > c 
Direct 
effect 
Indirect 
effect 
Mediation 
ESSI social support No     - -  
SPSI Positive problem orientation No     - -  
SPSI Rational problem solving No     - -  
SPSI Negative problem orientation No     - -  
SPSI Impulsivity No   p=0.058  - -  
SPSI Avoidance No     - -  
SPSI Total score No     - -  
PES Frequency No     - -  
PES Pleasantness No  p=0.054   - -  
PES Obtained pleasure No     - -  
Negative words endorsed No   p=0.058  - -  
Negative words recalled No     - -  
Proportion negative endorsed words recalled No     - -  
Positive affective homophones (%) No     - -  
Negative affective homophones (%) No     - -  
= significant =not significant. 
 
 
 
 
 
214 
 
5.4.6 Results of post-hoc analyses 
An interesting finding of this study was that negative cognitive biases (specifically 
the number of negative adjectives endorsed in the memory task at baseline) were 
greater in patients who had raised C-reactive protein (CRP) at hospital admission. 
Negative biases in the memory task were, in turn, found to be associated with 
concurrent depression. 
Increased inflammatory markers have been associated with worse outcomes in 
CHD patients[304, 305], and previous studies have shown that depression is associated 
with increases in inflammatory markers such as CRP (e.g.[363, 364]) including in 
people with CHD[310]. Negative cognitive biases, such as selective memory for 
negative material, are also hypothesised to be causally associated with 
depression[215, 365].  
Taken together this could reflect simply that worse severity of cardiac disease 
predicts depression. Alternatively, and more interestingly, it raises the possibility that 
inflammation may contribute to depression via negative biases in cognitive processing 
(or vice versa), and could explain why people with chronic physical illnesses 
characterised by elevated inflammation (such as CHD) are at greater risk of depression.  
The design of the present study does not allow these competing hypotheses to be 
formally tested. Nevertheless, a preliminary analysis was conducted to investigate 
which interpretation, if any, the findings would lend support to.   
First, to investigate whether higher levels of CRP during hospital admission were 
associated with depression a simple logistic regression model was conducted with CRP 
as the predictor variable and baseline depression as the outcome. To investigate 
whether higher levels of CRP during hospital admission were associated with worse 
severity of cardiac disease a bivariate correlation (Kendall’s Tau-b) between CRP and 
severity of cardiac disease (assessed using a summary measure of left ventricular 
function) was used.  Second, to investigate whether inflammation remained a 
significant predictor of depression after controlling for the severity of cardiac disease, 
a multiple regression model was used with CRP as the predictor variable, baseline 
depression as the outcome and severity of cardiac disease entered as a covariate. 
Next, to confirm that CRP was a significant predictor of number of negative 
adjectives endorsed, a simple logistic regression models was conducted with CRP as 
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the predictor and number of negative adjectives endorsed as the outcome variable. 
Since number of negative adjectives endorsed had previously been found to be 
associated with depression, the simple regression model was extended to control for 
baseline depression.  
The results showed there was a trend for raised CRP during hospital admission to 
be associated with baseline depression (B=-1.09, z=-1.91, p=0.057), and there was a 
small significant bivariate correlation between raised CRP and worse severity of cardiac 
disease during hospitalisation (r=0.32, p=0.0028). Together these findings suggest 
inflammation is associated both with depression and with worse severity of cardiac 
disease.  There was a trend for raised CRP during hospitalisation to be significantly 
associated with baseline depression (B=-1.16, z=1.77, p<0.077) suggesting that 
inflammation is associated with depression independently of severity of cardiac 
disease i.e. the association of inflammation with depression is not explained entirely 
by severity of cardiac disease. Finally, higher CRP during hospitalisation was associated 
with a greater number of negative adjectives endorsed at baseline (B=1.24, t=2.01, p-
0.044), and after controlling for baseline depression there was a trend for raised CRP 
during hospitalisation to be associated with a greater number of negative adjectives 
endorsed at baseline (B=1.13, t=1.76, p=0.078). These findings tentatively suggest that 
inflammation is associated with negative cognitive biases independently of depression.  
5.5 Summary of main findings 
The secondary aim of the observational prospective cohort study presented in 
this thesis was to explore, in patients with recent ACS, potential mechanisms by which 
perseverative negative thinking may impact on mood and poor physical health 
outcomes over 6 months following hospital admission. Reduced social support, 
impaired problem solving, reduced motivation to perform positive instrumental 
behaviours and increased negative cognitive biases were proposed as possible 
mechanisms.  
Unadjusted mediation analyses that considered each of the proposed 
mediators individually suggested that the association of baseline brooding with 6 
month depression was partially mediated by (1) low perceived availability of social 
support, (2) poor problem solving related to negative problem orientation, and (3) 
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lower pleasantness ratings of pleasant activities and lack of ‘obtained pleasure’ from 
engagement in pleasant activities at 2 months. In addition, unadjusted preliminary 
analyses suggested that negative biases in memory partially mediated the cross-
sectional association of brooding with depression.  
An unadjusted multiple mediation model was used to investigate the combined 
effects of social support, problem solving and engagement in pleasant activities as 
mediators of the association between baseline brooding with 6 month depression. This 
model suggested that poor problem solving was the strongest mediating variable. 
After adjusting for the effects of confounding variables (age, sex, 
socioeconomic status, history of depression, severity of cardiac disease and baseline 
values of the outcome variable) there was no longer any evidence to suggest that 
social support, problem solving, instrumental behaviours or negative cognitive biases 
mediated the association of baseline brooding with 6 month depression16. 
Finally, there was no evidence to suggest that social support, problem solving, 
instrumental behaviours or negative cognitive biases mediated the associations of 
brooding or worry with either general health-related quality of life or cardiac disease-
specific quality of life.  
                                                     
16Baseline depression in the models including negative cognitive biases. 
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Chapter 6 Discussion 
6.1 Chapter outline 
The broad aim of this thesis was to investigate the association between 
perseverative negative thinking with depression, anxiety and worse quality of life in 
people with coronary heart disease (CHD). 
First, a systematic review was conducted in order to identify, synthesise and 
evaluate existing empirical evidence of the prospective association of perseverative 
negative thinking with depression, anxiety and emotional distress in people with long 
term conditions (LTCs). 
Second, an observational prospective cohort study was conducted to: (a) 
investigate whether rumination and worry would prospectively predict depression, 
anxiety and worse health-related quality of life following hospital admission in people 
with CHD, and (b) explore potential mechanisms by which perseverative negative 
thinking may impact on mood and worse physical health outcomes following hospital 
admission. 
This chapter includes: 
i. A brief re-statement of the background and aims of the thesis. 
ii. A summary of findings of each of the empirical studies reported in this 
thesis. 
iii. A discussion of the methods and findings with reference to strengths, 
limitations and comparison with existing literature.  
iv. Consideration of the implications of this research and suggestions for future 
research.  
 
A discussion specific to the systematic review was presented with the methods and 
findings of the review in Chapter 2 and the main conclusion of that chapter will be re-
iterated here. A brief summary of findings was presented in Chapters 4 and 5, and 
discussion related to the observational prospective cohort study presented in those 
chapters is combined here.  
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6.2 Background and aims 
Depression is common in people with LTCs including CHD and is associated with 
worse physical outcomes. The nature of the causal association between depression 
and CHD is not fully understood, and the mechanism underpinning the association 
between depression and poor medical outcomes remains unclear.  
The effectiveness of antidepressant drugs and psychological interventions for 
depression appear to be limited in people with CHD. Furthermore trials have failed to 
demonstrate convincingly that improving depression also improves physical health 
outcomes, meaning proof that depression causes poor physical health outcomes 
among people with CHD is currently lacking.  
Better understanding the factors that contribute to the development of 
depression in people with CHD and the mechanisms underpinning the association of 
depression with worse physical health outcomes could (a) help predict which patients 
are at increased risk of developing depression and, as a consequence, are at increased 
risk of adverse medical outcomes, (b) facilitate personalisation of treatment based on 
risk of developing depression, and (c) inform the development of novel interventions 
that could target the identified mechanistic processes which might improve both 
physical and mental health outcomes.  
Perseverative negative thinking could predict depression and reduced quality of 
life in people with CHD. Perseverative negative thinking describes a number of 
cognitive processes, such as rumination and worry, in which individuals engage in 
repetitive, prolonged and recurrent negative thoughts about themselves, their 
symptoms or their problems and concerns. Perseverative negative thinking has been 
strongly associated with the onset and maintenance of depression in healthy and 
psychiatric populations, and also predicts adverse medical outcomes, such as poor 
cardiovascular health, impaired wound healing and immune dysfunction.  
Perseverative negative thinking could therefore be helpful in better 
understanding depression in people with LTCs including CHD, and could provide a 
potential target for interventions aimed at improving both psychological and physical 
health outcomes. Most previous prospective research investigating the association of 
perseverative negative thinking with depression has focused on physically healthy 
populations, however. Therefore, the nature of the association, and the mechanisms 
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by which perseverative negative thinking may impact on both mood and physical 
health outcomes in people with CHD are unclear. 
This thesis concerns perseverative negative thinking as a cognitive process that 
may contribute to or maintain depression in the context of chronic physical illness (in 
particular CHD), and seeks to (a) clarify the association of perseverative negative 
thinking with depression, anxiety and health-related quality of life, and (b) explore 
factors that may mediate the association of perseverative negative thinking with 
subsequent depression, anxiety and health-related quality of life. 
The aims of this thesis were to: 
i. Identify, synthesise and evaluate existing empirical evidence of the 
prospective association of perseverative negative thinking with depression, 
anxiety and emotional distress in people with LTCs.  
ii. Investigate whether rumination and worry would prospectively predict 
depression, anxiety and worse health-related quality of life following 
hospital admission in people with CHD.  
iii. Explore potential mechanisms by which perseverative negative thinking 
may impact on mood and worse physical health outcomes following 
hospital admission.  
 
The following main hypotheses were tested: 
i. In patients with recent acute coronary syndrome (ACS), rumination and 
worry following hospitalisation will predict depression at six month follow-
up, after controlling for other confounding variables including baseline 
levels of depression. 
ii. In patients with recent ACS, the impact of rumination following the initial 
cardiac event upon depression at six month follow-up will be mediated by 
four potentially complementary mechanistic factors (low social support, 
impaired problem solving, reduced instrumental behaviours, elevated 
negative cognitive biases17). 
                                                     
17The association of baseline rumination and baseline depression in the case of negative cognitive 
biases. 
220 
 
6.3 Summary of findings 
6.3.1 Systematic review 
Four electronic databases were searched for studies in adults with any LTC that 
included a standardised measure of perseverative negative thinking and a 
standardised measure of depression, anxiety or emotional distress, and which 
presented prospective associations.  
From the 30 studies identified the majority of uncontrolled studies found an 
association between measures of perseverative negative thinking and subsequent 
depression, anxiety or emotional distress (bivariate correlations ranged from r=0.23 to 
r=0.73). Studies that controlled for the effects of covariates, including depression at 
baseline, using multivariable analysis showed more mixed results, though the majority 
of studies still supported a significant association, with effects being small in 
magnitude. These studies fall short of proving causation, and findings were limited 
mainly to the association of rumination and/or catastrophizing with subsequent 
depression. Results varied according to LTC, and study quality was limited in many 
cases by failure to adequately control for potential confounding variables and by 
attrition. 
6.3.2 Observational prospective cohort study: Part I 
The main aim of this study was to explore in patients with recent ACS whether 
rumination and worry would prospectively predict depression, anxiety and worse 
health-related quality of life over 6 months following hospital admission.  
A sample of 169 ACS patients recruited within 6 months of hospital admission 
completed self-report assessments at baseline, and again at 2 month and 6 month 
follow-ups. The 14% of participants with depression were younger, more socially 
isolated, had a history of depression, worse socioeconomic status and reported greater 
severity of cardiac disease than those without depression.  
After controlling for the effects of key covariates baseline brooding was a 
significant predictor of depression at 6 months, accounting for 2% of the variance in 
depression. Baseline brooding did not predict 2 month depression however. In 
addition, baseline worry was a significant predictor of worse quality of life related to 
mobility problems at 6 months. Other strong predictors of worse 6 month outcomes 
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were baseline values of the relevant outcome variable, social support and greater 
severity of cardiac disease. 
Longitudinal multilevel (repeated measures) models were used to validate and 
extend the findings and indicated that trajectories of depression and anxiety varied 
between participants over time. Longitudinal models also showed that the association 
of brooding at the previous assessment time with depression at the next assessment 
time was on the threshold of significance after controlling for confounding variables 
including social support. A sensitivity analysis in which social support was removed 
from the model showed that brooding was a significant predictor of depression. The 
results of multilevel (repeated measures) models also indicated that both brooding 
and worry at the previous assessment time predicted worse subsequent health-related 
quality of life.  
With regards to the specific hypotheses tested, the main hypothesis that, in 
patients with recent ACS, rumination and worry following hospitalisation will predict 
depression at six month follow-up was partially supported, since brooding, but not 
worry, appeared to be a significant prospective predictor of subsequent depression. It 
was not clear from the findings whether the prospective association of brooding with 
depression was direct, or whether the association was confounded by the effect low of 
social support. 
The secondary hypothesis that, in patients with recent ACS, rumination and 
worry following hospitalisation will predict anxiety and quality of life at six month 
follow-up was also partially supported since both brooding and worry were significant 
prospective predictors of subsequent quality of life, but not of anxiety.  
6.3.3 Observational prospective cohort study: Part II 
The secondary aim of the study was to investigate, in patients with recent ACS, 
whether low social support, impaired problem solving, reduced instrumental 
behaviours or elevated negative cognitive biases mediate the association of 
perseverative negative thinking with depression and worse physical health outcomes 
over 6 months following hospital admission.  
Individual mediation models showed that the association of baseline brooding 
with 6 month depression was partially mediated by low perceived availability of social 
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support, poor problem solving, and reduced instrumental behaviours at 2 months. 
Negative cognitive biases partially mediated the cross-sectional association of baseline 
brooding and depression. In a combined mediation model poor problem solving 
(specifically greater negative problem orientation) at 2 months was the strongest 
mediator of the association between baseline brooding and 6 month depression.  
After adjusting for the effects of important confounding variables there was no 
longer any evidence to suggest that social support, problem solving, instrumental 
behaviours or negative cognitive biases mediated the association of baseline brooding 
with 6 month depression18, although all proposed mediators remained strong 
predictors of depression. 
With regards to the specific hypotheses tested, the main hypotheses that, in 
patients with recent ACS, the impact of rumination following the initial cardiac event 
upon depression at six month follow-up will be mediated by (1) low social support, (2) 
impaired problem solving, (3) reduced instrumental behaviours, and (4) elevated 
negative cognitive biases18 were partially supported, since the findings were consistent 
with partial mediation but only in models unadjusted for confounding variables.  
The secondary hypotheses that, in patients with recent ACS, the impact of 
rumination following the initial cardiac event upon quality of life at six month follow-
up will be mediated by (1) low social support, (2) impaired problem solving, (3) 
reduced instrumental behaviours, and (4) elevated negative cognitive biases18 were 
not supported. 
6.4 Strengths and limitations 
There were several main strengths of the observational cohort study presented 
in this thesis. 
First, important variables that might confound the association of brooding or 
worry with depression, anxiety and quality of life were controlled.  As identified in the 
systematic review presented in Chapter 2 previous studies failed to adequately control 
for potential confounding variables and could therefore have overestimated the effect 
                                                     
18The association of baseline brooding and baseline depression in the case of negative cognitive biases. 
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size of associations. Covariates were selected on the basis of previous literature that 
demonstrated an association with depression or anxiety. 
Second, to clarify whether perseverative negative thinking was prospectively 
associated not only with depression but also with worse physical health outcomes in 
people with CHD, health-related quality of life was included as an additional outcome 
measure. Furthermore due to the high comorbidity of depression and anxiety, anxiety 
was also assessed in order to gain a more complete understanding of factors that may 
predict depression in CHD. 
 Third, while previous studies in people with LTCs have tended to focus on a single 
aspect of perseverative negative thinking both rumination and worry were included as 
predictor variables in this study, in order to investigate the association of a broader 
range of perseverative negative thinking with depression and other outcomes.  
 Fourth, self-report measures of (1) rumination and depression, and (2) worry 
and anxiety were selected carefully to minimise artefactual associations. The 
Ruminative Responses Scale was previously decomposed into brooding and reflection 
subscales in order to eliminate ‘depression contaminated’ items[315]. The brooding 
subscale was therefore chosen for use in the current study to avoid a spurious 
association. Similarly, the Beck Anxiety Inventory was selected for use in this study due 
to its relative lack of items addressing cognitive aspects of anxiety including worry.   
 Fifth, previous studies have not addressed mechanisms that could explain why 
perseverative negative thinking is associated with depression in people with CHD. 
Previous research suggests that low social support, poor problem solving, reduced 
instrumental behaviours and negative cognitive biases may explain the association of 
rumination with depression[120], and these factors were explored in the current 
study. 
There were also several limitations of the observational prospective cohort 
study presented in this thesis, and these are addressed below in turn.  
6.4.1 Poor uptake, attrition and missing data 
Of the 397 individuals invited to participate only 44% completed at least 
baseline assessments. The age and gender ratio of the sample that took part was 
comparable to that of a group of individuals identified within the same setting who 
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were invited to participate but ultimately chose not to, and was also consistent with 
UK CHD prevalence statistics[3]. This suggests that the sample who participated in this 
study were crudely representative of the broader ACS population, although it is 
unknown whether the group who chose not to participate varied systematically from 
those who participated on other key variables such as depression scores. 
There was a high level of attrition over the course of the study; only 66% of 
participants who completed baseline assessments also completed assessments at 6 
months. Similar studies in CHD populations identified by the systematic review 
presented in Chapter 2 reported retention rates of between 67% to 85% [182, 183, 
251, 270]. Two of these studies used postal follow-ups and achieved 82% and 79% 
retention rates at 3 months and 1 year follow-up, respectively. Sample characteristics 
of completers compared to non-completers at 6 months were similar, and It is unclear 
why retention was comparatively poor in this study (although 3 of the 4 other studies 
had only one follow-up assessment, and therefore arguably imposed a smaller burden 
on participants). The poor retention rate at 6 month follow-up means that there could 
have been a reduction in power to detect associations, and a risk of sample bias which 
could limit generalisability of findings. 
Attrition can limit the generalisability of results where there are systematic 
differences between dropouts and completers (for example, participants with poorer 
physical health or depression may be more likely to drop out), meaning that the 
sample of completers does not accurately represent the whole patient population. 
Therefore, conclusions regarding prevalence of population characteristics (such as 
depression, for example) may not be accurate, and it is unclear whether the nature of 
any associations of interest may differ in dropouts compared to completers. Some 
studies suggest that non-participation in health surveys leads to underestimates of the 
prevalence of mental disorders although estimates of the associations between 
exposures and outcomes remain unbiased[366-368]. It is possible that attrition may 
have similar implications for findings. 
Baseline characteristics of participants who completed 6 month assessments 
for this study were compared with those of dropouts, to assess whether there were 
systematic differences between the two groups at baseline. The groups were broadly 
similar in terms of sociodemographic, lifestyle and disease variables. Mean depression 
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scores did not differ, although a greater proportion of dropouts were depressed 
(PHQ≥10) at baseline compared with completers at baseline. Cross-sectional 
associations of perseverative negative thinking with depression, anxiety and quality of 
life at baseline did not differ between completers and dropouts. However, exploratory 
analyses tentatively suggested that the prospective association of baseline brooding 
with 6 month depression was strongest in participants with elevated depressive 
symptoms at baseline, which is consistent with previous research. It is possible 
therefore that the estimates of prospective associations in this study may be 
conservative as a result of attrition. 
The number of cases with missing data for any of the main predictors or 
outcome variables (due to participants failing to complete specific assessments or 
items, or providing ambiguous responses) ranged from 0% to 9%. The quantity of 
missing data at case and item level was within acceptable ranges[358] and sample 
characteristics of participants with and without missing data were similar, indicating 
that missing data was unlikely to have biased the findings.  
6.4.2 Timing of assessments 
The timing of assessments was selected based on reports of elevated 
prevalence of depression in the 12 months post-MI[289-292] (participants for this 
study were recruited within 6 months of their hospital admission in order that follow-
up assessments could be completed within the first year post-ACS). However, it is 
unclear (1) how the temporal relationship between depression and CHD evolves[33, 
288], and (2) how the time course of rumination and worry following CHD may unfold. 
For example, rumination could be expected to be higher immediately post-MI due to 
the experience of a sudden life-threatening event (consistent with a study that 
reported a positive correlation between severity of negative life events and 
rumination[284]), or alternatively rumination might increase later in the process of 
recovery after patients have had time to reflect on the implications of their illness, 
particularly if it interferes with their usual lifestyle and attainment of other goals as 
control theory approaches to rumination suggest[115, 119]. 
Therefore the timings of assessments were largely arbitrary, and it is possible 
that the optimal timings of effects may have been missed, meaning the results 
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presented here could represent an underestimate of associations (although the 
systematic review presented in Chapter 2 suggested that follow-ups between 1 to 12 
months after baseline assessments would be optimal to detect associations). 
In addition, due to recruitment of patients from both inpatient and outpatient 
settings there was a degree of variability between participants in time from index 
event (defined here as the admission date of the most recent hospitalisation for ACS 
prior to completion of baseline assessments), and due to delays in returning the 
questionnaire packs (or in some cases owing to early completion) there was also some 
variability between participants in the timing of 2 month and 6 month assessments.  
Uneven spacing between assessment times makes interpretation of lag variables and 
other prospective analyses using assessment time as a factor more complicated, 
particularly if the associations of interest are not stable over time. One implication is 
that the ability to make recommendations about the most useful time to deliver 
potential interventions is limited. 
To explore the effect of the actual timings of the assessments, time from index 
event and time from baseline were entered as covariates and results showed that they 
did not significantly predict any outcome variable, meaning that time since index event 
and time between assessments did not impact on the associations between brooding 
and worry with depression, anxiety or quality of life. 
6.4.3 Data quality and violation of statistical assumptions 
Regression diagnostics indicated that the assumptions of normally distributed 
residuals and of homoscedasticity were violated in the majority of staged multivariable 
regression models, and all multilevel (repeated measures) models violated the 
assumption of normally distributed residuals. Transforming the data was not effective, 
and robust methods to estimate standard errors were either not available or failed to 
converge. Therefore it is possible that standard errors and significance values could be 
biased. However, multivariable regression is relatively robust to violations of normality 
and homoscedasticity (e.g. [357]) and such violations are common with clinical 
indicators such as depression and anxiety scales, particularly in non-clinical samples. In 
similar published studies with ACS samples[182, 183] the evaluation of model 
assumptions were not reported although findings were consistent with those reported 
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here. Additionally, the results of regression analyses and multilevel (repeated 
measures) models reported here corresponded with each other, and the findings were 
consistent at different assessment times suggesting they are reliable. 
A small number of outliers were identified for the majority of variables but 
upon inspection these were within expected ranges for the relevant assessments, and 
so were retained. Regression diagnostics indicated that outliers did not pose a risk of 
bias.  
6.4.4 Self-report assessments of physical health outcomes 
Physical health outcomes were assessed using self-report measures in this 
study. Mortality and morbidity were considered outcomes of interest and objective 
outcomes related to mortality and morbidity (such as monitoring hospital records for 
deaths and recurrences) would have been desirable. However, due to the relatively 
small sample size and the relatively short follow-up period few such events were 
anticipated.  Therefore physical health outcomes were assessed using two quality of 
life instruments: the EuroQol-5D measure of general health-related quality of life 
(EQ5D) and the Seattle Angina Questionnaire (SAQ) to measure cardiac disease-specific 
quality of life.  
Quality of life measures of health status are important tools that can 
complement more traditional objective measures of outcome such as morbidity and 
mortality, by providing information about the patients experience of health problems 
and treatments related to symptoms, physical function and other domains such as 
social functioning[285, 287]. However while these measures are widely used and many 
have well established psychometric properties, a key disadvantage is that subjective 
reports of physical health are not independent of mental health i.e. responses could be 
influenced by current mood state. For example, quality of life measures and 
depression measures correlate in patients with CHD[48, 369]. Therefore, although 
health-related quality of life is an important outcome in its own right, the results of 
this study do not allow inferences to be made about the association of perseverative 
negative thinking with objective physical health outcomes such as recurrence or 
mortality. 
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6.5 Interpretation of findings 
The main findings of this thesis are interpreted to mean that brooding appears to 
prospectively predict depression in people with recent ACS, possibly via impaired 
problem solving (specifically, high negative problem orientation). Additionally, 
brooding and worry both appear to prospectively predict some aspects of quality of 
life, although mechanisms to explain this association were not identified.  
The findings fall short of proving causation, and it remains possible that the 
apparent prospective association between brooding and depression is confounded, for 
example by poor social support. 
6.6 Comparison with existing literature 
6.6.1 Brooding and worry 
The psychometric properties and performance of the Ruminative Responses 
Scale (RRS) brooding subscale and the Penn State Worry Questionnaire (PSWQ) have 
been well established particularly in young healthy and clinically anxious/depressed 
samples (e.g. [133, 140, 164, 315, 316, 370, 371]), however they have not been well 
characterised in people with ACS.  The mean RRS brooding score in this study was 
consistent with that reported in a similar previous study with ACS patients[183], and 
the average PSWQ score in this study was similar to mean scores reported in previous 
studies that included participants with anxiety[316], cancer[264], a combination of 
long term conditions including CHD[178] and a healthy sample of older adults with a 
mean age similar to the sample included here[372]. Therefore, levels of brooding and 
worry in this study were as expected based on a limited amount of previous research. 
Questionnaire assessments generally provide a ‘snapshot’ of the construct of 
interest at a single moment in time. However, emotional and cognitive processes can 
fluctuate over time and therefore questionnaire assessments cannot capture subtle 
temporal changes unless the assessments are repeated very frequently (e.g. ecological 
momentary assessment). However, rumination and worry are usually conceptualized 
as trait measures of repetitive thought. That is, the extent to which individuals 
characteristically engage in ruminative or worrisome thinking. As such the Ruminative 
Responses Scale (RRS) and the Penn State Worry Questionnaire (PSWQ), ask 
respondents to rate whether they ‘generally’ or ‘typically’ ruminate or worry. 
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Assessments of trait measures ought to be highly positively correlated at different 
occasions, and in previous studies test-retest correlations have been reported in 
community and clinical samples of r=0.59 to r=0.62 for RRS[152, 373] and r=0.92 to 
r=0.93 for PSWQ[133], suggesting these measures are stable over time.  Consistent 
with this, in the current study there were large and highly significant correlations of 
brooding (r=0.76 to r=0.81) and worry (r=0.72 to r=0.77) across baseline and follow-up 
assessments, as would be expected of trait measures. Therefore, since rumination and 
worry appear to be stable over time, it is unlikely that the use of one-off questionnaire 
assessments of these constructs would have affected (weakened) the observed 
associations. 
6.6.2 Depression, anxiety and quality of life 
Mean depression (PHQ), anxiety (BAI), general health-related quality of life 
(EQ5D) and cardiac disease-specific quality of life (SAQ) scores indicated that overall 
the sample included in this study was not experiencing significant problems with 
depression, anxiety or poor quality of life at any of the assessment occasions. 
Participants in this study were less depressed and cardiac disease-specific quality of life 
was better than expected compared to previous studies. 
6.6.2.1 Low proportion of participants with depression 
 Mean  PHQ scores at baseline in this study (mean=4.3) were similar to a 
previous study of primary care CHD patients without previously identified depression 
(mean=4.5)[374] and a study of depression base rates in CHD inpatients and 
outpatients (mean=5.5)[375]. However, the proportion of participants with depression 
was low (14% at baseline falling to 10% at 2 month and 6 month assessments) 
compared to estimates of approximately 20% prevalence of depression in the first 12 
months post-MI in other studies[71, 376, 377]. It is not immediately obvious why this is 
the case. Sample characteristics related to age, gender social support and left 
ventricular function as a measure of severity of cardiac disease did not appear 
different in this study from those seen in other similar cohorts. One possibility that 
might explain the low proportion of depression is that the participants in this study 
had relatively stable CHD by the time they completed baseline assessments (the mean 
time from index event was 111 days), as lower prevalence has been reported in some 
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other studies that recruited patients with stable disease rather than immediately after 
an acute event e.g.[378]. 
The implication of limited representativeness of the sample with regards to 
prevalence of depression is that the findings may not be applicable to a clinically 
depressed or anxious sample of ACS patients. Indeed, Denton et al.[183] found among 
a sample of ACS patients that the effects of rumination immediately post-MI on 
depression 3 months later differed according to depression status at baseline.  
Specifically, they found a direct effect of rumination on depression in those who were 
depressed at baseline, whereas rumination in those who were not depressed at 
baseline led to depression only indirectly (by amplifying the impact of other 
psychosocial vulnerabilities). In this study an exploratory sensitivity analysis supported 
this, showing that baseline brooding was more strongly correlated with 6 month 
depression in participants who were depressed compared to those who were not 
depressed, although these findings were based on a very small sample of depressed 
participants who remained in the study at 6 months. 
6.6.2.2 Secondary outcome measures: anxiety and quality of life 
Mean BAI scores (mean=8.7) in this study indicated little anxiety, consistent 
with previous studies in a sample of female CHD patients <65 years (mean=10.1)[46], 
and a sample of patients with coronary slow flow (mean=13.0)[379]. The proportion of 
participants in this study with at least moderate anxiety (BAI ≥19; 16%) was 
approximately consistent with UK prevalence estimates of anxiety disorders[380], and 
prevalence estimates of anxiety in CHD patients[381, 382]. 
General health-related quality of life (EQ5D index values and EQ5D visual 
analogue scale; means at baseline 0.78 and 72.9, respectively) in this study was 
comparable to UK population norms for an equivalent age group (index value 
norm=0.79, VAS norm=77.3)[383], and was also similar to that found in previous 
studies in MI patients (e.g. [332, 334, 335]) and a large multicentre study of CHD 
patients[384]. 
Cardiac disease-specific quality of life (SAQ subscale scores) in this study 
appeared to be elevated (i.e. better) compared to other studies of patients with 
coronary artery disease and ACS [336, 385, 386]. This could be an artefact of the 
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relatively few studies available for comparison since many studies chose to present 
SAQ scores collapsed into frequencies (e.g. [387, 388]). Alternatively, since cardiac 
disease-specific quality of life and depression correlate (e.g.[48, 389]) it is possible that 
elevated SAQ scores are related to the low levels of depression observed in this study. 
Depression was correlated with most SAQ subscales at baseline which would support 
this interpretation.  
6.6.3 Stability of outcome variables over time 
There was little change in mean scores over assessment times for any of the 
outcome variables. PHQ, BAI, EQ5D and SAQ are all state measures of mood or quality 
of life over the preceding days/weeks which would be expected to fluctuate. Since 
there was little variation over time, it could be argued that responses at one 
assessment time would be strong predictors of the same outcome at the next 
assessment time, leaving little variance to be explained by other predictors. This could 
have led to underestimates of the importance of other predictor variables, such as 
rumination and worry.  
Interestingly, while mean values of the outcomes in the sample overall 
remained stable over time, multilevel (repeated measures) models showed that there 
was significant between-participant variation in trajectories of depression and anxiety 
over the course of the study. This raises the possibility that by identifying different 
trajectories of depression and anxiety it may be possible to reveal subgroups of post-
ACS patients and characterise which patients might be particularly at risk of worse 
outcomes. Understanding how depression evolves over time post-ACS could also 
provide important information about the optimal timing of interventions.  
Two approaches have been used previously in CHD patients; profiles of 
depression have been created by categorising patients using pre-defined clinical cut-
off scores at different assessment times(e.g.[390]), or in a more data-driven approach 
trajectories have been identified using latent class analysis (e.g.[376, 391, 392]). None 
of these studies have investigated how perseverative negative thinking may vary 
across subgroups with different trajectories, although one study in a sample of ACS 
patients[376] investigated whether other psychosocial vulnerabilities for depression 
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(including stressful life events, engagement in pleasant events, cognitive distortions 
and ‘Type D’ disposition) differentiated the trajectories. 
Due to the small sample size and low number of participants depressed at 
baseline it was not possible to explore the characteristics of subgroups with different 
trajectories in this study and how these might relate to worse outcomes. 
6.6.4 Prospective associations of brooding with depression 
In this study staged multivariable regression models that controlled for the 
effects of important confounding variables showed that baseline brooding was a 
significant predictor of depression at 6 months. Four previous studies investigating the 
prospective association of perseverative negative thinking (specifically rumination and 
catastrophizing) with depression and health related quality of life in patients with CHD 
were identified in the systematic review presented in Chapter 2[182, 183, 251, 270]. 
Consistent with the current study, 3 of the 4 previous studies found a significant 
association between baseline rumination with depression at between 3 to 12 months 
follow-up. The study which did not find an association[270] had a very low sample size 
at follow-up (n=17).   
In the current study, baseline RRS brooding accounted for 2% of variance in 6 
month depression. Effect sizes in the other studies with positive findings were similar. 
Denton et al. (2012) found that RRS brooding independently accounted for 1.2% of 
variance in 3 month depression after controlling for other confounding variables, and 
Baker (2014) reported that brooding independently accounted for 4% variance in 
depression (although in multivariable analyses they failed to control for socioeconomic 
status and history of depression which could explain the marginally larger effect size). 
Finally, Garnefski et al. (2010) did not present their findings in a way that allowed 
direct comparison as they combined rumination and catastrophizing into a single 
variable for multivariable analyses.  They did however present a bivariate correlation 
of r=0.45 between baseline rumination with 1 year depression which is consistent with 
the current study (r=0.47 between baseline RRS brooding and 6 month depression).  
The association of rumination with depression in people with ACS is consistent 
with the response styles theory[118, 120, 121] and with a large body of empirical work 
that supports an association in other populations (for reviews see e.g. [113, 168-170]). 
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6.6.4.1 Overlap of brooding and social support 
Low perceived availability of social support was a strong predictor of 
depression in the staged multivariable regression models presented in Chapter 4. This 
is consistent with research that shows CHD patients with depression report lower 
levels of social support than those without depression e.g.[71, 192, 393]. The findings 
of this study suggested that the effects of social support and brooding could be 
partially overlapping. In a fully adjusted multilevel (repeated measures) model that 
controlled for social support brooding was a marginally significant predictor of 
subsequent depression. When social support was removed from the model the 
association of brooding with subsequent depression became significant. This suggests 
that brooding is an independent predictor of depression, despite probable shared 
variance with low social support.  
Previous research shows that rumination is associated with less emotional 
support and more social friction[120], and that high ruminators create conflict and 
disturbances in their interpersonal relationships[200]. The association of rumination 
and social support and their shared association with depression, means that brooding 
could prove useful as an intervention target since it may be more amenable to change 
than social support. For example, in a systematic review and meta-regression to 
identify effective components of psychosocial interventions for depression in CHD 
patients Dickens et al. (2013) found that interventions to increase social support failed 
to improve depression[99]. In a large randomised controlled trial (the ENRICHD study) 
a CBT-based psychosocial intervention to increase social support resulted in only small 
improvements after 6 months in perceived social support and depression compared to 
treatment as usual, and the intervention did not improve outcomes related to 
recurrence or mortality[88]. 
Interestingly, interactive effects of social support and rumination on 
physiological outcomes have also been demonstrated in a previous study with healthy 
participants. Using an ecological momentary assessment technique combined with 
ambulatory monitoring of heart rate variability (HRV) Gerteis & Schwerdtfeger (2016) 
found that the impact of rumination on HRV differed according to availability of social 
support. Specifically rumination attenuated HRV when social support was low, and 
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increased HRV when social support was good, suggesting low availability of social 
support exacerbates the dysfunctional physiological consequences of rumination[394].  
6.6.4.2 Impact of covariates 
Simple regression models showed that brooding was significantly associated 
with depression, anxiety, general health-related quality of life and cardiac disease 
specific quality of life. However, after adding other covariates to the models the only 
association that remained significant was of brooding with depression. Covariates 
were selected for inclusion in the models based on previous literature demonstrating 
an association with depression. However, evidence suggests that at least some of the 
covariates chosen (e.g. history of depression, socioeconomic status, social support) 
may also be associated with rumination[162, 197, 395]. Therefore, the effects of 
brooding in the fully controlled models presented in this thesis may have been 
underestimated due to shared variance with other confounding variables.   
6.6.4.3 Delay between brooding and development of depression 
In the current study associations between (a) baseline predictors and 2 month 
outcomes, and (b) 2 month predictors and 6 month outcomes, were similar to those 
observed between baseline predictors and 6 month outcomes. Most associations were 
stronger when assessments were temporally closer together, although the pattern of 
associations appeared to be relatively stable over time. There was one notable 
exception which was that while RRS brooding at baseline significantly predicted 6 
month depression after controlling for other confounding variables including baseline 
depression, RRS brooding at baseline did not significantly predict depression at 2 
months.  
This could help to explain why the multilevel (repeated measures) model that 
investigated the association of brooding at the previous assessment time with 
depression at the next assessment time found only a marginally significant effect of 
brooding, since the overall effect was weakened by the lack of association between 
baseline and 2 month assessments. 
Since most associations appeared to be stronger when the assessments were 
temporally closer together the lack of association between baseline brooding and 2 
month, but not 6 month, depression seems puzzling. It  might be that baseline 
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depression was a stronger predictor of depression at 2 months than at 6 months, and 
therefore accounted for more of the variance, leaving less for brooding to explain.  
Alternatively, it could be argued the lack of association early on represents a 
delay between brooding and the subsequent development of depression. This is 
consistent with the predictions of the cognitive neuropsychological model of 
depression[215, 365]. The model proposes that alterations in monoamine function as a 
result of genetic and environmental factors are causally related to negative biases in 
emotional and social processing. Negative biases in turn are thought to propagate 
negative schemata that lead to the development of depressive symptoms due to 
repeated experience of negative cues over long periods of time. Thus, the effect of 
brooding on subsequent depressive symptoms could be expected to develop with 
some delay. This could lead to associations between brooding and subsequent 
depression being missed or underestimated if follow-ups are conducted too soon. 
6.6.5 Prospective association of worry with depression 
Contrary to expectation, worry did not prospectively predict depression in the 
current study, after controlling for other important confounding variables. There is 
cross-sectional evidence to suggest that worry is associated with elevated depression 
in a sample with mixed long term conditions including CHD[178]. However worry has 
traditionally been linked more closely with anxiety than depression[131, 158]. In the 
staged multivariable regression models presented in Chapter 4 worry predicted 
depression in models unadjusted for confounders, albeit more weakly than brooding 
predicted depression. It may be that the effect of worry was not large enough to 
survive correction for other strong predictors of outcome such as baseline depression 
and social support. Future work could clarify this (a) in samples with more variability in 
measures of worry and depression, and (b) by exploring subgroups with varying 
trajectories of depression. 
6.6.6 Prospective associations of brooding and worry with anxiety 
Neither brooding or worry prospectively predicted anxiety in the current study, 
which conflicts with previous work in healthy samples[152, 155, 167, 396] and cancer 
patients[264, 275], although there is no previous work in samples with CHD with which 
to make comparisons. 
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One possible explanation for the lack of association could be related to the 
measure of anxiety used in this study. In order to minimise any confounding caused by 
the overlap of worry and anxiety measures, the Beck Anxiety Inventory (BAI) was used. 
The BAI mainly consists of items related to somatic and autonomic rather than 
cognitive aspects of anxiety. It has been suggested that due to its focus on somatic 
symptoms the BAI may be more sensitive to panic disorder than to other types of 
anxiety, such as generalised anxiety disorder[397, 398], that may be more relevant in 
people with CHD. Therefore this study provided a very conservative test of the 
association between brooding and worry with subsequent anxiety, and associations 
may have been overlooked.   
6.6.7 Prospective associations of brooding and worry with quality of life 
In the current study, rumination and worry both prospectively predicted overall 
generic health-related quality of life. Worry also predicted problems with mobility and 
there were trends to suggest rumination predicted greater angina frequency and 
worse disease perceptions related to the cardiac problem. These findings are 
consistent with other work that has linked worry and rumination with health outcomes 
such as impaired wound healing[224], immune dysfunction[225], worse functional 
outcomes in rheumatoid arthritis and psoriasis[399, 400] and worse cardiac 
outcomes[228]. These findings also fit within the theoretical framework of the 
perseverative cognition hypothesis[229, 230, 233] which suggests that perseverative 
negative thinking such as rumination and worry adversely impacts on physiological and 
health outcomes by maintaining and prolonging physiological responses to stressors.  
The systematic review presented in Chapter 2 identified 4 studies in patients 
with CHD. Only 1 of those studies explored the association of perseverative negative 
thinking with physical health, and found that rumination did not predict general 
health-related quality of life or cardiac disease-specific quality of life[251]. However, 
this study used a different measure of generic health-related quality of life (the Short 
Form-12 Health Survey), and relied on a composite total score for SAQ which is not 
recommended as it does not allow investigation of the independent effects of different 
facets of cardiac disease-related quality of life.  
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Since the quality of life measures used to assess physical outcomes in this study 
were subjective self-report measures it is not known whether brooding and worry will 
prospectively predict objective physical health outcomes such as recurrence of MI or 
mortality. Future cohort studies in larger samples with a longer follow-up period would 
be required to confirm this. 
6.6.8 Mediators of the association between perseverative negative thinking and 
depression 
As hypothesised the results presented in Chapter 5 identified low social 
support, impaired problem solving and reduced engagement in pleasant activities as 
strong prospective predictors of depression and worse health-related quality of life, 
and in preliminary analyses negative cognitive biases (specifically biases related to 
memory) were concurrently associated with depression and worse health-related 
quality of life. 
Individual mediation models showed that the association of baseline brooding 
with 6 month depression was partially mediated by low social support, poor problem 
solving (specifically negative problem orientation) and lack of engagement in pleasant 
activities at 2 months. A combined model, in which the impact of all three mediators 
were evaluated together, revealed that the association of baseline brooding with 6 
month depression was mediated by poor problem solving at 2 months. 
Interestingly, problem solving (specifically negative problem orientation) 
improved significantly from baseline to 6 months. There were no significant changes in 
mean depression scores over time, although the mean values were consistent with 
improvement over time. These (tentative) improvements in depression could reflect 
improvements in problem solving in a proportion of individuals. These findings are 
consistent with studies in healthy participants that showed negative problem 
orientation was prospectively associated with depressive symptoms[202, 203].  
The strong association of problem solving with depression in this study 
suggests that interventions to improve problem solving may provide effective targets 
for treating depression in people with CHD. If problem solving does indeed lie on the 
causal pathway between brooding and depression, as the findings of mediation 
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analyses suggest here, then problem solving could prove to be a more proximal target 
for intervention. 
Problem solving therapy [401, 402] is an intervention that focuses on training 
constructive problem solving attitudes and skills.  The components of training relate to 
a number of core processes (problem orientation, problem definition and formulation, 
generation of alternatives, decision making, and solution implementation) and can 
include psychoeducation, problem-solving exercises and motivational approaches. 
Problem solving therapy has been shown to improve depression in clinically depressed 
samples[403, 404] and is well accepted in this group[405], although in patients with 
CHD research is more sparse. 
A randomised controlled trial of primary care patients with poorly controlled 
diabetes and/or CHD with comorbid depression was conducted to evaluate a 
collaborative care intervention that involved motivational coaching to improve 
problem solving[406]. The primary outcome measures in this study were disease 
control and depression. At 12 months patients in the intervention arm had significantly 
greater improvement in measures of disease control, depression, quality of life and 
treatment satisfaction. Since the intervention consisted of multiple components it is 
unclear to what extent problem solving was responsible for the improvements seen in 
depression and other outcomes in this study. Similarly, in a randomised controlled trial 
of enhanced care which included problem solving therapy for ACS patients with 
persistent depression, improvements in depression were observed after 6 months of 
treatment[407]. However, problem solving was an ‘opt-in’ component of the 
treatment, and it is unclear to what extent this component of the intervention was 
responsible for improvements in depression. A systematic review and meta-regression 
of randomised controlled trials of psychological interventions in patients with CHD 
found small significant effects of problem solving interventions on depression, but only 
in a subgroup of patients without depression[99].  
Evidence that improving problem solving in CHD patients can also reliably 
improve depression and physical health outcomes is therefore currently lacking. To 
confirm that poor problem solving mediates the association of brooding with the 
development of depression, and that problem solving is a valuable target for 
intervention, future work should seek to demonstrate in people with CHD that (a) high 
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ruminators have deficits in problem solving, (b) altering rumination changes problem 
solving, and (c) problem solving training improves depression.  
6.6.9 Association of inflammation, negative cognitive biases and depression 
An interesting exploratory post-hoc investigation was prompted by the finding 
that inflammation during hospitalisation was associated with negative cognitive biases 
(specifically biases related to self-referential endorsement of negative adjectives).  
Inflammation was found to be associated with negative cognitive biases even after 
controlling for depression. Speculatively, this might suggest that the association of 
inflammation with depression is not entirely explained by greater severity of cardiac 
disease and that inflammation may contribute to depression via negative cognitive 
biases which could explain why people with chronic physical illnesses such as CHD are 
at greater risk of depression.  
The mechanisms by which inflammation may contribute to depression are 
unclear. That inflammation may provoke negative cognitive biases and thereby cause 
depression would fit with the cognitive neuropsychological model of depression 
described previously, suggesting that changes in mood are a result of biases in 
emotional processing[215, 365]. This would also be consistent with the findings of a 
recent systematic review of experimental studies that induced acute inflammation in 
healthy participants and measured effects on cognition[408]. The results of the review 
were mixed and limited by methodological heterogeneity of the included studies, 
although the most consistent findings were of negative effects on measures of 
emotional and social processing (e.g. reduced ability to recall emotional faces and 
feelings of social disconnectedness). 
Previous studies have provided mixed evidence of an association between 
inflammation and depressive symptoms in people with CHD however(e.g.[310, 409-
411]), and it has been suggested that an association may be present only in a subgroup 
of post-ACS patients with new onset depression who are particularly at risk of worse 
cardiac outcomes[70, 310]. Furthermore, while studies have shown that cognitive bias 
modification has been successful in achieving change in cognitive biases themselves, 
the effects on mood and psychopathology are less clear, and effect sizes have typically 
been small e.g.[412, 413]. 
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Thus while the suggestion that inflammation may contribute to depression via 
negative cognitive biases is supported by a relevant theoretical framework, previous 
research has not clearly demonstrated that inflammation is causally related to 
depression or negative cognitive biases in people with CHD, and the utility of 
modifying negative cognitive biases for the treatment of depression is unknown. Still, 
there is the intriguing possibility that reducing inflammation or altering negative 
cognitive biases could provide future targets for treatments to improve depression. 
The findings presented here were based on marginally significant cross-
sectional associations among a small number of participants, and other potential 
confounding variables were not controlled. In addition a dichotomous variable was 
used to represent inflammation (C-reactive protein categorised as ‘inflammation 
present’ and ‘inflammation absent’) which could mean that important fine-grained 
information about the magnitude of inflammation was lost. These findings should 
therefore be treated as preliminary, and future research should aim to clarify the 
mechanism of the association between inflammation and depression in people with 
CHD. 
6.7 Implications  
The findings presented in this thesis have a number of clinical implications.  
First, it supports the view that detecting and treating depression in CHD patients is 
essential.  Studies suggest that, despite its high prevalence, depression in CHD patients 
is under-recognised by healthcare professionals in primary and secondary care 
settings[82, 414], and that when it is recognised it is frequently left untreated[415]. 
Detection and treatment of depression in CHD patients is especially important owing 
to the association of depression with increased morbidity, mortality[39, 41, 42] and 
increased healthcare costs[38] in this group. Brief screening instruments are 
recommended for case-finding in CHD patients[86]. The findings presented in this 
thesis are consistent with other research showing that rumination is prospectively 
associated with depression in people with CHD[183], and therefore in the future 
screening for rumination could prove a useful strategy for predicting which patients 
are at increased risk of becoming depressed. These patients could be monitored more 
closely for signs of depression at follow-up or preventative strategies could be 
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implemented to ward off the development of depression. Interventions such as 
rumination-focused cognitive behavioural therapy could be introduced for those at 
highest risk.  
Second, understanding the risk factors for depression can also improve our 
understanding of the mechanism of the association between depression and CHD. 
Since depression appears both to predict CHD and to worsen outcomes after the onset 
of CHD, risk factors for depression may also help to identify individuals at risk of 
CHD[416].  Identification of such risk factors could inform screening and prevention 
recommendations for CHD. 
Third, the findings presented here have highlighted some possible intervention 
targets for the development of evidence-based treatments that could improve 
depression and may also impact on physical outcomes in people with CHD. Rumination 
itself could be considered the most distal target for treatment in the context of the 
observational prospective cohort study presented here. Among existing treatment 
approaches behavioural activation, rumination-focused cognitive behavioural therapy 
(RFCBT) and mindfulness-based cognitive behavioural therapy (MCBT) all contain 
components that target rumination including (1) functional analysis and self-
monitoring to find alternative strategies with which to replace rumination, and (2) 
shifting thinking style or mode of thinking to increase concrete, process-focused 
thinking styles and reduce abstract and judgemental thinking. Beneficial effects of 
these treatment approaches have been demonstrated in patients with depression (e.g. 
[237, 239-241]) although evidence of their efficacy in treating depression in CHD 
populations is currently lacking. The current study demonstrated a large degree of 
overlap in the prospective association of brooding and low social support with 
subsequent depression. Coupled with previous research showing limited success of 
interventions involving social support in improving depression in people with CHD, this 
could suggest that focusing on the development of interventions to reduce rumination, 
or combining social support interventions with components that reduce rumination, 
may prove an alternative and more effective strategy in this population. 
Problem solving emerged as a particularly strong mediator of the prospective 
association between brooding and depression in the observational prospective cohort 
study presented in this thesis, and could therefore be considered a more proximal 
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target for treatment. Problem solving therapy has conferred small significant 
improvements in depression and physical outcomes in CHD patients, and although 
proof of a causal association needs to be established it would be reasonable to offer 
problem solving therapy as an intervention in people with CHD.  
Finally, the results presented here support the suggestion that there are 
subgroups of ACS patients with different trajectories of depression, and it is possible 
that risk factors for depression, and the association of depression with physical 
outcomes, may vary among these groups. Personalised treatment approaches 
according to the features of depression may therefore be warranted to improve the 
efficacy of treatments for depression in CHD. 
6.8 Future research 
This section provides some recommendations for future work, first by 
considering ways in which the methodology of the observational prospective cohort 
study presented in this thesis may inform future research, and second by considering 
new directions that the findings of this thesis indicate could be valuable to pursue. 
6.8.1 Suggestions based on methodological considerations 
There were some methodological limitations of the observational prospective 
cohort study reported in this thesis that have implications for the design of future 
work. 
First, due to a high level of attrition there is a risk of sample bias which means it 
is uncertain how well the findings of this study will generalise to other ACS 
populations, and power to detect effects could have been reduced. Due to the 
longitudinal design of the study some attrition was anticipated, and a number of 
strategies were employed to maximize retention: questionnaire assessments were 
provided in a visually appealing booklet format and pre-addressed freepost envelopes 
were provided to minimize participant perceptions of burden and to reduce 
inconvenience; a reminder phone call was made if the assessments were not returned 
after 2 weeks; assistance was offered with completion of questionnaires if necessary; 
scheduling of follow-up assessments was managed flexibly in order to work around 
participant availability; and participant records were kept updated with any changes of 
address or other contact information. 
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Previous systematic reviews and qualitative studies indicate that monetary 
incentives, multiple reminders via different media and a flexible approach to follow-up 
tailored to the specific cohort are the most successful retention strategies, and use of 
multiple strategies is recommended[417-421]. Retention strategies have been 
identified in a number of domains including aspects of the study design, conduct and 
personnel (e.g. [419, 422]) suggesting that embedding retention strategies into the 
very early design of a prospective cohort study is important. This could include 
community involvement in the study design (e.g. to minimize burden and to identify 
barriers to retention), fostering a study identity (e.g. by designing consistent patient-
facing study materials including logos, and maintaining a study website), managing 
participant expectations (e.g. describing follow-up requirements adequately), 
maintaining engagement (e.g. regular brief contact/updates), planning contact and 
scheduling methods flexibly, and providing benefits and incentives if possible. Some of 
these strategies were not feasible within the scope of this project, although they 
should be considered in similar future cohort studies in order to minimize attrition. 
Second, although a particular strength of the observational prospective cohort 
study presented in this thesis was that it controlled for the effect of several important 
confounding variables, in contrast to previous studies that failed to adequately control 
for appropriate confounding variables, the large number of covariates made for 
extremely stringent tests of the hypotheses. For example, baseline scores of the 
outcome variables were included as covariates and these were particularly strong 
predictors of outcomes at later assessment times, seemingly because the sample 
included in this study appeared to be particularly ‘well’ with little variability in 
depression, anxiety and quality of life over time. Since a large amount of variance was 
accounted for by baseline scores, small but significant effects of other variables could 
have been masked and effect sizes of brooding (and worry) could have been 
underestimated. Future research might select participants with elevated depression at 
baseline, as this would give more scope for depression scores to vary (both upward 
and downward), meaning baseline depression scores would account for less variance 
in follow-up depression and thereby allow other predictors with small but important 
effects to emerge. 
244 
 
Third, physical outcomes were assessed using self-report quality of life 
measures. The current study could be extended by the inclusion of more objective 
measures of physical outcomes such as death or recurrence in future studies. A larger 
sample and a longer follow-up period would be necessary to allow a meaningful 
frequency of such events to occur, although this would provide important information 
about the prospective association of brooding with cardiac outcomes that did not rely 
on self-report measures of physical function.  
Fourth, history of depression was ascertained from inspecting medical records. 
Although this could be considered a more reliable method of identifying patients with 
significant depressive disorder than self-reports, it may lack sensitivity to identify less 
severe depressive episodes or transient mood disturbances. History of depression was 
used as a covariate in the observational prospective cohort study reported here. 
Although it was correlated with depression and quality of life at baseline, history of 
depression was not a significant predictor of any outcomes in regression or multilevel 
(repeated measures) models. History of depression is important because it is related to 
post-MI depression, at least in a subgroup of patients, and depression that precedes an 
MI could have different risk factors compared to depression that develops post-MI 
e.g.[416]. Future studies should collect information regarding history of depression 
from self-reports or from diagnostic clinical interviews (e.g.[423, 424]), which would 
provide information regarding previous episodes and duration of current episode if 
applicable. This would (a) confirm the sensitivity of identifying previous depression 
from medical records, and (b) allow the effects of previous depression on later 
depression to be controlled. 
Fifth, due to time constraints follow-ups were limited to 6 months in the 
current study. A larger sample and longer follow-up period would be advantageous in 
understanding how the association of brooding with depression develops over the 
longer term (i.e. after 6 months) in people with ACS, particularly as the time course of 
the association between CHD and depression is unclear[33, 68]. 
6.8.2 Suggestions based on study findings 
Considering the findings presented in this thesis in relation to existing literature 
suggests that these findings could be extended in a number of ways. 
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First, consistent with previous research[183] the findings of exploratory 
analyses presented in Chapter 4 suggested that in post-ACS patients the prospective 
association of brooding with depression may be strongest in people with elevated 
baseline depressive symptoms. Therefore, selecting participants on the basis of 
elevated depression scores (or selecting participants based on presence and absence 
of depression according to pre-defined criteria) would indicate in which ACS patients 
rumination is prospectively associated with depression. 
Second, findings of multilevel (repeated measures) models presented in 
Chapter 4 suggested that trajectories of depression and anxiety varied significantly 
between participants. This suggests that it might be possible to identify subgroups of 
ACS patients based on different trajectories (e.g. never depressed, new onset 
depression, stable depression, remitted depression) and to characterise groups that 
might be particularly at risk of worse outcomes. Understanding how depression 
evolves over time post-ACS could also provide important information about the 
optimal timing of interventions. Previous research has begun to investigate how 
trajectories of depression and anxiety in ACS patients may relate to age, sex, severity 
of cardiac disease and psychosocial vulnerabilities to depression(e.g.[376, 390-392]) 
although to date no studies have investigated how perseverative negative thinking 
may vary across trajectories. Future work should assess perseverative negative 
thinking, depression, anxiety and physical outcomes in a large sample of ACS patients 
at multiple assessment times in order to provide enough observations for latent class 
analysis to identify different trajectories. This would also allow the associations of 
perseverative negative thinking with depression, anxiety and physical outcomes in 
groups with different trajectories to be compared. 
Third, preliminary post-hoc analyses tentatively suggested that, at least cross-
sectionally, the association of inflammation with depression may not be entirely 
explained by greater severity of cardiac disease and that inflammation may contribute 
to depression via negative cognitive biases. To support this hypothesis a cohort study 
could be used to observe prospective associations between levels of inflammation and 
negative cognitive biases post-CHD. In turn, the prospective association of negative 
cognitive biases with depression would also need to be established in the same 
sample, to test whether negative cognitive biases may mediate the association of 
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inflammation with subsequent depression. Theoretically, manipulating (reducing) 
inflammation and observing changes (improvements) in negative cognitive biases, or 
altering negative cognitive biases and observing changes in mood could provide an 
alternative experimental approach, although concerns regarding whether this would 
be feasible or ethical in a CHD population makes an observational study design 
preferable. 
Fourth, poor problem solving emerged as a particularly strong mediator of the 
association between baseline brooding and 6 month depression, and could therefore 
be considered a target for treatment of depression in people with CHD.  Psychological 
interventions for depression in people with CHD that involved problem solving have 
previously been linked with small significant improvements in depression and physical 
outcomes[99, 406]. However, these treatment effects remain to be confirmed in high 
quality studies such as randomised controlled trials, which would prove causation.  
Additionally, small cross-sectional and experimental studies could explore the nature 
of the prospective association between brooding and depression, and who may be 
likely to benefit from interventions to improve problem solving by investigating in 
people with CHD (a) whether high ruminators have deficits in problem solving, (b) if 
altering rumination changes problem solving, and (c) whether problem solving training 
improves mood. 
6.9 Final conclusion 
In conclusion, this thesis suggests that rumination is a significant independent 
predictor of depression, and that this association may be explained by deficits in 
problem solving ability. Whilst it is plausible that rumination causes depression by 
impairing problem solving, the findings presented here fall short of proving such a 
causal relationship and this hypothesis would need to be tested in a clinical trial.  
Future longitudinal research would aim to replicate the findings in a larger 
representative sample of ACS patients with a longer follow-up period.  
 Rumination and problem solving may provide useful targets for the 
development of evidence-based interventions to improve depression among people 
with CHD. Future trials could be used to investigate the causal nature of the 
association of rumination and problem solving with depression in people with ACS. 
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Appendix 1: Systematic review search strategy 
The same search strategy was used with alterations as appropriate for each database. 
1 depression.ti,ab,sh. 
2 depressive disorder.ti,ab,sh. 
3 anxiety.ti,ab,sh. 
4 anxiety disorder*.ti,ab. or anxiety disorders.sh. 
5 stress, psychological.sh. 
6 psychological distress.ti,ab. 
7 emotional distress.ti,ab. 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 perseverative.ti,ab. and cognition.ti,ab,sh. 
10 (perseverative and cognitive and processes).ti,ab. 
11 perseverative.ti,ab. and thinking.ti,ab,sh. 
12 (perseverative and thought).ti,ab. 
13 repetitive.ti,ab. and thinking.ti,ab,sh. 
14 (repetitive and thought).ti,ab. 
15 (worry* or worrie* or worrisome).ti,ab. 
16 ruminat*.ti,ab. 
17 response styles theory.ti,ab. 
18 brooding.ti,ab. 
19 preoccupation.ti,ab. 
20 (self focus or self focused attention).ti,ab. 
21 emotion regulation.ti,ab. 
22 coping strateg*.ti,ab. 
23 coping style.ti,ab. 
24 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
25 longitudinal studies.sh. or longitudinal study.ti,ab. 
26 prospective studies.sh. or prospective study.ti,ab. 
27 followup studies.sh. or follow up.ti,ab. 
28 baseline.ti,ab. 
29 experience sampling.ti,ab. 
30 time series.ti,ab. 
31 induction*.ti,ab. 
32 25 or 26 or 27 or 28 or 29 or 30 or 31 
33 8 and 24 and 32 
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Appendix 2: Vote count of associations (multivariable findings only) 
 
  
Depression Anxiety Negative 
affect 
Distress Psychological 
functioning 
Negative 
mood 
Heart disease Rumination 1 3 4 5      
Catastrophizing 5      
Rumination/catastrophizing 2      
Rheumatoid 
arthritis 
Rumination 8R      
Catastrophizing 6 7 9 9 7    
Cancer Anxious preoccupation 13 16 13 16 13 12   
Preoccupation with death 19 19R 19 19R     
Catastrophizing 10      
Rumination 10 14 15 14     
Infertility Catastrophizing 20      
Rumination 20      
Rumination/catastrophizing 21 21     
Muscular 
dystrophy/Cerebral 
palsy 
Catastrophizing     22C  
Pain-related 
conditions 
Catastrophizing 25CE 26C 27 28 
29 30 
27 28 30     
Rumination/catastrophizing      24 
Red=No association Green=Association Black=Mixed evidence. 
Numbers refer to study ID (see Tables 2.1, 2.2 and 2.3). 
Empty cells represent no relevant results. 
R=reverse relationship (i.e. T1 negative affect associated with T2 perseverative negative thinking). 
C=change scores (i.e. change in perseverative negative thinking associated with change in negative affect). 
E=association not in expected direction. 
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Appendix 3: Baseline questionnaire pack 
 
N.B. The 2 month and 6 month packs were almost identical to the baseline pack, although did 
not include sociodemographic questions and instead contained space to communicate 
additional information regarding health events since the last assessment and changes in 
personal circumstances. 
253 
 
 
 
254 
 
255 
 
256 
 
257 
 
 
 
258 
 
259 
 
260 
 
261 
 
262 
 
263 
 
264 
 
265 
 
266 
 
 
 
 
 
267 
 
268 
 
269 
 
270 
 
271 
 
272 
 
273 
 
 
 
 
274 
 
275 
 
276 
 
277 
 
 
 
 
278 
 
279 
 
280 
 
Appendix 4 Brief information sheet for participants 
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Appendix 5: Participant information sheet 
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Appendix 6: Consent form 
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Appendix 7: Example of boxplots for main predictors and main outcome variables 
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Appendix 8: Shapiro-Wilk tests of normality 
A: Normality tests for all continuous variables at baseline 
 N W p 
Demographic variables    
Age 169 0.98 ≤0.05 
Years of education 152 0.98 ≤0.05 
Disease variables     
Time since index event 161 0.83 ≤0.001 
Troponin 116 0.54 ≤0.001 
Main predictors     
Total PSWQ 163 0.95 0.00003 
RRS Brooding 162 0.89 ≤0.001 
Main outcomes     
Total PHQ 167 0.82 ≤0.001 
Total BAI 167 0.83 ≤0.001 
EQ5D VAS 167 0.95 ≤0.001 
EQ5D Index value 165 0.90 ≤0.001 
SAQ Physical limitations 162 0.94 ≤0.001 
SAQ Angina frequency 167 0.80 ≤0.001 
SAQ Angina stability 156 0.92 ≤0.001 
SAQ Treatment satisfaction 164 0.82 ≤0.001 
SAQ Disease perception 160 0.95 ≤0.001 
Covariates/mediators     
ENRICHD 169 0.83 ≤0.001 
SPSI Positive problem orientation 168 0.98 ≤0.05 
SPSI Rational problem solving 168 0.99 ns 
SPSI Negative problem orientation 168 0.90 ≤0.001 
SPSI Impulsivity 168 0.95 ≤0.001 
SPSI Avoidance 168 0.95 ≤0.001 
SPSI Total score 168 0.97 ≤0.001 
PES Frequency 169 0.86 ≤0.001 
PES Pleasantness 164 0.88 ≤0.001 
PES Obtained pleasure 164 0.95 ≤0.001 
Negative words recalled (%) 84 0.97 ≤0.05 
Endorsed negative words recalled (%) 75 0.73 ≤0.001 
% Positive affective 88 0.99 ns 
% Negative affective 88 0.99 ns 
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B: Normality tests for all continuous predictor and outcome variables at 2 months 
 N W p 
Main predictors    
Total PSWQ 124 0.94 ≤0.001 
RRS Brooding 124 0.85 ≤0.001 
Main outcomes     
Total PHQ 124 0.81 ≤0.001 
Total BAI 122 0.82 ≤0.001 
EQ5D VAS 124 0.90 ≤0.001 
EQ5D Index value 123 0.88 ≤0.001 
SAQ Physical limitations 120 0.91 ≤0.001 
SAQ Angina frequency 122 0.75 ≤0.001 
SAQ Angina stability 116 0.95 ≤0.001 
SAQ Treatment satisfaction 119 0.84 ≤0.001 
SAQ Disease perception 118 0.92 ≤0.001 
Covariates/mediators     
ENRICHD 123 0.82 ≤0.001 
SPSI Positive problem orientation 121 0.99 ns 
SPSI Rational problem solving 121 0.99 ns 
SPSI Negative problem orientation 121 0.88 ≤0.001 
SPSI Impulsivity 121 0.92 ≤0.001 
SPSI Avoidance 121 0.92 ≤0.001 
SPSI Total score 121 0.94 ≤0.001 
PES Frequency 123 0.88 ≤0.001 
PES Pleasantness 123 0.94 ≤0.001 
PES Obtained pleasure 123 0.95 ≤0.001 
Negative words recalled (%) 35 0.91 ≤0.001 
Endorsed negative words recalled (%)* - - - 
% Positive affective 34 0.97 ns 
% Negative affective 34 0.99 ns 
*Could not be calculated (no endorsed negative words recalled). 
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C: Normality tests for all continuous predictor and outcome variables at 6 months 
 N W p 
Main predictors    
Total PSWQ 110 0.93 ≤0.001 
RRS Brooding 108 0.87 ≤0.001 
Main outcomes     
Total PHQ 111 0.74 ≤0.001 
Total BAI 110 0.80 ≤0.001 
EQ5D VAS 110 0.88 ≤0.001 
EQ5D Index value 110 0.85 ≤0.001 
SAQ Physical limitations 107 0.88 ≤0.001 
SAQ Angina frequency 110 0.80 ≤0.001 
SAQ Angina stability 101 0.95 ≤0.001 
SAQ Treatment satisfaction 105 0.78 ≤0.001 
SAQ Disease perception 105 0.93 ≤0.001 
Covariates/mediators     
ENRICHD 111 0.78 ≤0.001 
SPSI Positive problem orientation 109 0.99 ns 
SPSI Rational problem solving 109 0.99 ns 
SPSI Negative problem orientation 109 0.88 ≤0.001 
SPSI Impulsivity 109 0.94 ≤0.001 
SPSI Avoidance 109 0.91 ≤0.001 
SPSI Total score 109 0.95 ≤0.001 
PES Frequency 109 0.81 ≤0.001 
PES Pleasantness 108 0.87 ≤0.001 
PES Obtained pleasure 108 0.92 ≤0.001 
Negative words recalled (%) 14 0.94 ns 
Endorsed negative words recalled (%)* - - - 
% Positive affective 14 0.82 ≤0.05 
% Negative affective 14 0.97 ns 
*Could not be calculated (no endorsed negative words recalled). 
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Appendix 9: Comparison of sample characteristics of depressed and non-depressed participants at baseline 
  Depressed at baseline (N=24) Not depressed at baseline 
(N=143) 
Between group 
differences 
  N Mean SD N Mean SD  
Demographic variables         
Age (years)   57.88 13.56  68.08 10.54 z=3.37a 
Sex Male / Female 16 / 8   114 / 29   Χ2(1)=2.03 
Years of education Secondary / Higher 10 / 11   48 / 82   Χ2(1)=0.87 
Employment status Employed / Not employed 13 / 11   52 / 91   Χ2(1)=2.74 
Relationship status Relationship / No relationship 12 / 12   109 / 33   Χ2(1)=7.44b 
Lives alone Yes / No 11 / 13   31 / 111   Χ2(1)=6.26c 
Index of multiple 
deprivation 
Least  deprived / Most deprived 7 / 17   74 / 63   Χ2(1)=5.04c 
History of depression Yes / No 7 / 17   9 / 134   Χ2(1)=12.41a 
Smoking status Smoker / Non-smoker 8 / 16   10 / 132   Χ2(1)=14.68a 
Alcohol use Infrequent / Regular 18 / 6   76 / 65   Χ2(1)=3.72p=0.054 
Drug use Infrequent / Regular 23 / 1   142 / 1   Χ2(1)=2.08 
Exercise Infrequent / Regular 13 / 11   43 / 98   Χ2(1)=5.13c 
ESSI social support   20.38 8.03  26.32 4.84 z=3.82a 
Table continues on following page… 
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  Depressed at baseline (N=24) Not depressed at baseline 
(N=143) 
Between group 
differences 
  N Mean SD N Mean SD  
Disease variables         
Diagnosis Angina / STEMI / NSTEMI 5 / 10 / 8   42 / 52 / 49   Χ2(2)=0.68 
Days since index event   122.41 65.92  109.45 76.94 z=-1.55 
Left ventricular function None / Mild / Moderate / Severe 9 / 4 / 3 / 1   53 / 38 / 17 / 5   Χ2(3)=0.71 
NYHA functional 
classification 
None / Mild / Moderate / Severe 4 / 8 / 10 / 2   74 / 49 / 15 / 3   Χ2(3)=21.22c 
Number of diseased 
vessels 
  1.54 0.98  1.81 0.81 z=1.31 
Comorbidity score 1 or less / 2 or more 15 / 9   105 / 38   Χ2(2)=1.21 
Troponin   1395.41 2462.33  869.47 1754.22 z=-0.86 
C-reactive protein Inflammation / No inflammation 9 / 5   28 / 49   Χ2(1)=3.83c 
White cell count Raised / Normal 8 / 14   41 / 98   Χ2(1)=0.42 
ap≤0.001 bp≤0.01 c≤0.05. 
 
 
 
291 
 
Appendix 10: Comparison of main predictors and outcomes of depressed and non-depressed participants at baseline 
 Depressed at baseline  
(N=24) 
Not depressed at baseline 
(N=143) 
 
 Mean SD Mean SD Group differences 
Main predictors      
RRS Brooding  12.54 3.40 7.33 2.22 z=-6.30a 
Total PSWQ 52.31 12.45 35.09 12.25 z=-5.28a 
Main outcomes      
Total PHQ 14.42 3.32 2.55 2.43 z=-7.90a 
Total BAI 25.17 9.53 5.98 5.56 z=-6.84a 
EQ5D VAS 56.88 17.70 75.47 16.10 z=4.52a 
EQ5D Index value 0.51 0.19 0.83 0.14 z=6.60a 
SAQ Physical limitations 56.44 25.26 77.31 22.37 z=3.38a 
SAQ Angina frequency 78.18 17.36 90.62 16.62 z=3.80a 
SAQ Angina stability 76.19 29.02 84.51 23.51 z=1.30 
SAQ Treatment satisfaction 84.38 13.05 90.71 14.85 z=2.84b 
SAQ Disease perception 49.05 25.78 73.90 23.39 z=4.02a 
ap≤0.001 bp≤0.01 c≤0.05. 
EQ5D subscales omitted since these are exploratory analyses.
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Appendix 11: Description of missing data at baseline (total N=169) 
 N % missing 
cases 
% cases with missing items* Total number 
of missing 
items* 
% missing 
items* 
   Total Item/s 
substituted 
Scale/subscale 
excluded 
Predictors        
Total PSWQ 163 3.55 8.28 4.73 3.55 50.00 1.85 
RRS Brooding 162 4.14 4.14 n/a 4.14 18.00 1.78 
Outcomes        
Total PHQ 167 1.18 2.96 1.78 1.18 17.00 1.26 
Total BAI 167 1.18 2.96 1.78 1.18 34.00 0.91 
EQ5D VAS 167 1.18 n/a   n/a n/a n/a n/a 
EQ5D Index value 165 2.37 n/a   n/a n/a n/a n/a 
EQ5D Mobility 167 1.18 n/a   n/a n/a n/a n/a 
EQ5D Self-care 167 1.18 n/a   n/a n/a n/a n/a 
EQ5D Usual activities 166 1.78 n/a   n/a n/a n/a n/a 
EQ5D Pain 167 1.18 n/a   n/a n/a n/a n/a 
EQ5D Anxiety / depression 166 1.78 n/a   n/a n/a n/a n/a 
SAQ Physical limitations 162 4.14 5.92 1.78 4.14 48.00 3.16 
SAQ Angina frequency 167 1.18 1.78 0.59 1.18 5.00 1.48 
SAQ Angina stability 156 7.69 n/a   n/a n/a n/a n/a 
SAQ Treatment satisfaction 164 2.96 7.10 4.14 2.96 29.00 4.29 
SAQ Disease perception 160 5.33 7.10 1.78 5.33 26.00 5.13 
*Does not apply to single item scales.  
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Appendix 12: Correlations between sample characteristics and main predictor 
variables at baseline 
 PSWQ RRS brooding 
Demographic variables   
Age -0.23b -0.20b 
Years of education 0.02 0.08 
Index of multiple deprivation -0.11 -0.13c 
ESSI social support -0.26a -0.27a 
Disease variables   
Time since index event 0.02 0.09 
Left ventricular function -0.18c -0.10 
NYHA classification 0.14c 0.15c 
Number of diseased vessels -0.03 -0.05 
Comorbidity score 0.07 0.00 
Troponin -0.02 -0-06 
ap≤0.001 bp≤0.01 c≤0.05. 
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Appendix 13: Correlations between sample characteristics with main outcome variables at baseline 
 Total PHQ Total BAI EQ5D VAS EQ5D Index 
value 
EQ5D 
Mobility 
EQ5D Self-
care 
EQ5D Usual 
activities 
EQ5D Pain EQ5D 
Anxiety / 
depression 
Demographic variables          
Age -0.31a -0.20b 0.07 0.08 0.15c 0.04 0.03 -0.15 -0.32a 
Years of education 0.00 -0.05 -0.11 0.04 -0.12 -0.03 0.03 -0.10 0.06 
Index of multiple deprivation -0.13c -0.15b 0.00 0.11 -0.11 -0.12 -0.09 -0.09 -0.20b 
ESSI social support -0.38a -0.37a 0.26a 0.30a -0.16c -0.17c -0.26a -0.19c -0.33a 
Disease variables          
Time since index event 0.04 -0.07 0.03 0.13 -0.07 0.06 -0.19c -0.16c 0.10 
Left ventricular function -0.10 -0.06 -0.04 -0.07 0.12 0.09 0.07 0.07 -0.07 
NYHA classification 0.33a 0.39a -0.38b 0.33a 0.51a 0.34a 0.53a 0.47a 0.22a 
Number of diseased vessels -0.11 -0.08 -0.02 -0.01 0.08 0.05 -0.01 0.04 -0.07 
Comorbidity score 0.05 0.08 -0.19c -0.21b 0.42a 0.28a 0.21b 0.09 -0.01 
Troponin -0.01 -0.09 0.08 0.06 0.05 0.05 -0.07 -0.07 -0.01 
Table continues on following page... 
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 SAQ 
Physical 
limitations 
SAQ Angina 
frequency 
SAQ Angina 
stability 
SAQ 
Treatment 
satisfaction 
SAQ 
Disease 
perception 
Demographic variables      
Age -0.27a 0.10 0.14 0.15 0.23b 
Years of education 0.18c 0.09 -0.07 0.10 0.09 
Index of multiple deprivation 0.02 0.10 0.03 0.07 0.11 
ESSI social support 0.27a 0.31a 0.19c 0.30a 0.40a 
Disease variables      
Time since index event 0.14 0.25b 0.14 0.07 0.19c 
Left ventricular function -0.06 -0.02 -0.11 0.00 -0.05 
NYHA classification -0.51a -0.51a -0.36a -0.18b -0.20b 
Number of diseased vessels -0.05 0.05 -0.04 -0.03 -0.02 
Comorbidity score -0.25a 0.01 -0.07 -0.05 -0.04 
Troponin 0.11 0.12 -0.17 0.17 0.05 
ap≤0.001 bp≤0.01 c≤0.05. 
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Appendix 14: Summary of differences in baseline outcomes according to sample 
characteristics 
 z Median 
Sex  Male Female 
SAQ Physical limitations -2.62b 83.33 69.44 
Employment status  Working Not working 
RRS Brooding -2.97b 7.50 7.00 
EQ5D Anxiety/depression -2.87b 1.81* 1.39* 
SAQ Angina stability 2.29c 77.87* 87.10* 
SAQ Disease perception 2.80b 75.00 83.33 
Relationship status  Partner No partner 
EQ5D Anxiety/depression 2.63b 1.00 1.50 
SAQ Physical limitations -2.94b 86.11 66.67 
History of depression  Yes No 
PHQ -2.93b 5.93  2.00 
EQ5D VAS 2.06c 65.00 80.00 
EQ5D Index value 2.82b 0.68 0.84 
EQ5D Usual activities 2.28c 2.00 1.00 
EQ5D Pain 3.37a 2.31* 1.66* 
EQ5D Anxiety/depression 2.60b 2.00 1.00 
SAQ Disease perception 2.06c 54.17 79.17 
Smoking status  Smoker Non-smoker 
PHQ 2.43c 6.50 2.00 
BAI 2.75b 13.50 5.00 
EQ5D Pain 2.27c 1.68* 2.06* 
EQ5D Anxiety/depression 2.65b 2.50 1.00 
SAQ Angina frequency 2.31c 90.00 100.00 
SAQ Treatment satisfaction 2.41c 84.38 100.00 
Alcohol use  Frequent Infrequent 
EQ5D VAS 3.00b 80.00 75.00 
EQ5D Index value 3.55a 0.85 0.77 
EQ5D Mobility 3.32a 1.00 1.50 
EQ5D Self-care 2.30c 1.08* 1.24* 
EQ5D Usual activities 3.98a 1.00 2.00 
EQ5D Pain 3.28a 1.00 2.00 
SAQ Physical limitations 3.86a 91.67  69.44 
Recreational drug use  Frequent Infrequent 
No significant differences    
Table continued on following page… 
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 z Median 
Exercise frequency  Frequent Infrequent 
PHQ 2.78b 2.00 4.00 
BAI 3.00b 5.00 8.50 
EQ5D VAS 2.88b 80.00 70.00 
EQ5D Index value 3.20a 0.84 0.75 
EQ5D Mobility 2.98b 1.00 2.00 
EQ5D Self-care 3.48a 1.07* 1.38* 
EQ5D Usual activities 2.92b 1.00 2.00 
EQ5D Pain 2.06c 1.62* 1.93* 
SAQ Physical limitations 3.43a 86.11 61.11 
SAQ Treatment satisfaction 2.59b 100.00 93.75 
SAQ Disease perception 3.22b 83.33 58.33 
Diagnosis type    
No significant differences    
C-reactive protein 
 
Inflammation No 
inflammation 
SAQ Treatment satisfaction -2.31c 100 87.5 
White cell count  Raised Normal 
No significant differences    
ap<0.001, bp≤0.01, cp≤0.05. 
*Medians identical, therefore means presented instead to illustrate direction of difference. 
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Appendix 15: Correlation matrix of main outcome variables at baseline 
 1 2 3 4 5 6 7 8 9 
1.Total PHQ 1         
2.Total BAI 0.71a 1        
3.EQ5D VAS -0.47a -0.55a 1       
4.EQ5D Index value -0.54a -0.64a 0.60a 1      
5.EQ5D Mobility 0.28a 0.37a -0.36a -0.61a 1     
6.EQ5D Self-care 0.23a 0.27a -0.40a -0.42a 0.42a 1    
7.EQ5D Usual activities 0.33a 0.41a -0.43a -0.70a 0.61a 0.47a 1   
8.EQ5D Pain 0.33a 0.41a -0.38a -0.73a 0.46a 0.37a 0.55a 1  
9.EQ5D Anxiety / depression 0.56a 0.48a -0.35a -0.45a 0.19b 0.18c 0.30a 0.30a 1 
10.SAQ Physical limitations -0.32a -0.43a 0.55a 0.46a -0.46a -0.39a -0.48a -0.33a -0.14c 
11.SAQ Angina frequency -0.33a -0.50a 0.31a 0.21b -0.28a -0.19b -0.36a -0.50a -0.29a 
12.SAQ Angina stability -0.14 -0.20c 0.21b 0.25b -0.20b -0.24b -0.18c -0.20b -0.11 
13.SAQ Treatment satisfaction -0.36a -0.50a 0.19c 0.22b -0.16c -0.20b -0.23a -0.24a -0.34a 
14.SAQ Disease perception -0.51a -0.59a 0.33a 0.32a -0.27a -0.27a -0.38a -0.41a -0.42a 
 
 10 11 12 13 14 
10.SAQ Physical limitations 1     
11.SAQ Angina frequency 0.41a 1    
12.SAQ Angina stability 0.18c 0.38a 1   
13.SAQ Treatment satisfaction 0.31a 0.49a 0.25b 1  
14.SAQ Disease perception 0.51a 0.57a 0.23b 0.59a 1 
ap≤0.001 bp≤0.01 c≤0.05.
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Appendix 16: Description of missing data at 2 months (total N=125) 
 N % missing 
cases 
% cases with missing items* Total number 
of missing 
items* 
% missing 
items* 
   Total Item/s 
substituted 
Scale/subscale 
excluded 
Predictors        
Total PSWQ 124 0.80 4.80 4.00 0.80 21.00 1.05 
RRS Brooding 124 0.80 0.80 0.00 0.80 4.00 0.64 
Outcomes        
Total PHQ 124 0.80 1.60 0.80 0.80 9.00 0.90 
Total BAI 122 2.40 7.20 4.80 2.40 37.00 1.35 
EQ5D VAS 124 0.80 n/a   n/a n/a n/a n/a 
EQ5D Index value 123 1.60 n/a   n/a n/a n/a n/a 
EQ5D Mobility 124 0.80 n/a   n/a n/a n/a n/a 
EQ5D Self-care 124 0.80 n/a   n/a n/a n/a n/a 
EQ5D Usual activities 124 0.80 n/a   n/a n/a n/a n/a 
EQ5D Pain 123 1.60 n/a   n/a n/a n/a n/a 
EQ5D Anxiety / depression 124 0.80 n/a   n/a n/a n/a n/a 
SAQ Physical limitations 120 4.00 6.40 2.40 4.00 45.00 4.00 
SAQ Angina frequency 122 2.40 4.00 1.60 2.40 8.00 3.20 
SAQ Angina stability 116 7.20 n/a   n/a n/a n/a n/a 
SAQ Treatment satisfaction 119 4.80 8.00 3.20 4.80 28.00 5.60 
SAQ Disease perception 118 5.60 8.00 2.40 5.60 20.00 5.33 
*Does not apply to single item scales.  
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Appendix 17: Description of missing data at 6 months (total N=111) 
 N % missing 
cases 
% cases with missing items* Total number 
of missing 
items* 
% missing 
items* 
   Total Item/s 
substituted 
Scale/subscale 
excluded 
Predictors        
Total PSWQ 110 0.90 5.41 4.50 0.90 19.00 1.07 
RRS Brooding 108 2.70 2.70 0.00 2.70 2.00 0.36 
Outcomes        
Total PHQ 111 0.00 0.00 0.00 0.00 0.00 0.00 
Total BAI 110 0.90 4.50 3.60 0.90 12.00 0.49 
EQ5D VAS 110 0.90 n/a n/a n/a n/a n/a 
EQ5D Index value 110 0.90 n/a n/a n/a n/a n/a 
EQ5D Mobility 110 0.90 n/a n/a n/a n/a n/a 
EQ5D Self-care 110 0.90 n/a n/a n/a n/a n/a 
EQ5D Usual activities 110 0.90 n/a n/a n/a n/a n/a 
EQ5D Pain 110 0.90 n/a n/a n/a n/a n/a 
EQ5D Anxiety / depression 110 0.90 n/a n/a n/a n/a n/a 
SAQ Physical limitations 107 3.60 3.60 0.00 3.60 27 2.70 
SAQ Angina frequency 110 0.90 1.80 0.90 0.90 3.00 1.35 
SAQ Angina stability 101 9.01 n/a n/a n/a n/a n/a 
SAQ Treatment satisfaction 105 5.41 9.91 4.50 5.41 27.00 6.08 
SAQ Disease perception 105 5.41 6.31 0.90 5.41 15.00 4.50 
*Does not apply to single item scales. 
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Appendix 18: Comparison of correlations between brooding and worry with main outcome measures at baseline for completers and non-
completers 
 RRS brooding PSWQ 
 Completers  Non-completers Completers Non-completers 
 N r N r N r N r 
Total PHQ 108 0.54a 54 0.57a 109 0.51a 54 0.35c 
Total BAI 108 0.52a 54 0.56a 108 0.46a 54 0.42b 
EQ5D VAS 107 -0.23c 54 -0.42c 108 -0.30b 54 -0.29c 
EQ5D Index value 106 -0.35a 54 -0.58a 107 -0.36a 53 -0.36b 
ap≤0.001 bp≤0.01 c≤0.05. 
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Appendix 19: Ordered logistic regression of baseline brooding with 6 month EQ5D 
subscales (N=103) 
 B SE z Model fit Pseudo 
R2 
EQ5D Mobility    LR χ2(7)=64.76a 0.33 
Age 0.05 0.03 1.66   
Sex 0.17 0.59 0.30   
IMD 0.29 0.12 2.53b   
Q1 ESSI -0.10 0.04 -2.43c   
Q1 NYHA 1.26 0.61 2.08c   
Q1 EQ5D Mobility 1.71 0.38 4.52a   
Q1 RRS Brooding -0.01 0.08 -0.15   
EQ5D Self-care    LR χ2(7)= 
35.96a 
0.48 
Age 0.08 0.06 1.19   
Sex 2.07 1.39 1.48   
IMD 0.12 0.20 0.63   
Q1 ESSI -0.15 0.08 -1.72   
Q1 NYHA 1.58 1.28 1.23   
Q1 EQ5D Self-care 3.45 1.01 3.43a   
Q1 RRS Brooding 0.05 0.16 0.35   
EQ5D Usual activities    LR χ2(7)= 
55.01a 
0.29 
Age 0.09 0.03 3.01a   
Sex 1.09 0.63 1.74   
IMD 0.08 0.10 0.79   
Q1 ESSI -0.14 0.04 -3.27a   
Q1 NYHA 1.51 0.56 2.70b   
Q1 EQ5D Usual activities 0.83 0.25 3.30a   
Q1 RRS Brooding 0.08 0.08 1.04   
EQ5D Pain    LR χ2(7)= 35.47a 0.15 
Age 0.03 0.02 1.26   
Sex 0.46 0.53 0.86   
IMD 0.07 0.09 0.73   
Q1 ESSI -0.09 0.04 -2.52b   
Q1 NYHA 0.65 0.49 1.34   
Q1 EQ5D Pain 0.98 0.33 3.01b   
Q1 RRS Brooding 0.03 0.07 0.45   
EQ5D Anxiety/depression    LR χ2(7)= 59.11a 0.33 
Age 0.00 0.03 0.02   
Sex 1.30 0.71 1.83   
IMD 0.06 0.11 0.52   
Q1 ESSI -0.18 0.04 -4.26a   
Q1 NYHA 1.20 0.58 2.07c   
Q1 EQ5D Anxiety/depression 1.04 0.41 2.55b   
Q1 RRS Brooding 0.08 0.10 0.82   
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Appendix 20: Ordered logistic regression of baseline worry with 6 month EQ5D 
subscales (N=104) 
 B SE z Model fit Pseudo 
R2 
EQ5D Mobility    LR χ2(7)=67.92a 0.34 
Age 0.07 0.03 2.44b   
Sex 0.27 0.60 0.45   
IMD 0.29 0.12 2.33c   
Q1 ESSI -0.07 0.04 -1.80   
Q1 NYHA 1.30 0.62 2.10b   
Q1 EQ5D Mobility 1.78 0.38 4.64a   
Q1 PSWQ 0.04 0.02 2.20c   
EQ5D Self-care    LR χ2(7)=35.53a 0.47 
Age 0.08 0.07 1.12   
Sex 1.99 1.39 1.43   
IMD 0.13 0.21 0.61   
Q1 ESSI -0.15 0.08 -1.86   
Q1 NYHA 1.44 1.25 1.15   
Q1 EQ5D Self-care 3.58 1.02 3.53a   
Q1 RRS PSWQ 0.00 0.04 0.11   
EQ5D Usual activities    LR χ2(7)=51.59a 0.27 
Age 0.08 0.03 2.73b   
Sex 0.90 0.62 1.46   
IMD 0.09 0.11 0.85   
Q1 ESSI -0.13 0.04 -3.10b   
Q1 NYHA 1.27 0.56 2.26c   
Q1 EQ5D Usual activities 0.87 0.25 3.51a   
Q1 RRS PSWQ 0.02 0.02 1.31   
EQ5D Pain    LR χ2(7)=32.94a 0.14 
Age 0.03 0.02 1.12   
Sex 0.31 0.52 0.60   
IMD 0.09 0.09 0.93   
Q1 ESSI -0.08 0.03 -2.25c   
Q1 NYHA 0.53 0.49 1.08   
Q1 EQ5D Pain 0.92 0.33 2.81b   
Q1 RRS PSWQ 0.02 0.02 1.07   
EQ5D Anxiety/depression    LR χ2(7)=56.01a 0.31 
Age 0.01 0.03 0.18   
Sex 1.07 0.69 1.55   
IMD 0.04 0.12 0.32   
Q1 ESSI -0.16 0.04 -3.94a   
Q1 NYHA 1.02 0.57 1.80   
Q1 EQ5D Anxiety/depression 0.98 0.35 2.82b   
Q1 RRS PSWQ 0.03 0.02 1.56   
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Appendix 21: Staged multivariable regression of baseline brooding with 6 month quality of life (SAQ subscales) 
A: Staged multivariable regression of baseline brooding with 6 month SAQ Physical limitations (N=100) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,94)=11.13a 0.34  
Age -0.26 -0.65 0.21 -3.02b    
Sex 0.05 2.99 4.87 0.61    
IMD -0.11 -1.06 0.86 -1.23    
Q1 ESSI 0.22 0.86 0.34 2.55c    
Q1 NYHA -0.42 -19.21 3.99 -4.81a    
Step 2     F(6,93)= 14.55a 0.45 0.11 (F(1,93)=20.25a) 
Age -0.16 -0.39 0.20 -1.92    
Sex 0.06 3.43 4.44 0.77    
IMD -0.08 -0.79 0.79 -1.01    
Q1 ESSI 0.18 0.69 0.31 2.23c    
Q1 NYHA -0.22 -9.90 4.18 -2.37c    
Q1 SAQ Physical limitations 0.41 0.42 0.09 4.50a    
Step 3     F(7,92)=12.34a 0.45 0.00 (F(1,92)=0.02 
Age -0.16 -0.40 0.21 -1.87    
Sex 0.06 3.40 4.47 0.76    
IMD -0.08 -0.80 0.79 -1.01    
Q1 ESSI 0.18 0.68 0.32 2.11c    
Q1 NYHA -0.22 -9.93 4.21 -2.36c    
Q1 SAQ Physical limitations 0.41 0.42 0.09 4.39a    
Q1 RRS Brooding -0.01 -0.09 0.61 -0.15    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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B: Staged multivariable regression of baseline brooding with 6 month SAQ Angina frequency (N=105) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,99)=5.28a 0.17  
Age 0.03 0.06 0.18 0.32    
Sex -0.11 -4.85 4.09 -1.19    
IMD 0.04 0.28 0.72 0.38    
Q1 ESSI 0.23 0.66 0.28 2.35c    
Q1 NYHA -0.35 -12.17 3.36 -3.63a    
Step 2     F(6,98)= 10.61a 0.36 0.18 (F(1,98)=29.59a) 
Age -0.04 -0.08 0.16 -0.52    
Sex -0.09 -3.92 3.60 -1.09    
IMD 0.01 0.11 0.63 0.17    
Q1 ESSI 0.11 0.33 0.25 1.29    
Q1 NYHA -0.22 -7.62 3.07 -2.48c    
Q1 SAQ Angina frequency 0.48 0.52 0.10 5.44a    
Step 3     F(7,97)=9.01a 0.35 0.00 (F(1,97)=0.04) 
Age -0.05 -0.09 0.17 -0.55    
Sex -0.09 -3.97 3.63 -1.09    
IMD 0.01 0.11 0.64 0.17    
Q1 ESSI 0.11 0.32 0.26 1.22    
Q1 NYHA -0.22 -7.65 3.09 -2.47c    
Q1 SAQ Angina frequency 0.47 0.52 0.10 5.08a    
Q1 RRS Brooding -0.02 -0.11 0.52 -0.21    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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C: Staged multivariable regression of baseline brooding with 6 month SAQ Angina stability (N=94) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,88)=3.03b 0.10  
Age 0.11 0.35 0.31 1.12    
Sex -0.14 -10.12 7.61 -1.33    
IMD -0.04 -0.44 1.28 -0.35    
Q1 ESSI 0.33 1.49 0.49 3.07b    
Q1 NYHA -0.10 -5.77 5.93 -0.97    
Step 2     F(6,87)=2.87b 0.11 0.02 (F(1,87)=1.90) 
Age 0.09 0.27 0.32 0.84    
Sex -0.15 -10.59 7.58 -1.40    
IMD -0.04 -0.48 1.27 -0.38    
Q1 ESSI 0.32 1.47 0.48 3.04b    
Q1 NYHA -0.09 -5.02 5.93 -0.85    
Q1 SAQ Angina stability 0.14 0.16 0.11 1.38    
Step 3     F(7,86)=2.50c 0.10 0.00 (F(1,86)=0.37) 
Age 0.10 0.31 0.33 0.95    
Sex -0.14 -10.24 7.63 -1.34    
IMD -0.03 -0.42 1.28 -0.33    
Q1 ESSI 0.34 1.54 0.50 3.08b    
Q1 NYHA -0.09 -5.05 5.95 -0.85    
Q1 SAQ Angina stability 0.14 0.16 0.12 1.38    
Q1 RRS Brooding 0.07 0.58 0.96 0.61    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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D: Staged multivariable regression of baseline brooding with 6 month SAQ Treatment satisfaction (N=97) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,91)=3.28b 0.11  
Age 0.03 0.06 0.17 0.34    
Sex -0.09 -3.42 4.08 -0.84    
IMD -0.01 -0.03 0.68 -0.05    
Q1 ESSI 0.33 0.87 0.28 3.13b    
Q1 NYHA -0.14 -4.40 3.18 -1.38    
Step 2     F(6,90)=4.09a 0.16 0.06 (F(1,90)=7.05b) 
Age 0.01 0.02 0.17 0.06    
Sex -0.11 -4.45 3.97 -1.12    
IMD -0.03 -0.20 0.66 -0.31    
Q1 ESSI 0.27 0.71 0.28 2.57b    
Q1 NYHA -0.10 -3.18 3.12 -1.02    
Q1 SAQ Treatment satisfaction 0.27 0.31 0.12 2.65b    
Step 3     F(7,89)=3.48b 0.15 0.00 (F(1,89)=0.11) 
Age 0.01 0.02 0.17 0.13    
Sex -0.11 -4.38 3.99 -1.10    
IMD -0.03 -0.20 0.66 -0.30    
Q1 ESSI 0.27 0.73 0.28 2.57b    
Q1 NYHA -0.10 -3.17 3.13 -1.01    
Q1 SAQ Treatment satisfaction 0.28 0.32 0.12 2.66b    
Q1 RRS Brooding 0.03 0.17 0.51 0.33    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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E: Staged multivariable regression of baseline brooding with 6 month SAQ Disease perception (N=96) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,90)=9.39a 0.31  
Age 0.19 0.43 0.20 2.14c    
Sex -0.03 -1.35 4.79 -0.28    
IMD 0.04 0.34 0.80 0.42    
Q1 ESSI 0.42 1.41 0.32 4.42a    
Q1 NYHA -0.21 -8.77 3.81 -2.30b    
Step 2     F(6,89)=12.16a 0.41 0.11 (F(1,89)=17.43a) 
Age 0.14 0.31 0.19 1.69    
Sex -0.03 -1.80 4.40 -0.41    
IMD 0.05 0.46 0.74 0.62    
Q1 ESSI 0.30 1.01 0.31 3.29a    
Q1 NYHA -0.13 -5.52 3.59 -1.53    
Q1 SAQ Disease perception 0.37 0.31 0.08 4.17a    
Step 3     F(7,88)=10.34a 0.41 0.00 (F(1,88)=0.13) 
Age 0.13 0.30 0.19 1.57    
Sex -0.04 -1.90 4.43 -0.43    
IMD 0.05 0.44 0.74 0.59    
Q1 ESSI 0.29 1.00 0.31 3.17b    
Q1 NYHA -0.13 -5.58 3.62 -1.54    
Q1 SAQ Disease perception 0.36 0.31 0.08 3.86a    
Q1 RRS Brooding -0.03 -0.21 0.60 -0.36    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Appendix 22: Staged multivariable regression of baseline worry with 6 month quality of life (SAQ subscales) 
A: Staged multivariable regression of baseline worry with 6 month SAQ Physical limitations (N=101) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,95)=10.07a 0.31  
Age -0.26 -0.65 0.22 -2.89b    
Sex 0.07 4.15 4.94 0.84    
IMD -0.09 -0.93 0.89 -1.05    
Q1 ESSI 0.21 0.80 0.34 2.39c    
Q1 NYHA -0.40 -18.17 4.06 -4.48a    
Step 2     F(6,94)=15.08a 0.46 0.14 (F(1,94)=26.59a) 
Age -0.17 -0.41 0.20 -2.04c    
Sex 0.07 4.02 4.38 0.92    
IMD -0.04 -0.38 0.80 -0.48    
Q1 ESSI 0.15 0.56 0.30 1.86    
Q1 NYHA -0.18 -8.31 4.08 -2.04c    
Q1 SAQ Physical limitations 0.46 0.49 0.10 5.16a    
Step 3     F(7,93)=13.74a 0.47 0.02 (F(1,93)=3.37) 
Age -0.21 -0.53 0.21 -2.53b    
Sex 0.07 4.01 4.33 0.93    
IMD -0.03 -0.33 0.79 -0.42    
Q1 ESSI 0.13 0.47 0.30 1.56    
Q1 NYHA -0.18 -8.23 4.03 -2.04c    
Q1 SAQ Physical limitations 0.45 0.48 0.09 5.06a    
Q1 PSWQ -0.14 -0.23 0.13 -1.84    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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B: Staged multivariable regression of baseline worry with 6 month SAQ Angina frequency (N=106) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,100)=4.95a 0.16  
Age 0.03 0.05 0.19 0.29    
Sex -0.10 -4.19 4.08 -1.03    
IMD 0.04 0.32 0.73 0.44    
Q1 ESSI 0.21 0.60 0.28 2.19c    
Q1 NYHA -0.34 -11.75 3.37 -3.49a    
Step 2     F(6,99)=9.57a 0.33 0.17 (F(1,99)=26.40a) 
Age -0.04 -0.08 0.17 -0.50    
Sex -0.07 -3.14 3.65 -0.86    
IMD 0.01 0.11 0.66 0.17    
Q1 ESSI 0.08 0.24 0.26 0.94    
Q1 NYHA -0.21 -7.48 3.12 -2.40c    
Q1 SAQ Angina frequency 0.47 0.50 0.10 5.14a    
Step 3     F(7,98)=8.20a 0.32 0.00 (F(1,98)=0.34) 
Age -0.06 -0.11 0.18 -0.64    
Sex -0.08 -3.25 3.66 -0.89    
IMD 0.02 0.13 0.66 0.20    
Q1 ESSI 0.08 0.22 0.26 0.83    
Q1 NYHA -0.21 -7.42 3.13 -2.37c    
Q1 SAQ Angina frequency 0.46 0.49 0.10 5.05a    
Q1 PSWQ -0.05 -0.06 0.11 -0.58    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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C: Staged multivariable regression of baseline worry with 6 month SAQ Angina stability (N=94) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,88)=2.24 0.06  
Age 0.09 0.30 0.33 0.91    
Sex -0.12 -8.73 7.73 -1.13    
IMD -0.03 -0.40 1.33 -0.30    
Q1 ESSI 0.28 1.23 0.49 2.54b    
Q1 NYHA -0.10 -5.83 6.10 -0.96    
Step 2     F(6,87)=2.16c 0.07 0.02 (F(1,87)=1.70) 
Age 0.07 0.22 0.33 0.66    
Sex -0.13 -9.17 7.71 -1.19    
IMD -0.04 -0.46 1.32 -0.35    
Q1 ESSI 0.27 1.22 0.48 2.51b    
Q1 NYHA -0.09 -5.05 6.10 -0.83    
Q1 SAQ Angina stability 0.13 0.15 0.12 1.30    
Step 3     F(7,86)=1.87 0.06 0.00 (F(1,86)=0.19) 
Age 0.06 0.18 0.35 0.51    
Sex -0.13 -9.43 7.76 -1.21    
IMD -0.04 -0.45 1.33 -0.34    
Q1 ESSI 0.27 1.18 0.49 2.39c    
Q1 NYHA -0.09 -4.95 6.14 -0.81    
Q1 SAQ Angina stability 0.13 0.15 0.12 1.30    
Q1 PSWQ -0.05 -0.09 0.21 -0.44    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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D: Staged multivariable regression of baseline worry with 6 month SAQ Treatment satisfaction (N=97) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,91)=2.89c 0.09  
Age 0.02 0.04 0.18 0.23    
Sex -0.08 -3.03 4.09 -0.74    
IMD 0.00 -0.01 0.69 -0.02    
Q1 ESSI 0.30 0.77 0.27 2.83b    
Q1 NYHA -0.15 -4.51 3.23 -1.40    
Step 2     F(6,90)=3.62b 0.14 0.06 (F(1,90)=6.42b) 
Age 0.00 0.00 0.17 -0.01    
Sex -0.10 -3.97 3.99 -0.99    
IMD -0.03 -0.21 0.68 -0.30    
Q1 ESSI 0.24 0.61 0.27 2.25c    
Q1 NYHA -0.11 -3.25 3.18 -1.02    
Q1 SAQ Treatment satisfaction 0.26 0.30 0.12 2.53b    
Step 3     F(7,89)=3.19b 0.14 0.01 (F(1,89)=0.69) 
Age -0.03 -0.05 0.18 -0.25    
Sex -0.10 -4.15 4.01 -1.03    
IMD -0.03 -0.18 0.68 -0.27    
Q1 ESSI 0.23 0.58 0.28 2.11c    
Q1 NYHA -0.10 -3.08 3.19 -0.96    
Q1 SAQ Treatment satisfaction 0.26 0.30 0.12 2.54b    
Q1 PSWQ -0.08 -0.09 0.11 -0.83    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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E: Staged multivariable regression of baseline worry with 6 month SAQ Disease perception (N=96) 
 β  B SE t Model fit Adj R2 Change in R2 
Step 1     F(5,90)=8.37a 0.30  
Age 0.19 0.44 0.21 2.09c    
Sex -0.01 -0.48 4.86 -0.10    
IMD 0.02 0.22 0.83 0.26    
Q1 ESSI 0.39 1.28 0.32 4.02a    
Q1 NYHA -0.21 -8.49 3.92 -2.17c    
Step 2     F(6,89)=11.00a 0.39 0.11 (F(1,89)=16.79a) 
Age 0.14 0.32 0.19 1.67    
Sex -0.02 -0.93 4.48 -0.21    
IMD 0.04 0.33 0.77 0.43    
Q1 ESSI 0.27 0.89 0.31 2.87b    
Q1 NYHA -0.13 -5.20 3.71 -1.40    
Q1 SAQ Disease perception 0.38 0.32 0.08 4.10a    
Step 3     F(7,88)=9.37a 0.38 0.00 (F(1,88)=0.20) 
Age 0.13 0.30 0.20 1.47    
Sex -0.02 -1.05 4.51 -0.23    
IMD 0.04 0.34 0.77 0.44    
Q1 ESSI 0.26 0.87 0.31 2.78b    
Q1 NYHA -0.12 -5.16 3.72 -1.39    
Q1 SAQ Disease perception 0.37 0.31 0.08 3.99a    
Q1 PSWQ -0.04 -0.06 0.13 -0.44    
ap≤0.001 bp≤0.01 c≤0.05. 
Q1=baseline. 
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Appendix 23: Summary of regression assumptions for staged multivariable regression models 
Model Shapiro-
Wilk test 
Breusch-
Pagan test* 
Durbin-
Watson test 
VIF 
 W  d Max Mean 
Baseline RRS brooding→6 month PHQ 0.93a 55.61a 0.52 2.57 1.45 
Baseline RRS brooding →6 month BAI 0.96b 9.97b 0.64 2.52 1.45 
Baseline RRS brooding →6 month EQ5D VAS 0.91a 1.36 0.69 1.41 1.23 
Baseline RRS brooding →6 month EQ5D Index value 0.92a 7.78b 0.88 1.76 1.32 
Baseline RRS brooding →6 month SAQ Physical limitations 0.96b 12.37a 0.51 1.81 1.35 
Baseline RRS brooding →6 month SAQ Angina frequency 0.90a 27.88a 0.76 1.27 1.19 
Baseline RRS brooding →6 month SAQ Angina stability 0.94a 1.30 0.55 1.20 1.13 
Baseline RRS brooding →6 month SAQ Treatment satisfaction 0.82a 2.42 0.48 1.20 1.15 
Baseline RRS brooding →6 month SAQ Disease perception 0.98 9.60b 0.87 1.50 1.25 
Baseline PSWQ→6 month PHQ 0.92a 62.40a 0.62 1.89 1.30 
Baseline PSWQ →6 month BAI 0.95a 11.37a 0.68 1.83 1.29 
Baseline PSWQ →6 month EQ5D VAS 0.91a 1.70 0.71 1.32 1.21 
Baseline PSWQ →6 month EQ5D Index value 0.93a 12.20a 0.96 1.53 1.25 
Baseline PSWQ →6 month SAQ Physical limitations 0.96b 13.28a 0.55 1.70 1.31 
Baseline PSWQ →6 month SAQ Angina frequency 0.90a 31.75a 0.80 1.27 1.19 
Baseline PSWQ →6 month SAQ Angina stability 0.94a 1.91 0.64 1.18 1.14 
Baseline PSWQ →6 month SAQ Treatment satisfaction 0.83a 2.94 0.51 1.19 1.15 
Baseline PSWQ →6 month SAQ Disease perception 0.98 11.79a 0.95 1.43 1.23 
ap≤0.001 bp≤0.01 c≤0.05. 
*Non-significant Breusch-Pagan test (p>0.05) indicates assumption of homoscedasticity met.   
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Appendix 24: Summary of regression diagnostics for staged multivariable regression models 
Model Studentized 
residuals >2 
Range of studentized 
residuals 
Cook’s distance 
 Cases % Min Max Min Max 
Baseline RRS brooding→6 month PHQ 6 5.66 -3.90 3.47 0.00 0.43 
Baseline RRS brooding →6 month BAI 7 6.54 -2.24 4.05 0.00 0.15 
Baseline RRS brooding →6 month EQ5D VAS 6 5.77 -4.25 2.07 0.00 0.19 
Baseline RRS brooding →6 month EQ5D Index value 5 4.85 -5.16 1.94 0.00 0.16 
Baseline RRS brooding →6 month SAQ Physical limitations 5 5.00 -4.47 2.57 0.00 0.14 
Baseline RRS brooding →6 month SAQ Angina frequency 5 4.76 -4.02 2.09 0.00 0.38 
Baseline RRS brooding →6 month SAQ Angina stability 1 1.06 -1.90 2.15 0.00 0.58 
Baseline RRS brooding →6 month SAQ Treatment satisfaction 3 3.09 -6.33 1.60 0.00 0.28 
Baseline RRS brooding →6 month SAQ Disease perception 3 3.13 -2.07 2.27 0.00 0.13 
Baseline PSWQ→6 month PHQ 7 6.54 -3.66 3.92 0.00 0.37 
Baseline PSWQ →6 month BAI 7 6.60 -2.05 4.16 0.00 0.15 
Baseline PSWQ →6 month EQ5D VAS 6 5.71 -4.26 1.87 0.00 0.18 
Baseline PSWQ →6 month EQ5D Index value 5 4.81 -4.87 2.61 0.00 0.25 
Baseline PSWQ →6 month SAQ Physical limitations 5 4.95 -4.18 2.56 0.00 0.20 
Baseline PSWQ →6 month SAQ Angina frequency 6 5.66 -4.07 2.08 0.00 0.31 
Baseline PSWQ →6 month SAQ Angina stability 1 1.06 -1.97 2.05 0.00 0.06 
Baseline PSWQ →6 month SAQ Treatment satisfaction 5 5.15 -6.24 1.63 0.00 0.17 
Baseline PSWQ →6 month SAQ Disease perception 4 4.17 -2.11 2.15 0.00 0.06 
 
 
316 
 
Appendix 25: Correlations between baseline PSWQ and RRS Brooding with main outcomes at 2 months 
 Baseline RRS brooding Baseline PSWQ 
 N r N r 
Total PHQ 120 0.46a 121 0.41a 
Total BAI 118 0.44a 119 0.36a 
EQ5D VAS 120 -0.27b 121 -0.30a 
EQ5D Index value 120 -0.34a 121 -0.35a 
EQ5D Mobility 120 0.12 121 0.13 
EQ5D Self-care 120 0.24b 121 0.16c 
EQ5D Usual activities 120 0.20b 121 0.13 
EQ5D Pain 120 0.22b 121 0.21b 
EQ5D Anxiety / depression 120 0.43a 121 0.41a 
SAQ Physical limitations 116 -0.11 117 -0.10 
SAQ Angina frequency 118 -0.23b 119 -0.20c 
SAQ Angina stability 112 -0.03 113 -0.18p=0.0529 
SAQ Treatment satisfaction 115 -0.29b 116 -0.21c 
SAQ Disease perception 114 -0.45a 115 -0.33a 
ap≤0.001 bp≤0.01 c≤0.05. 
 
  
317 
 
Appendix 26: Staged multivariable regression of baseline brooding with 2 month outcomes 
Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 PHQ (N=119)     F(8,110)=24.70a 0.62 0.00 (F(1,108)=0.61) 
Age -0.01 -0.01 0.03 -0.22    
Sex -0.19 -0.02 0.71 -0.26    
IMD -0.02 -0.01 0.13 -0.15    
Q1 ESSI -0.03 -0.03 0.05 -0.48    
Q1 NYHA 1.16 0.12 0.60 1.93p=0.056    
History of depression 0.53 0.03 1.00 0.53    
Q1 PHQ 0.70 0.68 0.10 7.28a    
Q1 RRS Brooding 0.10 0.07 0.13 0.78    
Q2 BAI (N=117)     F(8,108)=25.46a 0.63 0.00 (F(1,110)=3.53p=0.063) 
Age -0.02 -0.02 0.06 -0.29    
Sex -0.09 0.00 1.30 -0.07    
IMD 0.03 0.01 0.23 0.15    
Q1 ESSI -0.28 -0.18 0.10 -2.75b    
Q1 NYHA 1.75 0.10 1.15 1.52    
History of depression 1.16 0.04 1.86 0.62    
Q1 BAI 0.53 0.55 0.09 6.14a    
Q1 RRS Brooding 0.43 0.15 0.23 1.88p=0.063    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 EQ5D VAS (N=118)     F(7,110)=13.82a 0.43 0.00 (F(1,110)=0.91) 
Age 0.03 0.01 0.15 0.17    
Sex -2.19 -0.05 3.50 -0.63    
IMD 0.62 0.07 0.63 0.98    
Q1 ESSI 0.42 0.13 0.25 1.63    
Q1 NYHA 0.39 0.01 3.06 0.13    
Q1 EQ5D VAS 0.68 0.61 0.09 7.31a    
Q1 RRS Brooding -0.47 -0.08 0.49 -0.96    
Q2 EQ5D Index value (N=117)     F(7,109)=30.61a 0.64 0.01 (F(1,109)=2.70) 
Age 0.00 -0.13 0.00 -2.22c    
Sex -0.03 -0.07 0.03 -1.11    
IMD 0.00 0.02 0.00 0.35    
Q1 ESSI 0.01 0.21 0.00 3.40a    
Q1 NYHA -0.06 -0.16 0.03 -2.45c    
Q1 EQ5D Index value 0.58 0.58 0.07 8.13a    
Q1 RRS Brooding -0.01 -0.11 0.00 -1.64    
Q2 SAQ Physical limitations (N=113)     F(7,105)=22.09a 0.57 0.00 (F(1,105)=0.16) 
Age -0.21 -0.09 0.17 -1.22    
Sex 6.39 0.12 3.63 1.76    
IMD -0.96 -0.09 0.66 -1.46    
Q1 ESSI 0.71 0.17 0.27 2.59c    
Q1 NYHA -8.57 -0.19 3.67 -2.34c    
Q1 SAQ Physical limitations 0.47 0.51 0.08 5.81a    
Q1 RRS Brooding -0.23 -0.03 0.56 -0.40    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 SAQ Angina frequency (N=116)     F(7,108)=6.99a 0.27 0.01 (F(1,108)=2.13) 
Age -0.02 -0.01 0.14 -0.16    
Sex -1.25 -0.03 3.35 -0.37    
IMD 0.08 0.01 0.60 0.13    
Q1 ESSI 0.16 0.06 0.24 0.68    
Q1 NYHA -5.19 -0.16 2.82 -1.84p=0.068    
Q1 SAQ Angina frequency 0.35 0.38 0.09 4.01a    
Q1 RRS Brooding -0.69 -0.13 0.48 -1.46    
Q2 SAQ Angina stability (N=107)     F(7, 99)=2.07p=0.0542 0.07 0.00 (F(1,99)=0.04) 
Age 0.10 0.04 0.25 0.41    
Sex 0.77 0.01 6.30 0.12    
IMD -0.36 -0.03 1.11 -0.32    
Q1 ESSI 0.28 0.07 0.42 0.67    
Q1 NYHA -5.67 -0.11 4.97 -1.14    
Q1 SAQ Angina stability 0.31 0.30 0.10 3.05b    
Q1 RRS Brooding 0.15 0.02 0.83 0.19    
Q2 SAQ Treatment satisfaction 
(N=110)     
F(7,102)=8.99a 0.34 0.01 (F(1,102)= 2.07) 
Age 0.06 0.04 0.11 0.53    
Sex -4.99 -0.15 2.75 -1.82p=0.072    
IMD -0.33 -0.06 0.47 -0.70    
Q1 ESSI 0.41 0.18 0.19 2.15c    
Q1 NYHA -2.45 -0.09 2.17 -1.13    
Q1 SAQ Treatment satisfaction 0.44 0.46 0.08 5.34a    
Q1 RRS Brooding -0.52 -0.12 0.36 -1.44    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 SAQ Disease perception (N=108)     F(7, 100)=23.29a 0.59 0.01 (F(1,100)=3.34p=0.071) 
Age -0.05 -0.02 0.15 -0.33    
Sex -4.29 -0.08 3.58 -1.20    
IMD -0.91 -0.09 0.62 -1.46    
Q1 ESSI 0.56 0.15 0.25 2.25c    
Q1 NYHA -3.13 -0.07 3.04 -1.03    
Q1 SAQ Disease perception 0.53 0.64 0.07 8.15a    
Q1 RRS Brooding -0.91 -0.13 0.50 -1.83p=0.071    
ap≤0.001 bp≤0.01 c≤0.05. 
*Change in R2 attributable to addition of brooding in final step. 
Final steps only reported (for brevity). 
Q1=baseline, Q2=2 month. 
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Appendix 27: Staged multivariable regression of baseline worry with 2 month outcomes 
Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 PHQ (N=120)     F(8,111)=24.28a 0.61 0.00 (F(1,111)=0.11) 
Age -0.01 -0.02 0.03 -0.38    
Sex -0.24 -0.02 0.71 -0.34    
IMD 0.00 0.00 0.13 -0.02    
Q1 ESSI -0.02 -0.02 0.05 -0.29    
Q1 NYHA 1.03 0.11 0.60 1.72p=0.088    
History of depression 0.60 0.04 1.00 0.60    
Q1 PHQ 0.76 0.74 0.08 9.26a    
Q1 Total PSWQ -0.01 -0.02 0.02 -0.33    
Q2 BAI (N=117)     F(8,108)=24.58a 0.62 0.00 (F(1,108)=0.48) 
Age -0.03 -0.04 0.06 -0.58    
Sex -0.04 0.00 1.33 -0.03    
IMD 0.02 0.00 0.24 0.08    
Q1 ESSI -0.29 -0.19 0.10 -2.88b    
Q1 NYHA 1.41 0.08 1.15 1.23    
History of depression 0.92 0.03 1.89 0.49    
Q1 BAI 0.61 0.63 0.08 8.05a    
Q1 Total PSWQ 0.03 0.05 0.04 0.69    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 EQ5D VAS (N=119)     F(7, 111)=14.28a 0.44 0.01 (F(1,111)=2.64) 
Age 0.01 0.01 0.15 0.07    
Sex -2.12 -0.04 3.45 -0.61    
IMD 0.62 0.07 0.63 0.99    
Q1 ESSI 0.36 0.11 0.24 1.49    
Q1 NYHA 0.24 0.01 3.01 0.08    
Q1 EQ5D VAS 0.67 0.60 0.09 7.45a    
Q1 Total PSWQ -0.17 -0.12 0.10 -1.63    
Q2 EQ5D Index value (N=118)     F(7, 110)=30.18a 0.64 0.01 (F(1,110)=1.72) 
Age 0.00 -0.12 0.00 -2.07c    
Sex -0.02 -0.05 0.03 -0.88    
IMD 0.00 0.03 0.00 0.49    
Q1 ESSI 0.01 0.20 0.00 3.28a    
Q1 NYHA -0.06 -0.15 0.03 -2.26c    
Q1 EQ5D Index value 0.61 0.61 0.07 8.88a    
Q1 Total PSWQ 0.00 -0.08 0.00 -1.31    
Q2 SAQ Physical limitations (N=114)     F(7, 106)=21.87a 0.56 0.00 (F(1,106)=0.93) 
Age -0.22 -0.09 0.16 -1.37p=0.064    
Sex 6.72 0.12 3.60 1.87    
IMD -0.91 -0.09 0.66 -1.38    
Q1 ESSI 0.62 0.16 0.26 2.35c    
Q1 NYHA -7.91 -0.18 3.56 -2.23c    
Q1 SAQ Physical limitations 0.49 0.51 0.08 6.35a    
Q1 Total PSWQ -0.10 -0.06 0.11 -0.96    
Table continues on following page… 
 
  
323 
 
Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 SAQ Angina frequency (N=117)     F(7, 109)=6.29a 0.24 0.00 (F(1, 109)=0.41) 
Age 0.03 0.02 0.14 0.20    
Sex -0.45 -0.01 3.37 -0.13    
IMD 0.02 0.00 0.61 0.03    
Q1 ESSI 0.16 0.06 0.24 0.67    
Q1 NYHA -4.77 -0.15 2.84 -1.68    
Q1 SAQ Angina frequency 0.37 0.41 0.09 4.35a    
Q1 Total PSWQ -0.06 -0.06 0.10 -0.64    
Q2 SAQ Angina stability (N=107)     F(7, 99)=2.68c 0.10 0.03 (F(1,99)=3.49p=0.065) 
Age 0.08 0.03 0.25 0.34    
Sex 1.29 0.02 6.14 0.21    
IMD -0.72 -0.06 1.10 -0.66    
Q1 ESSI 0.07 0.02 0.40 0.17    
Q1 NYHA -4.00 -0.08 4.89 -0.82    
Q1 SAQ Angina stability 0.30 0.29 0.10 2.99b    
Q1 Total PSWQ -0.32 -0.18 0.17 -1.87p=0.065    
Q2 SAQ Treatment satisfaction 
(N=110)     
F(7, 102)=7.87a 0.31 0.00 (F(1,102)=0.19) 
Age 0.12 0.09 0.11 1.04    
Sex -4.24 -0.13 2.81 -1.51    
IMD -0.50 -0.09 0.49 -1.02    
Q1 ESSI 0.38 0.17 0.19 1.97    
Q1 NYHA -2.01 -0.08 2.24 -0.89    
Q1 SAQ Treatment satisfaction 0.47 0.49 0.08 5.57    
Q1 Total PSWQ -0.03 -0.04 0.08 -0.44    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q2 SAQ Disease perception(N=108)     F(7, 100)=20.79a 0.56 0.01 (F(1,100)=1.96) 
Age -0.02 -0.01 0.16 -0.16    
Sex -3.26 -0.06 3.70 -0.88    
IMD -0.97 -0.10 0.65 -1.49    
Q1 ESSI 0.45 0.13 0.25 1.76p=0.081    
Q1 NYHA -2.36 -0.05 3.17 -0.74    
Q1 SAQ Disease perception 0.57 0.68 0.06 8.76a    
Q1 Total PSWQ -0.15 -0.09 0.11 -1.40    
ap≤0.001 bp≤0.01 c≤0.05. 
*Change in R2 attributable to addition of brooding in final step. 
Final steps only reported (for brevity). 
Q1=baseline, Q2=2 month. 
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Appendix 28: Correlations between 2 month PSWQ and RRS Brooding with main 
outcomes at 6 months 
 2 month RRS brooding 2 month PSWQ 
 N r N r 
Total PHQ 105 0.52a 105 0.47a 
Total BAI 105 0.42a 104 0.42a 
EQ5D VAS 104 -0.26b 104 -0.35a 
EQ5D Index value 104 -0.31b 104 -0.41a 
EQ5D Mobility 104 0.15 104 0.24b 
EQ5D Self-care 104 0.23b 104 0.15 
EQ5D Usual activities 104 0.23b 104 0.23b 
EQ5D Pain 104 0.29a 104 0.32a 
EQ5D Anxiety / depression 104 0.35a 104 0.41a 
SAQ Physical limitations 101 -0.26b 101 -0.18 
SAQ Angina frequency 104 -0.37a 104 -0.24b 
SAQ Angina stability 95 -0.15 95 -0.16 
SAQ Treatment satisfaction 99 -0.32a 99 -0.30b 
SAQ Disease perception 99 -0.50a 99 -0.36a 
ap≤0.001 bp≤0.01 c≤0.05.
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Appendix 29: Staged multivariable regression of 2 month brooding with 6 month outcomes 
Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 PHQ (N=104)     F(8,95)= 33.57a 0.72 0.00 (F(1,95)=4.54c) 
Age -0.04 -0.07 0.03 -1.30    
Sex 0.59 0.05 0.64 0.93    
IMD 0.00 0.00 0.11 -0.04    
Q1 ESSI -0.16 -0.22 0.05 -3.46a    
Q1 NYHA 0.24 0.03 0.54 0.45    
History of depression -0.47 -0.03 0.95 -0.49    
Q2 PHQ 0.66 0.64 0.07 8.82a    
Q2 RRS Brooding 0.25 0.14 0.12 2.13c    
Q3 BAI (N=102)     F(8,93)=32.14a 0.71 0.00 (F(1,93)=0.02) 
Age -0.08 -0.08 0.06 -1.46    
Sex 1.04 0.05 1.15 0.91    
IMD 0.12 0.03 0.21 0.61    
Q1 ESSI -0.27 -0.19 0.09 -2.88b    
Q1 NYHA 1.40 0.08 1.00 1.40    
History of depression -0.89 -0.03 1.76 -0.51    
Q2 BAI 0.67 0.72 0.07 9.04a    
Q2 RRS Brooding -0.03 -0.01 0.23 -0.15    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 EQ5D VAS (N=103)     F(7,95)=15.15a 0.49 0.01 (F(1,95)=2.41) 
Age -0.18 -0.08 0.16 -1.12    
Sex -2.99 -0.07 3.41 -0.88    
IMD -0.91 -0.11 0.60 -1.52    
Q1 ESSI 0.66 0.22 0.24 2.72b    
Q1 NYHA -3.28 -0.09 2.86 -1.15    
Q2 EQ5D VAS 0.51 0.53 0.08 6.60a    
Q2 RRS Brooding -0.90 -0.13 0.58 -1.55    
Q3 EQ5D Index value (N=103)     F(7,95)=16.15a 0.51 0.01 (F(1,95)=2.37) 
Age 0.00 -0.04 0.00 -0.57    
Sex -0.05 -0.12 0.04 -1.55    
IMD -0.01 -0.10 0.01 -1.44    
Q1 ESSI 0.00 0.15 0.00 1.78p=0.078    
Q1 NYHA -0.04 -0.10 0.03 -1.26    
Q2 EQ5D Index value 0.57 0.53 0.10 5.51a    
Q2 RRS Brooding -0.01 -0.13 0.01 -1.54    
Q3 SAQ Physical limitations (N=97)     F(7,89)=18.35a 0.56 0.01 (F(1,89)=1.22) 
Age -0.18 -0.07 0.21 -0.84    
Sex 0.38 0.01 4.21 0.09    
IMD -0.29 -0.03 0.75 -0.39    
Q1 ESSI 0.23 0.06 0.33 0.71    
Q1 NYHA -7.67 -0.17 3.77 -2.04c    
Q2 SAQ Physical limitations 0.65 0.60 0.10 6.31a    
Q2 RRS Brooding -0.76 -0.09 0.68 -1.10    
Table continues on following page… 
 
 
  
328 
 
Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 SAQ Angina frequency (N=103)     F(7,95)=28.56a 0.65 0.00 (F(1,95)=0.56) 
Age 0.09 0.04 0.13 0.69    
Sex -2.03 -0.05 2.71 -0.75    
IMD 0.29 0.04 0.48 0.62    
Q1 ESSI 0.12 0.04 0.19 0.61    
Q1 NYHA -3.83 -0.11 2.30 -1.67    
Q2 SAQ Angina frequency 0.87 0.74 0.08 10.82a    
Q2 RRS Brooding -0.34 -0.05 0.45 -0.75    
Q3 SAQ Angina stability (N=91)     F(7,83)=5.27a 0.25 0.00 (F(1,83)=0.11) 
Age 0.08 0.02 0.31 0.25    
Sex -9.74 -0.13 7.19 -1.36    
IMD -0.36 -0.03 1.22 -0.30    
Q1 ESSI 1.20 0.27 0.46 2.61c    
Q1 NYHA -0.64 -0.01 5.68 -0.11    
Q2 SAQ Angina stability 0.50 0.45 0.11 4.69a    
Q2 RRS Brooding -0.35 -0.03 1.05 -0.33    
Q3 SAQ Treatment satisfaction 
(N=98)     
F(7,90)=10.13a 0.40 0.00 (F(1,90)=0.08) 
Age 0.01 0.00 0.15 0.06    
Sex -2.96 -0.08 3.30 -0.90    
IMD -0.14 -0.02 0.56 -0.24    
Q1 ESSI 0.30 0.12 0.24 1.24    
Q1 NYHA -0.58 -0.02 2.68 -0.22    
Q2 SAQ Treatment satisfaction 0.70 0.60 0.11 6.45a    
Q2 RRS Brooding -0.14 -0.02 0.53 -0.27    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 SAQ Disease perception (N=97)     F(7,89)=16.75a 0.53 0.01 (F(1,89)=1.12) 
Age 0.32 0.13 0.18 1.83p=0.071    
Sex 0.35 0.01 3.88 0.09    
IMD 0.72 0.08 0.67 1.08    
Q1 ESSI 0.48 0.14 0.28 1.69    
Q1 NYHA -4.07 -0.10 3.23 -1.26    
Q2 SAQ Disease perception 0.55 0.54 0.09 5.93a    
Q2 RRS Brooding -0.70 -0.09 0.66 -1.05    
ap≤0.001 bp≤0.01 c≤0.05. 
*Change in R2 attributable to addition of brooding in final step. 
Final steps only reported (for brevity). 
Q1=baseline, Q2=2 month, Q3=6 month. 
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Appendix 30: Staged multivariable regression of 2 month worry with 6 month outcomes 
Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 PHQ (N=103)     F(8,94)=31.68a 0.71 0.00 (F(1,94)=1.07) 
Age -0.04 -0.08 0.03 -1.44    
Sex 0.49 0.04 0.66 0.74    
IMD -0.01 -0.01 0.11 -0.09    
Q1 ESSI -0.17 -0.22 0.05 -3.50a    
Q1 NYHA 0.23 0.02 0.56 0.41    
History of depression -0.57 -0.03 0.98 -0.58    
Q2 PHQ 0.69 0.67 0.08 8.65a    
Q2 Total PSWQ 0.03 0.07 0.02 1.03    
Q3 BAI (N=101)     F(8,92)=32.17 0.71 0.00 (F(1,92)=0.17) 
Age -0.07 -0.07 0.06 -1.28    
Sex 0.96 0.05 1.16 0.83    
IMD 0.11 0.03 0.21 0.52    
Q1 ESSI -0.27 -0.19 0.09 -2.87b    
Q1 NYHA 1.32 0.08 1.01 1.31    
History of depression -0.92 -0.03 1.75 -0.52    
Q2 BAI 0.65 0.70 0.07 9.26a    
Q2 Total PSWQ 0.02 0.03 0.04 0.41    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 EQ5D VAS (N=102)     F(7,94)=15.64a 0.50 0.02 (F(1,94)=4.98c) 
Age -0.18 -0.08 0.16 -1.12    
Sex -2.41 -0.05 3.37 -0.71    
IMD -0.90 -0.11 0.59 -1.51    
Q1 ESSI 0.60 0.20 0.24 2.47c    
Q1 NYHA -3.53 -0.09 2.86 -1.23    
Q2 EQ5D VAS 0.49 0.51 0.08 6.39a    
Q2 Total PSWQ -0.24 -0.18 0.11 -2.23c    
Q3 EQ5D Index value (N=102)     F(7,94)=16.13a 0.51 0.01 (F(1,94)=2.82) 
Age 0.00 -0.04 0.00 -0.48    
Sex -0.05 -0.10 0.03 -1.41    
IMD -0.01 -0.10 0.01 -1.41    
Q1 ESSI 0.00 0.14 0.00 1.68    
Q1 NYHA -0.04 -0.11 0.03 -1.34    
Q2 EQ5D Index value 0.57 0.52 0.10 5.39a    
Q2 Total PSWQ 0.00 -0.14 0.00 -1.68    
Q3 SAQ Physical limitations (N=96)     F(7,88)=17.66a 0.55 0.00 (F(1,88)=0.04) 
Age -0.10 -0.04 0.21 -0.47    
Sex 0.28 0.00 4.27 0.07    
IMD -0.31 -0.03 0.76 -0.41    
Q1 ESSI 0.28 0.07 0.33 0.85    
Q1 NYHA -7.63 -0.17 3.85 -1.98p=0.051    
Q2 SAQ Physical limitations 0.68 0.61 0.10 6.49a    
Q2 Total PSWQ -0.02 -0.01 0.13 -0.19    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 SAQ Angina frequency (N=102)     F(7,94)=28.20a 0.65 0.00 F(1,94)=0.47) 
Age 0.14 0.07 0.13 1.07    
Sex -1.89 -0.04 2.72 -0.70    
IMD 0.27 0.04 0.48 0.57    
Q1 ESSI 0.17 0.06 0.19 0.90    
Q1 NYHA -3.93 -0.11 2.34 -1.68    
Q2 SAQ Angina frequency 0.90 0.76 0.08 11.43a    
Q2 Total PSWQ 0.06 0.05 0.08 0.69    
Q3 SAQ Angina stability (N=90)     F(7,82)=5.59a 0.27 0.00 (F(1,82)=0.46) 
Age 0.06 0.02 0.31 0.19    
Sex -8.49 -0.12 7.09 -1.20    
IMD -0.18 -0.01 1.22 -0.15    
Q1 ESSI 1.41 0.32 0.46 3.03b    
Q1 NYHA 1.01 0.02 5.73 0.18    
Q2 SAQ Angina stability 0.55 0.49 0.11 4.91a    
Q2 Total PSWQ 0.14 0.07 0.20 0.68    
Q3 SAQ Treatment satisfaction 
(N=97)     
F(7,89)=10.12a 0.40 0.01 (F(1,89)=0.80) 
Age 0.00 0.00 0.15 -0.01    
Sex -2.99 -0.08 3.30 -0.91    
IMD -0.14 -0.02 0.57 -0.25    
Q1 ESSI 0.26 0.10 0.24 1.07    
Q1 NYHA -0.67 -0.02 2.71 -0.25    
Q2 SAQ Treatment satisfaction 0.69 0.58 0.11 6.43a    
Q2 Total PSWQ -0.09 -0.08 0.10 -0.89    
Table continues on following page… 
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Model β  B SE t Model fit Adj R2 Change in R2* 
Q3 SAQ Disease perception (N=96)     F(7,88)=16.39 0.53 0.00 (F(1,88)=0.02) 
Age 0.33 0.14 0.18 1.84p=0.070    
Sex 0.88 0.02 3.90 0.22    
IMD 0.81 0.09 0.67 1.21    
Q1 ESSI 0.53 0.16 0.29 1.85p=0.068    
Q1 NYHA -3.35 -0.08 3.28 -1.02    
Q2 SAQ Disease perception 0.59 0.59 0.09 6.65a    
Q2 Total PSWQ -0.02 -0.01 0.12 -0.14    
ap≤0.001 bp≤0.01 c≤0.05. 
*Change in R2 attributable to addition of brooding in final step. 
Final steps only reported (for brevity). 
Q1=baseline, Q2=2 month, Q3=6 month. 
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Appendix 31: Results of variance components models 
 N β √ψ √θ *LR χbar2 ICC 
PHQ 402 4.01 4.41 2.13 249.07a 0.81 
BAI 399 8.29 7.87 4.10 232.42a 0.79 
EQ5D VAS 401 73.65 14.48 11.20 130.07a 0.63 
EQ5D Index value 398 0.79 0.17 0.11 161.85a 0.71 
SAQ Physical limitations 389 75.81 19.77 13.17 155.07a 0.70 
SAQ Angina frequency 399 89.21 13.25 10.89 117.51a 0.60 
SAQ Angina stability 373 77.86 13.62 22.38 21.09a 0.27 
SAQ Treatment satisfaction 388 89.65 10.71 10.09 73.66a 0.53 
SAQ Disease perception 383 73.43 18.94 13.52 133.27a 0.66 
ap≤0.001 bp≤0.01 c≤0.05. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
ICC=intra-class correlation coefficient. 
*LR χbar2 all df=1. 
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Appendix 32: Results of simple multilevel (repeated measures) models for depression (model i) (N=229) 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Fixed       
Χ2(2)=19.77a 
Time -0.13 0.44 -0.30 -0.13 0.37 -0.35 
Total PHQ (n-1 lag) 0.91 0.03 28.04a 0.82 0.04 20.09a 
Random       
Participant √ψ  11.11 661.53  0.00 0.00  
Participant √θ  1.42 397.29  2.80 0.13  
Time √ψ  4.36 259.31     
Overall model Wald χ2(2)=788.51a, Log likelihood=-550.97 Wald χ2(2)=405.47a, Log likelihood=-560.85 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
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Appendix 33: Random intercept models of the association between brooding and depression with and without social support as a covariate 
 Random intercept model not including social 
support as a covariate 
Random intercept model including social 
support as a covariate 
 β SE z β SE z 
Model iii (N=212)       
Fixed       
Time 0.03 0.38 0.08 -0.03 0.37 -0.07 
Total PHQ (n-1 lag) 0.68 0.06 11.10a 0.64 0.06 10.35a 
RRS Brooding (n-1 lag) 0.17 0.09 1.98c 0.15 0.09 1.77p=0.076 
Age -0.02 0.02 -1.03 -0.02 0.02 -0.76 
Sex 0.08 0.52 0.16 0.35 0.52 0.67 
IMD 0.00 0.09 0.01 0.01 0.09 0.13 
Q1 ESSI    -0.11 0.04 -2.89b 
Q1 NYHA 1.12 0.42 2.69b 0.84 0.42 2.01c 
History of depression 0.73 0.69 1.05 0.36 0.69 0.52 
Days since index event 0.00 0.00 0.63 0.00 0.00 0.44 
Random       
Participant √ψ  0.00 0.00  0.00 0.00  
Participant √θ  2.74 0.13  2.69 0.13  
Time √ψ       
Overall model Wald χ2(9)=365.00a, Log likelihood=-514.37 Wald χ2(10)=387.79a, Log likelihood=-510.27 
ap≤0.001 bp≤0.01 c≤0.05. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 34: Results of simple multilevel (repeated measures) models for anxiety (model i) (N=223) 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Fixed       
- 
Time - - - 0.11 0.69 0.17 
Total BAI (n-1 lag) - - - 0.76 0.04 19.88a 
Random       
Participant √ψ  - -  0.00 0.00  
Participant √θ  - -  5.11 0.24  
Time √ψ  - -     
Overall model Model failed to converge Wald χ2(2)=395.89a, Log likelihood=-680.36 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
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Appendix 35: Results of simple multilevel (repeated measures) models for EQ5D VAS (model i) (N=228) 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Fixed       
Χ2(2)=3.32 
Time 0.93 2.07 0.45 1.09 1.88 0.58 
EQ5D VAS (n-1 lag) 0.75 0.05 15.77a 0.68 0.05 13.11a 
Random       
Participant √ψ  36.56 139.93  0.00 0.00  
Participant √θ  11.96 32.85  14.14 0.66  
Time √ψ  14.49 54.32     
Overall model Wald χ2(2)=249.17a, Log likelihood=-925.80 Wald χ2(2)=172.45a, Log likelihood=-927.46 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
 
 
  
339 
 
Appendix 36: Results of simple multilevel (repeated measures) models for EQ5D Index value (model i) (N=225) 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Fixed       
Χ2(2)=2.07 
Time -0.02 0.02 -1.32 -0.02 0.02 -1.37 
EQ5D Index value (n-1 lag) 0.78 0.04 17.26a 0.76 0.05 16.27a 
Random       
Participant √ψ  0.26 2.27  0.00 0.00  
Participant √θ  0.11 0.41  0.13 0.01  
Time √ψ  0.11 0.83     
Overall model Wald χ2(2)=298.23a, Log likelihood=142.70 Wald χ2(2)=264.70a, Log likelihood=141.66 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
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Appendix 37: Ordered logistic regression (with cluster option) of brooding lag 
variable with EQ5D subscales (N=209) 
 OR Robust SE z Model fit  
(Wald test) 
Pseudo 
R2 
EQ5D Mobility    χ2(8)=105.55a 0.36 
Age 1.05 0.02 2.86b   
Sex 1.48 0.78 0.75   
IMD 1.19 0.09 2.26c   
Q1 ESSI 0.95 0.02 -2.34c   
Q1 NYHA 3.40 1.24 3.34a   
Days since index event 1.00 0.00 -0.82   
EQ5D Mobility (n-1 lag) 5.90 1.76 5.94a   
RRS Brooding (n-1 lag) 1.07 0.07 1.05   
EQ5D Self-care    χ2(8)=70.72a 0.48 
Age 1.02 0.03 0.56   
Sex 4.07 3.82 1.50   
IMD 1.10 0.13 0.78   
Q1 ESSI 0.91 0.03 -2.81b   
Q1 NYHA 8.81 10.46 1.83   
Days since index event 1.00 0.00 -0.57   
EQ5D Self-care (n-1 lag) 14.35 8.27 4.62a   
RRS Brooding (n-1 lag) 1.14 0.12 1.27   
EQ5D Usual activities    χ2(8)=108.19a 0.32 
Age 1.07 0.02 3.42a   
Sex 2.23 1.06 1.68   
IMD 1.11 0.09 1.18   
Q1 ESSI 0.91 0.03 -3.16b   
Q1 NYHA 5.22 2.20 3.91a   
Days since index event 1.00 0.00 -1.86   
EQ5D Usual activities (n-
1 lag) 2.72 0.76 3.59a 
  
RRS Brooding (n-1 lag) 1.18 0.08 2.38c   
EQ5D Pain    χ2(8)=107.79a 0.24 
Age 1.02 0.02 1.43   
Sex 1.62 0.68 1.15   
IMD 1.06 0.08 0.84   
Q1 ESSI 0.93 0.02 -3.16b   
Q1 NYHA 2.41 0.89 2.38c   
Days since index event 1.00 0.00 0.31   
EQ5D Pain (n-1 lag) 3.87 0.96 5.48a   
RRS Brooding (n-1 lag) 1.12 0.06 2.28c   
Table continues on following page… 
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 OR Robust 
SE 
z Model fit  
(Wald test) 
Pseudo 
R2 
EQ5D 
Anxiety/depression    
χ2(8)=72.52a 0.33 
Age 0.99 0.02 -0.80   
Sex 1.67 0.74 1.14   
IMD 1.00 0.07 -0.06   
Q1 ESSI 0.90 0.03 -3.30a   
Q1 NYHA 2.65 0.96 2.67b   
Days since index event 1.00 0.00 0.41   
EQ5D Anxiety/depression 
(n-1 lag) 4.48 1.55 4.34a 
  
RRS Brooding (n-1 lag) 1.12 0.07 1.70p=0.089   
ap≤0.001 bp≤0.01 c≤0.05. 
OR=Odds ratio. 
Q1=baseline. 
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Appendix 38: Ordered logistic regression (with cluster option) of worry lag variable 
with EQ5D subscales (N=209) 
 OR Robust SE z Model fit  
(Wald test) 
Pseudo 
R2 
EQ5D Mobility    χ2(8)=88.08a 0.36 
Age 1.06 0.02 3.11b   
Sex 1.44 0.76 0.70   
IMD 1.17 0.09 2.13c   
Q1 ESSI 0.96 0.02 -1.79p=0.074   
Q1 NYHA 3.49 1.27 3.44a   
Days since index event 1.00 0.00 -0.81   
EQ5D Mobility (n-1 lag) 6.13 1.82 6.11a   
Total PSWQ (n-1 lag) 1.03 0.01 2.33c   
EQ5D Self-care    χ2(8)=71.24a 0.47 
Age 1.01 0.04 0.34   
Sex 3.99 3.67 1.50   
IMD 1.11 0.12 0.94   
Q1 ESSI 0.89 0.04 -2.78b   
Q1 NYHA 7.82 8.88 1.81p=0.070   
Days since index event 1.00 0.00 -0.35   
EQ5D Usual activities (n-
1 lag) 17.34 9.57 5.17a 
  
Total PSWQ (n-1 lag) 1.01 0.02 0.47   
EQ5D Usual activities    χ2(8)=86.50a 0.31 
Age 1.06 0.02 2.96b   
Sex 1.98 0.93 1.46   
IMD 1.11 0.09 1.26   
Q1 ESSI 0.92 0.03 -2.63b   
Q1 NYHA 4.63 1.95 3.64a   
Days since index event 1.00 0.00 -1.38   
EQ5D Self-care (n-1 lag) 3.04 0.79 4.31a   
Total PSWQ (n-1 lag) 1.02 0.01 1.91p=0.056   
EQ5D Pain    χ2(8)=100.45a 0.23 
Age 1.02 0.02 1.19   
Sex 1.52 0.62 1.04   
IMD 1.05 0.08 0.60   
Q1 ESSI 0.93 0.02 -2.95b   
Q1 NYHA 2.53 0.92 2.55b   
Days since index event 1.00 0.00 0.52   
EQ5D Pain (n-1 lag) 3.77 0.86 5.80a   
Total PSWQ (n-1 lag) 1.02 0.01 2.35b   
Table continues on following page… 
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 OR Robust 
SE 
z Model fit  
(Wald test) 
Pseudo 
R2 
EQ5D 
Anxiety/depression    
χ2(8)=67.30a 0.34 
Age 0.98 0.02 -0.99   
Sex 1.41 0.63 0.76   
IMD 0.97 0.06 -0.45   
Q1 ESSI 0.90 0.03 -3.34a   
Q1 NYHA 2.65 0.95 2.72b   
Days since index event 1.00 0.00 0.88   
EQ5D Anxiety/depression 
(n-1 lag) 3.84 1.23 4.18a 
  
Total PSWQ (n-1 lag) 1.04 0.02 2.78b   
ap≤0.001 bp≤0.01 c≤0.05. 
OR=Odds ratio. 
Q1=baseline. 
 
 
344 
 
Appendix 39: Results of multilevel (repeated measures) models with SAQ Physical limitations as the outcome variable 
A: Simple multilevel (repeated measures) models for SAQ Physical limitations  
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model i (N=217)        
Fixed       
Χ2(2)=1.04 
Time -3.63 2.33 -1.56 -3.47 2.21 -1.57 
SAQ Physical limitations (n-1 lag) 0.74 0.05 16.17a 0.71 0.05 14.88a 
Random       
Participant √ψ  31.05 178.33  0.00 0.00  
Participant √θ  14.67 28.95  16.07 0.77  
Time √ψ  12.42 68.56     
Overall model Wald χ2(2)=261.72a, Log likelihood=-909.99 Wald χ2(2)=221.50a, Log likelihood=-910.51 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
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B: Multilevel (repeated measures) models of brooding with SAQ Physical limitations 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=212)        
Fixed       
Χ2(2)=1.30 
Time -2.86 2.30 -1.25 -2.74 2.19 -1.25 
SAQ Physical limitations (n-1 lag) 0.75 0.05 15.74a 0.71 0.05 14.39a 
RRS Brooding (n-1 lag) -0.21 0.38 -0.55 -0.24 0.40 -0.60 
Random       
Participant √ψ  31.34 136.94  0.00 0.00  
Participant √θ  14.34 22.95  15.70 0.76  
Time √ψ 12.00 55.04     
Overall model Wald χ2(3)=274.22a, Log likelihood= -883.97 Wald χ2(3)=231.03a, Log likelihood=-884.62 
Table continues on following page… 
 
  
346 
 
 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=199)        
Fixed       
Χ2(1)=0.17 
Time -2.17 2.21 -0.98 -2.15 2.15 -1.00 
SAQ Physical limitations (n-1 lag) 0.55 0.06 8.79a 0.53 0.06 8.36a 
RRS Brooding (n-1 lag) -0.37 0.44 -0.83 -0.42 0.45 -0.93 
Age -0.17 0.14 -1.27 -0.19 0.14 -1.34 
Sex 4.66 2.97 1.57 4.76 3.05 1.56 
IMD -0.74 0.50 -1.49 -0.75 0.51 -1.47 
Q1 ESSI 0.52 0.21 2.41c 0.52 0.22 2.35c 
Q1 NYHA -8.19 2.60 -3.15b -8.67 2.66 -3.26a 
Days since index event -0.01 0.01 -0.99 -0.01 0.01 -0.91 
Random       
Participant √ψ  27.97 1750.92  0.00 0.00  
Participant √θ  13.15 286.51  14.90 0.75  
Time √ψ 11.18 674.12     
Overall model Wald χ2(9)=291.18a, Log likelihood= -819.87 Wald χ2(9)=273.32a, Log likelihood= -819.96 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subjects standard deviation. 
Q1=baseline. 
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C: Multilevel (repeated measures) models of worry with SAQ Physical limitations 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=213)        
Fixed       
Χ2(2)=2.52 
Time -3.53 2.42 -1.46 -3.26 2.21 -1.47 
SAQ Physical limitations (n-1 lag) 0.78 0.05 16.70a 0.73 0.05 14.53a 
Total PSWQ (n-1 lag) -0.07 0.07 -0.99 -0.07 0.08 -0.87 
Random       
Participant √ψ  -1.00 0.35  0.00 0.00  
Participant √θ  13.50 101.46  16.01 0.78  
Time √ψ 16.25 168.55     
Overall model Wald χ2(3)=295.49a, Log likelihood=-891.69 Wald χ2(3)=224.19a, Log likelihood=-892.95 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=199)        
Fixed       
Χ2(1)=0.72 
Time -2.39 2.26 -1.06 -2.30 2.15 -1.07 
SAQ Physical limitations (n-1 lag) 0.59 0.06 9.80a 0.55 0.06 8.88a 
Total PSWQ (n-1 lag) -0.07 0.08 -0.82 -0.06 0.08 -0.73 
Age -0.15 0.13 -1.13 -0.16 0.14 -1.19 
Sex 4.63 2.88 1.61 4.81 3.05 1.58 
IMD -0.64 0.49 -1.30 -0.68 0.52 -1.32 
Q1 ESSI 0.45 0.20 2.19c 0.47 0.22 2.19c 
Q1 NYHA -7.43 2.51 -2.96b -8.40 2.64 -3.18a 
Days since index event -0.02 0.01 -1.23 -0.01 0.01 -1.05 
Random       
Participant √ψ  45.78 6.11  0.00 0.00  
Participant √θ  9.21 -  14.90 0.75  
Time √ψ 18.17 2.43     
Overall model Wald χ2(9)=307.93a, Log likelihood=-819.63 Wald χ2(9)=268.83a, Log likelihood= -819.99 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 40: Results of multilevel (repeated measures) models with SAQ Angina frequency as the outcome variable  
A: Simple multilevel (repeated measures) models for SAQ Angina frequency 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model i (N=226)        
Fixed       
Χ2(2)=10.12b 
Time 1.91 -1.46 0.15 1.65 -1.48 0.14 
SAQ Angina frequency (n-1 lag) 0.77 0.05 15.79a 0.55 0.06 10.04a 
Random       
Participant √ψ  43.55 522.36  5.97 4.07  
Participant √θ  9.33 187.55  12.24 1.73  
Time √ψ  15.73 222.43     
Overall model Wald χ2(2)=250.02a, Log likelihood=-903.73 Wald χ2(2)= 101.81a, Log likelihood=-908.79 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
 
  
350 
 
B: Multilevel (repeated measures) models of brooding with SAQ Angina frequency 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=221)        
Fixed       
Χ2(2)=1.34 
Time -3.34 1.61 -2.07c -3.15 1.33 -2.37b 
SAQ Angina frequency (n-1 lag) 0.64 0.06 11.03a 0.37 0.06 6.20a 
RRS Brooding (n-1 lag) -0.71 0.33 -2.13c -1.07 0.36 -2.96b 
Random       
Participant √ψ  25.12 174.25  9.20 2.15  
Participant √θ  10.47 32.18  9.60 1.20  
Time √ψ 8.16 82.49     
Overall model Wald χ2(3)=172.30a, Log likelihood=-871.43 Wald χ2(3)=70.10a, Log likelihood=-872.104 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=209)        
Fixed       
Χ2(2)=0.01 
Time -2.89 1.29 -2.23b -2.87 1.27 -2.25c 
SAQ Angina frequency (n-1 lag) 0.26 0.06 4.26a 0.25 0.06 3.97a 
RRS Brooding (n-1 lag) -0.65 0.38 -1.73p=0.083 -0.67 0.38 -1.77p=0.077 
Age 0.02 0.12 0.14 0.02 0.13 0.15 
Sex -5.05 3.05 -1.65 -5.09 3.10 -1.64 
IMD 0.20 0.50 0.39 0.21 0.51 0.41 
Q1 ESSI 0.35 0.20 1.76p=0.078 0.36 0.20 1.76p=0.078 
Q1 NYHA -7.91 2.37 -3.34a -8.04 2.40 -3.35a 
Days since index event -0.02 0.01 -1.49 -0.02 0.01 -1.48 
Random       
Participant √ψ  13.62 99.37  9.23 1.99  
Participant √θ  8.69 12.10  8.94 1.11  
Time √ψ 3.75 55.42     
Overall model Wald χ2(9)=76.82a, Log likelihood=-815.17 Wald χ2(9)=72.53a, Log likelihood=-815.18 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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C: Multilevel (repeated measures) models of worry with SAQ Angina frequency 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=222)        
Fixed       
Χ2(2)=0.74 
Time -3.22 1.49 -2.15c -3.13 1.37 -2.28c 
SAQ Angina frequency (n-1 lag) 0.54 0.05 9.88a 0.43 0.06 7.69a 
Total PSWQ (n-1 lag) -0.07 0.07 -1.00 -0.08 0.07 -1.11 
Random       
Participant √ψ  24.53 1741.30  8.83 2.06  
Participant √θ  9.32 352.63  10.01 1.15  
Time √ψ 8.33 789.35     
Overall model Wald χ2(3)=113.90a, Log likelihood=-878.99 Wald χ2(3)=72.06a, Log likelihood=-879.36 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=209)        
Fixed       
- 
Time    -2.92 1.27 -2.29c 
SAQ Angina frequency (n-1 lag)    0.26 0.06 4.30a 
Total PSWQ (n-1 lag)    0.02 0.07 0.21 
Age    0.08 0.13 0.61 
Sex    -4.87 3.13 -1.55 
IMD    0.16 0.52 0.30 
Q1 ESSI    0.43 0.21 2.07c 
Q1 NYHA    -8.13 2.43 -3.34a 
Days since index event    -0.02 0.01 -1.57 
Random       
Participant √ψ     9.39 1.91  
Participant √θ     8.96 1.07  
Time √ψ       
Overall model Model failed to converge Wald χ2(9)=66.58a, Log likelihood=-816.70 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 41: Results of multilevel (repeated measures) models with SAQ Angina stability as the outcome variable 
A: Simple multilevel (repeated measures) models for SAQ Angina stability  
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
model i (N=204)        
Fixed       
Χ2(2)=0.82 
Time -5.05 3.24 -1.56 -4.94 3.24 -1.52 
SAQ Angina stability (n-1 lag) 0.35 0.07 4.84a 0.37 0.07 5.11a 
Random       
Participant √ψ  44.92 2699.59  9.47 4.31  
Participant √θ  18.21 512.16  22.50 1.92  
Time √ψ  18.35 1016.66     
Overall model Wald χ2(2)=29.21a, Log likelihood=-939.80 Wald χ2(2)=31.96a, Log likelihood=-940.21 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
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B: Multilevel (repeated measures) models of brooding with SAQ Angina stability 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=200)        
Fixed       
Χ2(2)=0.66 
Time -5.17 3.33 -1.55 -5.10 3.33 -1.53 
SAQ Angina stability (n-1 lag) 0.36 0.07 4.93a 0.37 0.07 5.14a 
RRS Brooding (n-1 lag) -0.54 0.62 -0.87 -0.57 0.62 -0.92 
Random       
Participant √ψ  36.39 2228.80  8.03 5.08  
Participant √θ  20.07 310.95  22.86 1.97  
Time √ψ 15.16 823.00     
Overall model Wald χ2(3)=32.52a, Log likelihood=-920.41 Wald χ2(3)=34.95a, Log likelihood=-920.74 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=190)        
Fixed       
Χ2(2)=0.19 
Time -5.95 3.32 -1.79 -5.90 3.32 -1.78 
SAQ Angina stability (n-1 lag) 0.33 0.08 4.32a 0.34 0.08 4.47a 
RRS Brooding (n-1 lag) -0.08 0.67 -0.12 -0.09 0.67 -0.14 
Age 0.10 0.21 0.50 0.11 0.21 0.51 
Sex -4.67 5.21 -0.90 -4.81 5.19 -0.93 
IMD -0.67 0.86 -0.79 -0.68 0.85 -0.79 
Q1 ESSI 0.76 0.33 2.27c 0.77 0.33 2.33c 
Q1 NYHA -4.39 3.96 -1.11 -4.29 3.95 -1.09 
Days since index event 0.02 0.02 0.74 0.02 0.02 0.71 
Random       
Participant √ψ  38.29 506.96  7.52 5.47  
Participant √θ  19.32 77.38  22.25 2.03  
Time √ψ 15.36 194.44     
Overall model Wald χ2(9)=43.51a, Log likelihood=-868.80 Wald χ2(9)=45.61a, Log likelihood=-868.89 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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C: Multilevel (repeated measures) models of worry with SAQ Angina stability 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=200)        
Fixed       
Χ2(2)=1.40 
Time -6.07 3.23 -1.88p=0.060 -5.91 3.23 -1.83p=0.067 
SAQ Angina stability (n-1 lag) 0.32 0.07 4.44a 0.35 0.07 4.73a 
Total PSWQ (n-1 lag) -0.26 0.13 -2.02c -0.24 0.13 -1.88p=0.061 
Random       
Participant √ψ  39.94 3351.10  9.54 4.17  
Participant √θ  18.45 558.04  22.08 1.90  
Time √ψ 16.82 1223.82     
Overall model Wald χ2(3)=35.88a, Log likelihood=-918.09 Wald χ2(3)=38.68a, Log likelihood=-918.79 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=189)        
Fixed       
Χ2(2)=0.60 
Time -6.90 3.16 -2.18a -6.76 3.16 -2.14c 
SAQ Angina stability (n-1 lag) 0.27 0.08 3.61a 0.29 0.08 3.86a 
Total PSWQ (n-1 lag) -0.18 0.14 -1.29 -0.16 0.14 -1.15 
Age 0.12 0.22 0.57 0.13 0.22 0.58 
Sex -3.62 5.38 -0.67 -3.93 5.37 -0.73 
IMD -0.86 0.89 -0.96 -0.85 0.89 -0.96 
Q1 ESSI 0.63 0.34 1.86p=0.062 0.68 0.34 2.02c 
Q1 NYHA -3.59 4.12 -0.87 -3.43 4.11 -0.84 
Days since index event 0.02 0.02 0.66 0.01 0.02 0.61 
Random       
Participant √ψ  38.90 2075.05  10.40 3.83  
Participant √θ  17.62 352.51  20.99 1.89  
Time √ψ 15.80 785.98     
Overall model Wald χ2(9)=39.13a, Log likelihood=-862.35 Wald χ2(9)=42.06a, Log likelihood=-862.64 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 42: Results of multilevel (repeated measures) models with SAQ Treatment satisfaction as the outcome variable 
A: Simple multilevel (repeated measures) models for SAQ Treatment satisfaction 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
model i (N=214)        
Fixed       
Χ2(2)=1.22 
Time -0.08 1.41 -0.05 -0.07 1.42 -0.05 
SAQ Treatment satisfaction (n-1 lag) 0.55 0.06 8.87a 0.57 0.06 9.28a 
Random       
Participant √ψ  15.10 326.13  1.66 2.77  
Participant √θ  9.05 41.89  10.26 0.84  
Time √ψ  6.45 117.53     
Overall model Wald χ2(2)=78.92a, Log likelihood=-823.71 Wald χ2(2)=86.33a, Log likelihood=-824.32 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
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B: Multilevel (repeated measures) models of brooding with SAQ Treatment satisfaction 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=210)        
Fixed       
Χ2(2)=2.12 
Time -0.22 1.41 -0.16 -0.18 1.42 -0.13 
SAQ Treatment satisfaction (n-1 lag) 0.50 0.06 7.71a 0.53 0.07 8.16a 
RRS Brooding (n-1 lag) -0.72 0.30 -2.43c -0.68 0.30 -2.24c 
Random       
Participant √ψ  19.04 1187.55  5.28 1.56  
Participant √θ  8.11 214.55  10.07 0.81  
Time √ψ 8.08 430.64     
Overall model Wald χ2(3)=86.06a, Log likelihood=-805.23 Wald χ2(3)=93.67a, Log likelihood=-806.29 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=199)        
Fixed       
Χ2(2)=2.15 
Time -0.13 1.44 -0.09 -0.09 1.45 -0.06 
SAQ Treatment satisfaction (n-1 lag) 0.49 0.07 7.40a 0.51 0.07 7.74a 
RRS Brooding (n-1 lag) -0.38 0.31 -1.21 -0.32 0.32 -1.02 
Age 0.00 0.10 0.01 -0.01 0.10 -0.08 
Sex -6.46 2.42 -2.67b -6.36 2.42 -2.63b 
IMD -0.33 0.39 -0.84 -0.35 0.39 -0.90 
Q1 ESSI 0.47 0.16 2.89b 0.47 0.16 2.89b 
Q1 NYHA -1.99 1.83 -1.09 -1.77 1.82 -0.97 
Days since index event 0.00 0.01 -0.18 0.00 0.01 -0.18 
Random       
Participant √ψ  15.17 1093.70  4.36 1.83  
Participant √θ  8.66 147.33  10.03 0.84  
Time √ψ 6.76 377.50     
Overall model Wald χ2(9)=111.26a, Log likelihood=-756.13 Wald χ2(9)=117.78a, Log likelihood=-757.21 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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C: Multilevel (repeated measures) models of worry with SAQ Treatment satisfaction 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=210)        
Fixed       
Χ2(2)=1.19 
Time -0.33 1.41 -0.23 -0.32 1.42 -0.22 
SAQ Treatment satisfaction (n-1 lag) 0.53 0.06 8.45a 0.55 0.06 8.74a 
Total PSWQ (n-1 lag) -0.11 0.06 -1.83p=0.067 -0.11 0.06 -1.87p=0.062 
Random       
Participant √ψ  16.37 1143.21  5.32 1.59  
Participant √θ  8.74 1143.22  10.12 0.83  
Time √ψ 6.88 418.66     
Overall model Wald χ2(3)=83.77a, Log likelihood=-806.79 Wald χ2(3)=90.47a, Log likelihood=-807.38 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=198)        
Fixed       
Χ2(2)=1.57 
Time -0.47 1.43 -0.33 -0.46 1.44 -0.32 
SAQ Treatment satisfaction (n-1 lag) 0.49 0.07 7.55a 0.51 0.07 7.80a 
Total PSWQ (n-1 lag) -0.03 0.06 -0.51 -0.03 0.06 -0.52 
Age 0.05 0.10 0.46 0.03 0.10 0.33 
Sex -6.05 2.48 -2.44c -6.00 2.48 -2.43c 
IMD -0.46 0.40 -1.13 -0.46 0.40 -1.15 
Q1 ESSI 0.45 0.17 2.74b 0.45 0.17 2.73b 
Q1 NYHA -1.83 1.89 -0.97 -1.67 1.88 -0.89 
Days since index event 0.00 0.01 -0.38 0.00 0.01 -0.36 
Random       
Participant √ψ  15.20 529.33  4.81 1.70  
Participant √θ  8.70 71.17  9.97 0.84  
Time √ψ 6.60 187.62     
Overall model Wald χ2(9)=101.79a, Log likelihood=-754.57 Wald χ2(9)=107.78a, Log likelihood=-755.36 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 43: Results of multilevel (repeated measures) models with SAQ Disease perception as the outcome variable 
A: Simple multilevel (repeated measures) models for SAQ Disease perception 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
model i (N=210)        
Fixed       
Χ2(1)=0.10 
Time -2.58 2.07 -1.25 -2.55 2.04 -1.25 
SAQ Disease perception (n-1 lag) 0.66 0.04 15.42a 0.65 0.04 15.15a 
Random       
Participant √ψ  25.89 -  0.00 0.00  
Participant √θ  12.88 1.27  14.61 0.71  
Time √ψ  10.36 0.80     
Overall model Wald χ2(2)=238.74a, Log likelihood=-861.06 Wald χ2(2)=230.64a, Log likelihood=-861.11 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
 
 
  
365 
 
B: Multilevel (repeated measures) models of brooding with SAQ Disease perception 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=207)        
Fixed       
Χ2(2)=0.21 
Time -2.32 2.01 -1.15 -2.33 2.01 -1.16 
SAQ Disease perception (n-1 lag) 0.59 0.05 12.39a 0.60 0.05 12.35
a 
RRS Brooding (n-1 lag) -1.07 0.39 -2.75b -1.07 0.39 -2.74
b 
Random       
Participant √ψ  24.37 1955.00  0.88 13.61  
Participant √θ  12.41 295.22  14.25 1.10  
Time √ψ 9.92 739.02     
Overall model Wald χ2(3)=252.88a, Log likelihood=-844.00 Wald χ2(3)=251.78a, Log likelihood=-844.10 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=196)        
Fixed       
Χ2(2)=0.35 
Time -2.08 2.04 -1.02 -2.04 2.00 -1.02 
SAQ Disease perception (n-1 lag) 0.53 0.05 10.38a 0.53 0.05 10.07a 
RRS Brooding (n-1 lag) -0.77 0.40 -1.92p=0.054 -0.79 0.41 -1.94p=0.052 
Age 0.10 0.12 0.88 0.11 0.12 0.95 
Sex -4.02 2.79 -1.44 -3.92 2.85 -1.38 
IMD -0.17 0.45 -0.39 -0.14 0.46 -0.31 
Q1 ESSI 0.56 0.19 2.96b 0.56 0.19 2.92b 
Q1 NYHA -4.28 2.20 -1.94p=0.052 -4.39 2.24 -1.96c 
Days since index event -0.01 0.01 -0.72 -0.01 0.01 -0.69 
Random       
Participant √ψ  23.88 1852.54  0.00 0.00  
Participant √θ  12.19 279.18  13.77 0.70  
Time √ψ 9.82 692.62     
Overall model Wald χ2(9)=291.20a, Log likelihood=-791.70 Wald χ2(9)=278.74a, Log likelihood=-792.14 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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C: Multilevel (repeated measures) models of worry with SAQ Disease perception 
 Random coefficient model Random intercept model Likelihood ratio test* 
 β SE z β SE z 
Model ii (N=207)        
Fixed       
Χ2(1)=0.15 
Time -2.33 2.07 -1.12 -2.30 2.04 -1.13 
SAQ Disease perception (n-1 lag) 0.63 0.05 13.96a 0.63 0.05 13.67a 
Total PSWQ (n-1 lag) -0.15 0.08 -1.99c -0.15 0.08 -1.97c 
Random       
Participant √ψ  31.23 -  0.00 0.00  
Participant √θ  11.82 1.37  14.50 0.71  
Time √ψ 12.46 0.66     
Overall model Wald χ2(3)=248.99a, Log likelihood=-847.20 Wald χ2(3)=239.31a, Log likelihood=-847.28 
Table continues on following page… 
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 Random coefficient model Random intercept model  Likelihood ratio test* 
 β SE z β SE z 
Model iii (N=195)        
Fixed       
Χ2(2)=0.23 
Time -2.31 2.11 -1.10 -2.23 2.06 -1.08 
SAQ Disease perception (n-1 lag) 0.57 0.05 11.33a 0.56 0.05 10.94a 
Total PSWQ (n-1 lag) -0.09 0.08 -1.14 -0.09 0.08 -1.12 
Age 0.12 0.12 0.97 0.12 0.12 1.01 
Sex -3.36 2.85 -1.18 -3.37 2.91 -1.16 
IMD -0.16 0.46 -0.34 -0.14 0.47 -0.30 
Q1 ESSI 0.51 0.19 2.68b 0.52 0.20 2.67b 
Q1 NYHA -3.58 2.25 -1.59 -3.74 2.30 -1.62 
Days since index event -0.01 0.01 -1.00 -0.01 0.01 -0.96 
Random       
Participant √ψ  25.49 1787.67  0.00 0.00  
Participant √θ  12.52 279.98  14.11 0.71  
Time √ψ 10.26 683.11     
Overall model Wald χ2(9)=272.37a, Log likelihood=-792.75 Wald χ2(9)=257.38a, Log likelihood=-792.86 
ap≤0.001 bp≤0.01 c≤0.05. 
*Random intercept model nested in random coefficient model. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 44: Example of random intercept model with and without days from baseline as covariate  
 Random intercept model not including  days 
from baseline as a covariate 
Random intercept model including days from 
baseline as a covariate 
 β SE z β SE z 
Model iii (N=212)       
Fixed       
Time -0.03 0.37 -0.07 0.05 0.78 0.07 
Total PHQ (n-1 lag) 0.64 0.06 10.35a 0.64 0.06 10.35a 
RRS Brooding (n-1 lag) 0.15 0.09 1.77p=0.076 0.15 0.09 1.78 p=0.076 
Age -0.02 0.02 -0.76 -0.02 0.02 -0.77 
Sex 0.35 0.52 0.67 0.33 0.54 0.62 
IMD 0.01 0.09 0.13 0.01 0.09 0.11 
Q1 ESSI -0.11 0.04 -2.89b -0.11 0.04 -2.85b 
Q1 NYHA 0.84 0.42 2.01c 0.84 0.42 2.01c 
History of depression 0.36 0.69 0.52 0.36 0.69 0.52 
Days since index event 0.00 0.00 0.44 0.00 0.00 0.42 
Days from baseline    0.00 0.01 -0.12 
       
Random       
Participant √ψ  0.00 0.00  0.00 0.00  
Participant √θ  2.69 0.13  2.67 0.13  
Time √ψ       
Overall model Wald χ2(10)=830.74a, Log likelihood=-498.45 Wald χ2(11)= 387.83a, Log likelihood=-510.26 
ap≤0.001 bp≤0.01 c≤0.05. 
√ψ=between-subjects standard deviation. 
√θ=within-subject standard deviation. 
Q1=baseline. 
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Appendix 45: Summary of Shapiro Wilk tests (W) of normality for multilevel (repeated measures) models (model iii) 
Model Random coefficient model* Random intercept 
model* 
 Level 1 Level 2 
(Slope) 
Level 2 
(Intercept) 
Level 1 Level 2 
(Intercept) 
RRS brooding→ PHQ 0.92a 0.90a 0.91a   
PSWQ→ PHQ 0.92a 0.90a 0.91a   
RRS brooding → BAI 0.95a 0.95a 0.92a   
PSWQ → BAI 0.94a 0.95a 0.92a   
RRS brooding → EQ5D VAS    0.87a 0.92a 
PSWQ → EQ5D VAS    0.88a 0.93a 
RRS brooding → EQ5D Index value    0.92a 0.93a 
PSWQ → EQ5D Index value    0.92a 0.93a 
RRS brooding → SAQ Physical limitations    0.95a 0.97a 
PSWQ → SAQ Physical limitations    0.95a 0.97a 
RRS brooding → SAQ Angina frequency    0.86a 0.86a 
PSWQ → SAQ Angina frequency    0.86a 0.86a 
RRS brooding → SAQ Angina stability    0.97a 0.96a 
PSWQ → SAQ Angina stability    0.97a 0.96a 
RRS brooding → SAQ Treatment satisfaction    0.83a 0.90a 
PSWQ → SAQ Treatment satisfaction    0.83a 0.91a 
RRS brooding → SAQ Disease perception    0.97a 0.98a 
PSWQ → SAQ Disease perception    0.97a 0.98a 
ap≤0.001 bp≤0.01 c≤0.05. 
*Normality tests reported for selected model only. 
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Appendix 46: Example of residuals versus fitted values plot (homoscedasticity assumption check) 
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Appendix 47: Description of missing data (potential mediator variables) at baseline (total N=169)  
 N % missing 
cases 
% cases with missing items Total number 
of missing 
items 
% missing 
items 
   Total Item/s 
substituted 
Scale/subscale 
excluded 
Social support        
ESSI social support 169 0.00 0.59 0.59 0.00 1.00 0.10 
Problem solving        
SPSI Positive problem orientation 167 1.18 2.37 1.18 1.18 9.00 1.07 
SPSI Rational problem solving 167 1.18 1.78 0.59 1.18 10.00 1.18 
SPSI Negative problem orientation 167 1.18 2.37 1.18 1.18 8.00 0.95 
SPSI Impulsivity 167 1.18 1.78 0.59 1.18 10.00 1.18 
SPSI Avoidance 167 1.18 1.18 0.00 1.18 8.00 0.95 
SPSI Total score 167 1.18 4.73 3.55 1.18 45.00 1.07 
Pleasant events        
PES Frequency 169 0.00 11.24 11.24 0.00 33.00 0.98 
PES Pleasantness 164 2.96 22.49 19.53 2.96 179.00 5.30 
PES Obtained pleasure 164 2.96 24.85 21.89 2.96 188.00 5.56 
Negative biases        
Memory task 88 47.93 n/a n/a n/a n/a n/a 
Interpretation task 88 47.93 n/a n/a n/a n/a n/a 
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Appendix 48: Correlations between sample characteristics and potential mediator variables at baseline 
 ESSI social 
support 
SPSI 
Positive 
problem 
orientation 
SPSI 
Rational 
problem 
solving 
SPSI 
Negative 
problem 
orientation 
SPSI 
Impulsivity 
SPSI 
Avoidance 
SPSI Total PES 
Frequency 
PES 
Pleasantness 
Demographic variables          
Age 0.12 0.02 0.13 -0.10 -0.05 -0.13 0.14 -0.15 0.13 
Years of education -0.09 0.03 0.18c -0.12 -0.21c -0.01 0.16c 0.09 -0.09 
Index of multiple deprivation 0.07 0.08 0.10 -0.19a -0.11 -0.19a 0.18a 0.11 0.10 
Disease variables          
Time since index event -0.10 -0.05 -0.12 0.11 0.04 0.11 -0.09 -0.08 0.07 
Left ventricular function 0.13 0.06 0.05 -0.13 -0.05 -0.05 0.07 0.00 0.06 
NYHA classification -0.17b -0.10 -0.02 0.17b 0.21a 0.14c -0.20a -0.17 -0.09 
Number of diseased vessels 0.02 -0.04 0.09 -0.11 -0.05 -0.08 0.08 -0.12c -0.03 
Comorbidity score 0.03 -0.08 0.00 0.04 0.15c 0.06 -0.09 -0.19c 0.02 
Troponin 0.10 0.05 0.05 0.00 -0.06 0.21c -0.02 0.06 0.12 
 Table continues on following page... 
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 PES 
Obtained 
pleasure 
Negative 
words 
endorsed 
Negative 
words 
recalled (%) 
Endorsed 
negative words 
recalled (%) 
Positive 
affective 
homophones 
(%) 
Negative 
affective 
homophones 
(%) 
Demographic variables       
Age -0.02 -0.01 0.01 -0.23c -0.15 -0.02 
Years of education -0.01 -0.04 0.16 0.14 -0.17 -0.17 
Index of multiple deprivation 0.10 -0.09 0.13 0.09 0.19c 0.01 
Disease variables       
Time since index event -0.03 0.01 -0.11 0.11 -0.02 0.13 
Left ventricular function 0.00 0.01 0.04 -0.08 0.05 -0.13 
NYHA classification -0.14c 0.16 0.06 -0.14 -0.04 0.14 
Number of diseased vessels -0.09 -0.02 -0.09 0.00 -0.05 0.09 
Comorbidity score -0.09 0.02 0.02 0.02 -0.08 0.04 
Troponin 0.14 0.14 -0.03 0.01 0.04 -0.24 
ap≤0.001 bp≤0.01 c≤0.05. 
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Appendix 49: Summary of differences in potential mediators at baseline according to 
sample characteristics 
 z Median 
Sex  Male Female 
ESSI social support -2.72b 29.00 26.00 
Positive affective homophones (%) 2.11c 60.00 70.00 
Employment status  Working Not working 
Endorsed negative words recalled (%) -2.22c 11.49 4.33 
Relationship status  Partner No partner 
ESSI social support -6.28a 29.00 23.50 
PES Frequency -1.98c 1.65 1.55 
History of depression  Yes No 
SPSI Total score 2.07c 11.70 14.00 
PES Pleasantness 3.02b 1.40 1.75 
PES Obtained pleasure 2.89b 2.36 3.05 
Negative words endorsed -2.69b 1.00 0.00 
Endorsed negative words recalled (%) -2.76b 33.33 0.00 
Negative affective homophones (%) -1.96c 62.50 50.00 
Smoking status  Smoker Non-smoker 
SPSI Total score 2.24c 11.80 14.00 
Alcohol use  Frequent Infrequent 
No significant differences    
Recreational drug use  Frequent Infrequent 
No significant differences    
Exercise frequency  Frequent Infrequent 
ESSI social support -2.13c 29.00 26.00 
SPSI Rational problem solving -2.13c 10.00 9.00 
SPSI Total score -2.64b 14.20 13.00 
PES Frequency -2.32c 1.70 1.55 
Diagnosis type    
No significant differences    
C-reactive protein 
 
Inflammation No 
inflammation 
Negative words endorsed -2.14 1.00 0.00 
White cell count  Raised Normal 
No significant differences    
ap<0.001, bp≤0.01, cp≤0.05. 
Non-significant findings not reported for brevity. 
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Appendix 50: Correlation matrix of mediator variables at baseline 
 1 2 3 4 5 6 7 8 9 
1.ESSI social support 1         
2.SPSI Positive problem orientation 0.14 1        
3.SPSI Rational problem solving 0.09 0.47a 1       
4.SPSI Negative problem orientation -0.20b -0.33a -0.12 1      
5.SPSI Impulsivity -0.12 -0.22b -0.35a 0.45a 1     
6.SPSI Avoidance -0.10 -0.20c -0.17c 0.56a 0.33a 1    
7.SPSI Total score 0.20b 0.67a 0.67a -0.66a -0.65a -0.60a 1   
8.PES Frequency 0.36a 0.24b 0.18c -0.26a -0.18c -0.21b 0.31a 1  
9.PES Pleasantness 0.39a 0.14 0.14 -0.29a -0.16c -0.23b 0.29a 0.62a 1 
10.PES Obtained pleasure 0.38a 0.21b 0.19c -0.26a -0.16c -0.20c 0.32a 0.89a 0.84a 
11.Negative words endorsed 0.09 -0.17 -0.09 0.41a 0.19 0.37a -0.38a -0.16 -0.25c 
12.Negative words recalled (%) 0.05 -0.08 0.04 0.04 -0.14 0.10 -0.02 0.04 0.09 
13.Endorsed negative words recalled (%) -0.07 -0.07 0.07 0.35b 0.00 0.37a -0.23c -0.09 -0.23c 
14.Positive affective homophones (%) -0.03 -0.02 0.00 -0.10 -0.05 -0.22c 0.07 0.19 0.09 
15.Negative affective homophones (%) -0.23c -0.31c -0.14 -0.04 0.11 -0.07 -0.16 -0.12 -0.11 
 
 10 11 12 13 14 15 
10.PES Obtained pleasure 1      
11.Negative words endorsed -0.17 1     
12.Negative words recalled (%) 0.06 -0.06 1    
13.Endorsed negative words recalled (%) -0.19 0.57a 0.25c 1   
14.Positive affective homophones (%) 0.15 -0.03 -0.15 -0.23c 1  
15.Negative affective homophones (%) -0.10 0.13 0.10 0.10 0.02 1 
ap≤0.001 bp≤0.01 c≤0.05. 
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Appendix 51: Description of missing data (potential mediator variables) at 2 months (total N=125) 
 N % missing 
cases 
% cases with missing items Total number 
of missing 
items 
% missing 
items 
   Total Item/s 
substituted 
Scale/subscale 
excluded 
Social support        
ESSI social support 123 1.60 1.60 0.00 1.60 12.00 1.92 
Problem solving        
SPSI Positive problem orientation 121 3.20 4.00 0.80 3.20 12.00 1.92 
SPSI Rational problem solving 121 3.20 4.00 0.80 3.20 13.00 2.08 
SPSI Negative problem orientation 121 3.20 4.00 0.80 3.20 13.00 2.08 
SPSI Impulsivity 121 3.20 3.20 0.00 3.20 14.00 2.24 
SPSI Avoidance 121 3.20 4.00 0.80 3.20 12.00 1.92 
SPSI Total score 121 3.20 4.80 1.60 3.20 64.00 2.05 
Pleasant events        
PES Frequency 123 1.60 8.00 6.40 1.60 58.00 2.32 
PES Pleasantness 123 1.60 15.20 13.60 1.60 78.00 3.12 
PES Obtained pleasure 123 1.60 15.20 13.60 1.60 78.00 3.12 
Negative biases         
Memory task 35 72.00 n/a n/a n/a n/a n/a 
Interpretation task 34 72.80 n/a n/a n/a n/a n/a 
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Appendix 52: Description of missing data (potential mediator variables) at 6 months (total N=111) 
 N % missing 
cases 
% cases with missing items Total number 
of missing 
items 
% missing 
items 
   Total Item/s 
substituted 
Scale/subscale 
excluded 
Social support        
ESSI social support 111 0.00 0.00 0.00 0.00 0.00 0.00 
Problem solving        
SPSI Positive problem orientation 109 1.80 1.80 0.00 1.80 10.00 1.80 
SPSI Rational problem solving 109 1.80 1.80 0.00 1.80 7.00 1.26 
SPSI Negative problem orientation 109 1.80 1.80 0.00 1.80 9.00 1.62 
SPSI Impulsivity 109 1.80 1.80 0.00 1.80 7.00 1.26 
SPSI Avoidance 109 1.80 1.80 0.00 1.80 7.00 1.26 
SPSI Total score 109 1.80 1.80 0.00 1.80 40.00 1.44 
Pleasant events        
PES Frequency 109 1.80 9.01 7.21 1.80 31.00 1.40 
PES Pleasantness 108 2.70 19.82 17.12 2.70 83.00 3.74 
PES Obtained pleasure 108 2.70 20.72 18.02 2.70 85.00 3.83 
Negative biases        
Memory task 14 87.39 n/a n/a n/a n/a n/a 
Interpretation task 14 87.39 n/a n/a n/a n/a n/a 
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Appendix 53: Results of regression analyses exploring mediators of the association 
between brooding and depression 
 B SE* t 95% CI 
ESSI Social support     
Unadjusted model (n=103)      
Path c’ (total effect) 1.00 0.11 8.83a  
Path a (direct effect) -0.41 0.19 -2.12c  
Path b (direct effect) -0.25 0.05 -4.84a  
Indirect effect 0.10 0.07  0.00, 0.29 
Adjusted model (n=102)     
Path c’ (total effect) 0.32 0.13 2.45c  
Path a (direct effect) 0.20 0.27 0.76  
Path b (direct effect) -0.15 0.05 -3.20b  
Indirect effect -0.03 0.05  -0.14, – 0.06 
     
SPSI Positive problem 
orientation  
    
Unadjusted model (n=102)     
Path c’ (total effect) 1.00 0.11 8.78a  
Path a (direct effect) -0.50 0.11 -4.58a  
Path b (direct effect) -0.09 0.11 -0.90  
Indirect effect 0.05 0.06  -0.05, .21 
SPSI Rational problem solving      
Unadjusted model (n=102)     
Path c’ (total effect) 1.00 0.11 8.78a  
Path a (direct effect) -0.26 0.14 -1.87p=0.064  
Path b (direct effect) -0.03 0.08 -0.36  
Indirect effect 0.01 0.03  -0.03, 0.08 
SPSI  Negative problem 
orientation     
 
Unadjusted model (n=102)     
Path c’ (total effect) 1.00 0.11 8.78a  
Path a (direct effect) 0.88 0.09 9.75a  
Path b (direct effect) 0.46 0.12 3.87a  
Indirect effect 0.40 0.14  0.16, 0.73 
Adjusted model (n=101)     
Path c’ (total effect) 0.32 0.13 2.46c  
Path a (direct effect) 0.51 0.12 4.09a  
Path b (direct effect) 0.17 0.11 1.56  
Indirect effect 0.09 0.06  -0.01, 0.25 
SPSI Impulsivity      
Unadjusted model (n=102)     
Path c’ (total effect) 1.00 0.11 8.78a  
Path a (direct effect) 0.28 0.10 2.81b  
Path b (direct effect) 0.01 0.12 0.11  
Indirect effect 0.00 0.04  -0.07, 0.11 
Table continues on following page… 
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 B SE* t 95% CI 
SPSI Avoidance     
Unadjusted model (n=102)     
Path c’ (total effect) 1.00 0.11 8.78a  
Path a (direct effect) 0.27 0.11 2.51b  
Path b (direct effect) 0.04 0.10 0.40  
Indirect effect 0.01 0.05  -0.05, 0.16 
SPSI Total score      
Unadjusted model (n=102)     
Path c’ (total effect) 1.00 0.11 8.78a  
Path a (direct effect) -0.44 -0.07 -6.06a  
Path b (direct effect) -0.23 0.15 -1.48  
Indirect effect 0.10 0.10  -0.07, 0.34 
     
PES Frequency     
Unadjusted model (n=103)     
Path c’ (total effect) 1.00 0.11 8.83a  
Path a (direct effect) -0.03 0.01 -2.75b  
Path b (direct effect) -1.80 1.12 -1.61  
Indirect effect 0.05 0.05  -0.00, 0.21 
PES Pleasantness     
Unadjusted model (n=103)     
Path c’ (total effect) 1.00 0.11 8.83a  
Path a (direct effect) -0.03 0.01 -3.46a  
Path b (direct effect) -3.21 1.28 -2.50c  
Indirect effect 0.09 0.05  0.02, 0.24 
Adjusted model  (n=102)     
Path c’ (total effect) 0.32 0.13 2.45c  
Path a (direct effect) -0.02 0.01 -1.43  
Path b (direct effect) -1.51 1.14 -1.34  
Indirect effect 0.03 0.03  -0.01, 0.12 
PES Obtained pleasure     
Unadjusted model (n=103)     
Path c’ (total effect) 1.00 0.11 8.83a  
Path a (direct effect) -0.08 0.02 -3.41a  
Path b (direct effect) -1.13 0.46 -2.49c  
Indirect effect 0.09 0.06  0.02, 0.26 
Adjusted model  (n=102)     
Path c’ (total effect) 0.32 0.13 2.45c  
Path a (direct effect) -0.04 0.03 -1.31  
Path b (direct effect) 0.47 0.41 -1.13  
Indirect effect 0.02 0.03  -0.01, 0.11 
     
Table continues on following page… 
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 B SE* t 95% CI 
Negative words endorsed      
Unadjusted model (n=86)     
Path c’ (total effect) 0.99 0.12 8.61a  
Path a (direct effect) 0.30 0.06 4.75a  
Path b (direct effect) 0.22 0.20 1.08  
Indirect effect 0.06 0.11  -0.09, 0.37 
Negative words recalled (%)      
Unadjusted model (n=83)     
Path c’ (total effect) 0.95 0.12 8.03a  
Path a (direct effect) 0.27 0.88 0.31  
Path b (direct effect) 0.02 0.01 1.54  
Indirect effect 0.01 0.02  -0.02, 0.05 
Endorsed negative words 
recalled (%)     
 
Unadjusted model (n=74)     
Path c’ (total effect) 0.96 0.13 7.60a  
Path a (direct effect) 3.17 0.57 5.34a  
Path b (direct effect) 0.07 0.02 2.82b  
Indirect effect 0.21 0.16  -0.02, 0.65 
Adjusted model (n=72)     
Path c’ (total effect) 0.71 0.12 5.81a  
Path a (direct effect) 2.68 0.61 4.40a  
Path b (direct effect) 0.03 0.02 1.23  
Indirect effect 0.08 0.11  -0.08, 0.37 
Positive affective homophones 
(%)     
 
Unadjusted model (n=86)     
Path c’ (total effect) 0.99 0.12 8.61a  
Path a (direct effect) -0.11 0.46 -0.24  
Path b (direct effect) -0.04 0.03 -1.45  
Indirect effect 0.00 0.02  -0.03, 0.06 
Negative affective homophones 
(%)     
 
Unadjusted model (n=86)     
Path c’ (total effect) 0.99 0.12 8.61a  
Path a (direct effect) 0.99 0.63 1.57  
Path b (direct effect) 0.02 0.02 0.99  
Indirect effect 0.02 0.02  -0.01, 0.09 
ap≤0.001 bp≤0.01 c≤0.05. 
*Bootstrapped standard error for indirect effect. 
CI=95% bias corrected confidence interval. 
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Appendix 54: Results of regression analyses exploring mediators of the association 
between brooding and EQ5D index value 
 B SE* t 95% CI 
ESSI Social support     
Unadjusted model (n=102)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) -0.40 0.20 -2.07c  
Path b (direct effect) 0.02 0.00 5.65a  
Indirect effect -0.01 0.00  -0.02, 0.00 
     
SPSI Positive problem 
orientation 
    
Unadjusted model (n=101)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) -0.51 0.11 -4.68a  
Path b (direct effect) 0.01 0.01 1.34  
Indirect effect -0.00 0.00  -0.01, 0.00 
SPSI Rational problem solving      
Unadjusted model (n=101)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) -0.26 0.14 -1.87p=0.064  
Path b (direct effect) 0.00 0.00 -0.31  
Indirect effect 0.00 0.00  -0.00, 0.00 
SPSI Negative problem 
orientation     
 
Unadjusted model (n=101)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) 0.88 0.09 9.71a  
Path b (direct effect) -0.01 0.01 -0.96  
Indirect effect -0.01 0.01  -0.02, 0.01 
SPSI Impulsivity      
Unadjusted model (n=101)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) 0.28 0.10 2.86b  
Path b (direct effect) -0.01 0.01 -1.76p=0.081  
Indirect effect -0.00 0.00  -0.01, 0.00 
SPSI Avoidance     
Unadjusted model (n=101)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) 0.28 0.11 2.51c  
Path b (direct effect) -0.00 0.01 -0.79  
Indirect effect -0.00 0.00  -0.01, 0.00  
Table continues on following page… 
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 B SE* t 95% CI 
SPSI Total score      
Unadjusted model (n=101)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) 0.44 0.07 -6.11a  
Path b (direct effect) 0.01 0.01 1.25  
Indirect effect -0.00 0.00  -0.02, 0.00 
     
PES Frequency     
Unadjusted model (n=102)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) -0.03 0.01 2.88b  
Path b (direct effect) 0.16 0.06 2.75b  
Indirect effect -0.00 0.00  -0.01, -0.00 
PES Pleasantness     
Unadjusted model (n=102)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) -0.03 0.01 3.49a  
Path b (direct effect) 0.17 0.07 2.52c  
Indirect effect -0.01 0.00  -0.01, -0.00 
PES Obtained pleasure     
Unadjusted model (n=102)     
Path c’ (total effect) -0.02 0.01 -3.11b  
Path a (direct effect) -0.08 0.02 -3.45a  
Path b (direct effect) 0.08 0.02 3.38c  
Indirect effect -0.01 0.00  -0.02, -0.00 
 B SE* t 95% CI 
Negative words endorsed      
Unadjusted model (n=85)     
Path c’ (total effect) -0.03 0.01 -5.12a  
Path a (direct effect) 0.29 0.06 4.69a  
Path b (direct effect) -0.00 0.01 -0.25  
Indirect effect -0.00 0.00  -0.01, 0.00 
Negative words recalled (%)      
Unadjusted model (n=82)     
Path c’ (total effect) -0.03 0.01 -4.61a  
Path a (direct effect) 0.26 0.89 0.29  
Path b (direct effect) -0.00 0.00 -0.86  
Indirect effect -0.00 0.00  -0.01, 0.00 
Endorsed negative words 
recalled (%)     
 
Unadjusted model (n=73)     
Path c’ (total effect) -0.03 0.01 -4.53a  
Path a (direct effect) 3.18 0.60 5.29a  
Path b (direct effect) 0.00 0.00 1.31  
Indirect effect 0.01 0.01  -0.00, 0.02 
Table continues on following page… 
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 B SE* t 95% CI 
Positive affective (%)      
Unadjusted model (n=85)     
Path c’ (total effect) -0.03 0.01 -5.12a  
Path a (direct effect) -0.14 0.46 -0.30  
Path b (direct effect) 0.00 0.00 0.13  
Indirect effect 0.00 0.00  -0.00, 0.00 
Negative affective (%)      
Unadjusted model (n=85)     
Path c’ (total effect) -0.03 0.01 -5.12a  
Path a (direct effect) 0.91 0.63 1.44  
Path b (direct effect) -0.00 0.00 -0.85  
Indirect effect -0.00    
ap≤0.001 bp≤0.01 c≤0.05. 
*Bootstrapped standard error for indirect effect. 
CI=95% bias corrected confidence interval. 
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Appendix 55: Results of regression analyses exploring mediators of the association 
between brooding and SAQ disease perception 
 B SE* t 95% CI 
ESSI social support     
Unadjusted model (n=97)     
Path c’ (total effect) -2.35 0.65 -3.63a  
Path a (direct effect) -0.41 0.20 -2.06c  
Path b (direct effect) 1.44 0.30 4.75a  
Indirect effect -0.59 0.36  -1.54, -0.03 
     
SPSI Positive problem 
orientation    
 
Unadjusted model (n=96)     
Path c’ (total effect) -2.37 0.65 -3.64a  
Path a (direct effect) -0.49 0.11 -4.28a  
Path b (direct effect) 0.31 0.59 0.53  
Indirect effect -0.15 0.33  -0.86, 0.46 
SPSI Rational problem solving      
Unadjusted model (n=96)     
Path c’ (total effect) -2.37 0.65 -3.64a  
Path a (direct effect) -0.23 0.13 -1.70  
Path b (direct effect) 0.35 0.50 0.70  
Indirect effect -0.08 0.14  -0.52, 0.10 
SPSI Negative problem 
orientation     
 
Unadjusted model (n=96)     
Path c’ (total effect) -2.37 0.65 -3.64a  
Path a (direct effect) 0.88 0.09 9.52a  
Path b (direct effect) -1.49 0.71 -2.09c  
Indirect effect -1.31 0.72  -3.01, -0.12 
SPSI Impulsivity      
Unadjusted model (n=96)     
Path c’ (total effect) -2.37 0.65 -3.64a  
Path a (direct effect) 0.28 0.10 2.89b  
Path b (direct effect) -1.00 0.69 -1.46  
Indirect effect -0.28 0.28  -1.11, 0.07 
SPSI Avoidance     
Unadjusted model (n=96)     
Path c’ (total effect) -2.37 0.65 -3.64a  
Path a (direct effect) 0.31 0.11 2.76b  
Path b (direct effect) -0.17 0.60 -0.28  
Indirect effect -0.05 0.24  -0.71, 0.31 
SPSI Total score      
Unadjusted model (n=96)     
Path c’ (total effect) -2.37 0.65 -3.64a  
Path a (direct effect) -0.44 0.07 -5.91a  
Path b (direct effect) 1.27 0.90 1.41  
Indirect effect -0.56 0.49  -1.61, 0.32 
Table continues on following page… 
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 B SE* t 95% CI 
PES Frequency     
Unadjusted model (n=97)     
Path c’ (total effect) -2.35 0.65 3.63a  
Path a (direct effect) -0.03 0.01 -2.83b  
Path b (direct effect) 18.32 6.14 2.98b  
Indirect effect -0.54 0.30  -1.34, -0.13 
PES Pleasantness     
Unadjusted model (n=97)     
Path c’ (total effect) -2.35 0.65 3.63a  
Path a (direct effect) -0.03 0.01 -3.69a  
Path b (direct effect) 18.07 7.43 2.43c  
Indirect effect -0.58 0.34  -1.49, -0.10 
PES Obtained pleasure     
Unadjusted model (n=97)     
Path c’ (total effect) -2.35 0.65 3.63a  
Path a (direct effect) -0.09 0.02 -3.55a  
Path b (direct effect) 8.80 2.25 3.46a  
Indirect effect -0.77 0.35  -1.71, -0.28 
     
Negative words endorsed      
Unadjusted model (n=82)     
Path c’ (total effect) -3.17 0.78 -4.05a  
Path a (direct effect) 0.29 0.07 4.49a  
Path b (direct effect) 2.20 1.30 1.70  
Indirect effect 0.66 0.35  0.05, 1.42 
Negative words recalled (%)      
Unadjusted model (n=82)     
Path c’ (total effect) -3.20 0.80 -4.02a  
Path a (direct effect) 0.16 0.91 0.18  
Path b (direct effect) -0.16 0.10 -1.59  
Indirect effect -0.03 0.14  -0.39, 0.20 
Endorsed negative words 
recalled (%)     
 
Unadjusted model (n=71)     
Path c’ (total effect) -3.09 0.84 -3.70a  
Path a (direct effect) 3.11 0.61 5.09a  
Path b (direct effect) 0.32 0.16 1.96p=0.054  
Indirect effect 0.99 0.60  0.15, 2.58 
Positive affective homophones 
(%)     
 
Unadjusted model (n=82)     
Path c’ (total effect) -3.17 0.78 -4.05a  
Path a (direct effect) 0.04 0.47 0.09  
Path b (direct effect) -0.03 0.19 -0.15  
Indirect effect -0.00 0.09  -0.22, 0.18 
Table continues on following page… 
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 B SE* t 95% CI 
Negative affective homophones 
(%)     
 
Unadjusted model (n=82)     
Path c’ (total effect) -3.17 0.78 -4.05a  
Path a (direct effect) 0.77 0.66 1.16  
Path b (direct effect) -0.04 0.13 -0.30  
Indirect effect -0.03 0.12  -0.44, 0.12 
ap≤0.001 bp≤0.01 c≤0.05. 
*Bootstrapped standard error for indirect effect. 
CI=95% bias corrected confidence interval. 
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Appendix 56: Results of regression analyses exploring mediators of the association 
between worry and EQ5D VAS 
 B SE* t 95% CI 
ESSI social support     
Unadjusted model (n=103)     
Path c’ (total effect) -0.48 0.12 -3.88a  
Path a (direct effect) -0.07 0.04 -1.66  
Path b (direct effect) 1.29 0.25 5.08a  
Indirect effect -0.09 0.07  -0.27, 0.01 
     
SPSI Positive problem 
orientation     
 
Unadjusted model  (n=102)     
Path c’ (total effect) -0.48 0.12 -3.68a  
Path a (direct effect) -0.12 0.02 -4.88a  
Path b (direct effect) 0.70 0.52 1.33  
Indirect effect -0.08 0.06  -0.21, 0.03 
SPSI Rational problem solving      
Unadjusted model  (n=102)     
Path c’ (total effect) -0.48 0.12 -3.68a  
Path a (direct effect) -0.06 0.03 -2.13c  
Path b (direct effect) -0.16 0.41 -0.38  
Indirect effect 0.01 0.03  -0.04, 0.07 
SPSI Negative problem 
orientation     
 
Unadjusted model  (n=102)     
Path c’ (total effect) -0.48 0.12 -3.68a  
Path a (direct effect) 0.17 0.02 7.70a  
Path b (direct effect) -1.07 0.56 -1.91p=0.059  
Indirect effect -0.18 0.12  -0.40, 0.08 
SPSI Impulsivity      
Unadjusted model  (n=102)     
Path c’ (total effect) -0.48 0.12 -3.68a  
Path a (direct effect) 0.04 0.02 1.66  
Path b (direct effect) -0.02 0.58 -0.03  
Indirect effect -0.00 0.03  -0.06, 0.05 
SPSI Avoidance     
Unadjusted model  (n=102)     
Path c’ (total effect) -0.48 0.12 -3.68a  
Path a (direct effect) 0.05 0.02 2.02c  
Path b (direct effect) -0.32 0.51 -0.63  
Indirect effect -0.02 0.03  -0.13, 0.03 
SPSI Total score      
Unadjusted model  (n=102)     
Path c’ (total effect) -0.48 0.12 -3.68a  
Path a (direct effect) -0.09 0.02 -5.24a  
Path b (direct effect) 0.70 0.75 0.93  
Indirect effect -0.06 0.08  -0.21, 0.09 
Table continues on following page… 
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 B SE* t 95% CI 
PES Frequency     
Unadjusted model (n=103)     
Path c’ (total effect) -0.48 0.12 -3.98a  
Path a (direct effect) -0.00 0.00 -0.56  
Path b (direct effect) 16.90 5.11 3.31a  
Indirect effect -0.02 0,04  -0.12, 0.04 
PES Pleasantness     
Unadjusted model (n=103)     
Path c’ (total effect) -0.48 0.12 -3.98a  
Path a (direct effect) -0.00 0.00 -1.95p=0.054  
Path b (direct effect) 19.17 5.99 3.20b  
Indirect effect -0.07 0.05  -0.20,-0.00 
PES Obtained pleasure     
Unadjusted model (n=103)     
Path c’ (total effect) -0.48 0.12 -3.98a  
Path a (direct effect) -0.01 0.01 -1.58  
Path b (direct effect) 7.87 2.07 3.80a  
Indirect effect -0.07 0.05  -0.19, -0.00 
     
Negative words endorsed      
Unadjusted model (n=83)     
Path c’ (total effect) -0.34 0.14 -2.45c  
Path a (direct effect) 0.05 0.01 3.56a  
Path b (direct effect) -0.77 1.12 -0.69  
Indirect effect 0.04 0.07  -0.22, 0.07 
Negative words recalled (%)      
Unadjusted model (n=81)     
Path c’ (total effect) -0.33 0.14 -2.36c  
Path a (direct effect) -0.15 0.20 -0.74  
Path b (direct effect) -0.15 0.08 -1.88p=0.064  
Indirect effect 0.02 0.03  -0.02, 0.11 
 B SE* t 95% CI 
Endorsed negative words 
recalled (%)     
 
Unadjusted model (n=72)     
Path c’ (total effect) -0.39 0.14 -2.81b  
Path a (direct effect) 0.48 0.15 3.17b  
Path b (direct effect) -0.18 0.11 -1.70  
Indirect effect -0.09 0.07  -0.28, 0.02 
Positive affective homophones 
(%)     
 
Unadjusted model (n=83)     
Path c’ (total effect) -0.34 0.14 -2.45c  
Path a (direct effect) -0.00 0.11 -0.05  
Path b (direct effect) 0.22 0.14 1.53  
Indirect effect 0.00 0.03  -0.06, 0.06 
Table continues on following page… 
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 B SE* t 95% CI 
Negative affective homophones 
(%)     
 
Unadjusted model (n=83)     
Path c’ (total effect) -0.34 0.14 -2.45c  
Path a (direct effect) -0.01 0.15 -0.09  
Path b (direct effect) -0.06 0.10 -0.61  
Indirect effect 0.00 0.02  -0.03, 0.05 
ap≤0.001 bp≤0.01 c≤0.05. 
*Bootstrapped standard error for indirect effect. 
CI=95% bias corrected confidence interval. 
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Appendix 57: Results of regression analyses exploring mediators of the association 
between worry and EQ5D index value 
 B SE* t 95% CI 
ESSI social support     
Unadjusted model (n=103)     
Path c’ (total effect) -0.00 0.00 -3.66a  
Path a (direct effect) -0.07 0.04 -1.66  
Path b (direct effect) 0.01 0.00 5.69a  
Indirect effect -0.00 0.00  -0.00, 0.00 
     
SPSI Positive problem 
orientation     
 
Unadjusted model (n=102)     
Path c’ (total effect) -0.00 0.00 -3.64a  
Path a (direct effect) -0.12 0.02 -4.88a  
Path b (direct effect) 0.01 0.01 0.99  
Indirect effect -0.00 0.00  -0.00, 0.00 
SPSI Rational problem solving      
Unadjusted model (n=102)     
Path c’ (total effect) -0.00 0.00 -3.64a  
Path a (direct effect) -0.06 0.03 -2.13c  
Path b (direct effect) -0.00 0.00 -0.49  
Indirect effect 0.00 0.00  -0.00, 0.00 
SPSI Negative problem 
orientation     
 
Unadjusted model (n=102)     
Path c’ (total effect) -0.00 0.00 -3.64a  
Path a (direct effect) 0.17 0.02 7.70a  
Path b (direct effect) -0.01 0.01 -0.95  
Indirect effect -0.00 0.00  -0.00, 0.00 
SPSI Impulsivity      
Unadjusted model (n=102)     
Path c’ (total effect) -0.00 0.00 -3.64a  
Path a (direct effect) 0.02 0.04 1.66  
Path b (direct effect) -0.01 0.01 -1.92p=0.058  
Indirect effect -0.00 0.00  -0.00, 0.00 
SPSI Avoidance     
Unadjusted model (n=102)     
Path c’ (total effect) -0.00 0.00 -3.64a  
Path a (direct effect) 0.05 0.02 2.02c  
Path b (direct effect) -0.00 0.01 -0.84  
Indirect effect -0.00 0.00  -0.00, 0.00 
SPSI Total score      
Unadjusted model (n=102)     
Path c’ (total effect) -0.00 0.00 -3.64a  
Path a (direct effect) -0.09 0.02 -5.24a  
Path b (direct effect) 0.01 0.01 1.11  
Indirect effect -0.00 0.00  -0.00, 0.00 
Table continues on following page… 
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 B SE* t 95% CI 
PES Frequency     
Unadjusted model (n=103)     
Path c’ (total effect) -0.00 0.00 3.36a  
Path a (direct effect) -0.00 0.00 -0.56  
Path b (direct effect) 0.18 0.05 3.31a  
Indirect effect -0.00 0.00  -0.00, 0.00 
PES Pleasantness     
Unadjusted model (n=103)     
Path c’ (total effect) -0.00 0.00 3.36a  
Path a (direct effect) -0.00 0.00 -1.95p=0.054  
Path b (direct effect) 0.18 0.06 2.86b  
Indirect effect -0.00 0.00  -0.00, 0.00 
PES Obtained pleasure     
Unadjusted model (n=103)     
Path c’ (total effect) -0.00 0.00 3.36a  
Path a (direct effect) -0.01 0.01 -1.58  
Path b (direct effect) 0.08 0.02 3.75a  
Indirect effect -0.00 0.00  -0.00, -0.00 
     
Negative words endorsed      
Unadjusted model (n=83)     
Path c’ (total effect) -0.00 0.00 -3.07b  
Path a (direct effect) 0.05 0.01 3.44a     
Path b (direct effect) -0.02 0.01 -1.92p=0.058  
Indirect effect -0.00 0.00  -0.00, 0.00 
Negative words recalled (%)      
Unadjusted model (n=81)     
Path c’ (total effect) -0.00 0.00 -2.88b  
Path a (direct effect) -0.16 0.20 -0.69  
Path b (direct effect) -0.00 0.00 -1.13  
Indirect effect 0.00 0.00  -0.00, 0.00 
Endorsed negative words 
recalled (%)     
 
Unadjusted model (n=72)     
Path c’ (total effect) -0.00 0.00 -2.87b  
Path a (direct effect) 0.49 0.15 3.17b  
Path b (direct effect) -0.00 0.00 -0.15  
Indirect effect -0.00 0.00  -0.00, 0.00 
Positive affective homophones 
(%)     
 
Unadjusted model (n=83)     
Path c’ (total effect) -0.00 0.00 -3.07b  
Path a (direct effect) -0.03 0.11 -0.26  
Path b (direct effect) 0.00 0.00 0.25  
Indirect effect 0.00 0.00  -0.00, 0.00 
Table continues on following page… 
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 B SE* t 95% CI 
Negative affective homophones 
(%)    
 
Unadjusted model  (n=83)     
Path c’ (total effect) -0.00 0.00 -3.07b  
Path a (direct effect) 0.49 0.15 -0.33     
Path b (direct effect) -0.00 0.00 -1.64     
Indirect effect 0.00 0.00  -0.00, 0.00 
ap≤0.001 bp≤0.01 c≤0.05. 
*Bootstrapped standard error for indirect effect. 
CI=95% bias corrected confidence interval. 
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